pairs,labels
"['The response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P =.006).\tThe response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P =.006).', 'The response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P =.006).\tAll of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen.', 'The response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P =.006).\tTime to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05).', 'The response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P =.006).\tDepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041).', 'The response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P =.006).\tThe major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease.', 'The response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P =.006).\tDepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week.', 'All of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen.\tThe response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P =.006).', 'All of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen.\tAll of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen.', 'All of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen.\tTime to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05).', 'All of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen.\tDepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041).', 'All of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen.\tThe major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease.', 'All of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen.\tDepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week.', 'Time to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05).\tThe response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P =.006).', 'Time to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05).\tAll of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen.', 'Time to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05).\tTime to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05).', 'Time to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05).\tDepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041).', 'Time to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05).\tThe major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease.', 'Time to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05).\tDepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week.', 'DepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041).\tThe response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P =.006).', 'DepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041).\tAll of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen.', 'DepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041).\tTime to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05).', 'DepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041).\tDepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041).', 'DepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041).\tThe major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease.', 'DepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041).\tDepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week.', 'The major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease.\tThe response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P =.006).', 'The major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease.\tAll of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen.', 'The major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease.\tTime to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05).', 'The major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease.\tDepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041).', 'The major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease.\tThe major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease.', 'The major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease.\tDepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week.', 'DepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week.\tThe response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P =.006).', 'DepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week.\tAll of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen.', 'DepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week.\tTime to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05).', 'DepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week.\tDepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041).', 'DepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week.\tThe major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease.', 'DepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week.\tDepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week.']","[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.\tFor several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.', 'For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.\tOccurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).', 'For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.\tthe survival rates were by-and-large the same for the two groups.', 'For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.\tRegarding postoperative quality of life, the chemotherapy group presented a more favorable picture.', 'For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.\tThe long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.', 'For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.\tRegarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.', 'For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.\tAfter 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.', 'For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.\tA few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).', 'Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).\tFor several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.', 'Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).\tOccurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).', 'Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).\tthe survival rates were by-and-large the same for the two groups.', 'Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).\tRegarding postoperative quality of life, the chemotherapy group presented a more favorable picture.', 'Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).\tThe long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.', 'Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).\tRegarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.', 'Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).\tAfter 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.', 'Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).\tA few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).', 'the survival rates were by-and-large the same for the two groups.\tFor several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.', 'the survival rates were by-and-large the same for the two groups.\tOccurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).', 'the survival rates were by-and-large the same for the two groups.\tthe survival rates were by-and-large the same for the two groups.', 'the survival rates were by-and-large the same for the two groups.\tRegarding postoperative quality of life, the chemotherapy group presented a more favorable picture.', 'the survival rates were by-and-large the same for the two groups.\tThe long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.', 'the survival rates were by-and-large the same for the two groups.\tRegarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.', 'the survival rates were by-and-large the same for the two groups.\tAfter 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.', 'the survival rates were by-and-large the same for the two groups.\tA few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).', 'Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture.\tFor several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.', 'Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture.\tOccurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).', 'Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture.\tthe survival rates were by-and-large the same for the two groups.', 'Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture.\tRegarding postoperative quality of life, the chemotherapy group presented a more favorable picture.', 'Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture.\tThe long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.', 'Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture.\tRegarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.', 'Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture.\tAfter 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.', 'Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture.\tA few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).', 'The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.\tFor several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.', 'The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.\tOccurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).', 'The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.\tthe survival rates were by-and-large the same for the two groups.', 'The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.\tRegarding postoperative quality of life, the chemotherapy group presented a more favorable picture.', 'The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.\tThe long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.', 'The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.\tRegarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.', 'The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.\tAfter 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.', 'The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.\tA few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).', 'Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.\tFor several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.', 'Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.\tOccurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).', 'Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.\tthe survival rates were by-and-large the same for the two groups.', 'Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.\tRegarding postoperative quality of life, the chemotherapy group presented a more favorable picture.', 'Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.\tThe long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.', 'Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.\tRegarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.', 'Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.\tAfter 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.', 'Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.\tA few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).', 'After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.\tFor several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.', 'After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.\tOccurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).', 'After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.\tthe survival rates were by-and-large the same for the two groups.', 'After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.\tRegarding postoperative quality of life, the chemotherapy group presented a more favorable picture.', 'After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.\tThe long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.', 'After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.\tRegarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.', 'After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.\tAfter 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.', 'After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.\tA few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).', 'A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).\tFor several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.', 'A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).\tOccurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).', 'A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).\tthe survival rates were by-and-large the same for the two groups.', 'A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).\tRegarding postoperative quality of life, the chemotherapy group presented a more favorable picture.', 'A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).\tThe long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.', 'A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).\tRegarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.', 'A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).\tAfter 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.', 'A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).\tA few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0]"
"['Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).\tResponses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).', 'Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).\tThe rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.', 'Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).\tEight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.', 'Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).\tThe median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.', 'Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).\tThe following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).', 'Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).\tNo cases of drug-related neutropenic fever, sepsis, or death occurred.', 'Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).\tPancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.', 'Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).\tBexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.', 'Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).\tHypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.', 'The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.\tResponses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).', 'The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.\tThe rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.', 'The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.\tEight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.', 'The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.\tThe median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.', 'The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.\tThe following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).', 'The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.\tNo cases of drug-related neutropenic fever, sepsis, or death occurred.', 'The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.\tPancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.', 'The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.\tBexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.', 'The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.\tHypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.', 'Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.\tResponses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).', 'Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.\tThe rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.', 'Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.\tEight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.', 'Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.\tThe median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.', 'Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.\tThe following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).', 'Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.\tNo cases of drug-related neutropenic fever, sepsis, or death occurred.', 'Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.\tPancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.', 'Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.\tBexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.', 'Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.\tHypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.', 'The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.\tResponses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).', 'The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.\tThe rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.', 'The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.\tEight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.', 'The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.\tThe median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.', 'The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.\tThe following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).', 'The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.\tNo cases of drug-related neutropenic fever, sepsis, or death occurred.', 'The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.\tPancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.', 'The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.\tBexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.', 'The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.\tHypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.', 'The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).\tResponses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).', 'The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).\tThe rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.', 'The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).\tEight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.', 'The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).\tThe median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.', 'The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).\tThe following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).', 'The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).\tNo cases of drug-related neutropenic fever, sepsis, or death occurred.', 'The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).\tPancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.', 'The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).\tBexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.', 'The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).\tHypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.', 'No cases of drug-related neutropenic fever, sepsis, or death occurred.\tResponses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).', 'No cases of drug-related neutropenic fever, sepsis, or death occurred.\tThe rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.', 'No cases of drug-related neutropenic fever, sepsis, or death occurred.\tEight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.', 'No cases of drug-related neutropenic fever, sepsis, or death occurred.\tThe median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.', 'No cases of drug-related neutropenic fever, sepsis, or death occurred.\tThe following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).', 'No cases of drug-related neutropenic fever, sepsis, or death occurred.\tNo cases of drug-related neutropenic fever, sepsis, or death occurred.', 'No cases of drug-related neutropenic fever, sepsis, or death occurred.\tPancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.', 'No cases of drug-related neutropenic fever, sepsis, or death occurred.\tBexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.', 'No cases of drug-related neutropenic fever, sepsis, or death occurred.\tHypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.', 'Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.\tResponses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).', 'Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.\tThe rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.', 'Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.\tEight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.', 'Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.\tThe median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.', 'Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.\tThe following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).', 'Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.\tNo cases of drug-related neutropenic fever, sepsis, or death occurred.', 'Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.\tPancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.', 'Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.\tBexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.', 'Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.\tHypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.', 'Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.\tResponses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).', 'Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.\tThe rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.', 'Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.\tEight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.', 'Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.\tThe median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.', 'Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.\tThe following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).', 'Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.\tNo cases of drug-related neutropenic fever, sepsis, or death occurred.', 'Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.\tPancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.', 'Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.\tBexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.', 'Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.\tHypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.', 'Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.\tResponses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).', 'Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.\tThe rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.', 'Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.\tEight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.', 'Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.\tThe median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.', 'Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.\tThe following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).', 'Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.\tNo cases of drug-related neutropenic fever, sepsis, or death occurred.', 'Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.\tPancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.', 'Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.\tBexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.', 'Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.\tHypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.']","[0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['In recent years, encouraging results of preoperative radiotherapy have been reported.\tIn recent years, encouraging results of preoperative radiotherapy have been reported.', 'In recent years, encouraging results of preoperative radiotherapy have been reported.\tPostoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).', 'In recent years, encouraging results of preoperative radiotherapy have been reported.\tAcute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity', 'In recent years, encouraging results of preoperative radiotherapy have been reported.\tThe principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.', 'In recent years, encouraging results of preoperative radiotherapy have been reported.\tErythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.', 'In recent years, encouraging results of preoperative radiotherapy have been reported.\tPostoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.', 'In recent years, encouraging results of preoperative radiotherapy have been reported.\tThe patient accrual of our trial is satisfactory,', 'In recent years, encouraging results of preoperative radiotherapy have been reported.\tneoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.', 'Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).\tIn recent years, encouraging results of preoperative radiotherapy have been reported.', 'Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).\tPostoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).', 'Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).\tAcute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity', 'Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).\tThe principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.', 'Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).\tErythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.', 'Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).\tPostoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.', 'Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).\tThe patient accrual of our trial is satisfactory,', 'Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).\tneoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.', 'Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity\tIn recent years, encouraging results of preoperative radiotherapy have been reported.', 'Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity\tPostoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).', 'Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity\tAcute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity', 'Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity\tThe principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.', 'Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity\tErythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.', 'Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity\tPostoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.', 'Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity\tThe patient accrual of our trial is satisfactory,', 'Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity\tneoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.', 'The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.\tIn recent years, encouraging results of preoperative radiotherapy have been reported.', 'The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.\tPostoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).', 'The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.\tAcute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity', 'The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.\tThe principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.', 'The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.\tErythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.', 'The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.\tPostoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.', 'The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.\tThe patient accrual of our trial is satisfactory,', 'The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.\tneoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.', 'Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.\tIn recent years, encouraging results of preoperative radiotherapy have been reported.', 'Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.\tPostoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).', 'Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.\tAcute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity', 'Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.\tThe principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.', 'Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.\tErythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.', 'Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.\tPostoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.', 'Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.\tThe patient accrual of our trial is satisfactory,', 'Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.\tneoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.', 'Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.\tIn recent years, encouraging results of preoperative radiotherapy have been reported.', 'Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.\tPostoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).', 'Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.\tAcute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity', 'Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.\tThe principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.', 'Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.\tErythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.', 'Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.\tPostoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.', 'Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.\tThe patient accrual of our trial is satisfactory,', 'Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.\tneoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.', 'The patient accrual of our trial is satisfactory,\tIn recent years, encouraging results of preoperative radiotherapy have been reported.', 'The patient accrual of our trial is satisfactory,\tPostoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).', 'The patient accrual of our trial is satisfactory,\tAcute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity', 'The patient accrual of our trial is satisfactory,\tThe principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.', 'The patient accrual of our trial is satisfactory,\tErythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.', 'The patient accrual of our trial is satisfactory,\tPostoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.', 'The patient accrual of our trial is satisfactory,\tThe patient accrual of our trial is satisfactory,', 'The patient accrual of our trial is satisfactory,\tneoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.', 'neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.\tIn recent years, encouraging results of preoperative radiotherapy have been reported.', 'neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.\tPostoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).', 'neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.\tAcute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity', 'neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.\tThe principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.', 'neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.\tErythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.', 'neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.\tPostoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.', 'neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.\tThe patient accrual of our trial is satisfactory,', 'neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.\tneoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['Epoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001).\tEpoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001).', 'Epoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001).\tImprovement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.', 'Epoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001).\tKaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),', 'Epoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001).\tCox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.', 'Epoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001).\tAdverse events were comparable between groups.', 'Epoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001).\tEpoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.', 'Epoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001).\tEncouraging results regarding increased survival warrant another trial designed to confirm these findings.', 'Improvement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.\tEpoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001).', 'Improvement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.\tImprovement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.', 'Improvement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.\tKaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),', 'Improvement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.\tCox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.', 'Improvement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.\tAdverse events were comparable between groups.', 'Improvement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.\tEpoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.', 'Improvement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.\tEncouraging results regarding increased survival warrant another trial designed to confirm these findings.', 'Kaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),\tEpoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001).', 'Kaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),\tImprovement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.', 'Kaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),\tKaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),', 'Kaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),\tCox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.', 'Kaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),\tAdverse events were comparable between groups.', 'Kaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),\tEpoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.', 'Kaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),\tEncouraging results regarding increased survival warrant another trial designed to confirm these findings.', 'Cox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.\tEpoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001).', 'Cox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.\tImprovement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.', 'Cox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.\tKaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),', 'Cox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.\tCox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.', 'Cox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.\tAdverse events were comparable between groups.', 'Cox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.\tEpoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.', 'Cox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.\tEncouraging results regarding increased survival warrant another trial designed to confirm these findings.', 'Adverse events were comparable between groups.\tEpoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001).', 'Adverse events were comparable between groups.\tImprovement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.', 'Adverse events were comparable between groups.\tKaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),', 'Adverse events were comparable between groups.\tCox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.', 'Adverse events were comparable between groups.\tAdverse events were comparable between groups.', 'Adverse events were comparable between groups.\tEpoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.', 'Adverse events were comparable between groups.\tEncouraging results regarding increased survival warrant another trial designed to confirm these findings.', 'Epoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.\tEpoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001).', 'Epoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.\tImprovement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.', 'Epoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.\tKaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),', 'Epoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.\tCox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.', 'Epoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.\tAdverse events were comparable between groups.', 'Epoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.\tEpoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.', 'Epoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.\tEncouraging results regarding increased survival warrant another trial designed to confirm these findings.', 'Encouraging results regarding increased survival warrant another trial designed to confirm these findings.\tEpoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001).', 'Encouraging results regarding increased survival warrant another trial designed to confirm these findings.\tImprovement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.', 'Encouraging results regarding increased survival warrant another trial designed to confirm these findings.\tKaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),', 'Encouraging results regarding increased survival warrant another trial designed to confirm these findings.\tCox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.', 'Encouraging results regarding increased survival warrant another trial designed to confirm these findings.\tAdverse events were comparable between groups.', 'Encouraging results regarding increased survival warrant another trial designed to confirm these findings.\tEpoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.', 'Encouraging results regarding increased survival warrant another trial designed to confirm these findings.\tEncouraging results regarding increased survival warrant another trial designed to confirm these findings.']","[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.\tOver 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.', 'Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.\tThe mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.', 'Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.\tThe threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.', 'Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.\tFludarabine was consistently a better treatment than ChOP,', 'Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.\texcept in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.', 'Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.\tfrom a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).', 'Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.\tpatients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.', 'Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.\tThese two treatments are always superior to CAP.', 'The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.\tOver 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.', 'The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.\tThe mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.', 'The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.\tThe threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.', 'The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.\tFludarabine was consistently a better treatment than ChOP,', 'The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.\texcept in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.', 'The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.\tfrom a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).', 'The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.\tpatients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.', 'The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.\tThese two treatments are always superior to CAP.', 'The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.\tOver 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.', 'The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.\tThe mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.', 'The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.\tThe threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.', 'The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.\tFludarabine was consistently a better treatment than ChOP,', 'The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.\texcept in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.', 'The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.\tfrom a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).', 'The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.\tpatients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.', 'The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.\tThese two treatments are always superior to CAP.', 'Fludarabine was consistently a better treatment than ChOP,\tOver 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.', 'Fludarabine was consistently a better treatment than ChOP,\tThe mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.', 'Fludarabine was consistently a better treatment than ChOP,\tThe threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.', 'Fludarabine was consistently a better treatment than ChOP,\tFludarabine was consistently a better treatment than ChOP,', 'Fludarabine was consistently a better treatment than ChOP,\texcept in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.', 'Fludarabine was consistently a better treatment than ChOP,\tfrom a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).', 'Fludarabine was consistently a better treatment than ChOP,\tpatients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.', 'Fludarabine was consistently a better treatment than ChOP,\tThese two treatments are always superior to CAP.', 'except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.\tOver 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.', 'except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.\tThe mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.', 'except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.\tThe threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.', 'except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.\tFludarabine was consistently a better treatment than ChOP,', 'except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.\texcept in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.', 'except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.\tfrom a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).', 'except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.\tpatients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.', 'except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.\tThese two treatments are always superior to CAP.', 'from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).\tOver 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.', 'from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).\tThe mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.', 'from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).\tThe threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.', 'from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).\tFludarabine was consistently a better treatment than ChOP,', 'from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).\texcept in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.', 'from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).\tfrom a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).', 'from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).\tpatients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.', 'from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).\tThese two treatments are always superior to CAP.', 'patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.\tOver 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.', 'patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.\tThe mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.', 'patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.\tThe threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.', 'patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.\tFludarabine was consistently a better treatment than ChOP,', 'patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.\texcept in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.', 'patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.\tfrom a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).', 'patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.\tpatients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.', 'patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.\tThese two treatments are always superior to CAP.', 'These two treatments are always superior to CAP.\tOver 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.', 'These two treatments are always superior to CAP.\tThe mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.', 'These two treatments are always superior to CAP.\tThe threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.', 'These two treatments are always superior to CAP.\tFludarabine was consistently a better treatment than ChOP,', 'These two treatments are always superior to CAP.\texcept in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.', 'These two treatments are always superior to CAP.\tfrom a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).', 'These two treatments are always superior to CAP.\tpatients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.', 'These two treatments are always superior to CAP.\tThese two treatments are always superior to CAP.']","[0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['Cutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions.\tCutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions.', 'Cutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions.\tComposite FACT-G and most individual subscale scores (physical, social/family, emotional, and functional well being) in documented responders (n = 21) gradually increased during the study period, generally reaching statistical significance (P < 0.05) by cycle 3, and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint.', 'Cutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions.\tAdditionally for responders, assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline.', 'Cutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions.\tAdverse transfusion-related events (eg, hypersensitivity reactions, flu-like syndrome) were common during cycles 1 and 2, and vascular-leak syndrome occurred in 25% of patients.', 'Cutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions.\tDenileukin diftitox was not associated with any clinically significant myelosuppression.', 'Cutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions.\tHeavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity.', 'Composite FACT-G and most individual subscale scores (physical, social/family, emotional, and functional well being) in documented responders (n = 21) gradually increased during the study period, generally reaching statistical significance (P < 0.05) by cycle 3, and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint.\tCutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions.', 'Composite FACT-G and most individual subscale scores (physical, social/family, emotional, and functional well being) in documented responders (n = 21) gradually increased during the study period, generally reaching statistical significance (P < 0.05) by cycle 3, and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint.\tComposite FACT-G and most individual subscale scores (physical, social/family, emotional, and functional well being) in documented responders (n = 21) gradually increased during the study period, generally reaching statistical significance (P < 0.05) by cycle 3, and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint.', 'Composite FACT-G and most individual subscale scores (physical, social/family, emotional, and functional well being) in documented responders (n = 21) gradually increased during the study period, generally reaching statistical significance (P < 0.05) by cycle 3, and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint.\tAdditionally for responders, assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline.', 'Composite FACT-G and most individual subscale scores (physical, social/family, emotional, and functional well being) in documented responders (n = 21) gradually increased during the study period, generally reaching statistical significance (P < 0.05) by cycle 3, and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint.\tAdverse transfusion-related events (eg, hypersensitivity reactions, flu-like syndrome) were common during cycles 1 and 2, and vascular-leak syndrome occurred in 25% of patients.', 'Composite FACT-G and most individual subscale scores (physical, social/family, emotional, and functional well being) in documented responders (n = 21) gradually increased during the study period, generally reaching statistical significance (P < 0.05) by cycle 3, and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint.\tDenileukin diftitox was not associated with any clinically significant myelosuppression.', 'Composite FACT-G and most individual subscale scores (physical, social/family, emotional, and functional well being) in documented responders (n = 21) gradually increased during the study period, generally reaching statistical significance (P < 0.05) by cycle 3, and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint.\tHeavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity.', 'Additionally for responders, assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline.\tCutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions.', 'Additionally for responders, assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline.\tComposite FACT-G and most individual subscale scores (physical, social/family, emotional, and functional well being) in documented responders (n = 21) gradually increased during the study period, generally reaching statistical significance (P < 0.05) by cycle 3, and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint.', 'Additionally for responders, assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline.\tAdditionally for responders, assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline.', 'Additionally for responders, assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline.\tAdverse transfusion-related events (eg, hypersensitivity reactions, flu-like syndrome) were common during cycles 1 and 2, and vascular-leak syndrome occurred in 25% of patients.', 'Additionally for responders, assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline.\tDenileukin diftitox was not associated with any clinically significant myelosuppression.', 'Additionally for responders, assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline.\tHeavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity.', 'Adverse transfusion-related events (eg, hypersensitivity reactions, flu-like syndrome) were common during cycles 1 and 2, and vascular-leak syndrome occurred in 25% of patients.\tCutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions.', 'Adverse transfusion-related events (eg, hypersensitivity reactions, flu-like syndrome) were common during cycles 1 and 2, and vascular-leak syndrome occurred in 25% of patients.\tComposite FACT-G and most individual subscale scores (physical, social/family, emotional, and functional well being) in documented responders (n = 21) gradually increased during the study period, generally reaching statistical significance (P < 0.05) by cycle 3, and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint.', 'Adverse transfusion-related events (eg, hypersensitivity reactions, flu-like syndrome) were common during cycles 1 and 2, and vascular-leak syndrome occurred in 25% of patients.\tAdditionally for responders, assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline.', 'Adverse transfusion-related events (eg, hypersensitivity reactions, flu-like syndrome) were common during cycles 1 and 2, and vascular-leak syndrome occurred in 25% of patients.\tAdverse transfusion-related events (eg, hypersensitivity reactions, flu-like syndrome) were common during cycles 1 and 2, and vascular-leak syndrome occurred in 25% of patients.', 'Adverse transfusion-related events (eg, hypersensitivity reactions, flu-like syndrome) were common during cycles 1 and 2, and vascular-leak syndrome occurred in 25% of patients.\tDenileukin diftitox was not associated with any clinically significant myelosuppression.', 'Adverse transfusion-related events (eg, hypersensitivity reactions, flu-like syndrome) were common during cycles 1 and 2, and vascular-leak syndrome occurred in 25% of patients.\tHeavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity.', 'Denileukin diftitox was not associated with any clinically significant myelosuppression.\tCutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions.', 'Denileukin diftitox was not associated with any clinically significant myelosuppression.\tComposite FACT-G and most individual subscale scores (physical, social/family, emotional, and functional well being) in documented responders (n = 21) gradually increased during the study period, generally reaching statistical significance (P < 0.05) by cycle 3, and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint.', 'Denileukin diftitox was not associated with any clinically significant myelosuppression.\tAdditionally for responders, assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline.', 'Denileukin diftitox was not associated with any clinically significant myelosuppression.\tAdverse transfusion-related events (eg, hypersensitivity reactions, flu-like syndrome) were common during cycles 1 and 2, and vascular-leak syndrome occurred in 25% of patients.', 'Denileukin diftitox was not associated with any clinically significant myelosuppression.\tDenileukin diftitox was not associated with any clinically significant myelosuppression.', 'Denileukin diftitox was not associated with any clinically significant myelosuppression.\tHeavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity.', 'Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity.\tCutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions.', 'Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity.\tComposite FACT-G and most individual subscale scores (physical, social/family, emotional, and functional well being) in documented responders (n = 21) gradually increased during the study period, generally reaching statistical significance (P < 0.05) by cycle 3, and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint.', 'Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity.\tAdditionally for responders, assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline.', 'Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity.\tAdverse transfusion-related events (eg, hypersensitivity reactions, flu-like syndrome) were common during cycles 1 and 2, and vascular-leak syndrome occurred in 25% of patients.', 'Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity.\tDenileukin diftitox was not associated with any clinically significant myelosuppression.', 'Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity.\tHeavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity.']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.\tLow anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.', 'Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.\tHowever, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.', 'Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.\tproblems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.', 'Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.\tThe frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).', 'Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.\tin a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.', 'Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.\tthe expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.', 'Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.\tThe colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.', 'Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.\tstool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.', 'Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.\twe speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.', 'Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.\tbecause neorectal capacity decreased equally in both groups,', 'However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.\tLow anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.', 'However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.\tHowever, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.', 'However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.\tproblems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.', 'However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.\tThe frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).', 'However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.\tin a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.', 'However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.\tthe expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.', 'However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.\tThe colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.', 'However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.\tstool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.', 'However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.\twe speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.', 'However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.\tbecause neorectal capacity decreased equally in both groups,', 'problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.\tLow anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.', 'problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.\tHowever, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.', 'problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.\tproblems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.', 'problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.\tThe frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).', 'problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.\tin a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.', 'problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.\tthe expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.', 'problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.\tThe colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.', 'problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.\tstool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.', 'problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.\twe speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.', 'problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.\tbecause neorectal capacity decreased equally in both groups,', 'The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).\tLow anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.', 'The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).\tHowever, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.', 'The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).\tproblems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.', 'The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).\tThe frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).', 'The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).\tin a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.', 'The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).\tthe expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.', 'The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).\tThe colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.', 'The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).\tstool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.', 'The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).\twe speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.', 'The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).\tbecause neorectal capacity decreased equally in both groups,', 'in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.\tLow anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.', 'in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.\tHowever, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.', 'in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.\tproblems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.', 'in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.\tThe frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).', 'in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.\tin a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.', 'in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.\tthe expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.', 'in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.\tThe colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.', 'in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.\tstool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.', 'in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.\twe speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.', 'in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.\tbecause neorectal capacity decreased equally in both groups,', 'the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.\tLow anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.', 'the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.\tHowever, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.', 'the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.\tproblems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.', 'the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.\tThe frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).', 'the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.\tin a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.', 'the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.\tthe expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.', 'the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.\tThe colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.', 'the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.\tstool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.', 'the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.\twe speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.', 'the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.\tbecause neorectal capacity decreased equally in both groups,', 'The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.\tLow anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.', 'The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.\tHowever, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.', 'The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.\tproblems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.', 'The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.\tThe frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).', 'The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.\tin a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.', 'The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.\tthe expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.', 'The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.\tThe colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.', 'The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.\tstool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.', 'The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.\twe speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.', 'The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.\tbecause neorectal capacity decreased equally in both groups,', 'stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.\tLow anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.', 'stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.\tHowever, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.', 'stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.\tproblems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.', 'stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.\tThe frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).', 'stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.\tin a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.', 'stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.\tthe expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.', 'stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.\tThe colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.', 'stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.\tstool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.', 'stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.\twe speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.', 'stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.\tbecause neorectal capacity decreased equally in both groups,', 'we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.\tLow anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.', 'we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.\tHowever, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.', 'we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.\tproblems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.', 'we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.\tThe frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).', 'we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.\tin a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.', 'we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.\tthe expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.', 'we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.\tThe colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.', 'we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.\tstool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.', 'we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.\twe speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.', 'we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.\tbecause neorectal capacity decreased equally in both groups,', 'because neorectal capacity decreased equally in both groups,\tLow anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.', 'because neorectal capacity decreased equally in both groups,\tHowever, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.', 'because neorectal capacity decreased equally in both groups,\tproblems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.', 'because neorectal capacity decreased equally in both groups,\tThe frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).', 'because neorectal capacity decreased equally in both groups,\tin a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.', 'because neorectal capacity decreased equally in both groups,\tthe expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.', 'because neorectal capacity decreased equally in both groups,\tThe colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.', 'because neorectal capacity decreased equally in both groups,\tstool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.', 'because neorectal capacity decreased equally in both groups,\twe speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.', 'because neorectal capacity decreased equally in both groups,\tbecause neorectal capacity decreased equally in both groups,']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0]"
"['Transfusion-free (P =.0012) survival and transfusion- and severe anemia-free survival (P =.0001) were significantly greater in the epoetin beta group versus placebo (Wald chi(2) test), giving a relative risk reduction of 43% and 51%, respectively.\tTransfusion-free (P =.0012) survival and transfusion- and severe anemia-free survival (P =.0001) were significantly greater in the epoetin beta group versus placebo (Wald chi(2) test), giving a relative risk reduction of 43% and 51%, respectively.', 'Transfusion-free (P =.0012) survival and transfusion- and severe anemia-free survival (P =.0001) were significantly greater in the epoetin beta group versus placebo (Wald chi(2) test), giving a relative risk reduction of 43% and 51%, respectively.\tThe response rate was 67% and 27% in the epoetin beta versus the placebo group, respectively (P <.0001).', 'Transfusion-free (P =.0012) survival and transfusion- and severe anemia-free survival (P =.0001) were significantly greater in the epoetin beta group versus placebo (Wald chi(2) test), giving a relative risk reduction of 43% and 51%, respectively.\tAfter 12 and 16 weeks of treatment, QOL significantly improved in the epoetin beta group compared with placebo (P <.05);', 'Transfusion-free (P =.0012) survival and transfusion- and severe anemia-free survival (P =.0001) were significantly greater in the epoetin beta group versus placebo (Wald chi(2) test), giving a relative risk reduction of 43% and 51%, respectively.\tthis improvement correlated with an increase in Hb concentration (> or = 2 g/dL).', 'Transfusion-free (P =.0012) survival and transfusion- and severe anemia-free survival (P =.0001) were significantly greater in the epoetin beta group versus placebo (Wald chi(2) test), giving a relative risk reduction of 43% and 51%, respectively.\tMany severely anemic and transfusion-dependent patients with advanced MM, NHL, and CLL and a low performance status benefited from epoetin therapy, with elimination of severe anemia and transfusion need, and improvement in QOL.', 'The response rate was 67% and 27% in the epoetin beta versus the placebo group, respectively (P <.0001).\tTransfusion-free (P =.0012) survival and transfusion- and severe anemia-free survival (P =.0001) were significantly greater in the epoetin beta group versus placebo (Wald chi(2) test), giving a relative risk reduction of 43% and 51%, respectively.', 'The response rate was 67% and 27% in the epoetin beta versus the placebo group, respectively (P <.0001).\tThe response rate was 67% and 27% in the epoetin beta versus the placebo group, respectively (P <.0001).', 'The response rate was 67% and 27% in the epoetin beta versus the placebo group, respectively (P <.0001).\tAfter 12 and 16 weeks of treatment, QOL significantly improved in the epoetin beta group compared with placebo (P <.05);', 'The response rate was 67% and 27% in the epoetin beta versus the placebo group, respectively (P <.0001).\tthis improvement correlated with an increase in Hb concentration (> or = 2 g/dL).', 'The response rate was 67% and 27% in the epoetin beta versus the placebo group, respectively (P <.0001).\tMany severely anemic and transfusion-dependent patients with advanced MM, NHL, and CLL and a low performance status benefited from epoetin therapy, with elimination of severe anemia and transfusion need, and improvement in QOL.', 'After 12 and 16 weeks of treatment, QOL significantly improved in the epoetin beta group compared with placebo (P <.05);\tTransfusion-free (P =.0012) survival and transfusion- and severe anemia-free survival (P =.0001) were significantly greater in the epoetin beta group versus placebo (Wald chi(2) test), giving a relative risk reduction of 43% and 51%, respectively.', 'After 12 and 16 weeks of treatment, QOL significantly improved in the epoetin beta group compared with placebo (P <.05);\tThe response rate was 67% and 27% in the epoetin beta versus the placebo group, respectively (P <.0001).', 'After 12 and 16 weeks of treatment, QOL significantly improved in the epoetin beta group compared with placebo (P <.05);\tAfter 12 and 16 weeks of treatment, QOL significantly improved in the epoetin beta group compared with placebo (P <.05);', 'After 12 and 16 weeks of treatment, QOL significantly improved in the epoetin beta group compared with placebo (P <.05);\tthis improvement correlated with an increase in Hb concentration (> or = 2 g/dL).', 'After 12 and 16 weeks of treatment, QOL significantly improved in the epoetin beta group compared with placebo (P <.05);\tMany severely anemic and transfusion-dependent patients with advanced MM, NHL, and CLL and a low performance status benefited from epoetin therapy, with elimination of severe anemia and transfusion need, and improvement in QOL.', 'this improvement correlated with an increase in Hb concentration (> or = 2 g/dL).\tTransfusion-free (P =.0012) survival and transfusion- and severe anemia-free survival (P =.0001) were significantly greater in the epoetin beta group versus placebo (Wald chi(2) test), giving a relative risk reduction of 43% and 51%, respectively.', 'this improvement correlated with an increase in Hb concentration (> or = 2 g/dL).\tThe response rate was 67% and 27% in the epoetin beta versus the placebo group, respectively (P <.0001).', 'this improvement correlated with an increase in Hb concentration (> or = 2 g/dL).\tAfter 12 and 16 weeks of treatment, QOL significantly improved in the epoetin beta group compared with placebo (P <.05);', 'this improvement correlated with an increase in Hb concentration (> or = 2 g/dL).\tthis improvement correlated with an increase in Hb concentration (> or = 2 g/dL).', 'this improvement correlated with an increase in Hb concentration (> or = 2 g/dL).\tMany severely anemic and transfusion-dependent patients with advanced MM, NHL, and CLL and a low performance status benefited from epoetin therapy, with elimination of severe anemia and transfusion need, and improvement in QOL.', 'Many severely anemic and transfusion-dependent patients with advanced MM, NHL, and CLL and a low performance status benefited from epoetin therapy, with elimination of severe anemia and transfusion need, and improvement in QOL.\tTransfusion-free (P =.0012) survival and transfusion- and severe anemia-free survival (P =.0001) were significantly greater in the epoetin beta group versus placebo (Wald chi(2) test), giving a relative risk reduction of 43% and 51%, respectively.', 'Many severely anemic and transfusion-dependent patients with advanced MM, NHL, and CLL and a low performance status benefited from epoetin therapy, with elimination of severe anemia and transfusion need, and improvement in QOL.\tThe response rate was 67% and 27% in the epoetin beta versus the placebo group, respectively (P <.0001).', 'Many severely anemic and transfusion-dependent patients with advanced MM, NHL, and CLL and a low performance status benefited from epoetin therapy, with elimination of severe anemia and transfusion need, and improvement in QOL.\tAfter 12 and 16 weeks of treatment, QOL significantly improved in the epoetin beta group compared with placebo (P <.05);', 'Many severely anemic and transfusion-dependent patients with advanced MM, NHL, and CLL and a low performance status benefited from epoetin therapy, with elimination of severe anemia and transfusion need, and improvement in QOL.\tthis improvement correlated with an increase in Hb concentration (> or = 2 g/dL).', 'Many severely anemic and transfusion-dependent patients with advanced MM, NHL, and CLL and a low performance status benefited from epoetin therapy, with elimination of severe anemia and transfusion need, and improvement in QOL.\tMany severely anemic and transfusion-dependent patients with advanced MM, NHL, and CLL and a low performance status benefited from epoetin therapy, with elimination of severe anemia and transfusion need, and improvement in QOL.']","[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.\tThe hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.', 'The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.\tFor the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.', 'The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.\tAn increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.', ""The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.\tPatients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning."", 'The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.\tThe deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.', 'The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.\tThe Lokich regimen was associated with more central line complications and hand-foot syndrome.', 'The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.\tRaltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,', 'The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.\tbut resulted in greater toxicity and inferior quality of life.', 'For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.\tThe hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.', 'For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.\tFor the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.', 'For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.\tAn increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.', ""For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.\tPatients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning."", 'For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.\tThe deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.', 'For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.\tThe Lokich regimen was associated with more central line complications and hand-foot syndrome.', 'For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.\tRaltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,', 'For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.\tbut resulted in greater toxicity and inferior quality of life.', 'An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.\tThe hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.', 'An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.\tFor the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.', 'An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.\tAn increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.', ""An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.\tPatients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning."", 'An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.\tThe deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.', 'An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.\tThe Lokich regimen was associated with more central line complications and hand-foot syndrome.', 'An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.\tRaltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,', 'An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.\tbut resulted in greater toxicity and inferior quality of life.', ""Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning.\tThe hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed."", ""Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning.\tFor the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days."", ""Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning.\tAn increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity."", ""Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning.\tPatients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning."", ""Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning.\tThe deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates."", ""Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning.\tThe Lokich regimen was associated with more central line complications and hand-foot syndrome."", ""Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning.\tRaltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,"", ""Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning.\tbut resulted in greater toxicity and inferior quality of life."", 'The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.\tThe hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.', 'The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.\tFor the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.', 'The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.\tAn increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.', ""The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.\tPatients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning."", 'The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.\tThe deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.', 'The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.\tThe Lokich regimen was associated with more central line complications and hand-foot syndrome.', 'The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.\tRaltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,', 'The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.\tbut resulted in greater toxicity and inferior quality of life.', 'The Lokich regimen was associated with more central line complications and hand-foot syndrome.\tThe hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.', 'The Lokich regimen was associated with more central line complications and hand-foot syndrome.\tFor the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.', 'The Lokich regimen was associated with more central line complications and hand-foot syndrome.\tAn increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.', ""The Lokich regimen was associated with more central line complications and hand-foot syndrome.\tPatients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning."", 'The Lokich regimen was associated with more central line complications and hand-foot syndrome.\tThe deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.', 'The Lokich regimen was associated with more central line complications and hand-foot syndrome.\tThe Lokich regimen was associated with more central line complications and hand-foot syndrome.', 'The Lokich regimen was associated with more central line complications and hand-foot syndrome.\tRaltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,', 'The Lokich regimen was associated with more central line complications and hand-foot syndrome.\tbut resulted in greater toxicity and inferior quality of life.', 'Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,\tThe hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.', 'Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,\tFor the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.', 'Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,\tAn increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.', ""Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,\tPatients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning."", 'Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,\tThe deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.', 'Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,\tThe Lokich regimen was associated with more central line complications and hand-foot syndrome.', 'Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,\tRaltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,', 'Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,\tbut resulted in greater toxicity and inferior quality of life.', 'but resulted in greater toxicity and inferior quality of life.\tThe hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.', 'but resulted in greater toxicity and inferior quality of life.\tFor the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.', 'but resulted in greater toxicity and inferior quality of life.\tAn increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.', ""but resulted in greater toxicity and inferior quality of life.\tPatients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning."", 'but resulted in greater toxicity and inferior quality of life.\tThe deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.', 'but resulted in greater toxicity and inferior quality of life.\tThe Lokich regimen was associated with more central line complications and hand-foot syndrome.', 'but resulted in greater toxicity and inferior quality of life.\tRaltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,', 'but resulted in greater toxicity and inferior quality of life.\tbut resulted in greater toxicity and inferior quality of life.']","[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0]"
"['After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.\tAfter completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.', 'After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.\tHigher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.', 'After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.\tHigher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,', 'After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.\tThere were no differences in the proportions of patients in the two groups that reported worsening.', 'After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.\tStatistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.', 'After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.\tbut the differences were not statistically significant.', 'Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.\tAfter completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.', 'Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.\tHigher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.', 'Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.\tHigher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,', 'Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.\tThere were no differences in the proportions of patients in the two groups that reported worsening.', 'Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.\tStatistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.', 'Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.\tbut the differences were not statistically significant.', 'Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,\tAfter completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.', 'Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,\tHigher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.', 'Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,\tHigher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,', 'Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,\tThere were no differences in the proportions of patients in the two groups that reported worsening.', 'Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,\tStatistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.', 'Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,\tbut the differences were not statistically significant.', 'There were no differences in the proportions of patients in the two groups that reported worsening.\tAfter completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.', 'There were no differences in the proportions of patients in the two groups that reported worsening.\tHigher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.', 'There were no differences in the proportions of patients in the two groups that reported worsening.\tHigher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,', 'There were no differences in the proportions of patients in the two groups that reported worsening.\tThere were no differences in the proportions of patients in the two groups that reported worsening.', 'There were no differences in the proportions of patients in the two groups that reported worsening.\tStatistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.', 'There were no differences in the proportions of patients in the two groups that reported worsening.\tbut the differences were not statistically significant.', 'Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.\tAfter completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.', 'Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.\tHigher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.', 'Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.\tHigher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,', 'Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.\tThere were no differences in the proportions of patients in the two groups that reported worsening.', 'Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.\tStatistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.', 'Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.\tbut the differences were not statistically significant.', 'but the differences were not statistically significant.\tAfter completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.', 'but the differences were not statistically significant.\tHigher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.', 'but the differences were not statistically significant.\tHigher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,', 'but the differences were not statistically significant.\tThere were no differences in the proportions of patients in the two groups that reported worsening.', 'but the differences were not statistically significant.\tStatistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.', 'but the differences were not statistically significant.\tbut the differences were not statistically significant.']","[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0]"
"['The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).\tThe overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).', 'The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).\tMedian failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).', 'The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).\tMedian survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).', 'The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).\tToxicities in both arms were mild.', 'The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).\tThere was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.', 'The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).\tNo patients developed hemolytic uremic syndrome.', 'The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).\tGlobal QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,', 'The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).\talthough there was no statistically significant difference in QOL between arms.', 'The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).\tThese results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.', 'The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).\tPVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,', 'The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).\tbut this did not translate into a survival advantage.', 'Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).\tThe overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).', 'Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).\tMedian failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).', 'Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).\tMedian survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).', 'Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).\tToxicities in both arms were mild.', 'Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).\tThere was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.', 'Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).\tNo patients developed hemolytic uremic syndrome.', 'Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).\tGlobal QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,', 'Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).\talthough there was no statistically significant difference in QOL between arms.', 'Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).\tThese results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.', 'Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).\tPVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,', 'Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).\tbut this did not translate into a survival advantage.', 'Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).\tThe overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).', 'Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).\tMedian failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).', 'Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).\tMedian survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).', 'Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).\tToxicities in both arms were mild.', 'Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).\tThere was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.', 'Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).\tNo patients developed hemolytic uremic syndrome.', 'Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).\tGlobal QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,', 'Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).\talthough there was no statistically significant difference in QOL between arms.', 'Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).\tThese results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.', 'Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).\tPVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,', 'Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).\tbut this did not translate into a survival advantage.', 'Toxicities in both arms were mild.\tThe overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).', 'Toxicities in both arms were mild.\tMedian failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).', 'Toxicities in both arms were mild.\tMedian survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).', 'Toxicities in both arms were mild.\tToxicities in both arms were mild.', 'Toxicities in both arms were mild.\tThere was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.', 'Toxicities in both arms were mild.\tNo patients developed hemolytic uremic syndrome.', 'Toxicities in both arms were mild.\tGlobal QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,', 'Toxicities in both arms were mild.\talthough there was no statistically significant difference in QOL between arms.', 'Toxicities in both arms were mild.\tThese results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.', 'Toxicities in both arms were mild.\tPVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,', 'Toxicities in both arms were mild.\tbut this did not translate into a survival advantage.', 'There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.\tThe overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).', 'There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.\tMedian failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).', 'There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.\tMedian survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).', 'There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.\tToxicities in both arms were mild.', 'There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.\tThere was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.', 'There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.\tNo patients developed hemolytic uremic syndrome.', 'There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.\tGlobal QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,', 'There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.\talthough there was no statistically significant difference in QOL between arms.', 'There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.\tThese results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.', 'There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.\tPVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,', 'There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.\tbut this did not translate into a survival advantage.', 'No patients developed hemolytic uremic syndrome.\tThe overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).', 'No patients developed hemolytic uremic syndrome.\tMedian failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).', 'No patients developed hemolytic uremic syndrome.\tMedian survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).', 'No patients developed hemolytic uremic syndrome.\tToxicities in both arms were mild.', 'No patients developed hemolytic uremic syndrome.\tThere was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.', 'No patients developed hemolytic uremic syndrome.\tNo patients developed hemolytic uremic syndrome.', 'No patients developed hemolytic uremic syndrome.\tGlobal QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,', 'No patients developed hemolytic uremic syndrome.\talthough there was no statistically significant difference in QOL between arms.', 'No patients developed hemolytic uremic syndrome.\tThese results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.', 'No patients developed hemolytic uremic syndrome.\tPVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,', 'No patients developed hemolytic uremic syndrome.\tbut this did not translate into a survival advantage.', 'Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,\tThe overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).', 'Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,\tMedian failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).', 'Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,\tMedian survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).', 'Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,\tToxicities in both arms were mild.', 'Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,\tThere was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.', 'Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,\tNo patients developed hemolytic uremic syndrome.', 'Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,\tGlobal QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,', 'Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,\talthough there was no statistically significant difference in QOL between arms.', 'Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,\tThese results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.', 'Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,\tPVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,', 'Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,\tbut this did not translate into a survival advantage.', 'although there was no statistically significant difference in QOL between arms.\tThe overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).', 'although there was no statistically significant difference in QOL between arms.\tMedian failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).', 'although there was no statistically significant difference in QOL between arms.\tMedian survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).', 'although there was no statistically significant difference in QOL between arms.\tToxicities in both arms were mild.', 'although there was no statistically significant difference in QOL between arms.\tThere was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.', 'although there was no statistically significant difference in QOL between arms.\tNo patients developed hemolytic uremic syndrome.', 'although there was no statistically significant difference in QOL between arms.\tGlobal QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,', 'although there was no statistically significant difference in QOL between arms.\talthough there was no statistically significant difference in QOL between arms.', 'although there was no statistically significant difference in QOL between arms.\tThese results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.', 'although there was no statistically significant difference in QOL between arms.\tPVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,', 'although there was no statistically significant difference in QOL between arms.\tbut this did not translate into a survival advantage.', 'These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.\tThe overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).', 'These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.\tMedian failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).', 'These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.\tMedian survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).', 'These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.\tToxicities in both arms were mild.', 'These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.\tThere was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.', 'These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.\tNo patients developed hemolytic uremic syndrome.', 'These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.\tGlobal QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,', 'These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.\talthough there was no statistically significant difference in QOL between arms.', 'These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.\tThese results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.', 'These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.\tPVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,', 'These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.\tbut this did not translate into a survival advantage.', 'PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,\tThe overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).', 'PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,\tMedian failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).', 'PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,\tMedian survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).', 'PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,\tToxicities in both arms were mild.', 'PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,\tThere was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.', 'PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,\tNo patients developed hemolytic uremic syndrome.', 'PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,\tGlobal QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,', 'PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,\talthough there was no statistically significant difference in QOL between arms.', 'PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,\tThese results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.', 'PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,\tPVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,', 'PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,\tbut this did not translate into a survival advantage.', 'but this did not translate into a survival advantage.\tThe overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).', 'but this did not translate into a survival advantage.\tMedian failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).', 'but this did not translate into a survival advantage.\tMedian survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).', 'but this did not translate into a survival advantage.\tToxicities in both arms were mild.', 'but this did not translate into a survival advantage.\tThere was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.', 'but this did not translate into a survival advantage.\tNo patients developed hemolytic uremic syndrome.', 'but this did not translate into a survival advantage.\tGlobal QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,', 'but this did not translate into a survival advantage.\talthough there was no statistically significant difference in QOL between arms.', 'but this did not translate into a survival advantage.\tThese results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.', 'but this did not translate into a survival advantage.\tPVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,', 'but this did not translate into a survival advantage.\tbut this did not translate into a survival advantage.']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0]"
"['At radical prostatectomy, pathological variables were not significantly different in the two groups.\tAt radical prostatectomy, pathological variables were not significantly different in the two groups.', 'At radical prostatectomy, pathological variables were not significantly different in the two groups.\tSerum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),', 'At radical prostatectomy, pathological variables were not significantly different in the two groups.\tcomplete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.', 'At radical prostatectomy, pathological variables were not significantly different in the two groups.\tAfter neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.', 'At radical prostatectomy, pathological variables were not significantly different in the two groups.\tThis study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.', 'At radical prostatectomy, pathological variables were not significantly different in the two groups.\tAt a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.', 'Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),\tAt radical prostatectomy, pathological variables were not significantly different in the two groups.', 'Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),\tSerum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),', 'Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),\tcomplete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.', 'Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),\tAfter neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.', 'Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),\tThis study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.', 'Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),\tAt a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.', 'complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.\tAt radical prostatectomy, pathological variables were not significantly different in the two groups.', 'complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.\tSerum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),', 'complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.\tcomplete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.', 'complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.\tAfter neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.', 'complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.\tThis study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.', 'complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.\tAt a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.', 'After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.\tAt radical prostatectomy, pathological variables were not significantly different in the two groups.', 'After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.\tSerum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),', 'After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.\tcomplete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.', 'After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.\tAfter neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.', 'After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.\tThis study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.', 'After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.\tAt a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.', 'This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.\tAt radical prostatectomy, pathological variables were not significantly different in the two groups.', 'This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.\tSerum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),', 'This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.\tcomplete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.', 'This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.\tAfter neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.', 'This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.\tThis study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.', 'This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.\tAt a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.', 'At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.\tAt radical prostatectomy, pathological variables were not significantly different in the two groups.', 'At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.\tSerum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),', 'At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.\tcomplete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.', 'At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.\tAfter neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.', 'At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.\tThis study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.', 'At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.\tAt a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0]"
"['Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.\tBoth patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.', ""Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.\tSymptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis."", ""Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.\tCompared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008)."", 'Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.\tSymptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%.', 'Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.\tMost of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.', 'Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.\tBoth GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.', ""Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.\tGEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms."", 'Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.\tMost of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only.', ""Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis.\tBoth patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression."", ""Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis.\tSymptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis."", ""Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis.\tCompared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008)."", ""Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis.\tSymptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%."", ""Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis.\tMost of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only."", ""Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis.\tBoth GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR."", ""Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis.\tGEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms."", ""Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis.\tMost of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only."", ""Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008).\tBoth patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression."", ""Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008).\tSymptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis."", ""Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008).\tCompared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008)."", ""Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008).\tSymptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%."", ""Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008).\tMost of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only."", ""Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008).\tBoth GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR."", ""Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008).\tGEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms."", ""Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008).\tMost of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only."", 'Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%.\tBoth patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.', ""Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%.\tSymptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis."", ""Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%.\tCompared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008)."", 'Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%.\tSymptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%.', 'Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%.\tMost of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.', 'Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%.\tBoth GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.', ""Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%.\tGEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms."", 'Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%.\tMost of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only.', 'Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.\tBoth patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.', ""Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.\tSymptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis."", ""Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.\tCompared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008)."", 'Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.\tSymptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%.', 'Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.\tMost of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.', 'Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.\tBoth GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.', ""Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.\tGEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms."", 'Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.\tMost of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only.', 'Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.\tBoth patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.', ""Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.\tSymptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis."", ""Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.\tCompared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008)."", 'Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.\tSymptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%.', 'Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.\tMost of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.', 'Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.\tBoth GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.', ""Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.\tGEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms."", 'Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.\tMost of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only.', ""GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms.\tBoth patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression."", ""GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms.\tSymptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis."", ""GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms.\tCompared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008)."", ""GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms.\tSymptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%."", ""GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms.\tMost of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only."", ""GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms.\tBoth GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR."", ""GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms.\tGEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms."", ""GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms.\tMost of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only."", 'Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only.\tBoth patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.', ""Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only.\tSymptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis."", ""Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only.\tCompared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008)."", 'Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only.\tSymptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%.', 'Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only.\tMost of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.', 'Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only.\tBoth GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.', ""Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only.\tGEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms."", 'Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only.\tMost of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only.']","[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.\tAndrogen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.', 'Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.\tThese physical changes can negatively affect health-related quality of life.', 'Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.\tResistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.', 'Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.\tMen assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.', 'Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.\tMen in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.', 'Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.\tThe 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.', 'Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.\tResistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.', 'Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.\tThis form of exercise can be an important component of supportive care for these patients.', 'These physical changes can negatively affect health-related quality of life.\tAndrogen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.', 'These physical changes can negatively affect health-related quality of life.\tThese physical changes can negatively affect health-related quality of life.', 'These physical changes can negatively affect health-related quality of life.\tResistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.', 'These physical changes can negatively affect health-related quality of life.\tMen assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.', 'These physical changes can negatively affect health-related quality of life.\tMen in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.', 'These physical changes can negatively affect health-related quality of life.\tThe 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.', 'These physical changes can negatively affect health-related quality of life.\tResistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.', 'These physical changes can negatively affect health-related quality of life.\tThis form of exercise can be an important component of supportive care for these patients.', 'Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.\tAndrogen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.', 'Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.\tThese physical changes can negatively affect health-related quality of life.', 'Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.\tResistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.', 'Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.\tMen assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.', 'Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.\tMen in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.', 'Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.\tThe 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.', 'Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.\tResistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.', 'Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.\tThis form of exercise can be an important component of supportive care for these patients.', 'Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.\tAndrogen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.', 'Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.\tThese physical changes can negatively affect health-related quality of life.', 'Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.\tResistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.', 'Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.\tMen assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.', 'Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.\tMen in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.', 'Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.\tThe 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.', 'Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.\tResistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.', 'Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.\tThis form of exercise can be an important component of supportive care for these patients.', 'Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.\tAndrogen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.', 'Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.\tThese physical changes can negatively affect health-related quality of life.', 'Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.\tResistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.', 'Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.\tMen assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.', 'Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.\tMen in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.', 'Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.\tThe 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.', 'Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.\tResistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.', 'Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.\tThis form of exercise can be an important component of supportive care for these patients.', 'The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.\tAndrogen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.', 'The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.\tThese physical changes can negatively affect health-related quality of life.', 'The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.\tResistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.', 'The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.\tMen assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.', 'The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.\tMen in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.', 'The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.\tThe 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.', 'The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.\tResistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.', 'The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.\tThis form of exercise can be an important component of supportive care for these patients.', 'Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.\tAndrogen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.', 'Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.\tThese physical changes can negatively affect health-related quality of life.', 'Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.\tResistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.', 'Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.\tMen assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.', 'Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.\tMen in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.', 'Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.\tThe 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.', 'Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.\tResistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.', 'Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.\tThis form of exercise can be an important component of supportive care for these patients.', 'This form of exercise can be an important component of supportive care for these patients.\tAndrogen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.', 'This form of exercise can be an important component of supportive care for these patients.\tThese physical changes can negatively affect health-related quality of life.', 'This form of exercise can be an important component of supportive care for these patients.\tResistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.', 'This form of exercise can be an important component of supportive care for these patients.\tMen assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.', 'This form of exercise can be an important component of supportive care for these patients.\tMen in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.', 'This form of exercise can be an important component of supportive care for these patients.\tThe 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.', 'This form of exercise can be an important component of supportive care for these patients.\tResistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.', 'This form of exercise can be an important component of supportive care for these patients.\tThis form of exercise can be an important component of supportive care for these patients.']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]"
"['Peak oxygen consumption increased by 0.24 L/min in the exercise group,\tPeak oxygen consumption increased by 0.24 L/min in the exercise group,', 'Peak oxygen consumption increased by 0.24 L/min in the exercise group,\twhereas it decreased by 0.05 L/min in the control group (mean difference, 0.29 L/min; 95% confidence interval [CI], 0.18 to 0.40; P <.001).', 'Peak oxygen consumption increased by 0.24 L/min in the exercise group,\tOverall QOL increased by 9.1 points in the exercise group compared with 0.3 points in the control group (mean difference, 8.8 points; 95% CI, 3.6 to 14.0; P =.001).', 'Peak oxygen consumption increased by 0.24 L/min in the exercise group,\tPearson correlations indicated that change in peak oxygen consumption correlated with change in overall QOL (r = 0.45; P <.01).', 'Peak oxygen consumption increased by 0.24 L/min in the exercise group,\tExercise training had beneficial effects on cardiopulmonary function and QOL in postmenopausal breast cancer survivors.', 'whereas it decreased by 0.05 L/min in the control group (mean difference, 0.29 L/min; 95% confidence interval [CI], 0.18 to 0.40; P <.001).\tPeak oxygen consumption increased by 0.24 L/min in the exercise group,', 'whereas it decreased by 0.05 L/min in the control group (mean difference, 0.29 L/min; 95% confidence interval [CI], 0.18 to 0.40; P <.001).\twhereas it decreased by 0.05 L/min in the control group (mean difference, 0.29 L/min; 95% confidence interval [CI], 0.18 to 0.40; P <.001).', 'whereas it decreased by 0.05 L/min in the control group (mean difference, 0.29 L/min; 95% confidence interval [CI], 0.18 to 0.40; P <.001).\tOverall QOL increased by 9.1 points in the exercise group compared with 0.3 points in the control group (mean difference, 8.8 points; 95% CI, 3.6 to 14.0; P =.001).', 'whereas it decreased by 0.05 L/min in the control group (mean difference, 0.29 L/min; 95% confidence interval [CI], 0.18 to 0.40; P <.001).\tPearson correlations indicated that change in peak oxygen consumption correlated with change in overall QOL (r = 0.45; P <.01).', 'whereas it decreased by 0.05 L/min in the control group (mean difference, 0.29 L/min; 95% confidence interval [CI], 0.18 to 0.40; P <.001).\tExercise training had beneficial effects on cardiopulmonary function and QOL in postmenopausal breast cancer survivors.', 'Overall QOL increased by 9.1 points in the exercise group compared with 0.3 points in the control group (mean difference, 8.8 points; 95% CI, 3.6 to 14.0; P =.001).\tPeak oxygen consumption increased by 0.24 L/min in the exercise group,', 'Overall QOL increased by 9.1 points in the exercise group compared with 0.3 points in the control group (mean difference, 8.8 points; 95% CI, 3.6 to 14.0; P =.001).\twhereas it decreased by 0.05 L/min in the control group (mean difference, 0.29 L/min; 95% confidence interval [CI], 0.18 to 0.40; P <.001).', 'Overall QOL increased by 9.1 points in the exercise group compared with 0.3 points in the control group (mean difference, 8.8 points; 95% CI, 3.6 to 14.0; P =.001).\tOverall QOL increased by 9.1 points in the exercise group compared with 0.3 points in the control group (mean difference, 8.8 points; 95% CI, 3.6 to 14.0; P =.001).', 'Overall QOL increased by 9.1 points in the exercise group compared with 0.3 points in the control group (mean difference, 8.8 points; 95% CI, 3.6 to 14.0; P =.001).\tPearson correlations indicated that change in peak oxygen consumption correlated with change in overall QOL (r = 0.45; P <.01).', 'Overall QOL increased by 9.1 points in the exercise group compared with 0.3 points in the control group (mean difference, 8.8 points; 95% CI, 3.6 to 14.0; P =.001).\tExercise training had beneficial effects on cardiopulmonary function and QOL in postmenopausal breast cancer survivors.', 'Pearson correlations indicated that change in peak oxygen consumption correlated with change in overall QOL (r = 0.45; P <.01).\tPeak oxygen consumption increased by 0.24 L/min in the exercise group,', 'Pearson correlations indicated that change in peak oxygen consumption correlated with change in overall QOL (r = 0.45; P <.01).\twhereas it decreased by 0.05 L/min in the control group (mean difference, 0.29 L/min; 95% confidence interval [CI], 0.18 to 0.40; P <.001).', 'Pearson correlations indicated that change in peak oxygen consumption correlated with change in overall QOL (r = 0.45; P <.01).\tOverall QOL increased by 9.1 points in the exercise group compared with 0.3 points in the control group (mean difference, 8.8 points; 95% CI, 3.6 to 14.0; P =.001).', 'Pearson correlations indicated that change in peak oxygen consumption correlated with change in overall QOL (r = 0.45; P <.01).\tPearson correlations indicated that change in peak oxygen consumption correlated with change in overall QOL (r = 0.45; P <.01).', 'Pearson correlations indicated that change in peak oxygen consumption correlated with change in overall QOL (r = 0.45; P <.01).\tExercise training had beneficial effects on cardiopulmonary function and QOL in postmenopausal breast cancer survivors.', 'Exercise training had beneficial effects on cardiopulmonary function and QOL in postmenopausal breast cancer survivors.\tPeak oxygen consumption increased by 0.24 L/min in the exercise group,', 'Exercise training had beneficial effects on cardiopulmonary function and QOL in postmenopausal breast cancer survivors.\twhereas it decreased by 0.05 L/min in the control group (mean difference, 0.29 L/min; 95% confidence interval [CI], 0.18 to 0.40; P <.001).', 'Exercise training had beneficial effects on cardiopulmonary function and QOL in postmenopausal breast cancer survivors.\tOverall QOL increased by 9.1 points in the exercise group compared with 0.3 points in the control group (mean difference, 8.8 points; 95% CI, 3.6 to 14.0; P =.001).', 'Exercise training had beneficial effects on cardiopulmonary function and QOL in postmenopausal breast cancer survivors.\tPearson correlations indicated that change in peak oxygen consumption correlated with change in overall QOL (r = 0.45; P <.01).', 'Exercise training had beneficial effects on cardiopulmonary function and QOL in postmenopausal breast cancer survivors.\tExercise training had beneficial effects on cardiopulmonary function and QOL in postmenopausal breast cancer survivors.']","[0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0]"
"['Efficacy was similar for the 250- and 500-mg/d groups.\tEfficacy was similar for the 250- and 500-mg/d groups.', 'Efficacy was similar for the 250- and 500-mg/d groups.\tObjective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.', 'Efficacy was similar for the 250- and 500-mg/d groups.\tAdverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.', 'Efficacy was similar for the 250- and 500-mg/d groups.\tSymptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.', 'Efficacy was similar for the 250- and 500-mg/d groups.\tDrug-related toxicities were more frequent in the higher-dose group.', 'Efficacy was similar for the 250- and 500-mg/d groups.\tWithdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.', 'Efficacy was similar for the 250- and 500-mg/d groups.\tGefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.', 'Efficacy was similar for the 250- and 500-mg/d groups.\tAt 250 mg/d, gefitinib had a favorable AE profile.', 'Efficacy was similar for the 250- and 500-mg/d groups.\tGefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.', 'Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.\tEfficacy was similar for the 250- and 500-mg/d groups.', 'Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.\tObjective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.', 'Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.\tAdverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.', 'Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.\tSymptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.', 'Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.\tDrug-related toxicities were more frequent in the higher-dose group.', 'Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.\tWithdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.', 'Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.\tGefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.', 'Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.\tAt 250 mg/d, gefitinib had a favorable AE profile.', 'Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.\tGefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.', 'Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.\tEfficacy was similar for the 250- and 500-mg/d groups.', 'Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.\tObjective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.', 'Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.\tAdverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.', 'Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.\tSymptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.', 'Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.\tDrug-related toxicities were more frequent in the higher-dose group.', 'Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.\tWithdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.', 'Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.\tGefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.', 'Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.\tAt 250 mg/d, gefitinib had a favorable AE profile.', 'Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.\tGefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.', 'Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.\tEfficacy was similar for the 250- and 500-mg/d groups.', 'Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.\tObjective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.', 'Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.\tAdverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.', 'Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.\tSymptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.', 'Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.\tDrug-related toxicities were more frequent in the higher-dose group.', 'Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.\tWithdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.', 'Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.\tGefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.', 'Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.\tAt 250 mg/d, gefitinib had a favorable AE profile.', 'Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.\tGefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.', 'Drug-related toxicities were more frequent in the higher-dose group.\tEfficacy was similar for the 250- and 500-mg/d groups.', 'Drug-related toxicities were more frequent in the higher-dose group.\tObjective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.', 'Drug-related toxicities were more frequent in the higher-dose group.\tAdverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.', 'Drug-related toxicities were more frequent in the higher-dose group.\tSymptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.', 'Drug-related toxicities were more frequent in the higher-dose group.\tDrug-related toxicities were more frequent in the higher-dose group.', 'Drug-related toxicities were more frequent in the higher-dose group.\tWithdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.', 'Drug-related toxicities were more frequent in the higher-dose group.\tGefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.', 'Drug-related toxicities were more frequent in the higher-dose group.\tAt 250 mg/d, gefitinib had a favorable AE profile.', 'Drug-related toxicities were more frequent in the higher-dose group.\tGefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.', 'Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.\tEfficacy was similar for the 250- and 500-mg/d groups.', 'Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.\tObjective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.', 'Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.\tAdverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.', 'Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.\tSymptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.', 'Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.\tDrug-related toxicities were more frequent in the higher-dose group.', 'Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.\tWithdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.', 'Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.\tGefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.', 'Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.\tAt 250 mg/d, gefitinib had a favorable AE profile.', 'Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.\tGefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.', 'Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.\tEfficacy was similar for the 250- and 500-mg/d groups.', 'Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.\tObjective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.', 'Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.\tAdverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.', 'Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.\tSymptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.', 'Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.\tDrug-related toxicities were more frequent in the higher-dose group.', 'Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.\tWithdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.', 'Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.\tGefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.', 'Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.\tAt 250 mg/d, gefitinib had a favorable AE profile.', 'Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.\tGefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.', 'At 250 mg/d, gefitinib had a favorable AE profile.\tEfficacy was similar for the 250- and 500-mg/d groups.', 'At 250 mg/d, gefitinib had a favorable AE profile.\tObjective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.', 'At 250 mg/d, gefitinib had a favorable AE profile.\tAdverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.', 'At 250 mg/d, gefitinib had a favorable AE profile.\tSymptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.', 'At 250 mg/d, gefitinib had a favorable AE profile.\tDrug-related toxicities were more frequent in the higher-dose group.', 'At 250 mg/d, gefitinib had a favorable AE profile.\tWithdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.', 'At 250 mg/d, gefitinib had a favorable AE profile.\tGefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.', 'At 250 mg/d, gefitinib had a favorable AE profile.\tAt 250 mg/d, gefitinib had a favorable AE profile.', 'At 250 mg/d, gefitinib had a favorable AE profile.\tGefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.', 'Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.\tEfficacy was similar for the 250- and 500-mg/d groups.', 'Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.\tObjective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.', 'Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.\tAdverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.', 'Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.\tSymptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.', 'Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.\tDrug-related toxicities were more frequent in the higher-dose group.', 'Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.\tWithdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.', 'Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.\tGefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.', 'Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.\tAt 250 mg/d, gefitinib had a favorable AE profile.', 'Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.\tGefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"[""Imatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL).\tImatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL)."", ""Imatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL).\tTwo hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN."", ""Imatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL).\tThere was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT)."", ""Imatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL).\tMean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT)."", ""Imatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL).\tAfter crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores."", ""Imatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL).\tImatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML."", ""Imatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL).\tpatients who crossed over to imatinib reported higher QoL than those who remained on IFN."", ""Two hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.\tImatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL)."", 'Two hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.\tTwo hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.', 'Two hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.\tThere was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT).', 'Two hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.\tMean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT).', 'Two hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.\tAfter crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores.', 'Two hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.\tImatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.', 'Two hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.\tpatients who crossed over to imatinib reported higher QoL than those who remained on IFN.', ""There was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT).\tImatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL)."", 'There was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT).\tTwo hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.', 'There was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT).\tThere was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT).', 'There was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT).\tMean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT).', 'There was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT).\tAfter crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores.', 'There was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT).\tImatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.', 'There was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT).\tpatients who crossed over to imatinib reported higher QoL than those who remained on IFN.', ""Mean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT).\tImatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL)."", 'Mean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT).\tTwo hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.', 'Mean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT).\tThere was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT).', 'Mean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT).\tMean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT).', 'Mean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT).\tAfter crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores.', 'Mean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT).\tImatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.', 'Mean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT).\tpatients who crossed over to imatinib reported higher QoL than those who remained on IFN.', ""After crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores.\tImatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL)."", 'After crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores.\tTwo hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.', 'After crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores.\tThere was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT).', 'After crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores.\tMean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT).', 'After crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores.\tAfter crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores.', 'After crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores.\tImatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.', 'After crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores.\tpatients who crossed over to imatinib reported higher QoL than those who remained on IFN.', ""Imatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.\tImatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL)."", 'Imatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.\tTwo hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.', 'Imatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.\tThere was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT).', 'Imatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.\tMean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT).', 'Imatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.\tAfter crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores.', 'Imatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.\tImatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.', 'Imatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.\tpatients who crossed over to imatinib reported higher QoL than those who remained on IFN.', ""patients who crossed over to imatinib reported higher QoL than those who remained on IFN.\tImatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL)."", 'patients who crossed over to imatinib reported higher QoL than those who remained on IFN.\tTwo hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.', 'patients who crossed over to imatinib reported higher QoL than those who remained on IFN.\tThere was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT).', 'patients who crossed over to imatinib reported higher QoL than those who remained on IFN.\tMean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT).', 'patients who crossed over to imatinib reported higher QoL than those who remained on IFN.\tAfter crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores.', 'patients who crossed over to imatinib reported higher QoL than those who remained on IFN.\tImatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.', 'patients who crossed over to imatinib reported higher QoL than those who remained on IFN.\tpatients who crossed over to imatinib reported higher QoL than those who remained on IFN.']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).\tPatients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).', 'Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).\tThe 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.', 'Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).\tOverall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).', 'Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).\tMedian survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.', 'Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).\tNeutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.', 'Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).\tGrade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.', 'Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).\tPatients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.', 'Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).\tDC resulted in a more favorable overall response and survival rate than VC.', 'Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).\tBoth DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.', 'Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).\tThese findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.', 'The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.\tPatients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).', 'The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.\tThe 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.', 'The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.\tOverall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).', 'The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.\tMedian survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.', 'The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.\tNeutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.', 'The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.\tGrade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.', 'The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.\tPatients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.', 'The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.\tDC resulted in a more favorable overall response and survival rate than VC.', 'The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.\tBoth DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.', 'The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.\tThese findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.', 'Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).\tPatients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).', 'Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).\tThe 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.', 'Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).\tOverall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).', 'Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).\tMedian survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.', 'Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).\tNeutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.', 'Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).\tGrade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.', 'Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).\tPatients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.', 'Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).\tDC resulted in a more favorable overall response and survival rate than VC.', 'Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).\tBoth DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.', 'Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).\tThese findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.', 'Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.\tPatients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).', 'Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.\tThe 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.', 'Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.\tOverall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).', 'Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.\tMedian survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.', 'Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.\tNeutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.', 'Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.\tGrade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.', 'Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.\tPatients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.', 'Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.\tDC resulted in a more favorable overall response and survival rate than VC.', 'Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.\tBoth DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.', 'Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.\tThese findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.', 'Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.\tPatients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).', 'Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.\tThe 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.', 'Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.\tOverall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).', 'Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.\tMedian survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.', 'Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.\tNeutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.', 'Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.\tGrade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.', 'Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.\tPatients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.', 'Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.\tDC resulted in a more favorable overall response and survival rate than VC.', 'Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.\tBoth DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.', 'Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.\tThese findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.', 'Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.\tPatients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).', 'Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.\tThe 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.', 'Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.\tOverall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).', 'Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.\tMedian survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.', 'Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.\tNeutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.', 'Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.\tGrade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.', 'Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.\tPatients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.', 'Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.\tDC resulted in a more favorable overall response and survival rate than VC.', 'Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.\tBoth DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.', 'Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.\tThese findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.', 'Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.\tPatients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).', 'Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.\tThe 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.', 'Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.\tOverall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).', 'Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.\tMedian survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.', 'Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.\tNeutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.', 'Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.\tGrade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.', 'Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.\tPatients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.', 'Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.\tDC resulted in a more favorable overall response and survival rate than VC.', 'Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.\tBoth DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.', 'Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.\tThese findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.', 'DC resulted in a more favorable overall response and survival rate than VC.\tPatients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).', 'DC resulted in a more favorable overall response and survival rate than VC.\tThe 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.', 'DC resulted in a more favorable overall response and survival rate than VC.\tOverall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).', 'DC resulted in a more favorable overall response and survival rate than VC.\tMedian survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.', 'DC resulted in a more favorable overall response and survival rate than VC.\tNeutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.', 'DC resulted in a more favorable overall response and survival rate than VC.\tGrade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.', 'DC resulted in a more favorable overall response and survival rate than VC.\tPatients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.', 'DC resulted in a more favorable overall response and survival rate than VC.\tDC resulted in a more favorable overall response and survival rate than VC.', 'DC resulted in a more favorable overall response and survival rate than VC.\tBoth DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.', 'DC resulted in a more favorable overall response and survival rate than VC.\tThese findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.', 'Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.\tPatients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).', 'Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.\tThe 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.', 'Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.\tOverall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).', 'Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.\tMedian survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.', 'Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.\tNeutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.', 'Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.\tGrade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.', 'Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.\tPatients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.', 'Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.\tDC resulted in a more favorable overall response and survival rate than VC.', 'Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.\tBoth DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.', 'Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.\tThese findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.', 'These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.\tPatients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).', 'These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.\tThe 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.', 'These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.\tOverall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).', 'These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.\tMedian survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.', 'These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.\tNeutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.', 'These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.\tGrade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.', 'These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.\tPatients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.', 'These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.\tDC resulted in a more favorable overall response and survival rate than VC.', 'These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.\tBoth DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.', 'These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.\tThese findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.']","[0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.\tIn 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.', 'In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.\tThe complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).', 'In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.\tThe actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.', 'In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.\tPatients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).', 'In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.\tOnly the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.', 'In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.\tThe number of hospital admissions and the number of days in hospital were not different.', 'In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.\tIn elderly patients, G-CSF improved the RDI of CHOP,', 'In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.\tbut this did not lead to a higher complete response rate or better overall survival.', 'In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.\tG-CSF did not prevent serious infections.', 'The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).\tIn 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.', 'The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).\tThe complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).', 'The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).\tThe actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.', 'The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).\tPatients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).', 'The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).\tOnly the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.', 'The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).\tThe number of hospital admissions and the number of days in hospital were not different.', 'The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).\tIn elderly patients, G-CSF improved the RDI of CHOP,', 'The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).\tbut this did not lead to a higher complete response rate or better overall survival.', 'The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).\tG-CSF did not prevent serious infections.', 'The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.\tIn 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.', 'The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.\tThe complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).', 'The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.\tThe actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.', 'The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.\tPatients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).', 'The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.\tOnly the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.', 'The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.\tThe number of hospital admissions and the number of days in hospital were not different.', 'The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.\tIn elderly patients, G-CSF improved the RDI of CHOP,', 'The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.\tbut this did not lead to a higher complete response rate or better overall survival.', 'The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.\tG-CSF did not prevent serious infections.', 'Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).\tIn 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.', 'Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).\tThe complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).', 'Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).\tThe actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.', 'Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).\tPatients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).', 'Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).\tOnly the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.', 'Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).\tThe number of hospital admissions and the number of days in hospital were not different.', 'Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).\tIn elderly patients, G-CSF improved the RDI of CHOP,', 'Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).\tbut this did not lead to a higher complete response rate or better overall survival.', 'Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).\tG-CSF did not prevent serious infections.', 'Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.\tIn 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.', 'Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.\tThe complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).', 'Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.\tThe actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.', 'Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.\tPatients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).', 'Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.\tOnly the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.', 'Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.\tThe number of hospital admissions and the number of days in hospital were not different.', 'Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.\tIn elderly patients, G-CSF improved the RDI of CHOP,', 'Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.\tbut this did not lead to a higher complete response rate or better overall survival.', 'Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.\tG-CSF did not prevent serious infections.', 'The number of hospital admissions and the number of days in hospital were not different.\tIn 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.', 'The number of hospital admissions and the number of days in hospital were not different.\tThe complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).', 'The number of hospital admissions and the number of days in hospital were not different.\tThe actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.', 'The number of hospital admissions and the number of days in hospital were not different.\tPatients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).', 'The number of hospital admissions and the number of days in hospital were not different.\tOnly the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.', 'The number of hospital admissions and the number of days in hospital were not different.\tThe number of hospital admissions and the number of days in hospital were not different.', 'The number of hospital admissions and the number of days in hospital were not different.\tIn elderly patients, G-CSF improved the RDI of CHOP,', 'The number of hospital admissions and the number of days in hospital were not different.\tbut this did not lead to a higher complete response rate or better overall survival.', 'The number of hospital admissions and the number of days in hospital were not different.\tG-CSF did not prevent serious infections.', 'In elderly patients, G-CSF improved the RDI of CHOP,\tIn 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.', 'In elderly patients, G-CSF improved the RDI of CHOP,\tThe complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).', 'In elderly patients, G-CSF improved the RDI of CHOP,\tThe actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.', 'In elderly patients, G-CSF improved the RDI of CHOP,\tPatients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).', 'In elderly patients, G-CSF improved the RDI of CHOP,\tOnly the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.', 'In elderly patients, G-CSF improved the RDI of CHOP,\tThe number of hospital admissions and the number of days in hospital were not different.', 'In elderly patients, G-CSF improved the RDI of CHOP,\tIn elderly patients, G-CSF improved the RDI of CHOP,', 'In elderly patients, G-CSF improved the RDI of CHOP,\tbut this did not lead to a higher complete response rate or better overall survival.', 'In elderly patients, G-CSF improved the RDI of CHOP,\tG-CSF did not prevent serious infections.', 'but this did not lead to a higher complete response rate or better overall survival.\tIn 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.', 'but this did not lead to a higher complete response rate or better overall survival.\tThe complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).', 'but this did not lead to a higher complete response rate or better overall survival.\tThe actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.', 'but this did not lead to a higher complete response rate or better overall survival.\tPatients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).', 'but this did not lead to a higher complete response rate or better overall survival.\tOnly the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.', 'but this did not lead to a higher complete response rate or better overall survival.\tThe number of hospital admissions and the number of days in hospital were not different.', 'but this did not lead to a higher complete response rate or better overall survival.\tIn elderly patients, G-CSF improved the RDI of CHOP,', 'but this did not lead to a higher complete response rate or better overall survival.\tbut this did not lead to a higher complete response rate or better overall survival.', 'but this did not lead to a higher complete response rate or better overall survival.\tG-CSF did not prevent serious infections.', 'G-CSF did not prevent serious infections.\tIn 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.', 'G-CSF did not prevent serious infections.\tThe complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).', 'G-CSF did not prevent serious infections.\tThe actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.', 'G-CSF did not prevent serious infections.\tPatients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).', 'G-CSF did not prevent serious infections.\tOnly the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.', 'G-CSF did not prevent serious infections.\tThe number of hospital admissions and the number of days in hospital were not different.', 'G-CSF did not prevent serious infections.\tIn elderly patients, G-CSF improved the RDI of CHOP,', 'G-CSF did not prevent serious infections.\tbut this did not lead to a higher complete response rate or better overall survival.', 'G-CSF did not prevent serious infections.\tG-CSF did not prevent serious infections.']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['At the last follow-up visit, mean pre-operative IOP decreased from 31.1 (± 14.2) to 16.2 (± 1.5) mm Hg after trabeculectomy, and from 28.1 (± 9.0) to 15.7 (± 1.8) mm Hg after Ex-PRESS implantation (P=0.001).\tAt the last follow-up visit, mean pre-operative IOP decreased from 31.1 (± 14.2) to 16.2 (± 1.5) mm Hg after trabeculectomy, and from 28.1 (± 9.0) to 15.7 (± 1.8) mm Hg after Ex-PRESS implantation (P=0.001).', 'At the last follow-up visit, mean pre-operative IOP decreased from 31.1 (± 14.2) to 16.2 (± 1.5) mm Hg after trabeculectomy, and from 28.1 (± 9.0) to 15.7 (± 1.8) mm Hg after Ex-PRESS implantation (P=0.001).\tThe mean number of anti-glaucoma medicines prescribed at the last follow-up decreased from 3.7 pre-operatively (both groups) to 0.9 after trabeculectomy vs 0.3 after Ex-PRESS implantation (P=0.001).', 'At the last follow-up visit, mean pre-operative IOP decreased from 31.1 (± 14.2) to 16.2 (± 1.5) mm Hg after trabeculectomy, and from 28.1 (± 9.0) to 15.7 (± 1.8) mm Hg after Ex-PRESS implantation (P=0.001).\tComplete success rates (5<IOP<18 mm Hg without medications) were higher with Ex-PRESS compared with trabeculectomy (P=0.0024).', 'At the last follow-up visit, mean pre-operative IOP decreased from 31.1 (± 14.2) to 16.2 (± 1.5) mm Hg after trabeculectomy, and from 28.1 (± 9.0) to 15.7 (± 1.8) mm Hg after Ex-PRESS implantation (P=0.001).\tPostoperative complications were more frequent after trabeculectomy (33%) compared with Ex-PRESS (20%), with four trabeculectomy eyes (27%) needing postoperative interventions, compared with none with Ex-PRESS.', 'At the last follow-up visit, mean pre-operative IOP decreased from 31.1 (± 14.2) to 16.2 (± 1.5) mm Hg after trabeculectomy, and from 28.1 (± 9.0) to 15.7 (± 1.8) mm Hg after Ex-PRESS implantation (P=0.001).\tTrabeculectomy and Ex-PRESS implantation provided similar IOP control,', 'At the last follow-up visit, mean pre-operative IOP decreased from 31.1 (± 14.2) to 16.2 (± 1.5) mm Hg after trabeculectomy, and from 28.1 (± 9.0) to 15.7 (± 1.8) mm Hg after Ex-PRESS implantation (P=0.001).\tthe Ex-PRESS group had a lower rate of complications, fewer postoperative interventions, and needed less glaucoma medications.', 'The mean number of anti-glaucoma medicines prescribed at the last follow-up decreased from 3.7 pre-operatively (both groups) to 0.9 after trabeculectomy vs 0.3 after Ex-PRESS implantation (P=0.001).\tAt the last follow-up visit, mean pre-operative IOP decreased from 31.1 (± 14.2) to 16.2 (± 1.5) mm Hg after trabeculectomy, and from 28.1 (± 9.0) to 15.7 (± 1.8) mm Hg after Ex-PRESS implantation (P=0.001).', 'The mean number of anti-glaucoma medicines prescribed at the last follow-up decreased from 3.7 pre-operatively (both groups) to 0.9 after trabeculectomy vs 0.3 after Ex-PRESS implantation (P=0.001).\tThe mean number of anti-glaucoma medicines prescribed at the last follow-up decreased from 3.7 pre-operatively (both groups) to 0.9 after trabeculectomy vs 0.3 after Ex-PRESS implantation (P=0.001).', 'The mean number of anti-glaucoma medicines prescribed at the last follow-up decreased from 3.7 pre-operatively (both groups) to 0.9 after trabeculectomy vs 0.3 after Ex-PRESS implantation (P=0.001).\tComplete success rates (5<IOP<18 mm Hg without medications) were higher with Ex-PRESS compared with trabeculectomy (P=0.0024).', 'The mean number of anti-glaucoma medicines prescribed at the last follow-up decreased from 3.7 pre-operatively (both groups) to 0.9 after trabeculectomy vs 0.3 after Ex-PRESS implantation (P=0.001).\tPostoperative complications were more frequent after trabeculectomy (33%) compared with Ex-PRESS (20%), with four trabeculectomy eyes (27%) needing postoperative interventions, compared with none with Ex-PRESS.', 'The mean number of anti-glaucoma medicines prescribed at the last follow-up decreased from 3.7 pre-operatively (both groups) to 0.9 after trabeculectomy vs 0.3 after Ex-PRESS implantation (P=0.001).\tTrabeculectomy and Ex-PRESS implantation provided similar IOP control,', 'The mean number of anti-glaucoma medicines prescribed at the last follow-up decreased from 3.7 pre-operatively (both groups) to 0.9 after trabeculectomy vs 0.3 after Ex-PRESS implantation (P=0.001).\tthe Ex-PRESS group had a lower rate of complications, fewer postoperative interventions, and needed less glaucoma medications.', 'Complete success rates (5<IOP<18 mm Hg without medications) were higher with Ex-PRESS compared with trabeculectomy (P=0.0024).\tAt the last follow-up visit, mean pre-operative IOP decreased from 31.1 (± 14.2) to 16.2 (± 1.5) mm Hg after trabeculectomy, and from 28.1 (± 9.0) to 15.7 (± 1.8) mm Hg after Ex-PRESS implantation (P=0.001).', 'Complete success rates (5<IOP<18 mm Hg without medications) were higher with Ex-PRESS compared with trabeculectomy (P=0.0024).\tThe mean number of anti-glaucoma medicines prescribed at the last follow-up decreased from 3.7 pre-operatively (both groups) to 0.9 after trabeculectomy vs 0.3 after Ex-PRESS implantation (P=0.001).', 'Complete success rates (5<IOP<18 mm Hg without medications) were higher with Ex-PRESS compared with trabeculectomy (P=0.0024).\tComplete success rates (5<IOP<18 mm Hg without medications) were higher with Ex-PRESS compared with trabeculectomy (P=0.0024).', 'Complete success rates (5<IOP<18 mm Hg without medications) were higher with Ex-PRESS compared with trabeculectomy (P=0.0024).\tPostoperative complications were more frequent after trabeculectomy (33%) compared with Ex-PRESS (20%), with four trabeculectomy eyes (27%) needing postoperative interventions, compared with none with Ex-PRESS.', 'Complete success rates (5<IOP<18 mm Hg without medications) were higher with Ex-PRESS compared with trabeculectomy (P=0.0024).\tTrabeculectomy and Ex-PRESS implantation provided similar IOP control,', 'Complete success rates (5<IOP<18 mm Hg without medications) were higher with Ex-PRESS compared with trabeculectomy (P=0.0024).\tthe Ex-PRESS group had a lower rate of complications, fewer postoperative interventions, and needed less glaucoma medications.', 'Postoperative complications were more frequent after trabeculectomy (33%) compared with Ex-PRESS (20%), with four trabeculectomy eyes (27%) needing postoperative interventions, compared with none with Ex-PRESS.\tAt the last follow-up visit, mean pre-operative IOP decreased from 31.1 (± 14.2) to 16.2 (± 1.5) mm Hg after trabeculectomy, and from 28.1 (± 9.0) to 15.7 (± 1.8) mm Hg after Ex-PRESS implantation (P=0.001).', 'Postoperative complications were more frequent after trabeculectomy (33%) compared with Ex-PRESS (20%), with four trabeculectomy eyes (27%) needing postoperative interventions, compared with none with Ex-PRESS.\tThe mean number of anti-glaucoma medicines prescribed at the last follow-up decreased from 3.7 pre-operatively (both groups) to 0.9 after trabeculectomy vs 0.3 after Ex-PRESS implantation (P=0.001).', 'Postoperative complications were more frequent after trabeculectomy (33%) compared with Ex-PRESS (20%), with four trabeculectomy eyes (27%) needing postoperative interventions, compared with none with Ex-PRESS.\tComplete success rates (5<IOP<18 mm Hg without medications) were higher with Ex-PRESS compared with trabeculectomy (P=0.0024).', 'Postoperative complications were more frequent after trabeculectomy (33%) compared with Ex-PRESS (20%), with four trabeculectomy eyes (27%) needing postoperative interventions, compared with none with Ex-PRESS.\tPostoperative complications were more frequent after trabeculectomy (33%) compared with Ex-PRESS (20%), with four trabeculectomy eyes (27%) needing postoperative interventions, compared with none with Ex-PRESS.', 'Postoperative complications were more frequent after trabeculectomy (33%) compared with Ex-PRESS (20%), with four trabeculectomy eyes (27%) needing postoperative interventions, compared with none with Ex-PRESS.\tTrabeculectomy and Ex-PRESS implantation provided similar IOP control,', 'Postoperative complications were more frequent after trabeculectomy (33%) compared with Ex-PRESS (20%), with four trabeculectomy eyes (27%) needing postoperative interventions, compared with none with Ex-PRESS.\tthe Ex-PRESS group had a lower rate of complications, fewer postoperative interventions, and needed less glaucoma medications.', 'Trabeculectomy and Ex-PRESS implantation provided similar IOP control,\tAt the last follow-up visit, mean pre-operative IOP decreased from 31.1 (± 14.2) to 16.2 (± 1.5) mm Hg after trabeculectomy, and from 28.1 (± 9.0) to 15.7 (± 1.8) mm Hg after Ex-PRESS implantation (P=0.001).', 'Trabeculectomy and Ex-PRESS implantation provided similar IOP control,\tThe mean number of anti-glaucoma medicines prescribed at the last follow-up decreased from 3.7 pre-operatively (both groups) to 0.9 after trabeculectomy vs 0.3 after Ex-PRESS implantation (P=0.001).', 'Trabeculectomy and Ex-PRESS implantation provided similar IOP control,\tComplete success rates (5<IOP<18 mm Hg without medications) were higher with Ex-PRESS compared with trabeculectomy (P=0.0024).', 'Trabeculectomy and Ex-PRESS implantation provided similar IOP control,\tPostoperative complications were more frequent after trabeculectomy (33%) compared with Ex-PRESS (20%), with four trabeculectomy eyes (27%) needing postoperative interventions, compared with none with Ex-PRESS.', 'Trabeculectomy and Ex-PRESS implantation provided similar IOP control,\tTrabeculectomy and Ex-PRESS implantation provided similar IOP control,', 'Trabeculectomy and Ex-PRESS implantation provided similar IOP control,\tthe Ex-PRESS group had a lower rate of complications, fewer postoperative interventions, and needed less glaucoma medications.', 'the Ex-PRESS group had a lower rate of complications, fewer postoperative interventions, and needed less glaucoma medications.\tAt the last follow-up visit, mean pre-operative IOP decreased from 31.1 (± 14.2) to 16.2 (± 1.5) mm Hg after trabeculectomy, and from 28.1 (± 9.0) to 15.7 (± 1.8) mm Hg after Ex-PRESS implantation (P=0.001).', 'the Ex-PRESS group had a lower rate of complications, fewer postoperative interventions, and needed less glaucoma medications.\tThe mean number of anti-glaucoma medicines prescribed at the last follow-up decreased from 3.7 pre-operatively (both groups) to 0.9 after trabeculectomy vs 0.3 after Ex-PRESS implantation (P=0.001).', 'the Ex-PRESS group had a lower rate of complications, fewer postoperative interventions, and needed less glaucoma medications.\tComplete success rates (5<IOP<18 mm Hg without medications) were higher with Ex-PRESS compared with trabeculectomy (P=0.0024).', 'the Ex-PRESS group had a lower rate of complications, fewer postoperative interventions, and needed less glaucoma medications.\tPostoperative complications were more frequent after trabeculectomy (33%) compared with Ex-PRESS (20%), with four trabeculectomy eyes (27%) needing postoperative interventions, compared with none with Ex-PRESS.', 'the Ex-PRESS group had a lower rate of complications, fewer postoperative interventions, and needed less glaucoma medications.\tTrabeculectomy and Ex-PRESS implantation provided similar IOP control,', 'the Ex-PRESS group had a lower rate of complications, fewer postoperative interventions, and needed less glaucoma medications.\tthe Ex-PRESS group had a lower rate of complications, fewer postoperative interventions, and needed less glaucoma medications.']","[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['Both treatments demonstrated favorable ocular tolerability.\tBoth treatments demonstrated favorable ocular tolerability.', 'Both treatments demonstrated favorable ocular tolerability.\tFixed-combination brimonidine-timolol was as effective as latanoprost in reducing IOP in patients with glaucoma or ocular hypertension.', 'Both treatments demonstrated favorable ocular tolerability.\tThe percentage of patients achieving at least a 20% decrease from baseline diurnal IOP at week 12 was 87.7% in the brimonidine-timolol group and 77.3% in the latanoprost group (p = 0.131).', 'Both treatments demonstrated favorable ocular tolerability.\tAt week 12, the mean (SD) diurnal IOP was 17.8 (2.9) mmHg with brimonidine-timolol and 17.9 (3.9) mmHg with latanoprost (p = 0.794).', 'Both treatments demonstrated favorable ocular tolerability.\tMeasured biomicroscopic changes from baseline to week 12 were infrequent in both groups.', 'Fixed-combination brimonidine-timolol was as effective as latanoprost in reducing IOP in patients with glaucoma or ocular hypertension.\tBoth treatments demonstrated favorable ocular tolerability.', 'Fixed-combination brimonidine-timolol was as effective as latanoprost in reducing IOP in patients with glaucoma or ocular hypertension.\tFixed-combination brimonidine-timolol was as effective as latanoprost in reducing IOP in patients with glaucoma or ocular hypertension.', 'Fixed-combination brimonidine-timolol was as effective as latanoprost in reducing IOP in patients with glaucoma or ocular hypertension.\tThe percentage of patients achieving at least a 20% decrease from baseline diurnal IOP at week 12 was 87.7% in the brimonidine-timolol group and 77.3% in the latanoprost group (p = 0.131).', 'Fixed-combination brimonidine-timolol was as effective as latanoprost in reducing IOP in patients with glaucoma or ocular hypertension.\tAt week 12, the mean (SD) diurnal IOP was 17.8 (2.9) mmHg with brimonidine-timolol and 17.9 (3.9) mmHg with latanoprost (p = 0.794).', 'Fixed-combination brimonidine-timolol was as effective as latanoprost in reducing IOP in patients with glaucoma or ocular hypertension.\tMeasured biomicroscopic changes from baseline to week 12 were infrequent in both groups.', 'The percentage of patients achieving at least a 20% decrease from baseline diurnal IOP at week 12 was 87.7% in the brimonidine-timolol group and 77.3% in the latanoprost group (p = 0.131).\tBoth treatments demonstrated favorable ocular tolerability.', 'The percentage of patients achieving at least a 20% decrease from baseline diurnal IOP at week 12 was 87.7% in the brimonidine-timolol group and 77.3% in the latanoprost group (p = 0.131).\tFixed-combination brimonidine-timolol was as effective as latanoprost in reducing IOP in patients with glaucoma or ocular hypertension.', 'The percentage of patients achieving at least a 20% decrease from baseline diurnal IOP at week 12 was 87.7% in the brimonidine-timolol group and 77.3% in the latanoprost group (p = 0.131).\tThe percentage of patients achieving at least a 20% decrease from baseline diurnal IOP at week 12 was 87.7% in the brimonidine-timolol group and 77.3% in the latanoprost group (p = 0.131).', 'The percentage of patients achieving at least a 20% decrease from baseline diurnal IOP at week 12 was 87.7% in the brimonidine-timolol group and 77.3% in the latanoprost group (p = 0.131).\tAt week 12, the mean (SD) diurnal IOP was 17.8 (2.9) mmHg with brimonidine-timolol and 17.9 (3.9) mmHg with latanoprost (p = 0.794).', 'The percentage of patients achieving at least a 20% decrease from baseline diurnal IOP at week 12 was 87.7% in the brimonidine-timolol group and 77.3% in the latanoprost group (p = 0.131).\tMeasured biomicroscopic changes from baseline to week 12 were infrequent in both groups.', 'At week 12, the mean (SD) diurnal IOP was 17.8 (2.9) mmHg with brimonidine-timolol and 17.9 (3.9) mmHg with latanoprost (p = 0.794).\tBoth treatments demonstrated favorable ocular tolerability.', 'At week 12, the mean (SD) diurnal IOP was 17.8 (2.9) mmHg with brimonidine-timolol and 17.9 (3.9) mmHg with latanoprost (p = 0.794).\tFixed-combination brimonidine-timolol was as effective as latanoprost in reducing IOP in patients with glaucoma or ocular hypertension.', 'At week 12, the mean (SD) diurnal IOP was 17.8 (2.9) mmHg with brimonidine-timolol and 17.9 (3.9) mmHg with latanoprost (p = 0.794).\tThe percentage of patients achieving at least a 20% decrease from baseline diurnal IOP at week 12 was 87.7% in the brimonidine-timolol group and 77.3% in the latanoprost group (p = 0.131).', 'At week 12, the mean (SD) diurnal IOP was 17.8 (2.9) mmHg with brimonidine-timolol and 17.9 (3.9) mmHg with latanoprost (p = 0.794).\tAt week 12, the mean (SD) diurnal IOP was 17.8 (2.9) mmHg with brimonidine-timolol and 17.9 (3.9) mmHg with latanoprost (p = 0.794).', 'At week 12, the mean (SD) diurnal IOP was 17.8 (2.9) mmHg with brimonidine-timolol and 17.9 (3.9) mmHg with latanoprost (p = 0.794).\tMeasured biomicroscopic changes from baseline to week 12 were infrequent in both groups.', 'Measured biomicroscopic changes from baseline to week 12 were infrequent in both groups.\tBoth treatments demonstrated favorable ocular tolerability.', 'Measured biomicroscopic changes from baseline to week 12 were infrequent in both groups.\tFixed-combination brimonidine-timolol was as effective as latanoprost in reducing IOP in patients with glaucoma or ocular hypertension.', 'Measured biomicroscopic changes from baseline to week 12 were infrequent in both groups.\tThe percentage of patients achieving at least a 20% decrease from baseline diurnal IOP at week 12 was 87.7% in the brimonidine-timolol group and 77.3% in the latanoprost group (p = 0.131).', 'Measured biomicroscopic changes from baseline to week 12 were infrequent in both groups.\tAt week 12, the mean (SD) diurnal IOP was 17.8 (2.9) mmHg with brimonidine-timolol and 17.9 (3.9) mmHg with latanoprost (p = 0.794).', 'Measured biomicroscopic changes from baseline to week 12 were infrequent in both groups.\tMeasured biomicroscopic changes from baseline to week 12 were infrequent in both groups.']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]"
"['a 6-week treatment with LT or BT was equally effective in reducing IOP.\ta 6-week treatment with LT or BT was equally effective in reducing IOP.', 'a 6-week treatment with LT or BT was equally effective in reducing IOP.\tnone of the administered drugs induced a significant effect on ocular blood flow parameters.', 'a 6-week treatment with LT or BT was equally effective in reducing IOP.\tBoth drugs were equally effective in reducing IOP (LT: -35.0% ±10.0%; BT: -33.6% ±8.8%, P=0.463 between groups).', 'a 6-week treatment with LT or BT was equally effective in reducing IOP.\tno difference in ocular perfusion pressure was observed between the 2 treatment groups (P=0.1, between groups).', 'a 6-week treatment with LT or BT was equally effective in reducing IOP.\tNeither LT nor BT altered ONHBF (P=0.4, baseline vs. treatment)', 'a 6-week treatment with LT or BT was equally effective in reducing IOP.\tno effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments.', 'none of the administered drugs induced a significant effect on ocular blood flow parameters.\ta 6-week treatment with LT or BT was equally effective in reducing IOP.', 'none of the administered drugs induced a significant effect on ocular blood flow parameters.\tnone of the administered drugs induced a significant effect on ocular blood flow parameters.', 'none of the administered drugs induced a significant effect on ocular blood flow parameters.\tBoth drugs were equally effective in reducing IOP (LT: -35.0% ±10.0%; BT: -33.6% ±8.8%, P=0.463 between groups).', 'none of the administered drugs induced a significant effect on ocular blood flow parameters.\tno difference in ocular perfusion pressure was observed between the 2 treatment groups (P=0.1, between groups).', 'none of the administered drugs induced a significant effect on ocular blood flow parameters.\tNeither LT nor BT altered ONHBF (P=0.4, baseline vs. treatment)', 'none of the administered drugs induced a significant effect on ocular blood flow parameters.\tno effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments.', 'Both drugs were equally effective in reducing IOP (LT: -35.0% ±10.0%; BT: -33.6% ±8.8%, P=0.463 between groups).\ta 6-week treatment with LT or BT was equally effective in reducing IOP.', 'Both drugs were equally effective in reducing IOP (LT: -35.0% ±10.0%; BT: -33.6% ±8.8%, P=0.463 between groups).\tnone of the administered drugs induced a significant effect on ocular blood flow parameters.', 'Both drugs were equally effective in reducing IOP (LT: -35.0% ±10.0%; BT: -33.6% ±8.8%, P=0.463 between groups).\tBoth drugs were equally effective in reducing IOP (LT: -35.0% ±10.0%; BT: -33.6% ±8.8%, P=0.463 between groups).', 'Both drugs were equally effective in reducing IOP (LT: -35.0% ±10.0%; BT: -33.6% ±8.8%, P=0.463 between groups).\tno difference in ocular perfusion pressure was observed between the 2 treatment groups (P=0.1, between groups).', 'Both drugs were equally effective in reducing IOP (LT: -35.0% ±10.0%; BT: -33.6% ±8.8%, P=0.463 between groups).\tNeither LT nor BT altered ONHBF (P=0.4, baseline vs. treatment)', 'Both drugs were equally effective in reducing IOP (LT: -35.0% ±10.0%; BT: -33.6% ±8.8%, P=0.463 between groups).\tno effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments.', 'no difference in ocular perfusion pressure was observed between the 2 treatment groups (P=0.1, between groups).\ta 6-week treatment with LT or BT was equally effective in reducing IOP.', 'no difference in ocular perfusion pressure was observed between the 2 treatment groups (P=0.1, between groups).\tnone of the administered drugs induced a significant effect on ocular blood flow parameters.', 'no difference in ocular perfusion pressure was observed between the 2 treatment groups (P=0.1, between groups).\tBoth drugs were equally effective in reducing IOP (LT: -35.0% ±10.0%; BT: -33.6% ±8.8%, P=0.463 between groups).', 'no difference in ocular perfusion pressure was observed between the 2 treatment groups (P=0.1, between groups).\tno difference in ocular perfusion pressure was observed between the 2 treatment groups (P=0.1, between groups).', 'no difference in ocular perfusion pressure was observed between the 2 treatment groups (P=0.1, between groups).\tNeither LT nor BT altered ONHBF (P=0.4, baseline vs. treatment)', 'no difference in ocular perfusion pressure was observed between the 2 treatment groups (P=0.1, between groups).\tno effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments.', 'Neither LT nor BT altered ONHBF (P=0.4, baseline vs. treatment)\ta 6-week treatment with LT or BT was equally effective in reducing IOP.', 'Neither LT nor BT altered ONHBF (P=0.4, baseline vs. treatment)\tnone of the administered drugs induced a significant effect on ocular blood flow parameters.', 'Neither LT nor BT altered ONHBF (P=0.4, baseline vs. treatment)\tBoth drugs were equally effective in reducing IOP (LT: -35.0% ±10.0%; BT: -33.6% ±8.8%, P=0.463 between groups).', 'Neither LT nor BT altered ONHBF (P=0.4, baseline vs. treatment)\tno difference in ocular perfusion pressure was observed between the 2 treatment groups (P=0.1, between groups).', 'Neither LT nor BT altered ONHBF (P=0.4, baseline vs. treatment)\tNeither LT nor BT altered ONHBF (P=0.4, baseline vs. treatment)', 'Neither LT nor BT altered ONHBF (P=0.4, baseline vs. treatment)\tno effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments.', 'no effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments.\ta 6-week treatment with LT or BT was equally effective in reducing IOP.', 'no effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments.\tnone of the administered drugs induced a significant effect on ocular blood flow parameters.', 'no effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments.\tBoth drugs were equally effective in reducing IOP (LT: -35.0% ±10.0%; BT: -33.6% ±8.8%, P=0.463 between groups).', 'no effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments.\tno difference in ocular perfusion pressure was observed between the 2 treatment groups (P=0.1, between groups).', 'no effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments.\tNeither LT nor BT altered ONHBF (P=0.4, baseline vs. treatment)', 'no effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments.\tno effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments.']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]"
"['Both groups had a similar favorable long-term safety profile.\tBoth groups had a similar favorable long-term safety profile.', 'Both groups had a similar favorable long-term safety profile.\tThe incidence of adverse events was low in both groups through 24 months of follow-up.', 'Both groups had a similar favorable long-term safety profile.\tAt 24 months, the proportion of patients with an IOP of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036).', 'Both groups had a similar favorable long-term safety profile.\tthe mean IOP was stable between 12 months and 24 months (17.0 mm Hg ± 2.8 [SD] and 17.1 ± 2.9 mm Hg, respectively) in the stent group but increased (17.0 ± 3.1 mm Hg to 17.8 ± 3.3 mm Hg, respectively) in the control group.', 'Both groups had a similar favorable long-term safety profile.\tOcular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.', 'Both groups had a similar favorable long-term safety profile.\tPatients with combined single trabecular micro-bypass stent and cataract surgery had significantly better IOP control on no medication through 24 months than patients having cataract surgery alone.', 'The incidence of adverse events was low in both groups through 24 months of follow-up.\tBoth groups had a similar favorable long-term safety profile.', 'The incidence of adverse events was low in both groups through 24 months of follow-up.\tThe incidence of adverse events was low in both groups through 24 months of follow-up.', 'The incidence of adverse events was low in both groups through 24 months of follow-up.\tAt 24 months, the proportion of patients with an IOP of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036).', 'The incidence of adverse events was low in both groups through 24 months of follow-up.\tthe mean IOP was stable between 12 months and 24 months (17.0 mm Hg ± 2.8 [SD] and 17.1 ± 2.9 mm Hg, respectively) in the stent group but increased (17.0 ± 3.1 mm Hg to 17.8 ± 3.3 mm Hg, respectively) in the control group.', 'The incidence of adverse events was low in both groups through 24 months of follow-up.\tOcular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.', 'The incidence of adverse events was low in both groups through 24 months of follow-up.\tPatients with combined single trabecular micro-bypass stent and cataract surgery had significantly better IOP control on no medication through 24 months than patients having cataract surgery alone.', 'At 24 months, the proportion of patients with an IOP of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036).\tBoth groups had a similar favorable long-term safety profile.', 'At 24 months, the proportion of patients with an IOP of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036).\tThe incidence of adverse events was low in both groups through 24 months of follow-up.', 'At 24 months, the proportion of patients with an IOP of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036).\tAt 24 months, the proportion of patients with an IOP of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036).', 'At 24 months, the proportion of patients with an IOP of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036).\tthe mean IOP was stable between 12 months and 24 months (17.0 mm Hg ± 2.8 [SD] and 17.1 ± 2.9 mm Hg, respectively) in the stent group but increased (17.0 ± 3.1 mm Hg to 17.8 ± 3.3 mm Hg, respectively) in the control group.', 'At 24 months, the proportion of patients with an IOP of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036).\tOcular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.', 'At 24 months, the proportion of patients with an IOP of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036).\tPatients with combined single trabecular micro-bypass stent and cataract surgery had significantly better IOP control on no medication through 24 months than patients having cataract surgery alone.', 'the mean IOP was stable between 12 months and 24 months (17.0 mm Hg ± 2.8 [SD] and 17.1 ± 2.9 mm Hg, respectively) in the stent group but increased (17.0 ± 3.1 mm Hg to 17.8 ± 3.3 mm Hg, respectively) in the control group.\tBoth groups had a similar favorable long-term safety profile.', 'the mean IOP was stable between 12 months and 24 months (17.0 mm Hg ± 2.8 [SD] and 17.1 ± 2.9 mm Hg, respectively) in the stent group but increased (17.0 ± 3.1 mm Hg to 17.8 ± 3.3 mm Hg, respectively) in the control group.\tThe incidence of adverse events was low in both groups through 24 months of follow-up.', 'the mean IOP was stable between 12 months and 24 months (17.0 mm Hg ± 2.8 [SD] and 17.1 ± 2.9 mm Hg, respectively) in the stent group but increased (17.0 ± 3.1 mm Hg to 17.8 ± 3.3 mm Hg, respectively) in the control group.\tAt 24 months, the proportion of patients with an IOP of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036).', 'the mean IOP was stable between 12 months and 24 months (17.0 mm Hg ± 2.8 [SD] and 17.1 ± 2.9 mm Hg, respectively) in the stent group but increased (17.0 ± 3.1 mm Hg to 17.8 ± 3.3 mm Hg, respectively) in the control group.\tthe mean IOP was stable between 12 months and 24 months (17.0 mm Hg ± 2.8 [SD] and 17.1 ± 2.9 mm Hg, respectively) in the stent group but increased (17.0 ± 3.1 mm Hg to 17.8 ± 3.3 mm Hg, respectively) in the control group.', 'the mean IOP was stable between 12 months and 24 months (17.0 mm Hg ± 2.8 [SD] and 17.1 ± 2.9 mm Hg, respectively) in the stent group but increased (17.0 ± 3.1 mm Hg to 17.8 ± 3.3 mm Hg, respectively) in the control group.\tOcular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.', 'the mean IOP was stable between 12 months and 24 months (17.0 mm Hg ± 2.8 [SD] and 17.1 ± 2.9 mm Hg, respectively) in the stent group but increased (17.0 ± 3.1 mm Hg to 17.8 ± 3.3 mm Hg, respectively) in the control group.\tPatients with combined single trabecular micro-bypass stent and cataract surgery had significantly better IOP control on no medication through 24 months than patients having cataract surgery alone.', 'Ocular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.\tBoth groups had a similar favorable long-term safety profile.', 'Ocular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.\tThe incidence of adverse events was low in both groups through 24 months of follow-up.', 'Ocular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.\tAt 24 months, the proportion of patients with an IOP of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036).', 'Ocular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.\tthe mean IOP was stable between 12 months and 24 months (17.0 mm Hg ± 2.8 [SD] and 17.1 ± 2.9 mm Hg, respectively) in the stent group but increased (17.0 ± 3.1 mm Hg to 17.8 ± 3.3 mm Hg, respectively) in the control group.', 'Ocular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.\tOcular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.', 'Ocular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.\tPatients with combined single trabecular micro-bypass stent and cataract surgery had significantly better IOP control on no medication through 24 months than patients having cataract surgery alone.', 'Patients with combined single trabecular micro-bypass stent and cataract surgery had significantly better IOP control on no medication through 24 months than patients having cataract surgery alone.\tBoth groups had a similar favorable long-term safety profile.', 'Patients with combined single trabecular micro-bypass stent and cataract surgery had significantly better IOP control on no medication through 24 months than patients having cataract surgery alone.\tThe incidence of adverse events was low in both groups through 24 months of follow-up.', 'Patients with combined single trabecular micro-bypass stent and cataract surgery had significantly better IOP control on no medication through 24 months than patients having cataract surgery alone.\tAt 24 months, the proportion of patients with an IOP of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036).', 'Patients with combined single trabecular micro-bypass stent and cataract surgery had significantly better IOP control on no medication through 24 months than patients having cataract surgery alone.\tthe mean IOP was stable between 12 months and 24 months (17.0 mm Hg ± 2.8 [SD] and 17.1 ± 2.9 mm Hg, respectively) in the stent group but increased (17.0 ± 3.1 mm Hg to 17.8 ± 3.3 mm Hg, respectively) in the control group.', 'Patients with combined single trabecular micro-bypass stent and cataract surgery had significantly better IOP control on no medication through 24 months than patients having cataract surgery alone.\tOcular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.', 'Patients with combined single trabecular micro-bypass stent and cataract surgery had significantly better IOP control on no medication through 24 months than patients having cataract surgery alone.\tPatients with combined single trabecular micro-bypass stent and cataract surgery had significantly better IOP control on no medication through 24 months than patients having cataract surgery alone.']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]"
"['The current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.\tThe current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.', 'The current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.\tThis suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.', 'The current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.\tEyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).', 'The current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.\trandomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).', 'The current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.\trandomization to brimonidine 0.2% was protective compared to timolol 0.5%,', 'The current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.\tower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.', 'The current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.\tolder age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression', 'This suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.\tThe current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.', 'This suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.\tThis suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.', 'This suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.\tEyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).', 'This suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.\trandomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).', 'This suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.\trandomization to brimonidine 0.2% was protective compared to timolol 0.5%,', 'This suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.\tower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.', 'This suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.\tolder age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression', 'Eyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).\tThe current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.', 'Eyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).\tThis suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.', 'Eyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).\tEyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).', 'Eyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).\trandomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).', 'Eyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).\trandomization to brimonidine 0.2% was protective compared to timolol 0.5%,', 'Eyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).\tower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.', 'Eyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).\tolder age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression', 'randomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).\tThe current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.', 'randomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).\tThis suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.', 'randomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).\tEyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).', 'randomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).\trandomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).', 'randomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).\trandomization to brimonidine 0.2% was protective compared to timolol 0.5%,', 'randomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).\tower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.', 'randomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).\tolder age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression', 'randomization to brimonidine 0.2% was protective compared to timolol 0.5%,\tThe current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.', 'randomization to brimonidine 0.2% was protective compared to timolol 0.5%,\tThis suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.', 'randomization to brimonidine 0.2% was protective compared to timolol 0.5%,\tEyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).', 'randomization to brimonidine 0.2% was protective compared to timolol 0.5%,\trandomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).', 'randomization to brimonidine 0.2% was protective compared to timolol 0.5%,\trandomization to brimonidine 0.2% was protective compared to timolol 0.5%,', 'randomization to brimonidine 0.2% was protective compared to timolol 0.5%,\tower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.', 'randomization to brimonidine 0.2% was protective compared to timolol 0.5%,\tolder age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression', 'ower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.\tThe current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.', 'ower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.\tThis suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.', 'ower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.\tEyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).', 'ower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.\trandomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).', 'ower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.\trandomization to brimonidine 0.2% was protective compared to timolol 0.5%,', 'ower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.\tower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.', 'ower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.\tolder age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression', 'older age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression\tThe current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.', 'older age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression\tThis suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.', 'older age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression\tEyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).', 'older age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression\trandomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).', 'older age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression\trandomization to brimonidine 0.2% was protective compared to timolol 0.5%,', 'older age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression\tower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.', 'older age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression\tolder age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression']","[0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['Trabeculectomy is more effective than phacoemulsification in reducing dependence on glaucoma drugs, but is associated with more complications.\tTrabeculectomy is more effective than phacoemulsification in reducing dependence on glaucoma drugs, but is associated with more complications.', 'Trabeculectomy is more effective than phacoemulsification in reducing dependence on glaucoma drugs, but is associated with more complications.\tBoth phacoemulsification and trabeculectomy are effective in reducing IOP in medically uncontrolled CACG eyes without cataract.', 'Trabeculectomy is more effective than phacoemulsification in reducing dependence on glaucoma drugs, but is associated with more complications.\tEight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.', 'Trabeculectomy is more effective than phacoemulsification in reducing dependence on glaucoma drugs, but is associated with more complications.\ttrabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs 4%; P=0.001).', 'Trabeculectomy is more effective than phacoemulsification in reducing dependence on glaucoma drugs, but is associated with more complications.\tOver first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).', 'Trabeculectomy is more effective than phacoemulsification in reducing dependence on glaucoma drugs, but is associated with more complications.\tPhacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs 8.9 mmHg or 36% for trabeculectomy; P=0.76).', 'Both phacoemulsification and trabeculectomy are effective in reducing IOP in medically uncontrolled CACG eyes without cataract.\tTrabeculectomy is more effective than phacoemulsification in reducing dependence on glaucoma drugs, but is associated with more complications.', 'Both phacoemulsification and trabeculectomy are effective in reducing IOP in medically uncontrolled CACG eyes without cataract.\tBoth phacoemulsification and trabeculectomy are effective in reducing IOP in medically uncontrolled CACG eyes without cataract.', 'Both phacoemulsification and trabeculectomy are effective in reducing IOP in medically uncontrolled CACG eyes without cataract.\tEight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.', 'Both phacoemulsification and trabeculectomy are effective in reducing IOP in medically uncontrolled CACG eyes without cataract.\ttrabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs 4%; P=0.001).', 'Both phacoemulsification and trabeculectomy are effective in reducing IOP in medically uncontrolled CACG eyes without cataract.\tOver first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).', 'Both phacoemulsification and trabeculectomy are effective in reducing IOP in medically uncontrolled CACG eyes without cataract.\tPhacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs 8.9 mmHg or 36% for trabeculectomy; P=0.76).', 'Eight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.\tTrabeculectomy is more effective than phacoemulsification in reducing dependence on glaucoma drugs, but is associated with more complications.', 'Eight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.\tBoth phacoemulsification and trabeculectomy are effective in reducing IOP in medically uncontrolled CACG eyes without cataract.', 'Eight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.\tEight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.', 'Eight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.\ttrabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs 4%; P=0.001).', 'Eight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.\tOver first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).', 'Eight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.\tPhacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs 8.9 mmHg or 36% for trabeculectomy; P=0.76).', 'trabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs 4%; P=0.001).\tTrabeculectomy is more effective than phacoemulsification in reducing dependence on glaucoma drugs, but is associated with more complications.', 'trabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs 4%; P=0.001).\tBoth phacoemulsification and trabeculectomy are effective in reducing IOP in medically uncontrolled CACG eyes without cataract.', 'trabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs 4%; P=0.001).\tEight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.', 'trabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs 4%; P=0.001).\ttrabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs 4%; P=0.001).', 'trabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs 4%; P=0.001).\tOver first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).', 'trabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs 4%; P=0.001).\tPhacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs 8.9 mmHg or 36% for trabeculectomy; P=0.76).', 'Over first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).\tTrabeculectomy is more effective than phacoemulsification in reducing dependence on glaucoma drugs, but is associated with more complications.', 'Over first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).\tBoth phacoemulsification and trabeculectomy are effective in reducing IOP in medically uncontrolled CACG eyes without cataract.', 'Over first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).\tEight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.', 'Over first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).\ttrabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs 4%; P=0.001).', 'Over first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).\tOver first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).', 'Over first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).\tPhacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs 8.9 mmHg or 36% for trabeculectomy; P=0.76).', 'Phacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs 8.9 mmHg or 36% for trabeculectomy; P=0.76).\tTrabeculectomy is more effective than phacoemulsification in reducing dependence on glaucoma drugs, but is associated with more complications.', 'Phacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs 8.9 mmHg or 36% for trabeculectomy; P=0.76).\tBoth phacoemulsification and trabeculectomy are effective in reducing IOP in medically uncontrolled CACG eyes without cataract.', 'Phacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs 8.9 mmHg or 36% for trabeculectomy; P=0.76).\tEight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.', 'Phacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs 8.9 mmHg or 36% for trabeculectomy; P=0.76).\ttrabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs 4%; P=0.001).', 'Phacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs 8.9 mmHg or 36% for trabeculectomy; P=0.76).\tOver first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).', 'Phacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs 8.9 mmHg or 36% for trabeculectomy; P=0.76).\tPhacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs 8.9 mmHg or 36% for trabeculectomy; P=0.76).']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]"
"['The technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.\tThe technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.', 'The technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.\tThere was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).', 'The technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.\tThe incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);', 'The technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.\thypotony recovered in 80.8% (21/26) within 1 week.', 'The technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.\tThe IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),', 'The technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.\tno difference was observed after the second week (P=0.659 to 0.753).', 'The technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.\tReleasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.', 'There was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).\tThe technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.', 'There was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).\tThere was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).', 'There was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).\tThe incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);', 'There was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).\thypotony recovered in 80.8% (21/26) within 1 week.', 'There was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).\tThe IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),', 'There was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).\tno difference was observed after the second week (P=0.659 to 0.753).', 'There was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).\tReleasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.', 'The incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);\tThe technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.', 'The incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);\tThere was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).', 'The incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);\tThe incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);', 'The incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);\thypotony recovered in 80.8% (21/26) within 1 week.', 'The incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);\tThe IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),', 'The incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);\tno difference was observed after the second week (P=0.659 to 0.753).', 'The incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);\tReleasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.', 'hypotony recovered in 80.8% (21/26) within 1 week.\tThe technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.', 'hypotony recovered in 80.8% (21/26) within 1 week.\tThere was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).', 'hypotony recovered in 80.8% (21/26) within 1 week.\tThe incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);', 'hypotony recovered in 80.8% (21/26) within 1 week.\thypotony recovered in 80.8% (21/26) within 1 week.', 'hypotony recovered in 80.8% (21/26) within 1 week.\tThe IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),', 'hypotony recovered in 80.8% (21/26) within 1 week.\tno difference was observed after the second week (P=0.659 to 0.753).', 'hypotony recovered in 80.8% (21/26) within 1 week.\tReleasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.', 'The IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),\tThe technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.', 'The IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),\tThere was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).', 'The IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),\tThe incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);', 'The IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),\thypotony recovered in 80.8% (21/26) within 1 week.', 'The IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),\tThe IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),', 'The IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),\tno difference was observed after the second week (P=0.659 to 0.753).', 'The IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),\tReleasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.', 'no difference was observed after the second week (P=0.659 to 0.753).\tThe technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.', 'no difference was observed after the second week (P=0.659 to 0.753).\tThere was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).', 'no difference was observed after the second week (P=0.659 to 0.753).\tThe incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);', 'no difference was observed after the second week (P=0.659 to 0.753).\thypotony recovered in 80.8% (21/26) within 1 week.', 'no difference was observed after the second week (P=0.659 to 0.753).\tThe IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),', 'no difference was observed after the second week (P=0.659 to 0.753).\tno difference was observed after the second week (P=0.659 to 0.753).', 'no difference was observed after the second week (P=0.659 to 0.753).\tReleasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.', 'Releasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.\tThe technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.', 'Releasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.\tThere was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).', 'Releasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.\tThe incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);', 'Releasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.\thypotony recovered in 80.8% (21/26) within 1 week.', 'Releasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.\tThe IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),', 'Releasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.\tno difference was observed after the second week (P=0.659 to 0.753).', 'Releasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.\tReleasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.']","[0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['Preservative-free latanoprost has the same efficacy as BPL, with improved local tolerance.\tPreservative-free latanoprost has the same efficacy as BPL, with improved local tolerance.', 'Preservative-free latanoprost has the same efficacy as BPL, with improved local tolerance.\tUpon instillation, the global subjective ocular symptom score was significantly lower on T2345 than BPL on D42 (0.15 vs 0.41; p=0.001) and D84 (0.18 vs 0.46; p=0.001).', 'Preservative-free latanoprost has the same efficacy as BPL, with improved local tolerance.\tModerate to severe conjunctival hyperaemia was less frequent on T2345 than on BPL at D42 (20.2% vs 30.6%; p=0.003) and D84 (21.4% vs 29.1%; p=0.02).', 'Preservative-free latanoprost has the same efficacy as BPL, with improved local tolerance.\tThe most frequent ocular adverse event, drug intolerance, was reported in 1 (0.5%) patient on T2345 versus 4 (2.1%) patients on BPL.', 'Preservative-free latanoprost has the same efficacy as BPL, with improved local tolerance.\tMean IOP reduction (D0-D84) was -8.6 ±2.6 mm Hg (-36%) on T2345 and -9.0 ±2.4 mm Hg (-38%) on BPL, confirming non-inferiority of T2345 to BPL.', 'Upon instillation, the global subjective ocular symptom score was significantly lower on T2345 than BPL on D42 (0.15 vs 0.41; p=0.001) and D84 (0.18 vs 0.46; p=0.001).\tPreservative-free latanoprost has the same efficacy as BPL, with improved local tolerance.', 'Upon instillation, the global subjective ocular symptom score was significantly lower on T2345 than BPL on D42 (0.15 vs 0.41; p=0.001) and D84 (0.18 vs 0.46; p=0.001).\tUpon instillation, the global subjective ocular symptom score was significantly lower on T2345 than BPL on D42 (0.15 vs 0.41; p=0.001) and D84 (0.18 vs 0.46; p=0.001).', 'Upon instillation, the global subjective ocular symptom score was significantly lower on T2345 than BPL on D42 (0.15 vs 0.41; p=0.001) and D84 (0.18 vs 0.46; p=0.001).\tModerate to severe conjunctival hyperaemia was less frequent on T2345 than on BPL at D42 (20.2% vs 30.6%; p=0.003) and D84 (21.4% vs 29.1%; p=0.02).', 'Upon instillation, the global subjective ocular symptom score was significantly lower on T2345 than BPL on D42 (0.15 vs 0.41; p=0.001) and D84 (0.18 vs 0.46; p=0.001).\tThe most frequent ocular adverse event, drug intolerance, was reported in 1 (0.5%) patient on T2345 versus 4 (2.1%) patients on BPL.', 'Upon instillation, the global subjective ocular symptom score was significantly lower on T2345 than BPL on D42 (0.15 vs 0.41; p=0.001) and D84 (0.18 vs 0.46; p=0.001).\tMean IOP reduction (D0-D84) was -8.6 ±2.6 mm Hg (-36%) on T2345 and -9.0 ±2.4 mm Hg (-38%) on BPL, confirming non-inferiority of T2345 to BPL.', 'Moderate to severe conjunctival hyperaemia was less frequent on T2345 than on BPL at D42 (20.2% vs 30.6%; p=0.003) and D84 (21.4% vs 29.1%; p=0.02).\tPreservative-free latanoprost has the same efficacy as BPL, with improved local tolerance.', 'Moderate to severe conjunctival hyperaemia was less frequent on T2345 than on BPL at D42 (20.2% vs 30.6%; p=0.003) and D84 (21.4% vs 29.1%; p=0.02).\tUpon instillation, the global subjective ocular symptom score was significantly lower on T2345 than BPL on D42 (0.15 vs 0.41; p=0.001) and D84 (0.18 vs 0.46; p=0.001).', 'Moderate to severe conjunctival hyperaemia was less frequent on T2345 than on BPL at D42 (20.2% vs 30.6%; p=0.003) and D84 (21.4% vs 29.1%; p=0.02).\tModerate to severe conjunctival hyperaemia was less frequent on T2345 than on BPL at D42 (20.2% vs 30.6%; p=0.003) and D84 (21.4% vs 29.1%; p=0.02).', 'Moderate to severe conjunctival hyperaemia was less frequent on T2345 than on BPL at D42 (20.2% vs 30.6%; p=0.003) and D84 (21.4% vs 29.1%; p=0.02).\tThe most frequent ocular adverse event, drug intolerance, was reported in 1 (0.5%) patient on T2345 versus 4 (2.1%) patients on BPL.', 'Moderate to severe conjunctival hyperaemia was less frequent on T2345 than on BPL at D42 (20.2% vs 30.6%; p=0.003) and D84 (21.4% vs 29.1%; p=0.02).\tMean IOP reduction (D0-D84) was -8.6 ±2.6 mm Hg (-36%) on T2345 and -9.0 ±2.4 mm Hg (-38%) on BPL, confirming non-inferiority of T2345 to BPL.', 'The most frequent ocular adverse event, drug intolerance, was reported in 1 (0.5%) patient on T2345 versus 4 (2.1%) patients on BPL.\tPreservative-free latanoprost has the same efficacy as BPL, with improved local tolerance.', 'The most frequent ocular adverse event, drug intolerance, was reported in 1 (0.5%) patient on T2345 versus 4 (2.1%) patients on BPL.\tUpon instillation, the global subjective ocular symptom score was significantly lower on T2345 than BPL on D42 (0.15 vs 0.41; p=0.001) and D84 (0.18 vs 0.46; p=0.001).', 'The most frequent ocular adverse event, drug intolerance, was reported in 1 (0.5%) patient on T2345 versus 4 (2.1%) patients on BPL.\tModerate to severe conjunctival hyperaemia was less frequent on T2345 than on BPL at D42 (20.2% vs 30.6%; p=0.003) and D84 (21.4% vs 29.1%; p=0.02).', 'The most frequent ocular adverse event, drug intolerance, was reported in 1 (0.5%) patient on T2345 versus 4 (2.1%) patients on BPL.\tThe most frequent ocular adverse event, drug intolerance, was reported in 1 (0.5%) patient on T2345 versus 4 (2.1%) patients on BPL.', 'The most frequent ocular adverse event, drug intolerance, was reported in 1 (0.5%) patient on T2345 versus 4 (2.1%) patients on BPL.\tMean IOP reduction (D0-D84) was -8.6 ±2.6 mm Hg (-36%) on T2345 and -9.0 ±2.4 mm Hg (-38%) on BPL, confirming non-inferiority of T2345 to BPL.', 'Mean IOP reduction (D0-D84) was -8.6 ±2.6 mm Hg (-36%) on T2345 and -9.0 ±2.4 mm Hg (-38%) on BPL, confirming non-inferiority of T2345 to BPL.\tPreservative-free latanoprost has the same efficacy as BPL, with improved local tolerance.', 'Mean IOP reduction (D0-D84) was -8.6 ±2.6 mm Hg (-36%) on T2345 and -9.0 ±2.4 mm Hg (-38%) on BPL, confirming non-inferiority of T2345 to BPL.\tUpon instillation, the global subjective ocular symptom score was significantly lower on T2345 than BPL on D42 (0.15 vs 0.41; p=0.001) and D84 (0.18 vs 0.46; p=0.001).', 'Mean IOP reduction (D0-D84) was -8.6 ±2.6 mm Hg (-36%) on T2345 and -9.0 ±2.4 mm Hg (-38%) on BPL, confirming non-inferiority of T2345 to BPL.\tModerate to severe conjunctival hyperaemia was less frequent on T2345 than on BPL at D42 (20.2% vs 30.6%; p=0.003) and D84 (21.4% vs 29.1%; p=0.02).', 'Mean IOP reduction (D0-D84) was -8.6 ±2.6 mm Hg (-36%) on T2345 and -9.0 ±2.4 mm Hg (-38%) on BPL, confirming non-inferiority of T2345 to BPL.\tThe most frequent ocular adverse event, drug intolerance, was reported in 1 (0.5%) patient on T2345 versus 4 (2.1%) patients on BPL.', 'Mean IOP reduction (D0-D84) was -8.6 ±2.6 mm Hg (-36%) on T2345 and -9.0 ±2.4 mm Hg (-38%) on BPL, confirming non-inferiority of T2345 to BPL.\tMean IOP reduction (D0-D84) was -8.6 ±2.6 mm Hg (-36%) on T2345 and -9.0 ±2.4 mm Hg (-38%) on BPL, confirming non-inferiority of T2345 to BPL.']","[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 2, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0]"
"['Topical brimonidine showed an additive IOP-lowering effect to topical PG analogues,\tTopical brimonidine showed an additive IOP-lowering effect to topical PG analogues,', 'Topical brimonidine showed an additive IOP-lowering effect to topical PG analogues,\talthough its IOP-lowering effect was inferior to topical timolol as monotherapy.', 'Topical brimonidine showed an additive IOP-lowering effect to topical PG analogues,\tThe mean changes were -4.7 +/- 2.1 (S. D.) in the timolol and -4.0 +/- 2.0 mmHg in the brimonidine group (p = 0.0138).', 'Topical brimonidine showed an additive IOP-lowering effect to topical PG analogues,\tThe 95% confidence interval of the inter-group difference was greater than the pre-determined criterion of non-inferiority of brimonidine to timolol.', 'Topical brimonidine showed an additive IOP-lowering effect to topical PG analogues,\tWhen added to PG analogues, the IOP-lowering effect of brimonidine (-2.9 +/- 1.8 mmHg) was greater than that of the placebo (-2.1 +/- 1.8 mmHg) (p = 0.0010).', 'although its IOP-lowering effect was inferior to topical timolol as monotherapy.\tTopical brimonidine showed an additive IOP-lowering effect to topical PG analogues,', 'although its IOP-lowering effect was inferior to topical timolol as monotherapy.\talthough its IOP-lowering effect was inferior to topical timolol as monotherapy.', 'although its IOP-lowering effect was inferior to topical timolol as monotherapy.\tThe mean changes were -4.7 +/- 2.1 (S. D.) in the timolol and -4.0 +/- 2.0 mmHg in the brimonidine group (p = 0.0138).', 'although its IOP-lowering effect was inferior to topical timolol as monotherapy.\tThe 95% confidence interval of the inter-group difference was greater than the pre-determined criterion of non-inferiority of brimonidine to timolol.', 'although its IOP-lowering effect was inferior to topical timolol as monotherapy.\tWhen added to PG analogues, the IOP-lowering effect of brimonidine (-2.9 +/- 1.8 mmHg) was greater than that of the placebo (-2.1 +/- 1.8 mmHg) (p = 0.0010).', 'The mean changes were -4.7 +/- 2.1 (S. D.) in the timolol and -4.0 +/- 2.0 mmHg in the brimonidine group (p = 0.0138).\tTopical brimonidine showed an additive IOP-lowering effect to topical PG analogues,', 'The mean changes were -4.7 +/- 2.1 (S. D.) in the timolol and -4.0 +/- 2.0 mmHg in the brimonidine group (p = 0.0138).\talthough its IOP-lowering effect was inferior to topical timolol as monotherapy.', 'The mean changes were -4.7 +/- 2.1 (S. D.) in the timolol and -4.0 +/- 2.0 mmHg in the brimonidine group (p = 0.0138).\tThe mean changes were -4.7 +/- 2.1 (S. D.) in the timolol and -4.0 +/- 2.0 mmHg in the brimonidine group (p = 0.0138).', 'The mean changes were -4.7 +/- 2.1 (S. D.) in the timolol and -4.0 +/- 2.0 mmHg in the brimonidine group (p = 0.0138).\tThe 95% confidence interval of the inter-group difference was greater than the pre-determined criterion of non-inferiority of brimonidine to timolol.', 'The mean changes were -4.7 +/- 2.1 (S. D.) in the timolol and -4.0 +/- 2.0 mmHg in the brimonidine group (p = 0.0138).\tWhen added to PG analogues, the IOP-lowering effect of brimonidine (-2.9 +/- 1.8 mmHg) was greater than that of the placebo (-2.1 +/- 1.8 mmHg) (p = 0.0010).', 'The 95% confidence interval of the inter-group difference was greater than the pre-determined criterion of non-inferiority of brimonidine to timolol.\tTopical brimonidine showed an additive IOP-lowering effect to topical PG analogues,', 'The 95% confidence interval of the inter-group difference was greater than the pre-determined criterion of non-inferiority of brimonidine to timolol.\talthough its IOP-lowering effect was inferior to topical timolol as monotherapy.', 'The 95% confidence interval of the inter-group difference was greater than the pre-determined criterion of non-inferiority of brimonidine to timolol.\tThe mean changes were -4.7 +/- 2.1 (S. D.) in the timolol and -4.0 +/- 2.0 mmHg in the brimonidine group (p = 0.0138).', 'The 95% confidence interval of the inter-group difference was greater than the pre-determined criterion of non-inferiority of brimonidine to timolol.\tThe 95% confidence interval of the inter-group difference was greater than the pre-determined criterion of non-inferiority of brimonidine to timolol.', 'The 95% confidence interval of the inter-group difference was greater than the pre-determined criterion of non-inferiority of brimonidine to timolol.\tWhen added to PG analogues, the IOP-lowering effect of brimonidine (-2.9 +/- 1.8 mmHg) was greater than that of the placebo (-2.1 +/- 1.8 mmHg) (p = 0.0010).', 'When added to PG analogues, the IOP-lowering effect of brimonidine (-2.9 +/- 1.8 mmHg) was greater than that of the placebo (-2.1 +/- 1.8 mmHg) (p = 0.0010).\tTopical brimonidine showed an additive IOP-lowering effect to topical PG analogues,', 'When added to PG analogues, the IOP-lowering effect of brimonidine (-2.9 +/- 1.8 mmHg) was greater than that of the placebo (-2.1 +/- 1.8 mmHg) (p = 0.0010).\talthough its IOP-lowering effect was inferior to topical timolol as monotherapy.', 'When added to PG analogues, the IOP-lowering effect of brimonidine (-2.9 +/- 1.8 mmHg) was greater than that of the placebo (-2.1 +/- 1.8 mmHg) (p = 0.0010).\tThe mean changes were -4.7 +/- 2.1 (S. D.) in the timolol and -4.0 +/- 2.0 mmHg in the brimonidine group (p = 0.0138).', 'When added to PG analogues, the IOP-lowering effect of brimonidine (-2.9 +/- 1.8 mmHg) was greater than that of the placebo (-2.1 +/- 1.8 mmHg) (p = 0.0010).\tThe 95% confidence interval of the inter-group difference was greater than the pre-determined criterion of non-inferiority of brimonidine to timolol.', 'When added to PG analogues, the IOP-lowering effect of brimonidine (-2.9 +/- 1.8 mmHg) was greater than that of the placebo (-2.1 +/- 1.8 mmHg) (p = 0.0010).\tWhen added to PG analogues, the IOP-lowering effect of brimonidine (-2.9 +/- 1.8 mmHg) was greater than that of the placebo (-2.1 +/- 1.8 mmHg) (p = 0.0010).']","[0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0]"
"['Both drops provided effective IOP reduction that was greater\tBoth drops provided effective IOP reduction that was greater', 'Both drops provided effective IOP reduction that was greater\tpatients were more likely to achieve lower target pressures with BTFC than with TTFC.', 'Both drops provided effective IOP reduction that was greater\tBoth drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).', 'Both drops provided effective IOP reduction that was greater\tBTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001).', 'Both drops provided effective IOP reduction that was greater\tMean IOP reductions were 11.34 and 6.42 mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89 mmHg at 6 months (P=0.001) for BTFC and TTFC, respectively.', 'Both drops provided effective IOP reduction that was greater\tIOPs at 2 weeks were 18 mm Hg in 36 (90.8%) versus 22 (55%) eyes and 16 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, 18 mm Hg in 38 (95%) versus 28 (70%) eyes and 16 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).', 'patients were more likely to achieve lower target pressures with BTFC than with TTFC.\tBoth drops provided effective IOP reduction that was greater', 'patients were more likely to achieve lower target pressures with BTFC than with TTFC.\tpatients were more likely to achieve lower target pressures with BTFC than with TTFC.', 'patients were more likely to achieve lower target pressures with BTFC than with TTFC.\tBoth drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).', 'patients were more likely to achieve lower target pressures with BTFC than with TTFC.\tBTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001).', 'patients were more likely to achieve lower target pressures with BTFC than with TTFC.\tMean IOP reductions were 11.34 and 6.42 mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89 mmHg at 6 months (P=0.001) for BTFC and TTFC, respectively.', 'patients were more likely to achieve lower target pressures with BTFC than with TTFC.\tIOPs at 2 weeks were 18 mm Hg in 36 (90.8%) versus 22 (55%) eyes and 16 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, 18 mm Hg in 38 (95%) versus 28 (70%) eyes and 16 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).', 'Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).\tBoth drops provided effective IOP reduction that was greater', 'Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).\tpatients were more likely to achieve lower target pressures with BTFC than with TTFC.', 'Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).\tBoth drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).', 'Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).\tBTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001).', 'Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).\tMean IOP reductions were 11.34 and 6.42 mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89 mmHg at 6 months (P=0.001) for BTFC and TTFC, respectively.', 'Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).\tIOPs at 2 weeks were 18 mm Hg in 36 (90.8%) versus 22 (55%) eyes and 16 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, 18 mm Hg in 38 (95%) versus 28 (70%) eyes and 16 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).', 'BTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001).\tBoth drops provided effective IOP reduction that was greater', 'BTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001).\tpatients were more likely to achieve lower target pressures with BTFC than with TTFC.', 'BTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001).\tBoth drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).', 'BTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001).\tBTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001).', 'BTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001).\tMean IOP reductions were 11.34 and 6.42 mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89 mmHg at 6 months (P=0.001) for BTFC and TTFC, respectively.', 'BTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001).\tIOPs at 2 weeks were 18 mm Hg in 36 (90.8%) versus 22 (55%) eyes and 16 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, 18 mm Hg in 38 (95%) versus 28 (70%) eyes and 16 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).', 'Mean IOP reductions were 11.34 and 6.42 mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89 mmHg at 6 months (P=0.001) for BTFC and TTFC, respectively.\tBoth drops provided effective IOP reduction that was greater', 'Mean IOP reductions were 11.34 and 6.42 mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89 mmHg at 6 months (P=0.001) for BTFC and TTFC, respectively.\tpatients were more likely to achieve lower target pressures with BTFC than with TTFC.', 'Mean IOP reductions were 11.34 and 6.42 mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89 mmHg at 6 months (P=0.001) for BTFC and TTFC, respectively.\tBoth drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).', 'Mean IOP reductions were 11.34 and 6.42 mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89 mmHg at 6 months (P=0.001) for BTFC and TTFC, respectively.\tBTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001).', 'Mean IOP reductions were 11.34 and 6.42 mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89 mmHg at 6 months (P=0.001) for BTFC and TTFC, respectively.\tMean IOP reductions were 11.34 and 6.42 mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89 mmHg at 6 months (P=0.001) for BTFC and TTFC, respectively.', 'Mean IOP reductions were 11.34 and 6.42 mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89 mmHg at 6 months (P=0.001) for BTFC and TTFC, respectively.\tIOPs at 2 weeks were 18 mm Hg in 36 (90.8%) versus 22 (55%) eyes and 16 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, 18 mm Hg in 38 (95%) versus 28 (70%) eyes and 16 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).', 'IOPs at 2 weeks were 18 mm Hg in 36 (90.8%) versus 22 (55%) eyes and 16 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, 18 mm Hg in 38 (95%) versus 28 (70%) eyes and 16 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).\tBoth drops provided effective IOP reduction that was greater', 'IOPs at 2 weeks were 18 mm Hg in 36 (90.8%) versus 22 (55%) eyes and 16 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, 18 mm Hg in 38 (95%) versus 28 (70%) eyes and 16 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).\tpatients were more likely to achieve lower target pressures with BTFC than with TTFC.', 'IOPs at 2 weeks were 18 mm Hg in 36 (90.8%) versus 22 (55%) eyes and 16 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, 18 mm Hg in 38 (95%) versus 28 (70%) eyes and 16 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).\tBoth drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).', 'IOPs at 2 weeks were 18 mm Hg in 36 (90.8%) versus 22 (55%) eyes and 16 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, 18 mm Hg in 38 (95%) versus 28 (70%) eyes and 16 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).\tBTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001).', 'IOPs at 2 weeks were 18 mm Hg in 36 (90.8%) versus 22 (55%) eyes and 16 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, 18 mm Hg in 38 (95%) versus 28 (70%) eyes and 16 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).\tMean IOP reductions were 11.34 and 6.42 mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89 mmHg at 6 months (P=0.001) for BTFC and TTFC, respectively.', 'IOPs at 2 weeks were 18 mm Hg in 36 (90.8%) versus 22 (55%) eyes and 16 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, 18 mm Hg in 38 (95%) versus 28 (70%) eyes and 16 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).\tIOPs at 2 weeks were 18 mm Hg in 36 (90.8%) versus 22 (55%) eyes and 16 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, 18 mm Hg in 38 (95%) versus 28 (70%) eyes and 16 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0]"
"['Tenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks.\tTenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks.', 'Tenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks.\tAt week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).', 'Tenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks.\tRates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).', 'Tenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks.\tHepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).', 'Tenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks.\tOverall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.', 'Tenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks.\tNo TDF resistance was observed up to week 240.', 'Tenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks.\tTreatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%).', 'Tenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks.\tThe mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.', 'Tenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks.\tTDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.', 'At week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).\tTenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks.', 'At week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).\tAt week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).', 'At week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).\tRates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).', 'At week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).\tHepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).', 'At week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).\tOverall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.', 'At week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).\tNo TDF resistance was observed up to week 240.', 'At week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).\tTreatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%).', 'At week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).\tThe mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.', 'At week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).\tTDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.', 'Rates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).\tTenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks.', 'Rates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).\tAt week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).', 'Rates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).\tRates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).', 'Rates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).\tHepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).', 'Rates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).\tOverall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.', 'Rates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).\tNo TDF resistance was observed up to week 240.', 'Rates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).\tTreatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%).', 'Rates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).\tThe mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.', 'Rates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).\tTDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.', 'Hepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).\tTenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks.', 'Hepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).\tAt week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).', 'Hepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).\tRates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).', 'Hepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).\tHepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).', 'Hepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).\tOverall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.', 'Hepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).\tNo TDF resistance was observed up to week 240.', 'Hepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).\tTreatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%).', 'Hepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).\tThe mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.', 'Hepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).\tTDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.', 'Overall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.\tTenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks.', 'Overall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.\tAt week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).', 'Overall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.\tRates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).', 'Overall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.\tHepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).', 'Overall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.\tOverall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.', 'Overall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.\tNo TDF resistance was observed up to week 240.', 'Overall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.\tTreatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%).', 'Overall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.\tThe mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.', 'Overall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.\tTDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.', 'No TDF resistance was observed up to week 240.\tTenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks.', 'No TDF resistance was observed up to week 240.\tAt week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).', 'No TDF resistance was observed up to week 240.\tRates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).', 'No TDF resistance was observed up to week 240.\tHepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).', 'No TDF resistance was observed up to week 240.\tOverall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.', 'No TDF resistance was observed up to week 240.\tNo TDF resistance was observed up to week 240.', 'No TDF resistance was observed up to week 240.\tTreatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%).', 'No TDF resistance was observed up to week 240.\tThe mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.', 'No TDF resistance was observed up to week 240.\tTDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.', 'Treatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%).\tTenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks.', 'Treatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%).\tAt week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).', 'Treatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%).\tRates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).', 'Treatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%).\tHepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).', 'Treatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%).\tOverall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.', 'Treatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%).\tNo TDF resistance was observed up to week 240.', 'Treatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%).\tTreatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%).', 'Treatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%).\tThe mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.', 'Treatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%).\tTDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.', 'The mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.\tTenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks.', 'The mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.\tAt week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).', 'The mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.\tRates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).', 'The mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.\tHepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).', 'The mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.\tOverall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.', 'The mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.\tNo TDF resistance was observed up to week 240.', 'The mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.\tTreatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%).', 'The mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.\tThe mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.', 'The mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.\tTDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.', 'TDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.\tTenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks.', 'TDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.\tAt week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).', 'TDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.\tRates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).', 'TDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.\tHepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).', 'TDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.\tOverall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.', 'TDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.\tNo TDF resistance was observed up to week 240.', 'TDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.\tTreatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%).', 'TDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.\tThe mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.', 'TDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.\tTDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['This study suggests the possibility of Korean Red Ginseng as a complementary therapy for chronic hepatitis B.\tThis study suggests the possibility of Korean Red Ginseng as a complementary therapy for chronic hepatitis B.', 'This study suggests the possibility of Korean Red Ginseng as a complementary therapy for chronic hepatitis B.\tThe non-invasive fibrosis serologic markers were further decreased in the experimental group, with significant differences after treatment observed for hyaluronic acid (p\u2009=\u20090.032) and transforming growth factor-β (p\u2009=\u20090.008), but not for type IV collagen (p\u2009=\u20090.174).', 'This study suggests the possibility of Korean Red Ginseng as a complementary therapy for chronic hepatitis B.\tDifferences in several non-invasive fibrosis serologic markers (type IV collagen, hyaluronic acid, transforming growth factor-β) and in the hepatitis B virus DNA levels were compared between the groups.', 'The non-invasive fibrosis serologic markers were further decreased in the experimental group, with significant differences after treatment observed for hyaluronic acid (p\u2009=\u20090.032) and transforming growth factor-β (p\u2009=\u20090.008), but not for type IV collagen (p\u2009=\u20090.174).\tThis study suggests the possibility of Korean Red Ginseng as a complementary therapy for chronic hepatitis B.', 'The non-invasive fibrosis serologic markers were further decreased in the experimental group, with significant differences after treatment observed for hyaluronic acid (p\u2009=\u20090.032) and transforming growth factor-β (p\u2009=\u20090.008), but not for type IV collagen (p\u2009=\u20090.174).\tThe non-invasive fibrosis serologic markers were further decreased in the experimental group, with significant differences after treatment observed for hyaluronic acid (p\u2009=\u20090.032) and transforming growth factor-β (p\u2009=\u20090.008), but not for type IV collagen (p\u2009=\u20090.174).', 'The non-invasive fibrosis serologic markers were further decreased in the experimental group, with significant differences after treatment observed for hyaluronic acid (p\u2009=\u20090.032) and transforming growth factor-β (p\u2009=\u20090.008), but not for type IV collagen (p\u2009=\u20090.174).\tDifferences in several non-invasive fibrosis serologic markers (type IV collagen, hyaluronic acid, transforming growth factor-β) and in the hepatitis B virus DNA levels were compared between the groups.', 'Differences in several non-invasive fibrosis serologic markers (type IV collagen, hyaluronic acid, transforming growth factor-β) and in the hepatitis B virus DNA levels were compared between the groups.\tThis study suggests the possibility of Korean Red Ginseng as a complementary therapy for chronic hepatitis B.', 'Differences in several non-invasive fibrosis serologic markers (type IV collagen, hyaluronic acid, transforming growth factor-β) and in the hepatitis B virus DNA levels were compared between the groups.\tThe non-invasive fibrosis serologic markers were further decreased in the experimental group, with significant differences after treatment observed for hyaluronic acid (p\u2009=\u20090.032) and transforming growth factor-β (p\u2009=\u20090.008), but not for type IV collagen (p\u2009=\u20090.174).', 'Differences in several non-invasive fibrosis serologic markers (type IV collagen, hyaluronic acid, transforming growth factor-β) and in the hepatitis B virus DNA levels were compared between the groups.\tDifferences in several non-invasive fibrosis serologic markers (type IV collagen, hyaluronic acid, transforming growth factor-β) and in the hepatitis B virus DNA levels were compared between the groups.']","[0, 0, 0, 1, 0, 0, 1, 0, 0]"
"['In patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG-IFN) for 48-weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy.\tIn patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG-IFN) for 48-weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy.', 'In patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG-IFN) for 48-weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy.\tRates of HBsAg loss at Week 72 were significantly higher in the TDF/PI-48w group (6.5%) than in the TDF/PI-16w+TDF-32w (0.5%), TDF-120w (0%) and PI-48w (2.2%) groups (P = 0.09).', 'In patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG-IFN) for 48-weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy.\tHBsAg decline at Week 12 or 24 of treatment was associated with HBsAg loss at Week 72 (P < 0.001).', 'In patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG-IFN) for 48-weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy.\tHBsAg decline >3.5 log10 IU/mL at Week 24 in the TDF/PI-48w group resulted in a positive predictive value of 85% and a negative predictive value of 99% for HBsAg loss at Week 72.', 'In patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG-IFN) for 48-weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy.\tHBsAg decline at Week 24 of TDF plus PEG-IFN combination therapy may identify patients who, after completing 48 weeks of treatment, have a better chance of achieving HBsAg loss at Week 72.', 'Rates of HBsAg loss at Week 72 were significantly higher in the TDF/PI-48w group (6.5%) than in the TDF/PI-16w+TDF-32w (0.5%), TDF-120w (0%) and PI-48w (2.2%) groups (P = 0.09).\tIn patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG-IFN) for 48-weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy.', 'Rates of HBsAg loss at Week 72 were significantly higher in the TDF/PI-48w group (6.5%) than in the TDF/PI-16w+TDF-32w (0.5%), TDF-120w (0%) and PI-48w (2.2%) groups (P = 0.09).\tRates of HBsAg loss at Week 72 were significantly higher in the TDF/PI-48w group (6.5%) than in the TDF/PI-16w+TDF-32w (0.5%), TDF-120w (0%) and PI-48w (2.2%) groups (P = 0.09).', 'Rates of HBsAg loss at Week 72 were significantly higher in the TDF/PI-48w group (6.5%) than in the TDF/PI-16w+TDF-32w (0.5%), TDF-120w (0%) and PI-48w (2.2%) groups (P = 0.09).\tHBsAg decline at Week 12 or 24 of treatment was associated with HBsAg loss at Week 72 (P < 0.001).', 'Rates of HBsAg loss at Week 72 were significantly higher in the TDF/PI-48w group (6.5%) than in the TDF/PI-16w+TDF-32w (0.5%), TDF-120w (0%) and PI-48w (2.2%) groups (P = 0.09).\tHBsAg decline >3.5 log10 IU/mL at Week 24 in the TDF/PI-48w group resulted in a positive predictive value of 85% and a negative predictive value of 99% for HBsAg loss at Week 72.', 'Rates of HBsAg loss at Week 72 were significantly higher in the TDF/PI-48w group (6.5%) than in the TDF/PI-16w+TDF-32w (0.5%), TDF-120w (0%) and PI-48w (2.2%) groups (P = 0.09).\tHBsAg decline at Week 24 of TDF plus PEG-IFN combination therapy may identify patients who, after completing 48 weeks of treatment, have a better chance of achieving HBsAg loss at Week 72.', 'HBsAg decline at Week 12 or 24 of treatment was associated with HBsAg loss at Week 72 (P < 0.001).\tIn patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG-IFN) for 48-weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy.', 'HBsAg decline at Week 12 or 24 of treatment was associated with HBsAg loss at Week 72 (P < 0.001).\tRates of HBsAg loss at Week 72 were significantly higher in the TDF/PI-48w group (6.5%) than in the TDF/PI-16w+TDF-32w (0.5%), TDF-120w (0%) and PI-48w (2.2%) groups (P = 0.09).', 'HBsAg decline at Week 12 or 24 of treatment was associated with HBsAg loss at Week 72 (P < 0.001).\tHBsAg decline at Week 12 or 24 of treatment was associated with HBsAg loss at Week 72 (P < 0.001).', 'HBsAg decline at Week 12 or 24 of treatment was associated with HBsAg loss at Week 72 (P < 0.001).\tHBsAg decline >3.5 log10 IU/mL at Week 24 in the TDF/PI-48w group resulted in a positive predictive value of 85% and a negative predictive value of 99% for HBsAg loss at Week 72.', 'HBsAg decline at Week 12 or 24 of treatment was associated with HBsAg loss at Week 72 (P < 0.001).\tHBsAg decline at Week 24 of TDF plus PEG-IFN combination therapy may identify patients who, after completing 48 weeks of treatment, have a better chance of achieving HBsAg loss at Week 72.', 'HBsAg decline >3.5 log10 IU/mL at Week 24 in the TDF/PI-48w group resulted in a positive predictive value of 85% and a negative predictive value of 99% for HBsAg loss at Week 72.\tIn patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG-IFN) for 48-weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy.', 'HBsAg decline >3.5 log10 IU/mL at Week 24 in the TDF/PI-48w group resulted in a positive predictive value of 85% and a negative predictive value of 99% for HBsAg loss at Week 72.\tRates of HBsAg loss at Week 72 were significantly higher in the TDF/PI-48w group (6.5%) than in the TDF/PI-16w+TDF-32w (0.5%), TDF-120w (0%) and PI-48w (2.2%) groups (P = 0.09).', 'HBsAg decline >3.5 log10 IU/mL at Week 24 in the TDF/PI-48w group resulted in a positive predictive value of 85% and a negative predictive value of 99% for HBsAg loss at Week 72.\tHBsAg decline at Week 12 or 24 of treatment was associated with HBsAg loss at Week 72 (P < 0.001).', 'HBsAg decline >3.5 log10 IU/mL at Week 24 in the TDF/PI-48w group resulted in a positive predictive value of 85% and a negative predictive value of 99% for HBsAg loss at Week 72.\tHBsAg decline >3.5 log10 IU/mL at Week 24 in the TDF/PI-48w group resulted in a positive predictive value of 85% and a negative predictive value of 99% for HBsAg loss at Week 72.', 'HBsAg decline >3.5 log10 IU/mL at Week 24 in the TDF/PI-48w group resulted in a positive predictive value of 85% and a negative predictive value of 99% for HBsAg loss at Week 72.\tHBsAg decline at Week 24 of TDF plus PEG-IFN combination therapy may identify patients who, after completing 48 weeks of treatment, have a better chance of achieving HBsAg loss at Week 72.', 'HBsAg decline at Week 24 of TDF plus PEG-IFN combination therapy may identify patients who, after completing 48 weeks of treatment, have a better chance of achieving HBsAg loss at Week 72.\tIn patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG-IFN) for 48-weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy.', 'HBsAg decline at Week 24 of TDF plus PEG-IFN combination therapy may identify patients who, after completing 48 weeks of treatment, have a better chance of achieving HBsAg loss at Week 72.\tRates of HBsAg loss at Week 72 were significantly higher in the TDF/PI-48w group (6.5%) than in the TDF/PI-16w+TDF-32w (0.5%), TDF-120w (0%) and PI-48w (2.2%) groups (P = 0.09).', 'HBsAg decline at Week 24 of TDF plus PEG-IFN combination therapy may identify patients who, after completing 48 weeks of treatment, have a better chance of achieving HBsAg loss at Week 72.\tHBsAg decline at Week 12 or 24 of treatment was associated with HBsAg loss at Week 72 (P < 0.001).', 'HBsAg decline at Week 24 of TDF plus PEG-IFN combination therapy may identify patients who, after completing 48 weeks of treatment, have a better chance of achieving HBsAg loss at Week 72.\tHBsAg decline >3.5 log10 IU/mL at Week 24 in the TDF/PI-48w group resulted in a positive predictive value of 85% and a negative predictive value of 99% for HBsAg loss at Week 72.', 'HBsAg decline at Week 24 of TDF plus PEG-IFN combination therapy may identify patients who, after completing 48 weeks of treatment, have a better chance of achieving HBsAg loss at Week 72.\tHBsAg decline at Week 24 of TDF plus PEG-IFN combination therapy may identify patients who, after completing 48 weeks of treatment, have a better chance of achieving HBsAg loss at Week 72.']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0]"
"['eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7\u200amm Hg [P\u200a=\u200a0.002] vs -4.1\u200amm Hg [P\u200a<\u200a0.001], respectively).\teyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7\u200amm Hg [P\u200a=\u200a0.002] vs -4.1\u200amm Hg [P\u200a<\u200a0.001], respectively).', 'eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7\u200amm Hg [P\u200a=\u200a0.002] vs -4.1\u200amm Hg [P\u200a<\u200a0.001], respectively).\tNinety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3\u200amm Hg (P\u200a=\u200a0.01).', 'eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7\u200amm Hg [P\u200a=\u200a0.002] vs -4.1\u200amm Hg [P\u200a<\u200a0.001], respectively).\tSuccess in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P\u200a=\u200a0.005).', ""eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7\u200amm Hg [P\u200a=\u200a0.002] vs -4.1\u200amm Hg [P\u200a<\u200a0.001], respectively).\tthe SLT's effect was significant only during the nighttime."", 'eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7\u200amm Hg [P\u200a=\u200a0.002] vs -4.1\u200amm Hg [P\u200a<\u200a0.001], respectively).\tThe effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,', 'eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7\u200amm Hg [P\u200a=\u200a0.002] vs -4.1\u200amm Hg [P\u200a<\u200a0.001], respectively).\tBoth travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.', 'eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7\u200amm Hg [P\u200a=\u200a0.002] vs -4.1\u200amm Hg [P\u200a<\u200a0.001], respectively).\ttravoprost better controls IOP fluctuations than SLT, especially during the daytime.', 'Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3\u200amm Hg (P\u200a=\u200a0.01).\teyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7\u200amm Hg [P\u200a=\u200a0.002] vs -4.1\u200amm Hg [P\u200a<\u200a0.001], respectively).', 'Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3\u200amm Hg (P\u200a=\u200a0.01).\tNinety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3\u200amm Hg (P\u200a=\u200a0.01).', 'Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3\u200amm Hg (P\u200a=\u200a0.01).\tSuccess in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P\u200a=\u200a0.005).', ""Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3\u200amm Hg (P\u200a=\u200a0.01).\tthe SLT's effect was significant only during the nighttime."", 'Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3\u200amm Hg (P\u200a=\u200a0.01).\tThe effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,', 'Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3\u200amm Hg (P\u200a=\u200a0.01).\tBoth travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.', 'Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3\u200amm Hg (P\u200a=\u200a0.01).\ttravoprost better controls IOP fluctuations than SLT, especially during the daytime.', 'Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P\u200a=\u200a0.005).\teyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7\u200amm Hg [P\u200a=\u200a0.002] vs -4.1\u200amm Hg [P\u200a<\u200a0.001], respectively).', 'Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P\u200a=\u200a0.005).\tNinety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3\u200amm Hg (P\u200a=\u200a0.01).', 'Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P\u200a=\u200a0.005).\tSuccess in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P\u200a=\u200a0.005).', ""Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P\u200a=\u200a0.005).\tthe SLT's effect was significant only during the nighttime."", 'Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P\u200a=\u200a0.005).\tThe effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,', 'Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P\u200a=\u200a0.005).\tBoth travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.', 'Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P\u200a=\u200a0.005).\ttravoprost better controls IOP fluctuations than SLT, especially during the daytime.', ""the SLT's effect was significant only during the nighttime.\teyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7\u200amm Hg [P\u200a=\u200a0.002] vs -4.1\u200amm Hg [P\u200a<\u200a0.001], respectively)."", ""the SLT's effect was significant only during the nighttime.\tNinety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3\u200amm Hg (P\u200a=\u200a0.01)."", ""the SLT's effect was significant only during the nighttime.\tSuccess in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P\u200a=\u200a0.005)."", ""the SLT's effect was significant only during the nighttime.\tthe SLT's effect was significant only during the nighttime."", ""the SLT's effect was significant only during the nighttime.\tThe effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,"", ""the SLT's effect was significant only during the nighttime.\tBoth travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG."", ""the SLT's effect was significant only during the nighttime.\ttravoprost better controls IOP fluctuations than SLT, especially during the daytime."", 'The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,\teyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7\u200amm Hg [P\u200a=\u200a0.002] vs -4.1\u200amm Hg [P\u200a<\u200a0.001], respectively).', 'The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,\tNinety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3\u200amm Hg (P\u200a=\u200a0.01).', 'The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,\tSuccess in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P\u200a=\u200a0.005).', ""The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,\tthe SLT's effect was significant only during the nighttime."", 'The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,\tThe effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,', 'The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,\tBoth travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.', 'The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,\ttravoprost better controls IOP fluctuations than SLT, especially during the daytime.', 'Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.\teyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7\u200amm Hg [P\u200a=\u200a0.002] vs -4.1\u200amm Hg [P\u200a<\u200a0.001], respectively).', 'Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.\tNinety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3\u200amm Hg (P\u200a=\u200a0.01).', 'Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.\tSuccess in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P\u200a=\u200a0.005).', ""Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.\tthe SLT's effect was significant only during the nighttime."", 'Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.\tThe effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,', 'Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.\tBoth travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.', 'Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.\ttravoprost better controls IOP fluctuations than SLT, especially during the daytime.', 'travoprost better controls IOP fluctuations than SLT, especially during the daytime.\teyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7\u200amm Hg [P\u200a=\u200a0.002] vs -4.1\u200amm Hg [P\u200a<\u200a0.001], respectively).', 'travoprost better controls IOP fluctuations than SLT, especially during the daytime.\tNinety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3\u200amm Hg (P\u200a=\u200a0.01).', 'travoprost better controls IOP fluctuations than SLT, especially during the daytime.\tSuccess in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P\u200a=\u200a0.005).', ""travoprost better controls IOP fluctuations than SLT, especially during the daytime.\tthe SLT's effect was significant only during the nighttime."", 'travoprost better controls IOP fluctuations than SLT, especially during the daytime.\tThe effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,', 'travoprost better controls IOP fluctuations than SLT, especially during the daytime.\tBoth travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.', 'travoprost better controls IOP fluctuations than SLT, especially during the daytime.\ttravoprost better controls IOP fluctuations than SLT, especially during the daytime.']","[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['At the end of the 2-year follow-up period, the complete success and the failure rates were 67% and 15%, respectively, in the microcatheter-assisted group versus 47% and 50% in the rigid probe trabeculotomy group (p = 0.006).\tAt the end of the 2-year follow-up period, the complete success and the failure rates were 67% and 15%, respectively, in the microcatheter-assisted group versus 47% and 50% in the rigid probe trabeculotomy group (p = 0.006).', 'At the end of the 2-year follow-up period, the complete success and the failure rates were 67% and 15%, respectively, in the microcatheter-assisted group versus 47% and 50% in the rigid probe trabeculotomy group (p = 0.006).\tThere was a tendency towards lower IOP in the microcatheter group at 1, 3, 6, 12 and 24 months postoperatively, with the difference in IOP reaching statistical significance at 6 months (p = 0.004).', 'At the end of the 2-year follow-up period, the complete success and the failure rates were 67% and 15%, respectively, in the microcatheter-assisted group versus 47% and 50% in the rigid probe trabeculotomy group (p = 0.006).\tThe mean survival time was significantly longer for the microcatheter group (p = 0.01).', 'At the end of the 2-year follow-up period, the complete success and the failure rates were 67% and 15%, respectively, in the microcatheter-assisted group versus 47% and 50% in the rigid probe trabeculotomy group (p = 0.006).\tAt 2 years postoperatively, microcatheter-assisted trabeculotomy still yielded superior results in terms of IOP control and success rates in children with primary congenital glaucoma.', 'At the end of the 2-year follow-up period, the complete success and the failure rates were 67% and 15%, respectively, in the microcatheter-assisted group versus 47% and 50% in the rigid probe trabeculotomy group (p = 0.006).\tThe need for reoperation for glaucoma was significantly lower in the microcatheter group.', 'There was a tendency towards lower IOP in the microcatheter group at 1, 3, 6, 12 and 24 months postoperatively, with the difference in IOP reaching statistical significance at 6 months (p = 0.004).\tAt the end of the 2-year follow-up period, the complete success and the failure rates were 67% and 15%, respectively, in the microcatheter-assisted group versus 47% and 50% in the rigid probe trabeculotomy group (p = 0.006).', 'There was a tendency towards lower IOP in the microcatheter group at 1, 3, 6, 12 and 24 months postoperatively, with the difference in IOP reaching statistical significance at 6 months (p = 0.004).\tThere was a tendency towards lower IOP in the microcatheter group at 1, 3, 6, 12 and 24 months postoperatively, with the difference in IOP reaching statistical significance at 6 months (p = 0.004).', 'There was a tendency towards lower IOP in the microcatheter group at 1, 3, 6, 12 and 24 months postoperatively, with the difference in IOP reaching statistical significance at 6 months (p = 0.004).\tThe mean survival time was significantly longer for the microcatheter group (p = 0.01).', 'There was a tendency towards lower IOP in the microcatheter group at 1, 3, 6, 12 and 24 months postoperatively, with the difference in IOP reaching statistical significance at 6 months (p = 0.004).\tAt 2 years postoperatively, microcatheter-assisted trabeculotomy still yielded superior results in terms of IOP control and success rates in children with primary congenital glaucoma.', 'There was a tendency towards lower IOP in the microcatheter group at 1, 3, 6, 12 and 24 months postoperatively, with the difference in IOP reaching statistical significance at 6 months (p = 0.004).\tThe need for reoperation for glaucoma was significantly lower in the microcatheter group.', 'The mean survival time was significantly longer for the microcatheter group (p = 0.01).\tAt the end of the 2-year follow-up period, the complete success and the failure rates were 67% and 15%, respectively, in the microcatheter-assisted group versus 47% and 50% in the rigid probe trabeculotomy group (p = 0.006).', 'The mean survival time was significantly longer for the microcatheter group (p = 0.01).\tThere was a tendency towards lower IOP in the microcatheter group at 1, 3, 6, 12 and 24 months postoperatively, with the difference in IOP reaching statistical significance at 6 months (p = 0.004).', 'The mean survival time was significantly longer for the microcatheter group (p = 0.01).\tThe mean survival time was significantly longer for the microcatheter group (p = 0.01).', 'The mean survival time was significantly longer for the microcatheter group (p = 0.01).\tAt 2 years postoperatively, microcatheter-assisted trabeculotomy still yielded superior results in terms of IOP control and success rates in children with primary congenital glaucoma.', 'The mean survival time was significantly longer for the microcatheter group (p = 0.01).\tThe need for reoperation for glaucoma was significantly lower in the microcatheter group.', 'At 2 years postoperatively, microcatheter-assisted trabeculotomy still yielded superior results in terms of IOP control and success rates in children with primary congenital glaucoma.\tAt the end of the 2-year follow-up period, the complete success and the failure rates were 67% and 15%, respectively, in the microcatheter-assisted group versus 47% and 50% in the rigid probe trabeculotomy group (p = 0.006).', 'At 2 years postoperatively, microcatheter-assisted trabeculotomy still yielded superior results in terms of IOP control and success rates in children with primary congenital glaucoma.\tThere was a tendency towards lower IOP in the microcatheter group at 1, 3, 6, 12 and 24 months postoperatively, with the difference in IOP reaching statistical significance at 6 months (p = 0.004).', 'At 2 years postoperatively, microcatheter-assisted trabeculotomy still yielded superior results in terms of IOP control and success rates in children with primary congenital glaucoma.\tThe mean survival time was significantly longer for the microcatheter group (p = 0.01).', 'At 2 years postoperatively, microcatheter-assisted trabeculotomy still yielded superior results in terms of IOP control and success rates in children with primary congenital glaucoma.\tAt 2 years postoperatively, microcatheter-assisted trabeculotomy still yielded superior results in terms of IOP control and success rates in children with primary congenital glaucoma.', 'At 2 years postoperatively, microcatheter-assisted trabeculotomy still yielded superior results in terms of IOP control and success rates in children with primary congenital glaucoma.\tThe need for reoperation for glaucoma was significantly lower in the microcatheter group.', 'The need for reoperation for glaucoma was significantly lower in the microcatheter group.\tAt the end of the 2-year follow-up period, the complete success and the failure rates were 67% and 15%, respectively, in the microcatheter-assisted group versus 47% and 50% in the rigid probe trabeculotomy group (p = 0.006).', 'The need for reoperation for glaucoma was significantly lower in the microcatheter group.\tThere was a tendency towards lower IOP in the microcatheter group at 1, 3, 6, 12 and 24 months postoperatively, with the difference in IOP reaching statistical significance at 6 months (p = 0.004).', 'The need for reoperation for glaucoma was significantly lower in the microcatheter group.\tThe mean survival time was significantly longer for the microcatheter group (p = 0.01).', 'The need for reoperation for glaucoma was significantly lower in the microcatheter group.\tAt 2 years postoperatively, microcatheter-assisted trabeculotomy still yielded superior results in terms of IOP control and success rates in children with primary congenital glaucoma.', 'The need for reoperation for glaucoma was significantly lower in the microcatheter group.\tThe need for reoperation for glaucoma was significantly lower in the microcatheter group.']","[0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['The mean postoperative IOP was statistically significantly lower than the mean preoperative IOP at each follow-up in each group.\tThe mean postoperative IOP was statistically significantly lower than the mean preoperative IOP at each follow-up in each group.', 'The mean postoperative IOP was statistically significantly lower than the mean preoperative IOP at each follow-up in each group.\tAt 1 year, the mean postoperative IOP was significantly lower in group A.', 'The mean postoperative IOP was statistically significantly lower than the mean preoperative IOP at each follow-up in each group.\tAccording to the MBGS, blebs with an ologen implant showed significantly better scoring than those with MMC.', 'The mean postoperative IOP was statistically significantly lower than the mean preoperative IOP at each follow-up in each group.\tAS-OCT showed that ologen-induced blebs had significantly more fluid-filled spaces, cleavage planes, and less fibrosis.', 'The mean postoperative IOP was statistically significantly lower than the mean preoperative IOP at each follow-up in each group.\tOlogen resulted in a lower long-term postoperative IOP, a better bleb morphology, and fewer complications.', 'The mean postoperative IOP was statistically significantly lower than the mean preoperative IOP at each follow-up in each group.\tOur results suggest that ologen may be a useful alternative to MMC in JOAG.', 'At 1 year, the mean postoperative IOP was significantly lower in group A.\tThe mean postoperative IOP was statistically significantly lower than the mean preoperative IOP at each follow-up in each group.', 'At 1 year, the mean postoperative IOP was significantly lower in group A.\tAt 1 year, the mean postoperative IOP was significantly lower in group A.', 'At 1 year, the mean postoperative IOP was significantly lower in group A.\tAccording to the MBGS, blebs with an ologen implant showed significantly better scoring than those with MMC.', 'At 1 year, the mean postoperative IOP was significantly lower in group A.\tAS-OCT showed that ologen-induced blebs had significantly more fluid-filled spaces, cleavage planes, and less fibrosis.', 'At 1 year, the mean postoperative IOP was significantly lower in group A.\tOlogen resulted in a lower long-term postoperative IOP, a better bleb morphology, and fewer complications.', 'At 1 year, the mean postoperative IOP was significantly lower in group A.\tOur results suggest that ologen may be a useful alternative to MMC in JOAG.', 'According to the MBGS, blebs with an ologen implant showed significantly better scoring than those with MMC.\tThe mean postoperative IOP was statistically significantly lower than the mean preoperative IOP at each follow-up in each group.', 'According to the MBGS, blebs with an ologen implant showed significantly better scoring than those with MMC.\tAt 1 year, the mean postoperative IOP was significantly lower in group A.', 'According to the MBGS, blebs with an ologen implant showed significantly better scoring than those with MMC.\tAccording to the MBGS, blebs with an ologen implant showed significantly better scoring than those with MMC.', 'According to the MBGS, blebs with an ologen implant showed significantly better scoring than those with MMC.\tAS-OCT showed that ologen-induced blebs had significantly more fluid-filled spaces, cleavage planes, and less fibrosis.', 'According to the MBGS, blebs with an ologen implant showed significantly better scoring than those with MMC.\tOlogen resulted in a lower long-term postoperative IOP, a better bleb morphology, and fewer complications.', 'According to the MBGS, blebs with an ologen implant showed significantly better scoring than those with MMC.\tOur results suggest that ologen may be a useful alternative to MMC in JOAG.', 'AS-OCT showed that ologen-induced blebs had significantly more fluid-filled spaces, cleavage planes, and less fibrosis.\tThe mean postoperative IOP was statistically significantly lower than the mean preoperative IOP at each follow-up in each group.', 'AS-OCT showed that ologen-induced blebs had significantly more fluid-filled spaces, cleavage planes, and less fibrosis.\tAt 1 year, the mean postoperative IOP was significantly lower in group A.', 'AS-OCT showed that ologen-induced blebs had significantly more fluid-filled spaces, cleavage planes, and less fibrosis.\tAccording to the MBGS, blebs with an ologen implant showed significantly better scoring than those with MMC.', 'AS-OCT showed that ologen-induced blebs had significantly more fluid-filled spaces, cleavage planes, and less fibrosis.\tAS-OCT showed that ologen-induced blebs had significantly more fluid-filled spaces, cleavage planes, and less fibrosis.', 'AS-OCT showed that ologen-induced blebs had significantly more fluid-filled spaces, cleavage planes, and less fibrosis.\tOlogen resulted in a lower long-term postoperative IOP, a better bleb morphology, and fewer complications.', 'AS-OCT showed that ologen-induced blebs had significantly more fluid-filled spaces, cleavage planes, and less fibrosis.\tOur results suggest that ologen may be a useful alternative to MMC in JOAG.', 'Ologen resulted in a lower long-term postoperative IOP, a better bleb morphology, and fewer complications.\tThe mean postoperative IOP was statistically significantly lower than the mean preoperative IOP at each follow-up in each group.', 'Ologen resulted in a lower long-term postoperative IOP, a better bleb morphology, and fewer complications.\tAt 1 year, the mean postoperative IOP was significantly lower in group A.', 'Ologen resulted in a lower long-term postoperative IOP, a better bleb morphology, and fewer complications.\tAccording to the MBGS, blebs with an ologen implant showed significantly better scoring than those with MMC.', 'Ologen resulted in a lower long-term postoperative IOP, a better bleb morphology, and fewer complications.\tAS-OCT showed that ologen-induced blebs had significantly more fluid-filled spaces, cleavage planes, and less fibrosis.', 'Ologen resulted in a lower long-term postoperative IOP, a better bleb morphology, and fewer complications.\tOlogen resulted in a lower long-term postoperative IOP, a better bleb morphology, and fewer complications.', 'Ologen resulted in a lower long-term postoperative IOP, a better bleb morphology, and fewer complications.\tOur results suggest that ologen may be a useful alternative to MMC in JOAG.', 'Our results suggest that ologen may be a useful alternative to MMC in JOAG.\tThe mean postoperative IOP was statistically significantly lower than the mean preoperative IOP at each follow-up in each group.', 'Our results suggest that ologen may be a useful alternative to MMC in JOAG.\tAt 1 year, the mean postoperative IOP was significantly lower in group A.', 'Our results suggest that ologen may be a useful alternative to MMC in JOAG.\tAccording to the MBGS, blebs with an ologen implant showed significantly better scoring than those with MMC.', 'Our results suggest that ologen may be a useful alternative to MMC in JOAG.\tAS-OCT showed that ologen-induced blebs had significantly more fluid-filled spaces, cleavage planes, and less fibrosis.', 'Our results suggest that ologen may be a useful alternative to MMC in JOAG.\tOlogen resulted in a lower long-term postoperative IOP, a better bleb morphology, and fewer complications.', 'Our results suggest that ologen may be a useful alternative to MMC in JOAG.\tOur results suggest that ologen may be a useful alternative to MMC in JOAG.']","[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]"
"['TDF monotherapy was efficacious and safe for up to 144 weeks, providing an increasing rate of virologic response in heavily pretreated patients with multidrug-resistant HBV.\tTDF monotherapy was efficacious and safe for up to 144 weeks, providing an increasing rate of virologic response in heavily pretreated patients with multidrug-resistant HBV.', 'TDF monotherapy was efficacious and safe for up to 144 weeks, providing an increasing rate of virologic response in heavily pretreated patients with multidrug-resistant HBV.\tSerum HBV DNA <15 IU/mL at week 48, the primary efficacy endpoint, was achieved in 66.3% in the TDF-TDF group and 68.0% in the TDF/ETV-TDF group (P = 0.80).', 'TDF monotherapy was efficacious and safe for up to 144 weeks, providing an increasing rate of virologic response in heavily pretreated patients with multidrug-resistant HBV.\tAt week 144, the proportion with HBV DNA <15 IU/mL increased to 74.5%, which was significantly higher compared with that at week 48 (P = 0.03), without a significant difference between groups (P = 0.46).', 'TDF monotherapy was efficacious and safe for up to 144 weeks, providing an increasing rate of virologic response in heavily pretreated patients with multidrug-resistant HBV.\tBy on-treatment analysis, a total of 79.4% had HBV DNA <15 IU/mL at week 144.', 'TDF monotherapy was efficacious and safe for up to 144 weeks, providing an increasing rate of virologic response in heavily pretreated patients with multidrug-resistant HBV.\tTransient virologic breakthrough occurred in 6 patients, which was due to poor drug adherence.', 'TDF monotherapy was efficacious and safe for up to 144 weeks, providing an increasing rate of virologic response in heavily pretreated patients with multidrug-resistant HBV.\tAt week 144, 19 patients who had HBV DNA levels >60 IU/mL qualified for genotypic resistance analysis, and 6 retained some of their baseline resistance mutations of HBV.', 'TDF monotherapy was efficacious and safe for up to 144 weeks, providing an increasing rate of virologic response in heavily pretreated patients with multidrug-resistant HBV.\tNo patients developed additional resistance mutations throughout the study period.', 'Serum HBV DNA <15 IU/mL at week 48, the primary efficacy endpoint, was achieved in 66.3% in the TDF-TDF group and 68.0% in the TDF/ETV-TDF group (P = 0.80).\tTDF monotherapy was efficacious and safe for up to 144 weeks, providing an increasing rate of virologic response in heavily pretreated patients with multidrug-resistant HBV.', 'Serum HBV DNA <15 IU/mL at week 48, the primary efficacy endpoint, was achieved in 66.3% in the TDF-TDF group and 68.0% in the TDF/ETV-TDF group (P = 0.80).\tSerum HBV DNA <15 IU/mL at week 48, the primary efficacy endpoint, was achieved in 66.3% in the TDF-TDF group and 68.0% in the TDF/ETV-TDF group (P = 0.80).', 'Serum HBV DNA <15 IU/mL at week 48, the primary efficacy endpoint, was achieved in 66.3% in the TDF-TDF group and 68.0% in the TDF/ETV-TDF group (P = 0.80).\tAt week 144, the proportion with HBV DNA <15 IU/mL increased to 74.5%, which was significantly higher compared with that at week 48 (P = 0.03), without a significant difference between groups (P = 0.46).', 'Serum HBV DNA <15 IU/mL at week 48, the primary efficacy endpoint, was achieved in 66.3% in the TDF-TDF group and 68.0% in the TDF/ETV-TDF group (P = 0.80).\tBy on-treatment analysis, a total of 79.4% had HBV DNA <15 IU/mL at week 144.', 'Serum HBV DNA <15 IU/mL at week 48, the primary efficacy endpoint, was achieved in 66.3% in the TDF-TDF group and 68.0% in the TDF/ETV-TDF group (P = 0.80).\tTransient virologic breakthrough occurred in 6 patients, which was due to poor drug adherence.', 'Serum HBV DNA <15 IU/mL at week 48, the primary efficacy endpoint, was achieved in 66.3% in the TDF-TDF group and 68.0% in the TDF/ETV-TDF group (P = 0.80).\tAt week 144, 19 patients who had HBV DNA levels >60 IU/mL qualified for genotypic resistance analysis, and 6 retained some of their baseline resistance mutations of HBV.', 'Serum HBV DNA <15 IU/mL at week 48, the primary efficacy endpoint, was achieved in 66.3% in the TDF-TDF group and 68.0% in the TDF/ETV-TDF group (P = 0.80).\tNo patients developed additional resistance mutations throughout the study period.', 'At week 144, the proportion with HBV DNA <15 IU/mL increased to 74.5%, which was significantly higher compared with that at week 48 (P = 0.03), without a significant difference between groups (P = 0.46).\tTDF monotherapy was efficacious and safe for up to 144 weeks, providing an increasing rate of virologic response in heavily pretreated patients with multidrug-resistant HBV.', 'At week 144, the proportion with HBV DNA <15 IU/mL increased to 74.5%, which was significantly higher compared with that at week 48 (P = 0.03), without a significant difference between groups (P = 0.46).\tSerum HBV DNA <15 IU/mL at week 48, the primary efficacy endpoint, was achieved in 66.3% in the TDF-TDF group and 68.0% in the TDF/ETV-TDF group (P = 0.80).', 'At week 144, the proportion with HBV DNA <15 IU/mL increased to 74.5%, which was significantly higher compared with that at week 48 (P = 0.03), without a significant difference between groups (P = 0.46).\tAt week 144, the proportion with HBV DNA <15 IU/mL increased to 74.5%, which was significantly higher compared with that at week 48 (P = 0.03), without a significant difference between groups (P = 0.46).', 'At week 144, the proportion with HBV DNA <15 IU/mL increased to 74.5%, which was significantly higher compared with that at week 48 (P = 0.03), without a significant difference between groups (P = 0.46).\tBy on-treatment analysis, a total of 79.4% had HBV DNA <15 IU/mL at week 144.', 'At week 144, the proportion with HBV DNA <15 IU/mL increased to 74.5%, which was significantly higher compared with that at week 48 (P = 0.03), without a significant difference between groups (P = 0.46).\tTransient virologic breakthrough occurred in 6 patients, which was due to poor drug adherence.', 'At week 144, the proportion with HBV DNA <15 IU/mL increased to 74.5%, which was significantly higher compared with that at week 48 (P = 0.03), without a significant difference between groups (P = 0.46).\tAt week 144, 19 patients who had HBV DNA levels >60 IU/mL qualified for genotypic resistance analysis, and 6 retained some of their baseline resistance mutations of HBV.', 'At week 144, the proportion with HBV DNA <15 IU/mL increased to 74.5%, which was significantly higher compared with that at week 48 (P = 0.03), without a significant difference between groups (P = 0.46).\tNo patients developed additional resistance mutations throughout the study period.', 'By on-treatment analysis, a total of 79.4% had HBV DNA <15 IU/mL at week 144.\tTDF monotherapy was efficacious and safe for up to 144 weeks, providing an increasing rate of virologic response in heavily pretreated patients with multidrug-resistant HBV.', 'By on-treatment analysis, a total of 79.4% had HBV DNA <15 IU/mL at week 144.\tSerum HBV DNA <15 IU/mL at week 48, the primary efficacy endpoint, was achieved in 66.3% in the TDF-TDF group and 68.0% in the TDF/ETV-TDF group (P = 0.80).', 'By on-treatment analysis, a total of 79.4% had HBV DNA <15 IU/mL at week 144.\tAt week 144, the proportion with HBV DNA <15 IU/mL increased to 74.5%, which was significantly higher compared with that at week 48 (P = 0.03), without a significant difference between groups (P = 0.46).', 'By on-treatment analysis, a total of 79.4% had HBV DNA <15 IU/mL at week 144.\tBy on-treatment analysis, a total of 79.4% had HBV DNA <15 IU/mL at week 144.', 'By on-treatment analysis, a total of 79.4% had HBV DNA <15 IU/mL at week 144.\tTransient virologic breakthrough occurred in 6 patients, which was due to poor drug adherence.', 'By on-treatment analysis, a total of 79.4% had HBV DNA <15 IU/mL at week 144.\tAt week 144, 19 patients who had HBV DNA levels >60 IU/mL qualified for genotypic resistance analysis, and 6 retained some of their baseline resistance mutations of HBV.', 'By on-treatment analysis, a total of 79.4% had HBV DNA <15 IU/mL at week 144.\tNo patients developed additional resistance mutations throughout the study period.', 'Transient virologic breakthrough occurred in 6 patients, which was due to poor drug adherence.\tTDF monotherapy was efficacious and safe for up to 144 weeks, providing an increasing rate of virologic response in heavily pretreated patients with multidrug-resistant HBV.', 'Transient virologic breakthrough occurred in 6 patients, which was due to poor drug adherence.\tSerum HBV DNA <15 IU/mL at week 48, the primary efficacy endpoint, was achieved in 66.3% in the TDF-TDF group and 68.0% in the TDF/ETV-TDF group (P = 0.80).', 'Transient virologic breakthrough occurred in 6 patients, which was due to poor drug adherence.\tAt week 144, the proportion with HBV DNA <15 IU/mL increased to 74.5%, which was significantly higher compared with that at week 48 (P = 0.03), without a significant difference between groups (P = 0.46).', 'Transient virologic breakthrough occurred in 6 patients, which was due to poor drug adherence.\tBy on-treatment analysis, a total of 79.4% had HBV DNA <15 IU/mL at week 144.', 'Transient virologic breakthrough occurred in 6 patients, which was due to poor drug adherence.\tTransient virologic breakthrough occurred in 6 patients, which was due to poor drug adherence.', 'Transient virologic breakthrough occurred in 6 patients, which was due to poor drug adherence.\tAt week 144, 19 patients who had HBV DNA levels >60 IU/mL qualified for genotypic resistance analysis, and 6 retained some of their baseline resistance mutations of HBV.', 'Transient virologic breakthrough occurred in 6 patients, which was due to poor drug adherence.\tNo patients developed additional resistance mutations throughout the study period.', 'At week 144, 19 patients who had HBV DNA levels >60 IU/mL qualified for genotypic resistance analysis, and 6 retained some of their baseline resistance mutations of HBV.\tTDF monotherapy was efficacious and safe for up to 144 weeks, providing an increasing rate of virologic response in heavily pretreated patients with multidrug-resistant HBV.', 'At week 144, 19 patients who had HBV DNA levels >60 IU/mL qualified for genotypic resistance analysis, and 6 retained some of their baseline resistance mutations of HBV.\tSerum HBV DNA <15 IU/mL at week 48, the primary efficacy endpoint, was achieved in 66.3% in the TDF-TDF group and 68.0% in the TDF/ETV-TDF group (P = 0.80).', 'At week 144, 19 patients who had HBV DNA levels >60 IU/mL qualified for genotypic resistance analysis, and 6 retained some of their baseline resistance mutations of HBV.\tAt week 144, the proportion with HBV DNA <15 IU/mL increased to 74.5%, which was significantly higher compared with that at week 48 (P = 0.03), without a significant difference between groups (P = 0.46).', 'At week 144, 19 patients who had HBV DNA levels >60 IU/mL qualified for genotypic resistance analysis, and 6 retained some of their baseline resistance mutations of HBV.\tBy on-treatment analysis, a total of 79.4% had HBV DNA <15 IU/mL at week 144.', 'At week 144, 19 patients who had HBV DNA levels >60 IU/mL qualified for genotypic resistance analysis, and 6 retained some of their baseline resistance mutations of HBV.\tTransient virologic breakthrough occurred in 6 patients, which was due to poor drug adherence.', 'At week 144, 19 patients who had HBV DNA levels >60 IU/mL qualified for genotypic resistance analysis, and 6 retained some of their baseline resistance mutations of HBV.\tAt week 144, 19 patients who had HBV DNA levels >60 IU/mL qualified for genotypic resistance analysis, and 6 retained some of their baseline resistance mutations of HBV.', 'At week 144, 19 patients who had HBV DNA levels >60 IU/mL qualified for genotypic resistance analysis, and 6 retained some of their baseline resistance mutations of HBV.\tNo patients developed additional resistance mutations throughout the study period.', 'No patients developed additional resistance mutations throughout the study period.\tTDF monotherapy was efficacious and safe for up to 144 weeks, providing an increasing rate of virologic response in heavily pretreated patients with multidrug-resistant HBV.', 'No patients developed additional resistance mutations throughout the study period.\tSerum HBV DNA <15 IU/mL at week 48, the primary efficacy endpoint, was achieved in 66.3% in the TDF-TDF group and 68.0% in the TDF/ETV-TDF group (P = 0.80).', 'No patients developed additional resistance mutations throughout the study period.\tAt week 144, the proportion with HBV DNA <15 IU/mL increased to 74.5%, which was significantly higher compared with that at week 48 (P = 0.03), without a significant difference between groups (P = 0.46).', 'No patients developed additional resistance mutations throughout the study period.\tBy on-treatment analysis, a total of 79.4% had HBV DNA <15 IU/mL at week 144.', 'No patients developed additional resistance mutations throughout the study period.\tTransient virologic breakthrough occurred in 6 patients, which was due to poor drug adherence.', 'No patients developed additional resistance mutations throughout the study period.\tAt week 144, 19 patients who had HBV DNA levels >60 IU/mL qualified for genotypic resistance analysis, and 6 retained some of their baseline resistance mutations of HBV.', 'No patients developed additional resistance mutations throughout the study period.\tNo patients developed additional resistance mutations throughout the study period.']","[0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]"
"['Ocular irritation was frequently seen in DTFC group.\tOcular irritation was frequently seen in DTFC group.', 'Ocular irritation was frequently seen in DTFC group.\tIntra-ocular pressure (IOP) change from baseline at 9 AM/11 AM pooled over the 8 weeks was -3.3/-3.3 mmHg in the BTFC group and -2.9/-3.4 mmHg in the DTFC group,', 'Ocular irritation was frequently seen in DTFC group.\tblurred vision was frequently seen in BTFC group,', 'Ocular irritation was frequently seen in DTFC group.\tNon-inferiority of BTFC to DTFC in IOP reduction was demonstrated after adding onto PGA therapy in Japanese OAG/OH patients.', 'Ocular irritation was frequently seen in DTFC group.\tthe score of blurred vision was transiently higher in BTFC than DTFC,', 'Ocular irritation was frequently seen in DTFC group.\tBTFC can be considered as a safe and effective agent for glaucoma treatment.', 'Ocular irritation was frequently seen in DTFC group.\ttreatment difference decreased and disappeared with time.', 'Ocular irritation was frequently seen in DTFC group.\tNo noteworthy issue was observed in other safety outcome.', 'Intra-ocular pressure (IOP) change from baseline at 9 AM/11 AM pooled over the 8 weeks was -3.3/-3.3 mmHg in the BTFC group and -2.9/-3.4 mmHg in the DTFC group,\tOcular irritation was frequently seen in DTFC group.', 'Intra-ocular pressure (IOP) change from baseline at 9 AM/11 AM pooled over the 8 weeks was -3.3/-3.3 mmHg in the BTFC group and -2.9/-3.4 mmHg in the DTFC group,\tIntra-ocular pressure (IOP) change from baseline at 9 AM/11 AM pooled over the 8 weeks was -3.3/-3.3 mmHg in the BTFC group and -2.9/-3.4 mmHg in the DTFC group,', 'Intra-ocular pressure (IOP) change from baseline at 9 AM/11 AM pooled over the 8 weeks was -3.3/-3.3 mmHg in the BTFC group and -2.9/-3.4 mmHg in the DTFC group,\tblurred vision was frequently seen in BTFC group,', 'Intra-ocular pressure (IOP) change from baseline at 9 AM/11 AM pooled over the 8 weeks was -3.3/-3.3 mmHg in the BTFC group and -2.9/-3.4 mmHg in the DTFC group,\tNon-inferiority of BTFC to DTFC in IOP reduction was demonstrated after adding onto PGA therapy in Japanese OAG/OH patients.', 'Intra-ocular pressure (IOP) change from baseline at 9 AM/11 AM pooled over the 8 weeks was -3.3/-3.3 mmHg in the BTFC group and -2.9/-3.4 mmHg in the DTFC group,\tthe score of blurred vision was transiently higher in BTFC than DTFC,', 'Intra-ocular pressure (IOP) change from baseline at 9 AM/11 AM pooled over the 8 weeks was -3.3/-3.3 mmHg in the BTFC group and -2.9/-3.4 mmHg in the DTFC group,\tBTFC can be considered as a safe and effective agent for glaucoma treatment.', 'Intra-ocular pressure (IOP) change from baseline at 9 AM/11 AM pooled over the 8 weeks was -3.3/-3.3 mmHg in the BTFC group and -2.9/-3.4 mmHg in the DTFC group,\ttreatment difference decreased and disappeared with time.', 'Intra-ocular pressure (IOP) change from baseline at 9 AM/11 AM pooled over the 8 weeks was -3.3/-3.3 mmHg in the BTFC group and -2.9/-3.4 mmHg in the DTFC group,\tNo noteworthy issue was observed in other safety outcome.', 'blurred vision was frequently seen in BTFC group,\tOcular irritation was frequently seen in DTFC group.', 'blurred vision was frequently seen in BTFC group,\tIntra-ocular pressure (IOP) change from baseline at 9 AM/11 AM pooled over the 8 weeks was -3.3/-3.3 mmHg in the BTFC group and -2.9/-3.4 mmHg in the DTFC group,', 'blurred vision was frequently seen in BTFC group,\tblurred vision was frequently seen in BTFC group,', 'blurred vision was frequently seen in BTFC group,\tNon-inferiority of BTFC to DTFC in IOP reduction was demonstrated after adding onto PGA therapy in Japanese OAG/OH patients.', 'blurred vision was frequently seen in BTFC group,\tthe score of blurred vision was transiently higher in BTFC than DTFC,', 'blurred vision was frequently seen in BTFC group,\tBTFC can be considered as a safe and effective agent for glaucoma treatment.', 'blurred vision was frequently seen in BTFC group,\ttreatment difference decreased and disappeared with time.', 'blurred vision was frequently seen in BTFC group,\tNo noteworthy issue was observed in other safety outcome.', 'Non-inferiority of BTFC to DTFC in IOP reduction was demonstrated after adding onto PGA therapy in Japanese OAG/OH patients.\tOcular irritation was frequently seen in DTFC group.', 'Non-inferiority of BTFC to DTFC in IOP reduction was demonstrated after adding onto PGA therapy in Japanese OAG/OH patients.\tIntra-ocular pressure (IOP) change from baseline at 9 AM/11 AM pooled over the 8 weeks was -3.3/-3.3 mmHg in the BTFC group and -2.9/-3.4 mmHg in the DTFC group,', 'Non-inferiority of BTFC to DTFC in IOP reduction was demonstrated after adding onto PGA therapy in Japanese OAG/OH patients.\tblurred vision was frequently seen in BTFC group,', 'Non-inferiority of BTFC to DTFC in IOP reduction was demonstrated after adding onto PGA therapy in Japanese OAG/OH patients.\tNon-inferiority of BTFC to DTFC in IOP reduction was demonstrated after adding onto PGA therapy in Japanese OAG/OH patients.', 'Non-inferiority of BTFC to DTFC in IOP reduction was demonstrated after adding onto PGA therapy in Japanese OAG/OH patients.\tthe score of blurred vision was transiently higher in BTFC than DTFC,', 'Non-inferiority of BTFC to DTFC in IOP reduction was demonstrated after adding onto PGA therapy in Japanese OAG/OH patients.\tBTFC can be considered as a safe and effective agent for glaucoma treatment.', 'Non-inferiority of BTFC to DTFC in IOP reduction was demonstrated after adding onto PGA therapy in Japanese OAG/OH patients.\ttreatment difference decreased and disappeared with time.', 'Non-inferiority of BTFC to DTFC in IOP reduction was demonstrated after adding onto PGA therapy in Japanese OAG/OH patients.\tNo noteworthy issue was observed in other safety outcome.', 'the score of blurred vision was transiently higher in BTFC than DTFC,\tOcular irritation was frequently seen in DTFC group.', 'the score of blurred vision was transiently higher in BTFC than DTFC,\tIntra-ocular pressure (IOP) change from baseline at 9 AM/11 AM pooled over the 8 weeks was -3.3/-3.3 mmHg in the BTFC group and -2.9/-3.4 mmHg in the DTFC group,', 'the score of blurred vision was transiently higher in BTFC than DTFC,\tblurred vision was frequently seen in BTFC group,', 'the score of blurred vision was transiently higher in BTFC than DTFC,\tNon-inferiority of BTFC to DTFC in IOP reduction was demonstrated after adding onto PGA therapy in Japanese OAG/OH patients.', 'the score of blurred vision was transiently higher in BTFC than DTFC,\tthe score of blurred vision was transiently higher in BTFC than DTFC,', 'the score of blurred vision was transiently higher in BTFC than DTFC,\tBTFC can be considered as a safe and effective agent for glaucoma treatment.', 'the score of blurred vision was transiently higher in BTFC than DTFC,\ttreatment difference decreased and disappeared with time.', 'the score of blurred vision was transiently higher in BTFC than DTFC,\tNo noteworthy issue was observed in other safety outcome.', 'BTFC can be considered as a safe and effective agent for glaucoma treatment.\tOcular irritation was frequently seen in DTFC group.', 'BTFC can be considered as a safe and effective agent for glaucoma treatment.\tIntra-ocular pressure (IOP) change from baseline at 9 AM/11 AM pooled over the 8 weeks was -3.3/-3.3 mmHg in the BTFC group and -2.9/-3.4 mmHg in the DTFC group,', 'BTFC can be considered as a safe and effective agent for glaucoma treatment.\tblurred vision was frequently seen in BTFC group,', 'BTFC can be considered as a safe and effective agent for glaucoma treatment.\tNon-inferiority of BTFC to DTFC in IOP reduction was demonstrated after adding onto PGA therapy in Japanese OAG/OH patients.', 'BTFC can be considered as a safe and effective agent for glaucoma treatment.\tthe score of blurred vision was transiently higher in BTFC than DTFC,', 'BTFC can be considered as a safe and effective agent for glaucoma treatment.\tBTFC can be considered as a safe and effective agent for glaucoma treatment.', 'BTFC can be considered as a safe and effective agent for glaucoma treatment.\ttreatment difference decreased and disappeared with time.', 'BTFC can be considered as a safe and effective agent for glaucoma treatment.\tNo noteworthy issue was observed in other safety outcome.', 'treatment difference decreased and disappeared with time.\tOcular irritation was frequently seen in DTFC group.', 'treatment difference decreased and disappeared with time.\tIntra-ocular pressure (IOP) change from baseline at 9 AM/11 AM pooled over the 8 weeks was -3.3/-3.3 mmHg in the BTFC group and -2.9/-3.4 mmHg in the DTFC group,', 'treatment difference decreased and disappeared with time.\tblurred vision was frequently seen in BTFC group,', 'treatment difference decreased and disappeared with time.\tNon-inferiority of BTFC to DTFC in IOP reduction was demonstrated after adding onto PGA therapy in Japanese OAG/OH patients.', 'treatment difference decreased and disappeared with time.\tthe score of blurred vision was transiently higher in BTFC than DTFC,', 'treatment difference decreased and disappeared with time.\tBTFC can be considered as a safe and effective agent for glaucoma treatment.', 'treatment difference decreased and disappeared with time.\ttreatment difference decreased and disappeared with time.', 'treatment difference decreased and disappeared with time.\tNo noteworthy issue was observed in other safety outcome.', 'No noteworthy issue was observed in other safety outcome.\tOcular irritation was frequently seen in DTFC group.', 'No noteworthy issue was observed in other safety outcome.\tIntra-ocular pressure (IOP) change from baseline at 9 AM/11 AM pooled over the 8 weeks was -3.3/-3.3 mmHg in the BTFC group and -2.9/-3.4 mmHg in the DTFC group,', 'No noteworthy issue was observed in other safety outcome.\tblurred vision was frequently seen in BTFC group,', 'No noteworthy issue was observed in other safety outcome.\tNon-inferiority of BTFC to DTFC in IOP reduction was demonstrated after adding onto PGA therapy in Japanese OAG/OH patients.', 'No noteworthy issue was observed in other safety outcome.\tthe score of blurred vision was transiently higher in BTFC than DTFC,', 'No noteworthy issue was observed in other safety outcome.\tBTFC can be considered as a safe and effective agent for glaucoma treatment.', 'No noteworthy issue was observed in other safety outcome.\ttreatment difference decreased and disappeared with time.', 'No noteworthy issue was observed in other safety outcome.\tNo noteworthy issue was observed in other safety outcome.']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0]"
"['In Group 1 and 2, intraocular pressure was well controlled to approximately 14 mmHg (9.38-18.46% decrease).\tIn Group 1 and 2, intraocular pressure was well controlled to approximately 14 mmHg (9.38-18.46% decrease).', 'In Group 1 and 2, intraocular pressure was well controlled to approximately 14 mmHg (9.38-18.46% decrease).\tGenerally, subjective satisfaction was improved after changing from PT to NPT (p\u2009=\u20090.03) and TBUT using PT was numerically inferior to that using NPT (p\u2009=\u20090.06) but not when changing from NPT to PT.', 'In Group 1 and 2, intraocular pressure was well controlled to approximately 14 mmHg (9.38-18.46% decrease).\tBoth preservative containing and preservative-free 0.0015% tafluprost reduced intraocular pressure significantly.', 'In Group 1 and 2, intraocular pressure was well controlled to approximately 14 mmHg (9.38-18.46% decrease).\tchanging medication from PT to NPT might improve subjective satisfaction and tear break up time.', 'Generally, subjective satisfaction was improved after changing from PT to NPT (p\u2009=\u20090.03) and TBUT using PT was numerically inferior to that using NPT (p\u2009=\u20090.06) but not when changing from NPT to PT.\tIn Group 1 and 2, intraocular pressure was well controlled to approximately 14 mmHg (9.38-18.46% decrease).', 'Generally, subjective satisfaction was improved after changing from PT to NPT (p\u2009=\u20090.03) and TBUT using PT was numerically inferior to that using NPT (p\u2009=\u20090.06) but not when changing from NPT to PT.\tGenerally, subjective satisfaction was improved after changing from PT to NPT (p\u2009=\u20090.03) and TBUT using PT was numerically inferior to that using NPT (p\u2009=\u20090.06) but not when changing from NPT to PT.', 'Generally, subjective satisfaction was improved after changing from PT to NPT (p\u2009=\u20090.03) and TBUT using PT was numerically inferior to that using NPT (p\u2009=\u20090.06) but not when changing from NPT to PT.\tBoth preservative containing and preservative-free 0.0015% tafluprost reduced intraocular pressure significantly.', 'Generally, subjective satisfaction was improved after changing from PT to NPT (p\u2009=\u20090.03) and TBUT using PT was numerically inferior to that using NPT (p\u2009=\u20090.06) but not when changing from NPT to PT.\tchanging medication from PT to NPT might improve subjective satisfaction and tear break up time.', 'Both preservative containing and preservative-free 0.0015% tafluprost reduced intraocular pressure significantly.\tIn Group 1 and 2, intraocular pressure was well controlled to approximately 14 mmHg (9.38-18.46% decrease).', 'Both preservative containing and preservative-free 0.0015% tafluprost reduced intraocular pressure significantly.\tGenerally, subjective satisfaction was improved after changing from PT to NPT (p\u2009=\u20090.03) and TBUT using PT was numerically inferior to that using NPT (p\u2009=\u20090.06) but not when changing from NPT to PT.', 'Both preservative containing and preservative-free 0.0015% tafluprost reduced intraocular pressure significantly.\tBoth preservative containing and preservative-free 0.0015% tafluprost reduced intraocular pressure significantly.', 'Both preservative containing and preservative-free 0.0015% tafluprost reduced intraocular pressure significantly.\tchanging medication from PT to NPT might improve subjective satisfaction and tear break up time.', 'changing medication from PT to NPT might improve subjective satisfaction and tear break up time.\tIn Group 1 and 2, intraocular pressure was well controlled to approximately 14 mmHg (9.38-18.46% decrease).', 'changing medication from PT to NPT might improve subjective satisfaction and tear break up time.\tGenerally, subjective satisfaction was improved after changing from PT to NPT (p\u2009=\u20090.03) and TBUT using PT was numerically inferior to that using NPT (p\u2009=\u20090.06) but not when changing from NPT to PT.', 'changing medication from PT to NPT might improve subjective satisfaction and tear break up time.\tBoth preservative containing and preservative-free 0.0015% tafluprost reduced intraocular pressure significantly.', 'changing medication from PT to NPT might improve subjective satisfaction and tear break up time.\tchanging medication from PT to NPT might improve subjective satisfaction and tear break up time.']","[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['It is concluded that Safoof akseer e jigar possesses as effective a therapeutic value in treating hepatitis B as allopathic medicine.\tIt is concluded that Safoof akseer e jigar possesses as effective a therapeutic value in treating hepatitis B as allopathic medicine.', 'It is concluded that Safoof akseer e jigar possesses as effective a therapeutic value in treating hepatitis B as allopathic medicine.\tNo significant difference was identified after treatment and it was found that the efficacy of Alpha (Control drug) is same as Safoof akseer e jigar (Test drug).', 'It is concluded that Safoof akseer e jigar possesses as effective a therapeutic value in treating hepatitis B as allopathic medicine.\tThe data offered support to the null hypothesis and therefore research hypothesis was rejected.', 'It is concluded that Safoof akseer e jigar possesses as effective a therapeutic value in treating hepatitis B as allopathic medicine.\tAccording to the statistical analysis by chi square, hepatitis B was recorded as negative in 26 patients (57.77%) out of 45 patients by the use of Interferon Alpha (control therapy) and in 27 patients (64.28%) out of 42 patients by the use of Safoof akseer e jigar (test drug).', 'It is concluded that Safoof akseer e jigar possesses as effective a therapeutic value in treating hepatitis B as allopathic medicine.\tComparison of the data recorded of the patients was determined as both drugs showed significant improvement and p value>0.05.', 'It is concluded that Safoof akseer e jigar possesses as effective a therapeutic value in treating hepatitis B as allopathic medicine.\tThe efficacy response is equal in both drugs while test drug showed more safety response.', 'No significant difference was identified after treatment and it was found that the efficacy of Alpha (Control drug) is same as Safoof akseer e jigar (Test drug).\tIt is concluded that Safoof akseer e jigar possesses as effective a therapeutic value in treating hepatitis B as allopathic medicine.', 'No significant difference was identified after treatment and it was found that the efficacy of Alpha (Control drug) is same as Safoof akseer e jigar (Test drug).\tNo significant difference was identified after treatment and it was found that the efficacy of Alpha (Control drug) is same as Safoof akseer e jigar (Test drug).', 'No significant difference was identified after treatment and it was found that the efficacy of Alpha (Control drug) is same as Safoof akseer e jigar (Test drug).\tThe data offered support to the null hypothesis and therefore research hypothesis was rejected.', 'No significant difference was identified after treatment and it was found that the efficacy of Alpha (Control drug) is same as Safoof akseer e jigar (Test drug).\tAccording to the statistical analysis by chi square, hepatitis B was recorded as negative in 26 patients (57.77%) out of 45 patients by the use of Interferon Alpha (control therapy) and in 27 patients (64.28%) out of 42 patients by the use of Safoof akseer e jigar (test drug).', 'No significant difference was identified after treatment and it was found that the efficacy of Alpha (Control drug) is same as Safoof akseer e jigar (Test drug).\tComparison of the data recorded of the patients was determined as both drugs showed significant improvement and p value>0.05.', 'No significant difference was identified after treatment and it was found that the efficacy of Alpha (Control drug) is same as Safoof akseer e jigar (Test drug).\tThe efficacy response is equal in both drugs while test drug showed more safety response.', 'The data offered support to the null hypothesis and therefore research hypothesis was rejected.\tIt is concluded that Safoof akseer e jigar possesses as effective a therapeutic value in treating hepatitis B as allopathic medicine.', 'The data offered support to the null hypothesis and therefore research hypothesis was rejected.\tNo significant difference was identified after treatment and it was found that the efficacy of Alpha (Control drug) is same as Safoof akseer e jigar (Test drug).', 'The data offered support to the null hypothesis and therefore research hypothesis was rejected.\tThe data offered support to the null hypothesis and therefore research hypothesis was rejected.', 'The data offered support to the null hypothesis and therefore research hypothesis was rejected.\tAccording to the statistical analysis by chi square, hepatitis B was recorded as negative in 26 patients (57.77%) out of 45 patients by the use of Interferon Alpha (control therapy) and in 27 patients (64.28%) out of 42 patients by the use of Safoof akseer e jigar (test drug).', 'The data offered support to the null hypothesis and therefore research hypothesis was rejected.\tComparison of the data recorded of the patients was determined as both drugs showed significant improvement and p value>0.05.', 'The data offered support to the null hypothesis and therefore research hypothesis was rejected.\tThe efficacy response is equal in both drugs while test drug showed more safety response.', 'According to the statistical analysis by chi square, hepatitis B was recorded as negative in 26 patients (57.77%) out of 45 patients by the use of Interferon Alpha (control therapy) and in 27 patients (64.28%) out of 42 patients by the use of Safoof akseer e jigar (test drug).\tIt is concluded that Safoof akseer e jigar possesses as effective a therapeutic value in treating hepatitis B as allopathic medicine.', 'According to the statistical analysis by chi square, hepatitis B was recorded as negative in 26 patients (57.77%) out of 45 patients by the use of Interferon Alpha (control therapy) and in 27 patients (64.28%) out of 42 patients by the use of Safoof akseer e jigar (test drug).\tNo significant difference was identified after treatment and it was found that the efficacy of Alpha (Control drug) is same as Safoof akseer e jigar (Test drug).', 'According to the statistical analysis by chi square, hepatitis B was recorded as negative in 26 patients (57.77%) out of 45 patients by the use of Interferon Alpha (control therapy) and in 27 patients (64.28%) out of 42 patients by the use of Safoof akseer e jigar (test drug).\tThe data offered support to the null hypothesis and therefore research hypothesis was rejected.', 'According to the statistical analysis by chi square, hepatitis B was recorded as negative in 26 patients (57.77%) out of 45 patients by the use of Interferon Alpha (control therapy) and in 27 patients (64.28%) out of 42 patients by the use of Safoof akseer e jigar (test drug).\tAccording to the statistical analysis by chi square, hepatitis B was recorded as negative in 26 patients (57.77%) out of 45 patients by the use of Interferon Alpha (control therapy) and in 27 patients (64.28%) out of 42 patients by the use of Safoof akseer e jigar (test drug).', 'According to the statistical analysis by chi square, hepatitis B was recorded as negative in 26 patients (57.77%) out of 45 patients by the use of Interferon Alpha (control therapy) and in 27 patients (64.28%) out of 42 patients by the use of Safoof akseer e jigar (test drug).\tComparison of the data recorded of the patients was determined as both drugs showed significant improvement and p value>0.05.', 'According to the statistical analysis by chi square, hepatitis B was recorded as negative in 26 patients (57.77%) out of 45 patients by the use of Interferon Alpha (control therapy) and in 27 patients (64.28%) out of 42 patients by the use of Safoof akseer e jigar (test drug).\tThe efficacy response is equal in both drugs while test drug showed more safety response.', 'Comparison of the data recorded of the patients was determined as both drugs showed significant improvement and p value>0.05.\tIt is concluded that Safoof akseer e jigar possesses as effective a therapeutic value in treating hepatitis B as allopathic medicine.', 'Comparison of the data recorded of the patients was determined as both drugs showed significant improvement and p value>0.05.\tNo significant difference was identified after treatment and it was found that the efficacy of Alpha (Control drug) is same as Safoof akseer e jigar (Test drug).', 'Comparison of the data recorded of the patients was determined as both drugs showed significant improvement and p value>0.05.\tThe data offered support to the null hypothesis and therefore research hypothesis was rejected.', 'Comparison of the data recorded of the patients was determined as both drugs showed significant improvement and p value>0.05.\tAccording to the statistical analysis by chi square, hepatitis B was recorded as negative in 26 patients (57.77%) out of 45 patients by the use of Interferon Alpha (control therapy) and in 27 patients (64.28%) out of 42 patients by the use of Safoof akseer e jigar (test drug).', 'Comparison of the data recorded of the patients was determined as both drugs showed significant improvement and p value>0.05.\tComparison of the data recorded of the patients was determined as both drugs showed significant improvement and p value>0.05.', 'Comparison of the data recorded of the patients was determined as both drugs showed significant improvement and p value>0.05.\tThe efficacy response is equal in both drugs while test drug showed more safety response.', 'The efficacy response is equal in both drugs while test drug showed more safety response.\tIt is concluded that Safoof akseer e jigar possesses as effective a therapeutic value in treating hepatitis B as allopathic medicine.', 'The efficacy response is equal in both drugs while test drug showed more safety response.\tNo significant difference was identified after treatment and it was found that the efficacy of Alpha (Control drug) is same as Safoof akseer e jigar (Test drug).', 'The efficacy response is equal in both drugs while test drug showed more safety response.\tThe data offered support to the null hypothesis and therefore research hypothesis was rejected.', 'The efficacy response is equal in both drugs while test drug showed more safety response.\tAccording to the statistical analysis by chi square, hepatitis B was recorded as negative in 26 patients (57.77%) out of 45 patients by the use of Interferon Alpha (control therapy) and in 27 patients (64.28%) out of 42 patients by the use of Safoof akseer e jigar (test drug).', 'The efficacy response is equal in both drugs while test drug showed more safety response.\tComparison of the data recorded of the patients was determined as both drugs showed significant improvement and p value>0.05.', 'The efficacy response is equal in both drugs while test drug showed more safety response.\tThe efficacy response is equal in both drugs while test drug showed more safety response.']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0]"
"['For the IMCT group and CPT groups, respectively, the absolute success rates were 80% (16/20) and 60% (12/20) (P < .001) and qualified success rates were 90% (18/20) and 70% (14/20) (P < .001).\tFor the IMCT group and CPT groups, respectively, the absolute success rates were 80% (16/20) and 60% (12/20) (P < .001) and qualified success rates were 90% (18/20) and 70% (14/20) (P < .001).', 'For the IMCT group and CPT groups, respectively, the absolute success rates were 80% (16/20) and 60% (12/20) (P < .001) and qualified success rates were 90% (18/20) and 70% (14/20) (P < .001).\tBoth procedures produced a statistically significant reduction in IOP,', 'For the IMCT group and CPT groups, respectively, the absolute success rates were 80% (16/20) and 60% (12/20) (P < .001) and qualified success rates were 90% (18/20) and 70% (14/20) (P < .001).\teyes undergoing IMCT achieved a lower IOP than CPT group eyes at 12 months follow-up (9.5 ± 2.4 mm Hg and 11.7 ± 2.1 mm Hg, respectively, P < .001).', 'For the IMCT group and CPT groups, respectively, the absolute success rates were 80% (16/20) and 60% (12/20) (P < .001) and qualified success rates were 90% (18/20) and 70% (14/20) (P < .001).\tIn primary congential glaucoma, illuminated microcatheter-assisted 360-degree circumferential trabeculotomy performed better than conventional partial trabeculotomy at 1 year follow-up and resulted in significantly lower IOP measurements.', 'For the IMCT group and CPT groups, respectively, the absolute success rates were 80% (16/20) and 60% (12/20) (P < .001) and qualified success rates were 90% (18/20) and 70% (14/20) (P < .001).\tIn the IMCT group, 360-degree cannulation was achieved in 80% (16/20) of eyes.', 'Both procedures produced a statistically significant reduction in IOP,\tFor the IMCT group and CPT groups, respectively, the absolute success rates were 80% (16/20) and 60% (12/20) (P < .001) and qualified success rates were 90% (18/20) and 70% (14/20) (P < .001).', 'Both procedures produced a statistically significant reduction in IOP,\tBoth procedures produced a statistically significant reduction in IOP,', 'Both procedures produced a statistically significant reduction in IOP,\teyes undergoing IMCT achieved a lower IOP than CPT group eyes at 12 months follow-up (9.5 ± 2.4 mm Hg and 11.7 ± 2.1 mm Hg, respectively, P < .001).', 'Both procedures produced a statistically significant reduction in IOP,\tIn primary congential glaucoma, illuminated microcatheter-assisted 360-degree circumferential trabeculotomy performed better than conventional partial trabeculotomy at 1 year follow-up and resulted in significantly lower IOP measurements.', 'Both procedures produced a statistically significant reduction in IOP,\tIn the IMCT group, 360-degree cannulation was achieved in 80% (16/20) of eyes.', 'eyes undergoing IMCT achieved a lower IOP than CPT group eyes at 12 months follow-up (9.5 ± 2.4 mm Hg and 11.7 ± 2.1 mm Hg, respectively, P < .001).\tFor the IMCT group and CPT groups, respectively, the absolute success rates were 80% (16/20) and 60% (12/20) (P < .001) and qualified success rates were 90% (18/20) and 70% (14/20) (P < .001).', 'eyes undergoing IMCT achieved a lower IOP than CPT group eyes at 12 months follow-up (9.5 ± 2.4 mm Hg and 11.7 ± 2.1 mm Hg, respectively, P < .001).\tBoth procedures produced a statistically significant reduction in IOP,', 'eyes undergoing IMCT achieved a lower IOP than CPT group eyes at 12 months follow-up (9.5 ± 2.4 mm Hg and 11.7 ± 2.1 mm Hg, respectively, P < .001).\teyes undergoing IMCT achieved a lower IOP than CPT group eyes at 12 months follow-up (9.5 ± 2.4 mm Hg and 11.7 ± 2.1 mm Hg, respectively, P < .001).', 'eyes undergoing IMCT achieved a lower IOP than CPT group eyes at 12 months follow-up (9.5 ± 2.4 mm Hg and 11.7 ± 2.1 mm Hg, respectively, P < .001).\tIn primary congential glaucoma, illuminated microcatheter-assisted 360-degree circumferential trabeculotomy performed better than conventional partial trabeculotomy at 1 year follow-up and resulted in significantly lower IOP measurements.', 'eyes undergoing IMCT achieved a lower IOP than CPT group eyes at 12 months follow-up (9.5 ± 2.4 mm Hg and 11.7 ± 2.1 mm Hg, respectively, P < .001).\tIn the IMCT group, 360-degree cannulation was achieved in 80% (16/20) of eyes.', 'In primary congential glaucoma, illuminated microcatheter-assisted 360-degree circumferential trabeculotomy performed better than conventional partial trabeculotomy at 1 year follow-up and resulted in significantly lower IOP measurements.\tFor the IMCT group and CPT groups, respectively, the absolute success rates were 80% (16/20) and 60% (12/20) (P < .001) and qualified success rates were 90% (18/20) and 70% (14/20) (P < .001).', 'In primary congential glaucoma, illuminated microcatheter-assisted 360-degree circumferential trabeculotomy performed better than conventional partial trabeculotomy at 1 year follow-up and resulted in significantly lower IOP measurements.\tBoth procedures produced a statistically significant reduction in IOP,', 'In primary congential glaucoma, illuminated microcatheter-assisted 360-degree circumferential trabeculotomy performed better than conventional partial trabeculotomy at 1 year follow-up and resulted in significantly lower IOP measurements.\teyes undergoing IMCT achieved a lower IOP than CPT group eyes at 12 months follow-up (9.5 ± 2.4 mm Hg and 11.7 ± 2.1 mm Hg, respectively, P < .001).', 'In primary congential glaucoma, illuminated microcatheter-assisted 360-degree circumferential trabeculotomy performed better than conventional partial trabeculotomy at 1 year follow-up and resulted in significantly lower IOP measurements.\tIn primary congential glaucoma, illuminated microcatheter-assisted 360-degree circumferential trabeculotomy performed better than conventional partial trabeculotomy at 1 year follow-up and resulted in significantly lower IOP measurements.', 'In primary congential glaucoma, illuminated microcatheter-assisted 360-degree circumferential trabeculotomy performed better than conventional partial trabeculotomy at 1 year follow-up and resulted in significantly lower IOP measurements.\tIn the IMCT group, 360-degree cannulation was achieved in 80% (16/20) of eyes.', 'In the IMCT group, 360-degree cannulation was achieved in 80% (16/20) of eyes.\tFor the IMCT group and CPT groups, respectively, the absolute success rates were 80% (16/20) and 60% (12/20) (P < .001) and qualified success rates were 90% (18/20) and 70% (14/20) (P < .001).', 'In the IMCT group, 360-degree cannulation was achieved in 80% (16/20) of eyes.\tBoth procedures produced a statistically significant reduction in IOP,', 'In the IMCT group, 360-degree cannulation was achieved in 80% (16/20) of eyes.\teyes undergoing IMCT achieved a lower IOP than CPT group eyes at 12 months follow-up (9.5 ± 2.4 mm Hg and 11.7 ± 2.1 mm Hg, respectively, P < .001).', 'In the IMCT group, 360-degree cannulation was achieved in 80% (16/20) of eyes.\tIn primary congential glaucoma, illuminated microcatheter-assisted 360-degree circumferential trabeculotomy performed better than conventional partial trabeculotomy at 1 year follow-up and resulted in significantly lower IOP measurements.', 'In the IMCT group, 360-degree cannulation was achieved in 80% (16/20) of eyes.\tIn the IMCT group, 360-degree cannulation was achieved in 80% (16/20) of eyes.']","[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['Compared with baseline, IOP drop at last visit was 11.76±5.51 and 13.43±5.92 in the bevacizumab and MMC groups, respectively (P=0.207).\tCompared with baseline, IOP drop at last visit was 11.76±5.51 and 13.43±5.92 in the bevacizumab and MMC groups, respectively (P=0.207).', 'Compared with baseline, IOP drop at last visit was 11.76±5.51 and 13.43±5.92 in the bevacizumab and MMC groups, respectively (P=0.207).\tAt last visit, complete success was achieved in 25 cases (61%) of bevacizumab group and 23 cases (66%) of MMC group (P=0.669).', 'Compared with baseline, IOP drop at last visit was 11.76±5.51 and 13.43±5.92 in the bevacizumab and MMC groups, respectively (P=0.207).\tEarly filtering bleb leak was more prevalent in bevacizumab group (29% vs. 11%).', 'Compared with baseline, IOP drop at last visit was 11.76±5.51 and 13.43±5.92 in the bevacizumab and MMC groups, respectively (P=0.207).\tA single 1.25\u2009mg dose of intracameral bevacizumab improves the success of trabeculectomy comparable with MMC;', 'Compared with baseline, IOP drop at last visit was 11.76±5.51 and 13.43±5.92 in the bevacizumab and MMC groups, respectively (P=0.207).\thowever, it increases the risk of early filtering bleb leakage.', 'Compared with baseline, IOP drop at last visit was 11.76±5.51 and 13.43±5.92 in the bevacizumab and MMC groups, respectively (P=0.207).\tThe preoperative IOP was 29.17±3.94 and 28.8±4.08\u2009mm\u2009Hg in the bevacizumab and MMC groups, respectively (P=0.689).', 'Compared with baseline, IOP drop at last visit was 11.76±5.51 and 13.43±5.92 in the bevacizumab and MMC groups, respectively (P=0.207).\tLast visit IOP was 17.41±3.11\u2009mm\u2009Hg in the bevacizumab group and 15.34±3.62\u2009mm Hg in the MMC group (P<0.009).', 'At last visit, complete success was achieved in 25 cases (61%) of bevacizumab group and 23 cases (66%) of MMC group (P=0.669).\tCompared with baseline, IOP drop at last visit was 11.76±5.51 and 13.43±5.92 in the bevacizumab and MMC groups, respectively (P=0.207).', 'At last visit, complete success was achieved in 25 cases (61%) of bevacizumab group and 23 cases (66%) of MMC group (P=0.669).\tAt last visit, complete success was achieved in 25 cases (61%) of bevacizumab group and 23 cases (66%) of MMC group (P=0.669).', 'At last visit, complete success was achieved in 25 cases (61%) of bevacizumab group and 23 cases (66%) of MMC group (P=0.669).\tEarly filtering bleb leak was more prevalent in bevacizumab group (29% vs. 11%).', 'At last visit, complete success was achieved in 25 cases (61%) of bevacizumab group and 23 cases (66%) of MMC group (P=0.669).\tA single 1.25\u2009mg dose of intracameral bevacizumab improves the success of trabeculectomy comparable with MMC;', 'At last visit, complete success was achieved in 25 cases (61%) of bevacizumab group and 23 cases (66%) of MMC group (P=0.669).\thowever, it increases the risk of early filtering bleb leakage.', 'At last visit, complete success was achieved in 25 cases (61%) of bevacizumab group and 23 cases (66%) of MMC group (P=0.669).\tThe preoperative IOP was 29.17±3.94 and 28.8±4.08\u2009mm\u2009Hg in the bevacizumab and MMC groups, respectively (P=0.689).', 'At last visit, complete success was achieved in 25 cases (61%) of bevacizumab group and 23 cases (66%) of MMC group (P=0.669).\tLast visit IOP was 17.41±3.11\u2009mm\u2009Hg in the bevacizumab group and 15.34±3.62\u2009mm Hg in the MMC group (P<0.009).', 'Early filtering bleb leak was more prevalent in bevacizumab group (29% vs. 11%).\tCompared with baseline, IOP drop at last visit was 11.76±5.51 and 13.43±5.92 in the bevacizumab and MMC groups, respectively (P=0.207).', 'Early filtering bleb leak was more prevalent in bevacizumab group (29% vs. 11%).\tAt last visit, complete success was achieved in 25 cases (61%) of bevacizumab group and 23 cases (66%) of MMC group (P=0.669).', 'Early filtering bleb leak was more prevalent in bevacizumab group (29% vs. 11%).\tEarly filtering bleb leak was more prevalent in bevacizumab group (29% vs. 11%).', 'Early filtering bleb leak was more prevalent in bevacizumab group (29% vs. 11%).\tA single 1.25\u2009mg dose of intracameral bevacizumab improves the success of trabeculectomy comparable with MMC;', 'Early filtering bleb leak was more prevalent in bevacizumab group (29% vs. 11%).\thowever, it increases the risk of early filtering bleb leakage.', 'Early filtering bleb leak was more prevalent in bevacizumab group (29% vs. 11%).\tThe preoperative IOP was 29.17±3.94 and 28.8±4.08\u2009mm\u2009Hg in the bevacizumab and MMC groups, respectively (P=0.689).', 'Early filtering bleb leak was more prevalent in bevacizumab group (29% vs. 11%).\tLast visit IOP was 17.41±3.11\u2009mm\u2009Hg in the bevacizumab group and 15.34±3.62\u2009mm Hg in the MMC group (P<0.009).', 'A single 1.25\u2009mg dose of intracameral bevacizumab improves the success of trabeculectomy comparable with MMC;\tCompared with baseline, IOP drop at last visit was 11.76±5.51 and 13.43±5.92 in the bevacizumab and MMC groups, respectively (P=0.207).', 'A single 1.25\u2009mg dose of intracameral bevacizumab improves the success of trabeculectomy comparable with MMC;\tAt last visit, complete success was achieved in 25 cases (61%) of bevacizumab group and 23 cases (66%) of MMC group (P=0.669).', 'A single 1.25\u2009mg dose of intracameral bevacizumab improves the success of trabeculectomy comparable with MMC;\tEarly filtering bleb leak was more prevalent in bevacizumab group (29% vs. 11%).', 'A single 1.25\u2009mg dose of intracameral bevacizumab improves the success of trabeculectomy comparable with MMC;\tA single 1.25\u2009mg dose of intracameral bevacizumab improves the success of trabeculectomy comparable with MMC;', 'A single 1.25\u2009mg dose of intracameral bevacizumab improves the success of trabeculectomy comparable with MMC;\thowever, it increases the risk of early filtering bleb leakage.', 'A single 1.25\u2009mg dose of intracameral bevacizumab improves the success of trabeculectomy comparable with MMC;\tThe preoperative IOP was 29.17±3.94 and 28.8±4.08\u2009mm\u2009Hg in the bevacizumab and MMC groups, respectively (P=0.689).', 'A single 1.25\u2009mg dose of intracameral bevacizumab improves the success of trabeculectomy comparable with MMC;\tLast visit IOP was 17.41±3.11\u2009mm\u2009Hg in the bevacizumab group and 15.34±3.62\u2009mm Hg in the MMC group (P<0.009).', 'however, it increases the risk of early filtering bleb leakage.\tCompared with baseline, IOP drop at last visit was 11.76±5.51 and 13.43±5.92 in the bevacizumab and MMC groups, respectively (P=0.207).', 'however, it increases the risk of early filtering bleb leakage.\tAt last visit, complete success was achieved in 25 cases (61%) of bevacizumab group and 23 cases (66%) of MMC group (P=0.669).', 'however, it increases the risk of early filtering bleb leakage.\tEarly filtering bleb leak was more prevalent in bevacizumab group (29% vs. 11%).', 'however, it increases the risk of early filtering bleb leakage.\tA single 1.25\u2009mg dose of intracameral bevacizumab improves the success of trabeculectomy comparable with MMC;', 'however, it increases the risk of early filtering bleb leakage.\thowever, it increases the risk of early filtering bleb leakage.', 'however, it increases the risk of early filtering bleb leakage.\tThe preoperative IOP was 29.17±3.94 and 28.8±4.08\u2009mm\u2009Hg in the bevacizumab and MMC groups, respectively (P=0.689).', 'however, it increases the risk of early filtering bleb leakage.\tLast visit IOP was 17.41±3.11\u2009mm\u2009Hg in the bevacizumab group and 15.34±3.62\u2009mm Hg in the MMC group (P<0.009).', 'The preoperative IOP was 29.17±3.94 and 28.8±4.08\u2009mm\u2009Hg in the bevacizumab and MMC groups, respectively (P=0.689).\tCompared with baseline, IOP drop at last visit was 11.76±5.51 and 13.43±5.92 in the bevacizumab and MMC groups, respectively (P=0.207).', 'The preoperative IOP was 29.17±3.94 and 28.8±4.08\u2009mm\u2009Hg in the bevacizumab and MMC groups, respectively (P=0.689).\tAt last visit, complete success was achieved in 25 cases (61%) of bevacizumab group and 23 cases (66%) of MMC group (P=0.669).', 'The preoperative IOP was 29.17±3.94 and 28.8±4.08\u2009mm\u2009Hg in the bevacizumab and MMC groups, respectively (P=0.689).\tEarly filtering bleb leak was more prevalent in bevacizumab group (29% vs. 11%).', 'The preoperative IOP was 29.17±3.94 and 28.8±4.08\u2009mm\u2009Hg in the bevacizumab and MMC groups, respectively (P=0.689).\tA single 1.25\u2009mg dose of intracameral bevacizumab improves the success of trabeculectomy comparable with MMC;', 'The preoperative IOP was 29.17±3.94 and 28.8±4.08\u2009mm\u2009Hg in the bevacizumab and MMC groups, respectively (P=0.689).\thowever, it increases the risk of early filtering bleb leakage.', 'The preoperative IOP was 29.17±3.94 and 28.8±4.08\u2009mm\u2009Hg in the bevacizumab and MMC groups, respectively (P=0.689).\tThe preoperative IOP was 29.17±3.94 and 28.8±4.08\u2009mm\u2009Hg in the bevacizumab and MMC groups, respectively (P=0.689).', 'The preoperative IOP was 29.17±3.94 and 28.8±4.08\u2009mm\u2009Hg in the bevacizumab and MMC groups, respectively (P=0.689).\tLast visit IOP was 17.41±3.11\u2009mm\u2009Hg in the bevacizumab group and 15.34±3.62\u2009mm Hg in the MMC group (P<0.009).', 'Last visit IOP was 17.41±3.11\u2009mm\u2009Hg in the bevacizumab group and 15.34±3.62\u2009mm Hg in the MMC group (P<0.009).\tCompared with baseline, IOP drop at last visit was 11.76±5.51 and 13.43±5.92 in the bevacizumab and MMC groups, respectively (P=0.207).', 'Last visit IOP was 17.41±3.11\u2009mm\u2009Hg in the bevacizumab group and 15.34±3.62\u2009mm Hg in the MMC group (P<0.009).\tAt last visit, complete success was achieved in 25 cases (61%) of bevacizumab group and 23 cases (66%) of MMC group (P=0.669).', 'Last visit IOP was 17.41±3.11\u2009mm\u2009Hg in the bevacizumab group and 15.34±3.62\u2009mm Hg in the MMC group (P<0.009).\tEarly filtering bleb leak was more prevalent in bevacizumab group (29% vs. 11%).', 'Last visit IOP was 17.41±3.11\u2009mm\u2009Hg in the bevacizumab group and 15.34±3.62\u2009mm Hg in the MMC group (P<0.009).\tA single 1.25\u2009mg dose of intracameral bevacizumab improves the success of trabeculectomy comparable with MMC;', 'Last visit IOP was 17.41±3.11\u2009mm\u2009Hg in the bevacizumab group and 15.34±3.62\u2009mm Hg in the MMC group (P<0.009).\thowever, it increases the risk of early filtering bleb leakage.', 'Last visit IOP was 17.41±3.11\u2009mm\u2009Hg in the bevacizumab group and 15.34±3.62\u2009mm Hg in the MMC group (P<0.009).\tThe preoperative IOP was 29.17±3.94 and 28.8±4.08\u2009mm\u2009Hg in the bevacizumab and MMC groups, respectively (P=0.689).', 'Last visit IOP was 17.41±3.11\u2009mm\u2009Hg in the bevacizumab group and 15.34±3.62\u2009mm Hg in the MMC group (P<0.009).\tLast visit IOP was 17.41±3.11\u2009mm\u2009Hg in the bevacizumab group and 15.34±3.62\u2009mm Hg in the MMC group (P<0.009).']","[0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['In sildenafil versus placebo arms, week-12 6MWD increases were similar (least squares mean difference [sildenafil-placebo], -2.4 m [90% CI: -21.8 to 17.1 m]; P = 0.6); mean ± SD changes from baseline were 26.4 ± 45.7 versus 11.8 ± 57.4 m, respectively, in IPAH (65% of population) and -18.3 ± 82.0 versus 17.5 ± 59.1 m in APAH-CTD (35% of population).\tIn sildenafil versus placebo arms, week-12 6MWD increases were similar (least squares mean difference [sildenafil-placebo], -2.4 m [90% CI: -21.8 to 17.1 m]; P = 0.6); mean ± SD changes from baseline were 26.4 ± 45.7 versus 11.8 ± 57.4 m, respectively, in IPAH (65% of population) and -18.3 ± 82.0 versus 17.5 ± 59.1 m in APAH-CTD (35% of population).', 'In sildenafil versus placebo arms, week-12 6MWD increases were similar (least squares mean difference [sildenafil-placebo], -2.4 m [90% CI: -21.8 to 17.1 m]; P = 0.6); mean ± SD changes from baseline were 26.4 ± 45.7 versus 11.8 ± 57.4 m, respectively, in IPAH (65% of population) and -18.3 ± 82.0 versus 17.5 ± 59.1 m in APAH-CTD (35% of population).\tChanges in WHO functional class and Borg dyspnoea score and incidence of clinical worsening did not differ.', 'In sildenafil versus placebo arms, week-12 6MWD increases were similar (least squares mean difference [sildenafil-placebo], -2.4 m [90% CI: -21.8 to 17.1 m]; P = 0.6); mean ± SD changes from baseline were 26.4 ± 45.7 versus 11.8 ± 57.4 m, respectively, in IPAH (65% of population) and -18.3 ± 82.0 versus 17.5 ± 59.1 m in APAH-CTD (35% of population).\tHeadache, diarrhoea, and flushing were more common with sildenafil.', 'In sildenafil versus placebo arms, week-12 6MWD increases were similar (least squares mean difference [sildenafil-placebo], -2.4 m [90% CI: -21.8 to 17.1 m]; P = 0.6); mean ± SD changes from baseline were 26.4 ± 45.7 versus 11.8 ± 57.4 m, respectively, in IPAH (65% of population) and -18.3 ± 82.0 versus 17.5 ± 59.1 m in APAH-CTD (35% of population).\tSildenafil, in addition to stable (≥3 months) bosentan therapy, had no benefit over placebo for 12-week change from baseline in 6MWD.', 'Changes in WHO functional class and Borg dyspnoea score and incidence of clinical worsening did not differ.\tIn sildenafil versus placebo arms, week-12 6MWD increases were similar (least squares mean difference [sildenafil-placebo], -2.4 m [90% CI: -21.8 to 17.1 m]; P = 0.6); mean ± SD changes from baseline were 26.4 ± 45.7 versus 11.8 ± 57.4 m, respectively, in IPAH (65% of population) and -18.3 ± 82.0 versus 17.5 ± 59.1 m in APAH-CTD (35% of population).', 'Changes in WHO functional class and Borg dyspnoea score and incidence of clinical worsening did not differ.\tChanges in WHO functional class and Borg dyspnoea score and incidence of clinical worsening did not differ.', 'Changes in WHO functional class and Borg dyspnoea score and incidence of clinical worsening did not differ.\tHeadache, diarrhoea, and flushing were more common with sildenafil.', 'Changes in WHO functional class and Borg dyspnoea score and incidence of clinical worsening did not differ.\tSildenafil, in addition to stable (≥3 months) bosentan therapy, had no benefit over placebo for 12-week change from baseline in 6MWD.', 'Headache, diarrhoea, and flushing were more common with sildenafil.\tIn sildenafil versus placebo arms, week-12 6MWD increases were similar (least squares mean difference [sildenafil-placebo], -2.4 m [90% CI: -21.8 to 17.1 m]; P = 0.6); mean ± SD changes from baseline were 26.4 ± 45.7 versus 11.8 ± 57.4 m, respectively, in IPAH (65% of population) and -18.3 ± 82.0 versus 17.5 ± 59.1 m in APAH-CTD (35% of population).', 'Headache, diarrhoea, and flushing were more common with sildenafil.\tChanges in WHO functional class and Borg dyspnoea score and incidence of clinical worsening did not differ.', 'Headache, diarrhoea, and flushing were more common with sildenafil.\tHeadache, diarrhoea, and flushing were more common with sildenafil.', 'Headache, diarrhoea, and flushing were more common with sildenafil.\tSildenafil, in addition to stable (≥3 months) bosentan therapy, had no benefit over placebo for 12-week change from baseline in 6MWD.', 'Sildenafil, in addition to stable (≥3 months) bosentan therapy, had no benefit over placebo for 12-week change from baseline in 6MWD.\tIn sildenafil versus placebo arms, week-12 6MWD increases were similar (least squares mean difference [sildenafil-placebo], -2.4 m [90% CI: -21.8 to 17.1 m]; P = 0.6); mean ± SD changes from baseline were 26.4 ± 45.7 versus 11.8 ± 57.4 m, respectively, in IPAH (65% of population) and -18.3 ± 82.0 versus 17.5 ± 59.1 m in APAH-CTD (35% of population).', 'Sildenafil, in addition to stable (≥3 months) bosentan therapy, had no benefit over placebo for 12-week change from baseline in 6MWD.\tChanges in WHO functional class and Borg dyspnoea score and incidence of clinical worsening did not differ.', 'Sildenafil, in addition to stable (≥3 months) bosentan therapy, had no benefit over placebo for 12-week change from baseline in 6MWD.\tHeadache, diarrhoea, and flushing were more common with sildenafil.', 'Sildenafil, in addition to stable (≥3 months) bosentan therapy, had no benefit over placebo for 12-week change from baseline in 6MWD.\tSildenafil, in addition to stable (≥3 months) bosentan therapy, had no benefit over placebo for 12-week change from baseline in 6MWD.']","[0, 0, 0, 1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]"
"['The results highlight the need to promote the benefits of this drug combination in helping chronic hepatitis B patients with interferon resistance, and to promote its application in clinical practices.\tThe results highlight the need to promote the benefits of this drug combination in helping chronic hepatitis B patients with interferon resistance, and to promote its application in clinical practices.', 'The results highlight the need to promote the benefits of this drug combination in helping chronic hepatitis B patients with interferon resistance, and to promote its application in clinical practices.\tAfter treatment, the levels of the indexes in both groups (the combination treatment group vs. the entecavir group) were as follows: bilirubin (67.5±7.7 vs. 82.4±13.5 μmol/L); International Normalized Ratio (INR) (1.21±0.8 vs. 1.14±0.7); creatinine (147.3±12.4 vs. 287.4±21.6 mg/dL); GGT (67.4±23.2 vs. 88.4±23.7 U/L); and ALT (63.4±40.8 vs. 96.5±23.5 U/L).', 'The results highlight the need to promote the benefits of this drug combination in helping chronic hepatitis B patients with interferon resistance, and to promote its application in clinical practices.\tIn comparison of the indexes of hepatic fibrosis between the two groups, we found the following differences: PCIII (67.5±7.7 vs. 82.4±13.5 μg/L); IV-C (61.3±18.7 vs. 74.5±17.9 μg/L); HA (147.3±12.4 vs. 87.4±31.6 μg/L); and LN (88.7±13.2 vs 102.5±23.4 μg/L).', 'The results highlight the need to promote the benefits of this drug combination in helping chronic hepatitis B patients with interferon resistance, and to promote its application in clinical practices.\tThe results showed that the differences in comparison of the indexes before and after the treatment were statistically significant (P<0.05).', 'The results highlight the need to promote the benefits of this drug combination in helping chronic hepatitis B patients with interferon resistance, and to promote its application in clinical practices.\tAfter treatment, the MELD score of patients in the combination treatment group was significantly lower than that in the entecavir group (18.7±3.2 vs. 22.5±3.4), with a statistically significant difference (P<0.05).', 'The results highlight the need to promote the benefits of this drug combination in helping chronic hepatitis B patients with interferon resistance, and to promote its application in clinical practices.\tIn the chronic hepatitis B patients with interferon resistance, the combined administration of entecavir and adefovir dipivoxil can significantly improve liver function, hepatic fibrosis and MELD scores.', 'After treatment, the levels of the indexes in both groups (the combination treatment group vs. the entecavir group) were as follows: bilirubin (67.5±7.7 vs. 82.4±13.5 μmol/L); International Normalized Ratio (INR) (1.21±0.8 vs. 1.14±0.7); creatinine (147.3±12.4 vs. 287.4±21.6 mg/dL); GGT (67.4±23.2 vs. 88.4±23.7 U/L); and ALT (63.4±40.8 vs. 96.5±23.5 U/L).\tThe results highlight the need to promote the benefits of this drug combination in helping chronic hepatitis B patients with interferon resistance, and to promote its application in clinical practices.', 'After treatment, the levels of the indexes in both groups (the combination treatment group vs. the entecavir group) were as follows: bilirubin (67.5±7.7 vs. 82.4±13.5 μmol/L); International Normalized Ratio (INR) (1.21±0.8 vs. 1.14±0.7); creatinine (147.3±12.4 vs. 287.4±21.6 mg/dL); GGT (67.4±23.2 vs. 88.4±23.7 U/L); and ALT (63.4±40.8 vs. 96.5±23.5 U/L).\tAfter treatment, the levels of the indexes in both groups (the combination treatment group vs. the entecavir group) were as follows: bilirubin (67.5±7.7 vs. 82.4±13.5 μmol/L); International Normalized Ratio (INR) (1.21±0.8 vs. 1.14±0.7); creatinine (147.3±12.4 vs. 287.4±21.6 mg/dL); GGT (67.4±23.2 vs. 88.4±23.7 U/L); and ALT (63.4±40.8 vs. 96.5±23.5 U/L).', 'After treatment, the levels of the indexes in both groups (the combination treatment group vs. the entecavir group) were as follows: bilirubin (67.5±7.7 vs. 82.4±13.5 μmol/L); International Normalized Ratio (INR) (1.21±0.8 vs. 1.14±0.7); creatinine (147.3±12.4 vs. 287.4±21.6 mg/dL); GGT (67.4±23.2 vs. 88.4±23.7 U/L); and ALT (63.4±40.8 vs. 96.5±23.5 U/L).\tIn comparison of the indexes of hepatic fibrosis between the two groups, we found the following differences: PCIII (67.5±7.7 vs. 82.4±13.5 μg/L); IV-C (61.3±18.7 vs. 74.5±17.9 μg/L); HA (147.3±12.4 vs. 87.4±31.6 μg/L); and LN (88.7±13.2 vs 102.5±23.4 μg/L).', 'After treatment, the levels of the indexes in both groups (the combination treatment group vs. the entecavir group) were as follows: bilirubin (67.5±7.7 vs. 82.4±13.5 μmol/L); International Normalized Ratio (INR) (1.21±0.8 vs. 1.14±0.7); creatinine (147.3±12.4 vs. 287.4±21.6 mg/dL); GGT (67.4±23.2 vs. 88.4±23.7 U/L); and ALT (63.4±40.8 vs. 96.5±23.5 U/L).\tThe results showed that the differences in comparison of the indexes before and after the treatment were statistically significant (P<0.05).', 'After treatment, the levels of the indexes in both groups (the combination treatment group vs. the entecavir group) were as follows: bilirubin (67.5±7.7 vs. 82.4±13.5 μmol/L); International Normalized Ratio (INR) (1.21±0.8 vs. 1.14±0.7); creatinine (147.3±12.4 vs. 287.4±21.6 mg/dL); GGT (67.4±23.2 vs. 88.4±23.7 U/L); and ALT (63.4±40.8 vs. 96.5±23.5 U/L).\tAfter treatment, the MELD score of patients in the combination treatment group was significantly lower than that in the entecavir group (18.7±3.2 vs. 22.5±3.4), with a statistically significant difference (P<0.05).', 'After treatment, the levels of the indexes in both groups (the combination treatment group vs. the entecavir group) were as follows: bilirubin (67.5±7.7 vs. 82.4±13.5 μmol/L); International Normalized Ratio (INR) (1.21±0.8 vs. 1.14±0.7); creatinine (147.3±12.4 vs. 287.4±21.6 mg/dL); GGT (67.4±23.2 vs. 88.4±23.7 U/L); and ALT (63.4±40.8 vs. 96.5±23.5 U/L).\tIn the chronic hepatitis B patients with interferon resistance, the combined administration of entecavir and adefovir dipivoxil can significantly improve liver function, hepatic fibrosis and MELD scores.', 'In comparison of the indexes of hepatic fibrosis between the two groups, we found the following differences: PCIII (67.5±7.7 vs. 82.4±13.5 μg/L); IV-C (61.3±18.7 vs. 74.5±17.9 μg/L); HA (147.3±12.4 vs. 87.4±31.6 μg/L); and LN (88.7±13.2 vs 102.5±23.4 μg/L).\tThe results highlight the need to promote the benefits of this drug combination in helping chronic hepatitis B patients with interferon resistance, and to promote its application in clinical practices.', 'In comparison of the indexes of hepatic fibrosis between the two groups, we found the following differences: PCIII (67.5±7.7 vs. 82.4±13.5 μg/L); IV-C (61.3±18.7 vs. 74.5±17.9 μg/L); HA (147.3±12.4 vs. 87.4±31.6 μg/L); and LN (88.7±13.2 vs 102.5±23.4 μg/L).\tAfter treatment, the levels of the indexes in both groups (the combination treatment group vs. the entecavir group) were as follows: bilirubin (67.5±7.7 vs. 82.4±13.5 μmol/L); International Normalized Ratio (INR) (1.21±0.8 vs. 1.14±0.7); creatinine (147.3±12.4 vs. 287.4±21.6 mg/dL); GGT (67.4±23.2 vs. 88.4±23.7 U/L); and ALT (63.4±40.8 vs. 96.5±23.5 U/L).', 'In comparison of the indexes of hepatic fibrosis between the two groups, we found the following differences: PCIII (67.5±7.7 vs. 82.4±13.5 μg/L); IV-C (61.3±18.7 vs. 74.5±17.9 μg/L); HA (147.3±12.4 vs. 87.4±31.6 μg/L); and LN (88.7±13.2 vs 102.5±23.4 μg/L).\tIn comparison of the indexes of hepatic fibrosis between the two groups, we found the following differences: PCIII (67.5±7.7 vs. 82.4±13.5 μg/L); IV-C (61.3±18.7 vs. 74.5±17.9 μg/L); HA (147.3±12.4 vs. 87.4±31.6 μg/L); and LN (88.7±13.2 vs 102.5±23.4 μg/L).', 'In comparison of the indexes of hepatic fibrosis between the two groups, we found the following differences: PCIII (67.5±7.7 vs. 82.4±13.5 μg/L); IV-C (61.3±18.7 vs. 74.5±17.9 μg/L); HA (147.3±12.4 vs. 87.4±31.6 μg/L); and LN (88.7±13.2 vs 102.5±23.4 μg/L).\tThe results showed that the differences in comparison of the indexes before and after the treatment were statistically significant (P<0.05).', 'In comparison of the indexes of hepatic fibrosis between the two groups, we found the following differences: PCIII (67.5±7.7 vs. 82.4±13.5 μg/L); IV-C (61.3±18.7 vs. 74.5±17.9 μg/L); HA (147.3±12.4 vs. 87.4±31.6 μg/L); and LN (88.7±13.2 vs 102.5±23.4 μg/L).\tAfter treatment, the MELD score of patients in the combination treatment group was significantly lower than that in the entecavir group (18.7±3.2 vs. 22.5±3.4), with a statistically significant difference (P<0.05).', 'In comparison of the indexes of hepatic fibrosis between the two groups, we found the following differences: PCIII (67.5±7.7 vs. 82.4±13.5 μg/L); IV-C (61.3±18.7 vs. 74.5±17.9 μg/L); HA (147.3±12.4 vs. 87.4±31.6 μg/L); and LN (88.7±13.2 vs 102.5±23.4 μg/L).\tIn the chronic hepatitis B patients with interferon resistance, the combined administration of entecavir and adefovir dipivoxil can significantly improve liver function, hepatic fibrosis and MELD scores.', 'The results showed that the differences in comparison of the indexes before and after the treatment were statistically significant (P<0.05).\tThe results highlight the need to promote the benefits of this drug combination in helping chronic hepatitis B patients with interferon resistance, and to promote its application in clinical practices.', 'The results showed that the differences in comparison of the indexes before and after the treatment were statistically significant (P<0.05).\tAfter treatment, the levels of the indexes in both groups (the combination treatment group vs. the entecavir group) were as follows: bilirubin (67.5±7.7 vs. 82.4±13.5 μmol/L); International Normalized Ratio (INR) (1.21±0.8 vs. 1.14±0.7); creatinine (147.3±12.4 vs. 287.4±21.6 mg/dL); GGT (67.4±23.2 vs. 88.4±23.7 U/L); and ALT (63.4±40.8 vs. 96.5±23.5 U/L).', 'The results showed that the differences in comparison of the indexes before and after the treatment were statistically significant (P<0.05).\tIn comparison of the indexes of hepatic fibrosis between the two groups, we found the following differences: PCIII (67.5±7.7 vs. 82.4±13.5 μg/L); IV-C (61.3±18.7 vs. 74.5±17.9 μg/L); HA (147.3±12.4 vs. 87.4±31.6 μg/L); and LN (88.7±13.2 vs 102.5±23.4 μg/L).', 'The results showed that the differences in comparison of the indexes before and after the treatment were statistically significant (P<0.05).\tThe results showed that the differences in comparison of the indexes before and after the treatment were statistically significant (P<0.05).', 'The results showed that the differences in comparison of the indexes before and after the treatment were statistically significant (P<0.05).\tAfter treatment, the MELD score of patients in the combination treatment group was significantly lower than that in the entecavir group (18.7±3.2 vs. 22.5±3.4), with a statistically significant difference (P<0.05).', 'The results showed that the differences in comparison of the indexes before and after the treatment were statistically significant (P<0.05).\tIn the chronic hepatitis B patients with interferon resistance, the combined administration of entecavir and adefovir dipivoxil can significantly improve liver function, hepatic fibrosis and MELD scores.', 'After treatment, the MELD score of patients in the combination treatment group was significantly lower than that in the entecavir group (18.7±3.2 vs. 22.5±3.4), with a statistically significant difference (P<0.05).\tThe results highlight the need to promote the benefits of this drug combination in helping chronic hepatitis B patients with interferon resistance, and to promote its application in clinical practices.', 'After treatment, the MELD score of patients in the combination treatment group was significantly lower than that in the entecavir group (18.7±3.2 vs. 22.5±3.4), with a statistically significant difference (P<0.05).\tAfter treatment, the levels of the indexes in both groups (the combination treatment group vs. the entecavir group) were as follows: bilirubin (67.5±7.7 vs. 82.4±13.5 μmol/L); International Normalized Ratio (INR) (1.21±0.8 vs. 1.14±0.7); creatinine (147.3±12.4 vs. 287.4±21.6 mg/dL); GGT (67.4±23.2 vs. 88.4±23.7 U/L); and ALT (63.4±40.8 vs. 96.5±23.5 U/L).', 'After treatment, the MELD score of patients in the combination treatment group was significantly lower than that in the entecavir group (18.7±3.2 vs. 22.5±3.4), with a statistically significant difference (P<0.05).\tIn comparison of the indexes of hepatic fibrosis between the two groups, we found the following differences: PCIII (67.5±7.7 vs. 82.4±13.5 μg/L); IV-C (61.3±18.7 vs. 74.5±17.9 μg/L); HA (147.3±12.4 vs. 87.4±31.6 μg/L); and LN (88.7±13.2 vs 102.5±23.4 μg/L).', 'After treatment, the MELD score of patients in the combination treatment group was significantly lower than that in the entecavir group (18.7±3.2 vs. 22.5±3.4), with a statistically significant difference (P<0.05).\tThe results showed that the differences in comparison of the indexes before and after the treatment were statistically significant (P<0.05).', 'After treatment, the MELD score of patients in the combination treatment group was significantly lower than that in the entecavir group (18.7±3.2 vs. 22.5±3.4), with a statistically significant difference (P<0.05).\tAfter treatment, the MELD score of patients in the combination treatment group was significantly lower than that in the entecavir group (18.7±3.2 vs. 22.5±3.4), with a statistically significant difference (P<0.05).', 'After treatment, the MELD score of patients in the combination treatment group was significantly lower than that in the entecavir group (18.7±3.2 vs. 22.5±3.4), with a statistically significant difference (P<0.05).\tIn the chronic hepatitis B patients with interferon resistance, the combined administration of entecavir and adefovir dipivoxil can significantly improve liver function, hepatic fibrosis and MELD scores.', 'In the chronic hepatitis B patients with interferon resistance, the combined administration of entecavir and adefovir dipivoxil can significantly improve liver function, hepatic fibrosis and MELD scores.\tThe results highlight the need to promote the benefits of this drug combination in helping chronic hepatitis B patients with interferon resistance, and to promote its application in clinical practices.', 'In the chronic hepatitis B patients with interferon resistance, the combined administration of entecavir and adefovir dipivoxil can significantly improve liver function, hepatic fibrosis and MELD scores.\tAfter treatment, the levels of the indexes in both groups (the combination treatment group vs. the entecavir group) were as follows: bilirubin (67.5±7.7 vs. 82.4±13.5 μmol/L); International Normalized Ratio (INR) (1.21±0.8 vs. 1.14±0.7); creatinine (147.3±12.4 vs. 287.4±21.6 mg/dL); GGT (67.4±23.2 vs. 88.4±23.7 U/L); and ALT (63.4±40.8 vs. 96.5±23.5 U/L).', 'In the chronic hepatitis B patients with interferon resistance, the combined administration of entecavir and adefovir dipivoxil can significantly improve liver function, hepatic fibrosis and MELD scores.\tIn comparison of the indexes of hepatic fibrosis between the two groups, we found the following differences: PCIII (67.5±7.7 vs. 82.4±13.5 μg/L); IV-C (61.3±18.7 vs. 74.5±17.9 μg/L); HA (147.3±12.4 vs. 87.4±31.6 μg/L); and LN (88.7±13.2 vs 102.5±23.4 μg/L).', 'In the chronic hepatitis B patients with interferon resistance, the combined administration of entecavir and adefovir dipivoxil can significantly improve liver function, hepatic fibrosis and MELD scores.\tThe results showed that the differences in comparison of the indexes before and after the treatment were statistically significant (P<0.05).', 'In the chronic hepatitis B patients with interferon resistance, the combined administration of entecavir and adefovir dipivoxil can significantly improve liver function, hepatic fibrosis and MELD scores.\tAfter treatment, the MELD score of patients in the combination treatment group was significantly lower than that in the entecavir group (18.7±3.2 vs. 22.5±3.4), with a statistically significant difference (P<0.05).', 'In the chronic hepatitis B patients with interferon resistance, the combined administration of entecavir and adefovir dipivoxil can significantly improve liver function, hepatic fibrosis and MELD scores.\tIn the chronic hepatitis B patients with interferon resistance, the combined administration of entecavir and adefovir dipivoxil can significantly improve liver function, hepatic fibrosis and MELD scores.']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0]"
"['By ITT analysis, HBV reactivation was 0% (0/33) in the study group and 10.7% (3/28) in the observation group (p = 0.091).\tBy ITT analysis, HBV reactivation was 0% (0/33) in the study group and 10.7% (3/28) in the observation group (p = 0.091).', 'By ITT analysis, HBV reactivation was 0% (0/33) in the study group and 10.7% (3/28) in the observation group (p = 0.091).\tNone of the patients in either group showed significant differences in liver function parameters between baseline and the last follow-up sample.', 'By ITT analysis, HBV reactivation was 0% (0/33) in the study group and 10.7% (3/28) in the observation group (p = 0.091).\tTDF was generally well tolerated and there were no severe treatment-related adverse events.', 'By ITT analysis, HBV reactivation was 0% (0/33) in the study group and 10.7% (3/28) in the observation group (p = 0.091).\tIn patients with hematological malignancy and resolved hepatitis B infection receiving RTX-based regimens, HBV reactivation did not occur in patients given TDF prophylaxis.', 'None of the patients in either group showed significant differences in liver function parameters between baseline and the last follow-up sample.\tBy ITT analysis, HBV reactivation was 0% (0/33) in the study group and 10.7% (3/28) in the observation group (p = 0.091).', 'None of the patients in either group showed significant differences in liver function parameters between baseline and the last follow-up sample.\tNone of the patients in either group showed significant differences in liver function parameters between baseline and the last follow-up sample.', 'None of the patients in either group showed significant differences in liver function parameters between baseline and the last follow-up sample.\tTDF was generally well tolerated and there were no severe treatment-related adverse events.', 'None of the patients in either group showed significant differences in liver function parameters between baseline and the last follow-up sample.\tIn patients with hematological malignancy and resolved hepatitis B infection receiving RTX-based regimens, HBV reactivation did not occur in patients given TDF prophylaxis.', 'TDF was generally well tolerated and there were no severe treatment-related adverse events.\tBy ITT analysis, HBV reactivation was 0% (0/33) in the study group and 10.7% (3/28) in the observation group (p = 0.091).', 'TDF was generally well tolerated and there were no severe treatment-related adverse events.\tNone of the patients in either group showed significant differences in liver function parameters between baseline and the last follow-up sample.', 'TDF was generally well tolerated and there were no severe treatment-related adverse events.\tTDF was generally well tolerated and there were no severe treatment-related adverse events.', 'TDF was generally well tolerated and there were no severe treatment-related adverse events.\tIn patients with hematological malignancy and resolved hepatitis B infection receiving RTX-based regimens, HBV reactivation did not occur in patients given TDF prophylaxis.', 'In patients with hematological malignancy and resolved hepatitis B infection receiving RTX-based regimens, HBV reactivation did not occur in patients given TDF prophylaxis.\tBy ITT analysis, HBV reactivation was 0% (0/33) in the study group and 10.7% (3/28) in the observation group (p = 0.091).', 'In patients with hematological malignancy and resolved hepatitis B infection receiving RTX-based regimens, HBV reactivation did not occur in patients given TDF prophylaxis.\tNone of the patients in either group showed significant differences in liver function parameters between baseline and the last follow-up sample.', 'In patients with hematological malignancy and resolved hepatitis B infection receiving RTX-based regimens, HBV reactivation did not occur in patients given TDF prophylaxis.\tTDF was generally well tolerated and there were no severe treatment-related adverse events.', 'In patients with hematological malignancy and resolved hepatitis B infection receiving RTX-based regimens, HBV reactivation did not occur in patients given TDF prophylaxis.\tIn patients with hematological malignancy and resolved hepatitis B infection receiving RTX-based regimens, HBV reactivation did not occur in patients given TDF prophylaxis.']","[0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['Fewer complications were noted in eyes receiving sclerostomy (5/29, 17.2%) as compared to control group eyes (12/31, 38.7%), though differences were marginally significant (P = .065).\tFewer complications were noted in eyes receiving sclerostomy (5/29, 17.2%) as compared to control group eyes (12/31, 38.7%), though differences were marginally significant (P = .065).', 'Fewer complications were noted in eyes receiving sclerostomy (5/29, 17.2%) as compared to control group eyes (12/31, 38.7%), though differences were marginally significant (P = .065).\tFour control group, but no sclerostomy group, eyes developed postoperative uveal effusions (P = .04).', 'Fewer complications were noted in eyes receiving sclerostomy (5/29, 17.2%) as compared to control group eyes (12/31, 38.7%), though differences were marginally significant (P = .065).\tIn multivariable models, sclerostomy decreased the odds of an intraoperative or postoperative complication by 80% (odds ratio [OR] = 0.2, 95% confidence interval [CI] = 0.04-0.92, P = .039);', 'Fewer complications were noted in eyes receiving sclerostomy (5/29, 17.2%) as compared to control group eyes (12/31, 38.7%), though differences were marginally significant (P = .065).\tSICS was associated with a significantly higher risk of complications as compared to phacoemulsification (OR = 5.95, 95% CI = 1.49-23.73, P = .012), while high preoperative intraocular pressure (OR = 4.54, 95% CI = 0.99-20.9, P = .052) and greater lens thickness (OR = 3.38, 95% CI = 0.88-12.91, P = .075) demonstrated a marginally significant association.', 'Fewer complications were noted in eyes receiving sclerostomy (5/29, 17.2%) as compared to control group eyes (12/31, 38.7%), though differences were marginally significant (P = .065).\tCataract surgery in eyes with nanophthalmos is associated with a high risk for vision-threatening complications.', 'Fewer complications were noted in eyes receiving sclerostomy (5/29, 17.2%) as compared to control group eyes (12/31, 38.7%), though differences were marginally significant (P = .065).\tPerforming a simultaneous prophylactic sclerostomy with cataract surgery reduces complication rates, particularly uveal effusions.', 'Fewer complications were noted in eyes receiving sclerostomy (5/29, 17.2%) as compared to control group eyes (12/31, 38.7%), though differences were marginally significant (P = .065).\tCataract surgery at earlier stages by phacoemulsification may be more beneficial than undergoing manual SICS.', 'Four control group, but no sclerostomy group, eyes developed postoperative uveal effusions (P = .04).\tFewer complications were noted in eyes receiving sclerostomy (5/29, 17.2%) as compared to control group eyes (12/31, 38.7%), though differences were marginally significant (P = .065).', 'Four control group, but no sclerostomy group, eyes developed postoperative uveal effusions (P = .04).\tFour control group, but no sclerostomy group, eyes developed postoperative uveal effusions (P = .04).', 'Four control group, but no sclerostomy group, eyes developed postoperative uveal effusions (P = .04).\tIn multivariable models, sclerostomy decreased the odds of an intraoperative or postoperative complication by 80% (odds ratio [OR] = 0.2, 95% confidence interval [CI] = 0.04-0.92, P = .039);', 'Four control group, but no sclerostomy group, eyes developed postoperative uveal effusions (P = .04).\tSICS was associated with a significantly higher risk of complications as compared to phacoemulsification (OR = 5.95, 95% CI = 1.49-23.73, P = .012), while high preoperative intraocular pressure (OR = 4.54, 95% CI = 0.99-20.9, P = .052) and greater lens thickness (OR = 3.38, 95% CI = 0.88-12.91, P = .075) demonstrated a marginally significant association.', 'Four control group, but no sclerostomy group, eyes developed postoperative uveal effusions (P = .04).\tCataract surgery in eyes with nanophthalmos is associated with a high risk for vision-threatening complications.', 'Four control group, but no sclerostomy group, eyes developed postoperative uveal effusions (P = .04).\tPerforming a simultaneous prophylactic sclerostomy with cataract surgery reduces complication rates, particularly uveal effusions.', 'Four control group, but no sclerostomy group, eyes developed postoperative uveal effusions (P = .04).\tCataract surgery at earlier stages by phacoemulsification may be more beneficial than undergoing manual SICS.', 'In multivariable models, sclerostomy decreased the odds of an intraoperative or postoperative complication by 80% (odds ratio [OR] = 0.2, 95% confidence interval [CI] = 0.04-0.92, P = .039);\tFewer complications were noted in eyes receiving sclerostomy (5/29, 17.2%) as compared to control group eyes (12/31, 38.7%), though differences were marginally significant (P = .065).', 'In multivariable models, sclerostomy decreased the odds of an intraoperative or postoperative complication by 80% (odds ratio [OR] = 0.2, 95% confidence interval [CI] = 0.04-0.92, P = .039);\tFour control group, but no sclerostomy group, eyes developed postoperative uveal effusions (P = .04).', 'In multivariable models, sclerostomy decreased the odds of an intraoperative or postoperative complication by 80% (odds ratio [OR] = 0.2, 95% confidence interval [CI] = 0.04-0.92, P = .039);\tIn multivariable models, sclerostomy decreased the odds of an intraoperative or postoperative complication by 80% (odds ratio [OR] = 0.2, 95% confidence interval [CI] = 0.04-0.92, P = .039);', 'In multivariable models, sclerostomy decreased the odds of an intraoperative or postoperative complication by 80% (odds ratio [OR] = 0.2, 95% confidence interval [CI] = 0.04-0.92, P = .039);\tSICS was associated with a significantly higher risk of complications as compared to phacoemulsification (OR = 5.95, 95% CI = 1.49-23.73, P = .012), while high preoperative intraocular pressure (OR = 4.54, 95% CI = 0.99-20.9, P = .052) and greater lens thickness (OR = 3.38, 95% CI = 0.88-12.91, P = .075) demonstrated a marginally significant association.', 'In multivariable models, sclerostomy decreased the odds of an intraoperative or postoperative complication by 80% (odds ratio [OR] = 0.2, 95% confidence interval [CI] = 0.04-0.92, P = .039);\tCataract surgery in eyes with nanophthalmos is associated with a high risk for vision-threatening complications.', 'In multivariable models, sclerostomy decreased the odds of an intraoperative or postoperative complication by 80% (odds ratio [OR] = 0.2, 95% confidence interval [CI] = 0.04-0.92, P = .039);\tPerforming a simultaneous prophylactic sclerostomy with cataract surgery reduces complication rates, particularly uveal effusions.', 'In multivariable models, sclerostomy decreased the odds of an intraoperative or postoperative complication by 80% (odds ratio [OR] = 0.2, 95% confidence interval [CI] = 0.04-0.92, P = .039);\tCataract surgery at earlier stages by phacoemulsification may be more beneficial than undergoing manual SICS.', 'SICS was associated with a significantly higher risk of complications as compared to phacoemulsification (OR = 5.95, 95% CI = 1.49-23.73, P = .012), while high preoperative intraocular pressure (OR = 4.54, 95% CI = 0.99-20.9, P = .052) and greater lens thickness (OR = 3.38, 95% CI = 0.88-12.91, P = .075) demonstrated a marginally significant association.\tFewer complications were noted in eyes receiving sclerostomy (5/29, 17.2%) as compared to control group eyes (12/31, 38.7%), though differences were marginally significant (P = .065).', 'SICS was associated with a significantly higher risk of complications as compared to phacoemulsification (OR = 5.95, 95% CI = 1.49-23.73, P = .012), while high preoperative intraocular pressure (OR = 4.54, 95% CI = 0.99-20.9, P = .052) and greater lens thickness (OR = 3.38, 95% CI = 0.88-12.91, P = .075) demonstrated a marginally significant association.\tFour control group, but no sclerostomy group, eyes developed postoperative uveal effusions (P = .04).', 'SICS was associated with a significantly higher risk of complications as compared to phacoemulsification (OR = 5.95, 95% CI = 1.49-23.73, P = .012), while high preoperative intraocular pressure (OR = 4.54, 95% CI = 0.99-20.9, P = .052) and greater lens thickness (OR = 3.38, 95% CI = 0.88-12.91, P = .075) demonstrated a marginally significant association.\tIn multivariable models, sclerostomy decreased the odds of an intraoperative or postoperative complication by 80% (odds ratio [OR] = 0.2, 95% confidence interval [CI] = 0.04-0.92, P = .039);', 'SICS was associated with a significantly higher risk of complications as compared to phacoemulsification (OR = 5.95, 95% CI = 1.49-23.73, P = .012), while high preoperative intraocular pressure (OR = 4.54, 95% CI = 0.99-20.9, P = .052) and greater lens thickness (OR = 3.38, 95% CI = 0.88-12.91, P = .075) demonstrated a marginally significant association.\tSICS was associated with a significantly higher risk of complications as compared to phacoemulsification (OR = 5.95, 95% CI = 1.49-23.73, P = .012), while high preoperative intraocular pressure (OR = 4.54, 95% CI = 0.99-20.9, P = .052) and greater lens thickness (OR = 3.38, 95% CI = 0.88-12.91, P = .075) demonstrated a marginally significant association.', 'SICS was associated with a significantly higher risk of complications as compared to phacoemulsification (OR = 5.95, 95% CI = 1.49-23.73, P = .012), while high preoperative intraocular pressure (OR = 4.54, 95% CI = 0.99-20.9, P = .052) and greater lens thickness (OR = 3.38, 95% CI = 0.88-12.91, P = .075) demonstrated a marginally significant association.\tCataract surgery in eyes with nanophthalmos is associated with a high risk for vision-threatening complications.', 'SICS was associated with a significantly higher risk of complications as compared to phacoemulsification (OR = 5.95, 95% CI = 1.49-23.73, P = .012), while high preoperative intraocular pressure (OR = 4.54, 95% CI = 0.99-20.9, P = .052) and greater lens thickness (OR = 3.38, 95% CI = 0.88-12.91, P = .075) demonstrated a marginally significant association.\tPerforming a simultaneous prophylactic sclerostomy with cataract surgery reduces complication rates, particularly uveal effusions.', 'SICS was associated with a significantly higher risk of complications as compared to phacoemulsification (OR = 5.95, 95% CI = 1.49-23.73, P = .012), while high preoperative intraocular pressure (OR = 4.54, 95% CI = 0.99-20.9, P = .052) and greater lens thickness (OR = 3.38, 95% CI = 0.88-12.91, P = .075) demonstrated a marginally significant association.\tCataract surgery at earlier stages by phacoemulsification may be more beneficial than undergoing manual SICS.', 'Cataract surgery in eyes with nanophthalmos is associated with a high risk for vision-threatening complications.\tFewer complications were noted in eyes receiving sclerostomy (5/29, 17.2%) as compared to control group eyes (12/31, 38.7%), though differences were marginally significant (P = .065).', 'Cataract surgery in eyes with nanophthalmos is associated with a high risk for vision-threatening complications.\tFour control group, but no sclerostomy group, eyes developed postoperative uveal effusions (P = .04).', 'Cataract surgery in eyes with nanophthalmos is associated with a high risk for vision-threatening complications.\tIn multivariable models, sclerostomy decreased the odds of an intraoperative or postoperative complication by 80% (odds ratio [OR] = 0.2, 95% confidence interval [CI] = 0.04-0.92, P = .039);', 'Cataract surgery in eyes with nanophthalmos is associated with a high risk for vision-threatening complications.\tSICS was associated with a significantly higher risk of complications as compared to phacoemulsification (OR = 5.95, 95% CI = 1.49-23.73, P = .012), while high preoperative intraocular pressure (OR = 4.54, 95% CI = 0.99-20.9, P = .052) and greater lens thickness (OR = 3.38, 95% CI = 0.88-12.91, P = .075) demonstrated a marginally significant association.', 'Cataract surgery in eyes with nanophthalmos is associated with a high risk for vision-threatening complications.\tCataract surgery in eyes with nanophthalmos is associated with a high risk for vision-threatening complications.', 'Cataract surgery in eyes with nanophthalmos is associated with a high risk for vision-threatening complications.\tPerforming a simultaneous prophylactic sclerostomy with cataract surgery reduces complication rates, particularly uveal effusions.', 'Cataract surgery in eyes with nanophthalmos is associated with a high risk for vision-threatening complications.\tCataract surgery at earlier stages by phacoemulsification may be more beneficial than undergoing manual SICS.', 'Performing a simultaneous prophylactic sclerostomy with cataract surgery reduces complication rates, particularly uveal effusions.\tFewer complications were noted in eyes receiving sclerostomy (5/29, 17.2%) as compared to control group eyes (12/31, 38.7%), though differences were marginally significant (P = .065).', 'Performing a simultaneous prophylactic sclerostomy with cataract surgery reduces complication rates, particularly uveal effusions.\tFour control group, but no sclerostomy group, eyes developed postoperative uveal effusions (P = .04).', 'Performing a simultaneous prophylactic sclerostomy with cataract surgery reduces complication rates, particularly uveal effusions.\tIn multivariable models, sclerostomy decreased the odds of an intraoperative or postoperative complication by 80% (odds ratio [OR] = 0.2, 95% confidence interval [CI] = 0.04-0.92, P = .039);', 'Performing a simultaneous prophylactic sclerostomy with cataract surgery reduces complication rates, particularly uveal effusions.\tSICS was associated with a significantly higher risk of complications as compared to phacoemulsification (OR = 5.95, 95% CI = 1.49-23.73, P = .012), while high preoperative intraocular pressure (OR = 4.54, 95% CI = 0.99-20.9, P = .052) and greater lens thickness (OR = 3.38, 95% CI = 0.88-12.91, P = .075) demonstrated a marginally significant association.', 'Performing a simultaneous prophylactic sclerostomy with cataract surgery reduces complication rates, particularly uveal effusions.\tCataract surgery in eyes with nanophthalmos is associated with a high risk for vision-threatening complications.', 'Performing a simultaneous prophylactic sclerostomy with cataract surgery reduces complication rates, particularly uveal effusions.\tPerforming a simultaneous prophylactic sclerostomy with cataract surgery reduces complication rates, particularly uveal effusions.', 'Performing a simultaneous prophylactic sclerostomy with cataract surgery reduces complication rates, particularly uveal effusions.\tCataract surgery at earlier stages by phacoemulsification may be more beneficial than undergoing manual SICS.', 'Cataract surgery at earlier stages by phacoemulsification may be more beneficial than undergoing manual SICS.\tFewer complications were noted in eyes receiving sclerostomy (5/29, 17.2%) as compared to control group eyes (12/31, 38.7%), though differences were marginally significant (P = .065).', 'Cataract surgery at earlier stages by phacoemulsification may be more beneficial than undergoing manual SICS.\tFour control group, but no sclerostomy group, eyes developed postoperative uveal effusions (P = .04).', 'Cataract surgery at earlier stages by phacoemulsification may be more beneficial than undergoing manual SICS.\tIn multivariable models, sclerostomy decreased the odds of an intraoperative or postoperative complication by 80% (odds ratio [OR] = 0.2, 95% confidence interval [CI] = 0.04-0.92, P = .039);', 'Cataract surgery at earlier stages by phacoemulsification may be more beneficial than undergoing manual SICS.\tSICS was associated with a significantly higher risk of complications as compared to phacoemulsification (OR = 5.95, 95% CI = 1.49-23.73, P = .012), while high preoperative intraocular pressure (OR = 4.54, 95% CI = 0.99-20.9, P = .052) and greater lens thickness (OR = 3.38, 95% CI = 0.88-12.91, P = .075) demonstrated a marginally significant association.', 'Cataract surgery at earlier stages by phacoemulsification may be more beneficial than undergoing manual SICS.\tCataract surgery in eyes with nanophthalmos is associated with a high risk for vision-threatening complications.', 'Cataract surgery at earlier stages by phacoemulsification may be more beneficial than undergoing manual SICS.\tPerforming a simultaneous prophylactic sclerostomy with cataract surgery reduces complication rates, particularly uveal effusions.', 'Cataract surgery at earlier stages by phacoemulsification may be more beneficial than undergoing manual SICS.\tCataract surgery at earlier stages by phacoemulsification may be more beneficial than undergoing manual SICS.']","[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['Compared with metformin, COC plus spironolactone caused larger decreases in hirsutism score (mean difference 4.6 points, 95% CI: 2.6-6.7), total testosterone (1.1\u2009nmol/L, 0.4-1.7), free testosterone (25\u2009pmol/L, 12-39), androstenedione (5.5\u2009nmol/L, 1.8-9.2) and dehydroepiandrosterone sulfate (2.7\u2009μmol/L, 1.4-4.0).\tCompared with metformin, COC plus spironolactone caused larger decreases in hirsutism score (mean difference 4.6 points, 95% CI: 2.6-6.7), total testosterone (1.1\u2009nmol/L, 0.4-1.7), free testosterone (25\u2009pmol/L, 12-39), androstenedione (5.5\u2009nmol/L, 1.8-9.2) and dehydroepiandrosterone sulfate (2.7\u2009μmol/L, 1.4-4.0).', 'Compared with metformin, COC plus spironolactone caused larger decreases in hirsutism score (mean difference 4.6 points, 95% CI: 2.6-6.7), total testosterone (1.1\u2009nmol/L, 0.4-1.7), free testosterone (25\u2009pmol/L, 12-39), androstenedione (5.5\u2009nmol/L, 1.8-9.2) and dehydroepiandrosterone sulfate (2.7\u2009μmol/L, 1.4-4.0).\tMenstrual dysfunction was less frequent with COC plus spironolactone (OR: 0.06, 95% CI: 0.02-0.23).', 'Compared with metformin, COC plus spironolactone caused larger decreases in hirsutism score (mean difference 4.6 points, 95% CI: 2.6-6.7), total testosterone (1.1\u2009nmol/L, 0.4-1.7), free testosterone (25\u2009pmol/L, 12-39), androstenedione (5.5\u2009nmol/L, 1.8-9.2) and dehydroepiandrosterone sulfate (2.7\u2009μmol/L, 1.4-4.0).\tNo differences were found in frequencies of abnormal glucose tolerance (OR: 1.7, 95% CI: 0.7-4.4), dyslipidemia (OR: 0.6, 95% CI: 0.2-1.8) or hypertension (OR: 0.3, 95% CI: 0.5-2.0).', 'Compared with metformin, COC plus spironolactone caused larger decreases in hirsutism score (mean difference 4.6 points, 95% CI: 2.6-6.7), total testosterone (1.1\u2009nmol/L, 0.4-1.7), free testosterone (25\u2009pmol/L, 12-39), androstenedione (5.5\u2009nmol/L, 1.8-9.2) and dehydroepiandrosterone sulfate (2.7\u2009μmol/L, 1.4-4.0).\tNo major adverse events occurred and biochemical markers were similarly safe with both treatments.', 'Compared with metformin, COC plus spironolactone caused larger decreases in hirsutism score (mean difference 4.6 points, 95% CI: 2.6-6.7), total testosterone (1.1\u2009nmol/L, 0.4-1.7), free testosterone (25\u2009pmol/L, 12-39), androstenedione (5.5\u2009nmol/L, 1.8-9.2) and dehydroepiandrosterone sulfate (2.7\u2009μmol/L, 1.4-4.0).\tCOC plus spironolactone was more effective than metformin for symptoms of PCOS showing similar safety and overall neutral effects on cardiometabolic risk factors.', 'Menstrual dysfunction was less frequent with COC plus spironolactone (OR: 0.06, 95% CI: 0.02-0.23).\tCompared with metformin, COC plus spironolactone caused larger decreases in hirsutism score (mean difference 4.6 points, 95% CI: 2.6-6.7), total testosterone (1.1\u2009nmol/L, 0.4-1.7), free testosterone (25\u2009pmol/L, 12-39), androstenedione (5.5\u2009nmol/L, 1.8-9.2) and dehydroepiandrosterone sulfate (2.7\u2009μmol/L, 1.4-4.0).', 'Menstrual dysfunction was less frequent with COC plus spironolactone (OR: 0.06, 95% CI: 0.02-0.23).\tMenstrual dysfunction was less frequent with COC plus spironolactone (OR: 0.06, 95% CI: 0.02-0.23).', 'Menstrual dysfunction was less frequent with COC plus spironolactone (OR: 0.06, 95% CI: 0.02-0.23).\tNo differences were found in frequencies of abnormal glucose tolerance (OR: 1.7, 95% CI: 0.7-4.4), dyslipidemia (OR: 0.6, 95% CI: 0.2-1.8) or hypertension (OR: 0.3, 95% CI: 0.5-2.0).', 'Menstrual dysfunction was less frequent with COC plus spironolactone (OR: 0.06, 95% CI: 0.02-0.23).\tNo major adverse events occurred and biochemical markers were similarly safe with both treatments.', 'Menstrual dysfunction was less frequent with COC plus spironolactone (OR: 0.06, 95% CI: 0.02-0.23).\tCOC plus spironolactone was more effective than metformin for symptoms of PCOS showing similar safety and overall neutral effects on cardiometabolic risk factors.', 'No differences were found in frequencies of abnormal glucose tolerance (OR: 1.7, 95% CI: 0.7-4.4), dyslipidemia (OR: 0.6, 95% CI: 0.2-1.8) or hypertension (OR: 0.3, 95% CI: 0.5-2.0).\tCompared with metformin, COC plus spironolactone caused larger decreases in hirsutism score (mean difference 4.6 points, 95% CI: 2.6-6.7), total testosterone (1.1\u2009nmol/L, 0.4-1.7), free testosterone (25\u2009pmol/L, 12-39), androstenedione (5.5\u2009nmol/L, 1.8-9.2) and dehydroepiandrosterone sulfate (2.7\u2009μmol/L, 1.4-4.0).', 'No differences were found in frequencies of abnormal glucose tolerance (OR: 1.7, 95% CI: 0.7-4.4), dyslipidemia (OR: 0.6, 95% CI: 0.2-1.8) or hypertension (OR: 0.3, 95% CI: 0.5-2.0).\tMenstrual dysfunction was less frequent with COC plus spironolactone (OR: 0.06, 95% CI: 0.02-0.23).', 'No differences were found in frequencies of abnormal glucose tolerance (OR: 1.7, 95% CI: 0.7-4.4), dyslipidemia (OR: 0.6, 95% CI: 0.2-1.8) or hypertension (OR: 0.3, 95% CI: 0.5-2.0).\tNo differences were found in frequencies of abnormal glucose tolerance (OR: 1.7, 95% CI: 0.7-4.4), dyslipidemia (OR: 0.6, 95% CI: 0.2-1.8) or hypertension (OR: 0.3, 95% CI: 0.5-2.0).', 'No differences were found in frequencies of abnormal glucose tolerance (OR: 1.7, 95% CI: 0.7-4.4), dyslipidemia (OR: 0.6, 95% CI: 0.2-1.8) or hypertension (OR: 0.3, 95% CI: 0.5-2.0).\tNo major adverse events occurred and biochemical markers were similarly safe with both treatments.', 'No differences were found in frequencies of abnormal glucose tolerance (OR: 1.7, 95% CI: 0.7-4.4), dyslipidemia (OR: 0.6, 95% CI: 0.2-1.8) or hypertension (OR: 0.3, 95% CI: 0.5-2.0).\tCOC plus spironolactone was more effective than metformin for symptoms of PCOS showing similar safety and overall neutral effects on cardiometabolic risk factors.', 'No major adverse events occurred and biochemical markers were similarly safe with both treatments.\tCompared with metformin, COC plus spironolactone caused larger decreases in hirsutism score (mean difference 4.6 points, 95% CI: 2.6-6.7), total testosterone (1.1\u2009nmol/L, 0.4-1.7), free testosterone (25\u2009pmol/L, 12-39), androstenedione (5.5\u2009nmol/L, 1.8-9.2) and dehydroepiandrosterone sulfate (2.7\u2009μmol/L, 1.4-4.0).', 'No major adverse events occurred and biochemical markers were similarly safe with both treatments.\tMenstrual dysfunction was less frequent with COC plus spironolactone (OR: 0.06, 95% CI: 0.02-0.23).', 'No major adverse events occurred and biochemical markers were similarly safe with both treatments.\tNo differences were found in frequencies of abnormal glucose tolerance (OR: 1.7, 95% CI: 0.7-4.4), dyslipidemia (OR: 0.6, 95% CI: 0.2-1.8) or hypertension (OR: 0.3, 95% CI: 0.5-2.0).', 'No major adverse events occurred and biochemical markers were similarly safe with both treatments.\tNo major adverse events occurred and biochemical markers were similarly safe with both treatments.', 'No major adverse events occurred and biochemical markers were similarly safe with both treatments.\tCOC plus spironolactone was more effective than metformin for symptoms of PCOS showing similar safety and overall neutral effects on cardiometabolic risk factors.', 'COC plus spironolactone was more effective than metformin for symptoms of PCOS showing similar safety and overall neutral effects on cardiometabolic risk factors.\tCompared with metformin, COC plus spironolactone caused larger decreases in hirsutism score (mean difference 4.6 points, 95% CI: 2.6-6.7), total testosterone (1.1\u2009nmol/L, 0.4-1.7), free testosterone (25\u2009pmol/L, 12-39), androstenedione (5.5\u2009nmol/L, 1.8-9.2) and dehydroepiandrosterone sulfate (2.7\u2009μmol/L, 1.4-4.0).', 'COC plus spironolactone was more effective than metformin for symptoms of PCOS showing similar safety and overall neutral effects on cardiometabolic risk factors.\tMenstrual dysfunction was less frequent with COC plus spironolactone (OR: 0.06, 95% CI: 0.02-0.23).', 'COC plus spironolactone was more effective than metformin for symptoms of PCOS showing similar safety and overall neutral effects on cardiometabolic risk factors.\tNo differences were found in frequencies of abnormal glucose tolerance (OR: 1.7, 95% CI: 0.7-4.4), dyslipidemia (OR: 0.6, 95% CI: 0.2-1.8) or hypertension (OR: 0.3, 95% CI: 0.5-2.0).', 'COC plus spironolactone was more effective than metformin for symptoms of PCOS showing similar safety and overall neutral effects on cardiometabolic risk factors.\tNo major adverse events occurred and biochemical markers were similarly safe with both treatments.', 'COC plus spironolactone was more effective than metformin for symptoms of PCOS showing similar safety and overall neutral effects on cardiometabolic risk factors.\tCOC plus spironolactone was more effective than metformin for symptoms of PCOS showing similar safety and overall neutral effects on cardiometabolic risk factors.']","[0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0]"
"['The results of our study suggest that patients previously infected with HBV and naturally immune to HBV were at greater odds of being diagnosed with ENKTL.\tThe results of our study suggest that patients previously infected with HBV and naturally immune to HBV were at greater odds of being diagnosed with ENKTL.', 'The results of our study suggest that patients previously infected with HBV and naturally immune to HBV were at greater odds of being diagnosed with ENKTL.\tThe results of the multivariable analysis showed that after adjustment for a set of known risk factors, patients previously infected with HBV (HBsAg-seronegative/anti-HBc-seropositive) and naturally immune to HBV (anti-HBs-seropositive/anti-HBc-seropositive) were at significantly greater odds of being diagnosed with ENKTL (AOR, 1.497; 95% CI 1.098-2.042, P=0.033 and AOR, 1.871; 95% CI 1.302-2.689, P=0.001, respectively).', 'The results of our study suggest that patients previously infected with HBV and naturally immune to HBV were at greater odds of being diagnosed with ENKTL.\tAfter adjusting for other factors, significantly greater odds of being diagnosed with ENKTL were observed among cases who reported ever drinking alcohol (AOR, 1.675; 95% CI 1.054-2.660, P=0.029).', 'The results of our study suggest that patients previously infected with HBV and naturally immune to HBV were at greater odds of being diagnosed with ENKTL.\tThe odds of ENKTL diagnosis were not significantly associated with ABO blood type, cigarette smoking status or family history of cancer.', 'The results of the multivariable analysis showed that after adjustment for a set of known risk factors, patients previously infected with HBV (HBsAg-seronegative/anti-HBc-seropositive) and naturally immune to HBV (anti-HBs-seropositive/anti-HBc-seropositive) were at significantly greater odds of being diagnosed with ENKTL (AOR, 1.497; 95% CI 1.098-2.042, P=0.033 and AOR, 1.871; 95% CI 1.302-2.689, P=0.001, respectively).\tThe results of our study suggest that patients previously infected with HBV and naturally immune to HBV were at greater odds of being diagnosed with ENKTL.', 'The results of the multivariable analysis showed that after adjustment for a set of known risk factors, patients previously infected with HBV (HBsAg-seronegative/anti-HBc-seropositive) and naturally immune to HBV (anti-HBs-seropositive/anti-HBc-seropositive) were at significantly greater odds of being diagnosed with ENKTL (AOR, 1.497; 95% CI 1.098-2.042, P=0.033 and AOR, 1.871; 95% CI 1.302-2.689, P=0.001, respectively).\tThe results of the multivariable analysis showed that after adjustment for a set of known risk factors, patients previously infected with HBV (HBsAg-seronegative/anti-HBc-seropositive) and naturally immune to HBV (anti-HBs-seropositive/anti-HBc-seropositive) were at significantly greater odds of being diagnosed with ENKTL (AOR, 1.497; 95% CI 1.098-2.042, P=0.033 and AOR, 1.871; 95% CI 1.302-2.689, P=0.001, respectively).', 'The results of the multivariable analysis showed that after adjustment for a set of known risk factors, patients previously infected with HBV (HBsAg-seronegative/anti-HBc-seropositive) and naturally immune to HBV (anti-HBs-seropositive/anti-HBc-seropositive) were at significantly greater odds of being diagnosed with ENKTL (AOR, 1.497; 95% CI 1.098-2.042, P=0.033 and AOR, 1.871; 95% CI 1.302-2.689, P=0.001, respectively).\tAfter adjusting for other factors, significantly greater odds of being diagnosed with ENKTL were observed among cases who reported ever drinking alcohol (AOR, 1.675; 95% CI 1.054-2.660, P=0.029).', 'The results of the multivariable analysis showed that after adjustment for a set of known risk factors, patients previously infected with HBV (HBsAg-seronegative/anti-HBc-seropositive) and naturally immune to HBV (anti-HBs-seropositive/anti-HBc-seropositive) were at significantly greater odds of being diagnosed with ENKTL (AOR, 1.497; 95% CI 1.098-2.042, P=0.033 and AOR, 1.871; 95% CI 1.302-2.689, P=0.001, respectively).\tThe odds of ENKTL diagnosis were not significantly associated with ABO blood type, cigarette smoking status or family history of cancer.', 'After adjusting for other factors, significantly greater odds of being diagnosed with ENKTL were observed among cases who reported ever drinking alcohol (AOR, 1.675; 95% CI 1.054-2.660, P=0.029).\tThe results of our study suggest that patients previously infected with HBV and naturally immune to HBV were at greater odds of being diagnosed with ENKTL.', 'After adjusting for other factors, significantly greater odds of being diagnosed with ENKTL were observed among cases who reported ever drinking alcohol (AOR, 1.675; 95% CI 1.054-2.660, P=0.029).\tThe results of the multivariable analysis showed that after adjustment for a set of known risk factors, patients previously infected with HBV (HBsAg-seronegative/anti-HBc-seropositive) and naturally immune to HBV (anti-HBs-seropositive/anti-HBc-seropositive) were at significantly greater odds of being diagnosed with ENKTL (AOR, 1.497; 95% CI 1.098-2.042, P=0.033 and AOR, 1.871; 95% CI 1.302-2.689, P=0.001, respectively).', 'After adjusting for other factors, significantly greater odds of being diagnosed with ENKTL were observed among cases who reported ever drinking alcohol (AOR, 1.675; 95% CI 1.054-2.660, P=0.029).\tAfter adjusting for other factors, significantly greater odds of being diagnosed with ENKTL were observed among cases who reported ever drinking alcohol (AOR, 1.675; 95% CI 1.054-2.660, P=0.029).', 'After adjusting for other factors, significantly greater odds of being diagnosed with ENKTL were observed among cases who reported ever drinking alcohol (AOR, 1.675; 95% CI 1.054-2.660, P=0.029).\tThe odds of ENKTL diagnosis were not significantly associated with ABO blood type, cigarette smoking status or family history of cancer.', 'The odds of ENKTL diagnosis were not significantly associated with ABO blood type, cigarette smoking status or family history of cancer.\tThe results of our study suggest that patients previously infected with HBV and naturally immune to HBV were at greater odds of being diagnosed with ENKTL.', 'The odds of ENKTL diagnosis were not significantly associated with ABO blood type, cigarette smoking status or family history of cancer.\tThe results of the multivariable analysis showed that after adjustment for a set of known risk factors, patients previously infected with HBV (HBsAg-seronegative/anti-HBc-seropositive) and naturally immune to HBV (anti-HBs-seropositive/anti-HBc-seropositive) were at significantly greater odds of being diagnosed with ENKTL (AOR, 1.497; 95% CI 1.098-2.042, P=0.033 and AOR, 1.871; 95% CI 1.302-2.689, P=0.001, respectively).', 'The odds of ENKTL diagnosis were not significantly associated with ABO blood type, cigarette smoking status or family history of cancer.\tAfter adjusting for other factors, significantly greater odds of being diagnosed with ENKTL were observed among cases who reported ever drinking alcohol (AOR, 1.675; 95% CI 1.054-2.660, P=0.029).', 'The odds of ENKTL diagnosis were not significantly associated with ABO blood type, cigarette smoking status or family history of cancer.\tThe odds of ENKTL diagnosis were not significantly associated with ABO blood type, cigarette smoking status or family history of cancer.']","[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['The data of the full analysis set showed that HBeAg seroconversion rate at week 72 was 27.32% in the trial group and 22.70% in the control group with a rate difference of 4.63% (95% CI -1.54% to 10.80%, P = 0.1493).\tThe data of the full analysis set showed that HBeAg seroconversion rate at week 72 was 27.32% in the trial group and 22.70% in the control group with a rate difference of 4.63% (95% CI -1.54% to 10.80%, P = 0.1493).', 'The data of the full analysis set showed that HBeAg seroconversion rate at week 72 was 27.32% in the trial group and 22.70% in the control group with a rate difference of 4.63% (95% CI -1.54% to 10.80%, P = 0.1493).\tThe data of the per-protocol set showed that HBeAg seroconversion rate at week 72 was 30.75% in the trial group and 27.14% in the control group with a rate difference of 3.61% (95% CI -3.87% to 11.09%, P = 0.3436).', 'The data of the full analysis set showed that HBeAg seroconversion rate at week 72 was 27.32% in the trial group and 22.70% in the control group with a rate difference of 4.63% (95% CI -1.54% to 10.80%, P = 0.1493).\t95% CI met the non-inferiority criteria, and the trial group was non-inferior to the control group.', 'The data of the full analysis set showed that HBeAg seroconversion rate at week 72 was 27.32% in the trial group and 22.70% in the control group with a rate difference of 4.63% (95% CI -1.54% to 10.80%, P = 0.1493).\tThe two groups had similar incidence rates of adverse events, serious adverse events, and common adverse events.', 'The data of the full analysis set showed that HBeAg seroconversion rate at week 72 was 27.32% in the trial group and 22.70% in the control group with a rate difference of 4.63% (95% CI -1.54% to 10.80%, P = 0.1493).\tIn Peg-IFN-α regimen for HBeAg-positive CHB patients, the new drug Peg-IFN-α-2b (Y shape, 40 kD) has comparable effect and safety to the control drug Peg-IFN-α-2a.', 'The data of the per-protocol set showed that HBeAg seroconversion rate at week 72 was 30.75% in the trial group and 27.14% in the control group with a rate difference of 3.61% (95% CI -3.87% to 11.09%, P = 0.3436).\tThe data of the full analysis set showed that HBeAg seroconversion rate at week 72 was 27.32% in the trial group and 22.70% in the control group with a rate difference of 4.63% (95% CI -1.54% to 10.80%, P = 0.1493).', 'The data of the per-protocol set showed that HBeAg seroconversion rate at week 72 was 30.75% in the trial group and 27.14% in the control group with a rate difference of 3.61% (95% CI -3.87% to 11.09%, P = 0.3436).\tThe data of the per-protocol set showed that HBeAg seroconversion rate at week 72 was 30.75% in the trial group and 27.14% in the control group with a rate difference of 3.61% (95% CI -3.87% to 11.09%, P = 0.3436).', 'The data of the per-protocol set showed that HBeAg seroconversion rate at week 72 was 30.75% in the trial group and 27.14% in the control group with a rate difference of 3.61% (95% CI -3.87% to 11.09%, P = 0.3436).\t95% CI met the non-inferiority criteria, and the trial group was non-inferior to the control group.', 'The data of the per-protocol set showed that HBeAg seroconversion rate at week 72 was 30.75% in the trial group and 27.14% in the control group with a rate difference of 3.61% (95% CI -3.87% to 11.09%, P = 0.3436).\tThe two groups had similar incidence rates of adverse events, serious adverse events, and common adverse events.', 'The data of the per-protocol set showed that HBeAg seroconversion rate at week 72 was 30.75% in the trial group and 27.14% in the control group with a rate difference of 3.61% (95% CI -3.87% to 11.09%, P = 0.3436).\tIn Peg-IFN-α regimen for HBeAg-positive CHB patients, the new drug Peg-IFN-α-2b (Y shape, 40 kD) has comparable effect and safety to the control drug Peg-IFN-α-2a.', '95% CI met the non-inferiority criteria, and the trial group was non-inferior to the control group.\tThe data of the full analysis set showed that HBeAg seroconversion rate at week 72 was 27.32% in the trial group and 22.70% in the control group with a rate difference of 4.63% (95% CI -1.54% to 10.80%, P = 0.1493).', '95% CI met the non-inferiority criteria, and the trial group was non-inferior to the control group.\tThe data of the per-protocol set showed that HBeAg seroconversion rate at week 72 was 30.75% in the trial group and 27.14% in the control group with a rate difference of 3.61% (95% CI -3.87% to 11.09%, P = 0.3436).', '95% CI met the non-inferiority criteria, and the trial group was non-inferior to the control group.\t95% CI met the non-inferiority criteria, and the trial group was non-inferior to the control group.', '95% CI met the non-inferiority criteria, and the trial group was non-inferior to the control group.\tThe two groups had similar incidence rates of adverse events, serious adverse events, and common adverse events.', '95% CI met the non-inferiority criteria, and the trial group was non-inferior to the control group.\tIn Peg-IFN-α regimen for HBeAg-positive CHB patients, the new drug Peg-IFN-α-2b (Y shape, 40 kD) has comparable effect and safety to the control drug Peg-IFN-α-2a.', 'The two groups had similar incidence rates of adverse events, serious adverse events, and common adverse events.\tThe data of the full analysis set showed that HBeAg seroconversion rate at week 72 was 27.32% in the trial group and 22.70% in the control group with a rate difference of 4.63% (95% CI -1.54% to 10.80%, P = 0.1493).', 'The two groups had similar incidence rates of adverse events, serious adverse events, and common adverse events.\tThe data of the per-protocol set showed that HBeAg seroconversion rate at week 72 was 30.75% in the trial group and 27.14% in the control group with a rate difference of 3.61% (95% CI -3.87% to 11.09%, P = 0.3436).', 'The two groups had similar incidence rates of adverse events, serious adverse events, and common adverse events.\t95% CI met the non-inferiority criteria, and the trial group was non-inferior to the control group.', 'The two groups had similar incidence rates of adverse events, serious adverse events, and common adverse events.\tThe two groups had similar incidence rates of adverse events, serious adverse events, and common adverse events.', 'The two groups had similar incidence rates of adverse events, serious adverse events, and common adverse events.\tIn Peg-IFN-α regimen for HBeAg-positive CHB patients, the new drug Peg-IFN-α-2b (Y shape, 40 kD) has comparable effect and safety to the control drug Peg-IFN-α-2a.', 'In Peg-IFN-α regimen for HBeAg-positive CHB patients, the new drug Peg-IFN-α-2b (Y shape, 40 kD) has comparable effect and safety to the control drug Peg-IFN-α-2a.\tThe data of the full analysis set showed that HBeAg seroconversion rate at week 72 was 27.32% in the trial group and 22.70% in the control group with a rate difference of 4.63% (95% CI -1.54% to 10.80%, P = 0.1493).', 'In Peg-IFN-α regimen for HBeAg-positive CHB patients, the new drug Peg-IFN-α-2b (Y shape, 40 kD) has comparable effect and safety to the control drug Peg-IFN-α-2a.\tThe data of the per-protocol set showed that HBeAg seroconversion rate at week 72 was 30.75% in the trial group and 27.14% in the control group with a rate difference of 3.61% (95% CI -3.87% to 11.09%, P = 0.3436).', 'In Peg-IFN-α regimen for HBeAg-positive CHB patients, the new drug Peg-IFN-α-2b (Y shape, 40 kD) has comparable effect and safety to the control drug Peg-IFN-α-2a.\t95% CI met the non-inferiority criteria, and the trial group was non-inferior to the control group.', 'In Peg-IFN-α regimen for HBeAg-positive CHB patients, the new drug Peg-IFN-α-2b (Y shape, 40 kD) has comparable effect and safety to the control drug Peg-IFN-α-2a.\tThe two groups had similar incidence rates of adverse events, serious adverse events, and common adverse events.', 'In Peg-IFN-α regimen for HBeAg-positive CHB patients, the new drug Peg-IFN-α-2b (Y shape, 40 kD) has comparable effect and safety to the control drug Peg-IFN-α-2a.\tIn Peg-IFN-α regimen for HBeAg-positive CHB patients, the new drug Peg-IFN-α-2b (Y shape, 40 kD) has comparable effect and safety to the control drug Peg-IFN-α-2a.']","[0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0]"
"['Vesatolimod was safe and well-tolerated in patients with CHB, demonstrating consistent dose-dependent pharmacodynamic induction of ISG15 without significant systemic induction of IFNα expression or related symptoms.\tVesatolimod was safe and well-tolerated in patients with CHB, demonstrating consistent dose-dependent pharmacodynamic induction of ISG15 without significant systemic induction of IFNα expression or related symptoms.', 'Vesatolimod was safe and well-tolerated in patients with CHB, demonstrating consistent dose-dependent pharmacodynamic induction of ISG15 without significant systemic induction of IFNα expression or related symptoms.\tMost (41-80%) experienced ≥1 AE during the study with the majority of AEs mild or moderate in severity.', 'Vesatolimod was safe and well-tolerated in patients with CHB, demonstrating consistent dose-dependent pharmacodynamic induction of ISG15 without significant systemic induction of IFNα expression or related symptoms.\tNo significant declines in HBsAg were observed at the primary (Week 24) or secondary endpoints (Weeks 4, 8, 12, and 48).', 'Vesatolimod was safe and well-tolerated in patients with CHB, demonstrating consistent dose-dependent pharmacodynamic induction of ISG15 without significant systemic induction of IFNα expression or related symptoms.\tISG15 induction was dose-dependent and consistent after repeat dosing, returning closer to baseline by one week after treatment at all dose levels;', 'Vesatolimod was safe and well-tolerated in patients with CHB, demonstrating consistent dose-dependent pharmacodynamic induction of ISG15 without significant systemic induction of IFNα expression or related symptoms.\tno patient demonstrated significant serum interferon alpha (IFNα) expression at any timepoint evaluated.', 'Vesatolimod was safe and well-tolerated in patients with CHB, demonstrating consistent dose-dependent pharmacodynamic induction of ISG15 without significant systemic induction of IFNα expression or related symptoms.\tMultivariate analyses showed that ≥2-fold ISG15 induction is associated with 2- or 4-mg vesatolimod dose and female sex.', 'Most (41-80%) experienced ≥1 AE during the study with the majority of AEs mild or moderate in severity.\tVesatolimod was safe and well-tolerated in patients with CHB, demonstrating consistent dose-dependent pharmacodynamic induction of ISG15 without significant systemic induction of IFNα expression or related symptoms.', 'Most (41-80%) experienced ≥1 AE during the study with the majority of AEs mild or moderate in severity.\tMost (41-80%) experienced ≥1 AE during the study with the majority of AEs mild or moderate in severity.', 'Most (41-80%) experienced ≥1 AE during the study with the majority of AEs mild or moderate in severity.\tNo significant declines in HBsAg were observed at the primary (Week 24) or secondary endpoints (Weeks 4, 8, 12, and 48).', 'Most (41-80%) experienced ≥1 AE during the study with the majority of AEs mild or moderate in severity.\tISG15 induction was dose-dependent and consistent after repeat dosing, returning closer to baseline by one week after treatment at all dose levels;', 'Most (41-80%) experienced ≥1 AE during the study with the majority of AEs mild or moderate in severity.\tno patient demonstrated significant serum interferon alpha (IFNα) expression at any timepoint evaluated.', 'Most (41-80%) experienced ≥1 AE during the study with the majority of AEs mild or moderate in severity.\tMultivariate analyses showed that ≥2-fold ISG15 induction is associated with 2- or 4-mg vesatolimod dose and female sex.', 'No significant declines in HBsAg were observed at the primary (Week 24) or secondary endpoints (Weeks 4, 8, 12, and 48).\tVesatolimod was safe and well-tolerated in patients with CHB, demonstrating consistent dose-dependent pharmacodynamic induction of ISG15 without significant systemic induction of IFNα expression or related symptoms.', 'No significant declines in HBsAg were observed at the primary (Week 24) or secondary endpoints (Weeks 4, 8, 12, and 48).\tMost (41-80%) experienced ≥1 AE during the study with the majority of AEs mild or moderate in severity.', 'No significant declines in HBsAg were observed at the primary (Week 24) or secondary endpoints (Weeks 4, 8, 12, and 48).\tNo significant declines in HBsAg were observed at the primary (Week 24) or secondary endpoints (Weeks 4, 8, 12, and 48).', 'No significant declines in HBsAg were observed at the primary (Week 24) or secondary endpoints (Weeks 4, 8, 12, and 48).\tISG15 induction was dose-dependent and consistent after repeat dosing, returning closer to baseline by one week after treatment at all dose levels;', 'No significant declines in HBsAg were observed at the primary (Week 24) or secondary endpoints (Weeks 4, 8, 12, and 48).\tno patient demonstrated significant serum interferon alpha (IFNα) expression at any timepoint evaluated.', 'No significant declines in HBsAg were observed at the primary (Week 24) or secondary endpoints (Weeks 4, 8, 12, and 48).\tMultivariate analyses showed that ≥2-fold ISG15 induction is associated with 2- or 4-mg vesatolimod dose and female sex.', 'ISG15 induction was dose-dependent and consistent after repeat dosing, returning closer to baseline by one week after treatment at all dose levels;\tVesatolimod was safe and well-tolerated in patients with CHB, demonstrating consistent dose-dependent pharmacodynamic induction of ISG15 without significant systemic induction of IFNα expression or related symptoms.', 'ISG15 induction was dose-dependent and consistent after repeat dosing, returning closer to baseline by one week after treatment at all dose levels;\tMost (41-80%) experienced ≥1 AE during the study with the majority of AEs mild or moderate in severity.', 'ISG15 induction was dose-dependent and consistent after repeat dosing, returning closer to baseline by one week after treatment at all dose levels;\tNo significant declines in HBsAg were observed at the primary (Week 24) or secondary endpoints (Weeks 4, 8, 12, and 48).', 'ISG15 induction was dose-dependent and consistent after repeat dosing, returning closer to baseline by one week after treatment at all dose levels;\tISG15 induction was dose-dependent and consistent after repeat dosing, returning closer to baseline by one week after treatment at all dose levels;', 'ISG15 induction was dose-dependent and consistent after repeat dosing, returning closer to baseline by one week after treatment at all dose levels;\tno patient demonstrated significant serum interferon alpha (IFNα) expression at any timepoint evaluated.', 'ISG15 induction was dose-dependent and consistent after repeat dosing, returning closer to baseline by one week after treatment at all dose levels;\tMultivariate analyses showed that ≥2-fold ISG15 induction is associated with 2- or 4-mg vesatolimod dose and female sex.', 'no patient demonstrated significant serum interferon alpha (IFNα) expression at any timepoint evaluated.\tVesatolimod was safe and well-tolerated in patients with CHB, demonstrating consistent dose-dependent pharmacodynamic induction of ISG15 without significant systemic induction of IFNα expression or related symptoms.', 'no patient demonstrated significant serum interferon alpha (IFNα) expression at any timepoint evaluated.\tMost (41-80%) experienced ≥1 AE during the study with the majority of AEs mild or moderate in severity.', 'no patient demonstrated significant serum interferon alpha (IFNα) expression at any timepoint evaluated.\tNo significant declines in HBsAg were observed at the primary (Week 24) or secondary endpoints (Weeks 4, 8, 12, and 48).', 'no patient demonstrated significant serum interferon alpha (IFNα) expression at any timepoint evaluated.\tISG15 induction was dose-dependent and consistent after repeat dosing, returning closer to baseline by one week after treatment at all dose levels;', 'no patient demonstrated significant serum interferon alpha (IFNα) expression at any timepoint evaluated.\tno patient demonstrated significant serum interferon alpha (IFNα) expression at any timepoint evaluated.', 'no patient demonstrated significant serum interferon alpha (IFNα) expression at any timepoint evaluated.\tMultivariate analyses showed that ≥2-fold ISG15 induction is associated with 2- or 4-mg vesatolimod dose and female sex.', 'Multivariate analyses showed that ≥2-fold ISG15 induction is associated with 2- or 4-mg vesatolimod dose and female sex.\tVesatolimod was safe and well-tolerated in patients with CHB, demonstrating consistent dose-dependent pharmacodynamic induction of ISG15 without significant systemic induction of IFNα expression or related symptoms.', 'Multivariate analyses showed that ≥2-fold ISG15 induction is associated with 2- or 4-mg vesatolimod dose and female sex.\tMost (41-80%) experienced ≥1 AE during the study with the majority of AEs mild or moderate in severity.', 'Multivariate analyses showed that ≥2-fold ISG15 induction is associated with 2- or 4-mg vesatolimod dose and female sex.\tNo significant declines in HBsAg were observed at the primary (Week 24) or secondary endpoints (Weeks 4, 8, 12, and 48).', 'Multivariate analyses showed that ≥2-fold ISG15 induction is associated with 2- or 4-mg vesatolimod dose and female sex.\tISG15 induction was dose-dependent and consistent after repeat dosing, returning closer to baseline by one week after treatment at all dose levels;', 'Multivariate analyses showed that ≥2-fold ISG15 induction is associated with 2- or 4-mg vesatolimod dose and female sex.\tno patient demonstrated significant serum interferon alpha (IFNα) expression at any timepoint evaluated.', 'Multivariate analyses showed that ≥2-fold ISG15 induction is associated with 2- or 4-mg vesatolimod dose and female sex.\tMultivariate analyses showed that ≥2-fold ISG15 induction is associated with 2- or 4-mg vesatolimod dose and female sex.']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['Overall, 6.6% of patients modified their initial treatment, with ETV having lower rates of treatment modification than other major NUCs (P<0.05).\tOverall, 6.6% of patients modified their initial treatment, with ETV having lower rates of treatment modification than other major NUCs (P<0.05).', 'Overall, 6.6% of patients modified their initial treatment, with ETV having lower rates of treatment modification than other major NUCs (P<0.05).\tAt week 52, the virologic response rate was higher with ETV than with LAM-based treatment (77.0% versus 61.4%, P<0.0001).', 'Overall, 6.6% of patients modified their initial treatment, with ETV having lower rates of treatment modification than other major NUCs (P<0.05).\tLAM-based treatment was associated with a higher probability of virologic breakthrough and genotypic resistance (21.4% and 19.6%, respectively) than ETV (1.6% and 0.1%, respectively) (P<0.0001).', 'Overall, 6.6% of patients modified their initial treatment, with ETV having lower rates of treatment modification than other major NUCs (P<0.05).\tTreatment-related adverse events or serious adverse events were uncommon.', 'Overall, 6.6% of patients modified their initial treatment, with ETV having lower rates of treatment modification than other major NUCs (P<0.05).\tConsistent with clinical trial results, ETV was more effective than LAM-based treatments in a real-world setting, with treatment modification being relatively low in ETV-treated patients.', 'At week 52, the virologic response rate was higher with ETV than with LAM-based treatment (77.0% versus 61.4%, P<0.0001).\tOverall, 6.6% of patients modified their initial treatment, with ETV having lower rates of treatment modification than other major NUCs (P<0.05).', 'At week 52, the virologic response rate was higher with ETV than with LAM-based treatment (77.0% versus 61.4%, P<0.0001).\tAt week 52, the virologic response rate was higher with ETV than with LAM-based treatment (77.0% versus 61.4%, P<0.0001).', 'At week 52, the virologic response rate was higher with ETV than with LAM-based treatment (77.0% versus 61.4%, P<0.0001).\tLAM-based treatment was associated with a higher probability of virologic breakthrough and genotypic resistance (21.4% and 19.6%, respectively) than ETV (1.6% and 0.1%, respectively) (P<0.0001).', 'At week 52, the virologic response rate was higher with ETV than with LAM-based treatment (77.0% versus 61.4%, P<0.0001).\tTreatment-related adverse events or serious adverse events were uncommon.', 'At week 52, the virologic response rate was higher with ETV than with LAM-based treatment (77.0% versus 61.4%, P<0.0001).\tConsistent with clinical trial results, ETV was more effective than LAM-based treatments in a real-world setting, with treatment modification being relatively low in ETV-treated patients.', 'LAM-based treatment was associated with a higher probability of virologic breakthrough and genotypic resistance (21.4% and 19.6%, respectively) than ETV (1.6% and 0.1%, respectively) (P<0.0001).\tOverall, 6.6% of patients modified their initial treatment, with ETV having lower rates of treatment modification than other major NUCs (P<0.05).', 'LAM-based treatment was associated with a higher probability of virologic breakthrough and genotypic resistance (21.4% and 19.6%, respectively) than ETV (1.6% and 0.1%, respectively) (P<0.0001).\tAt week 52, the virologic response rate was higher with ETV than with LAM-based treatment (77.0% versus 61.4%, P<0.0001).', 'LAM-based treatment was associated with a higher probability of virologic breakthrough and genotypic resistance (21.4% and 19.6%, respectively) than ETV (1.6% and 0.1%, respectively) (P<0.0001).\tLAM-based treatment was associated with a higher probability of virologic breakthrough and genotypic resistance (21.4% and 19.6%, respectively) than ETV (1.6% and 0.1%, respectively) (P<0.0001).', 'LAM-based treatment was associated with a higher probability of virologic breakthrough and genotypic resistance (21.4% and 19.6%, respectively) than ETV (1.6% and 0.1%, respectively) (P<0.0001).\tTreatment-related adverse events or serious adverse events were uncommon.', 'LAM-based treatment was associated with a higher probability of virologic breakthrough and genotypic resistance (21.4% and 19.6%, respectively) than ETV (1.6% and 0.1%, respectively) (P<0.0001).\tConsistent with clinical trial results, ETV was more effective than LAM-based treatments in a real-world setting, with treatment modification being relatively low in ETV-treated patients.', 'Treatment-related adverse events or serious adverse events were uncommon.\tOverall, 6.6% of patients modified their initial treatment, with ETV having lower rates of treatment modification than other major NUCs (P<0.05).', 'Treatment-related adverse events or serious adverse events were uncommon.\tAt week 52, the virologic response rate was higher with ETV than with LAM-based treatment (77.0% versus 61.4%, P<0.0001).', 'Treatment-related adverse events or serious adverse events were uncommon.\tLAM-based treatment was associated with a higher probability of virologic breakthrough and genotypic resistance (21.4% and 19.6%, respectively) than ETV (1.6% and 0.1%, respectively) (P<0.0001).', 'Treatment-related adverse events or serious adverse events were uncommon.\tTreatment-related adverse events or serious adverse events were uncommon.', 'Treatment-related adverse events or serious adverse events were uncommon.\tConsistent with clinical trial results, ETV was more effective than LAM-based treatments in a real-world setting, with treatment modification being relatively low in ETV-treated patients.', 'Consistent with clinical trial results, ETV was more effective than LAM-based treatments in a real-world setting, with treatment modification being relatively low in ETV-treated patients.\tOverall, 6.6% of patients modified their initial treatment, with ETV having lower rates of treatment modification than other major NUCs (P<0.05).', 'Consistent with clinical trial results, ETV was more effective than LAM-based treatments in a real-world setting, with treatment modification being relatively low in ETV-treated patients.\tAt week 52, the virologic response rate was higher with ETV than with LAM-based treatment (77.0% versus 61.4%, P<0.0001).', 'Consistent with clinical trial results, ETV was more effective than LAM-based treatments in a real-world setting, with treatment modification being relatively low in ETV-treated patients.\tLAM-based treatment was associated with a higher probability of virologic breakthrough and genotypic resistance (21.4% and 19.6%, respectively) than ETV (1.6% and 0.1%, respectively) (P<0.0001).', 'Consistent with clinical trial results, ETV was more effective than LAM-based treatments in a real-world setting, with treatment modification being relatively low in ETV-treated patients.\tTreatment-related adverse events or serious adverse events were uncommon.', 'Consistent with clinical trial results, ETV was more effective than LAM-based treatments in a real-world setting, with treatment modification being relatively low in ETV-treated patients.\tConsistent with clinical trial results, ETV was more effective than LAM-based treatments in a real-world setting, with treatment modification being relatively low in ETV-treated patients.']","[0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['Complete success (defined as IOP <16 mmHg on no medication) could be achieved in 85% eyes in study group while it was 60% in control group (P = 0.04).\tComplete success (defined as IOP <16 mmHg on no medication) could be achieved in 85% eyes in study group while it was 60% in control group (P = 0.04).', 'Complete success (defined as IOP <16 mmHg on no medication) could be achieved in 85% eyes in study group while it was 60% in control group (P = 0.04).\tIOP reduced by 71.1% in study group from 41.9 ± 10.6 to 12.1 ± 2.7 mmHg and from 40.5 ± 8.5 to 12.8 ± 4.5 mmHg in control group, a decline of 68.29%.', 'Complete success (defined as IOP <16 mmHg on no medication) could be achieved in 85% eyes in study group while it was 60% in control group (P = 0.04).\tBlebs in AMT group showed better bleb morphology in terms of significantly better extent (E3) on day 1 (P = 0.03) and better height (H2 and H3) (P = 0.04), according to the Indiana Bleb Appearance Grading Scale, at all follow-up visits along with normal vascularity.', 'Complete success (defined as IOP <16 mmHg on no medication) could be achieved in 85% eyes in study group while it was 60% in control group (P = 0.04).\tThe study group required significantly lesser (P = 0.03) bleb needlings as compared to control group.', 'Complete success (defined as IOP <16 mmHg on no medication) could be achieved in 85% eyes in study group while it was 60% in control group (P = 0.04).\tAmnion enhanced the efficacy of MMC-modulated trabeculectomy in terms of eyes with complete success and lesser interventions such as bleb needling.', 'Complete success (defined as IOP <16 mmHg on no medication) could be achieved in 85% eyes in study group while it was 60% in control group (P = 0.04).\tThis reiterates the role of amnion as a safe and effective bleb modulator.', 'IOP reduced by 71.1% in study group from 41.9 ± 10.6 to 12.1 ± 2.7 mmHg and from 40.5 ± 8.5 to 12.8 ± 4.5 mmHg in control group, a decline of 68.29%.\tComplete success (defined as IOP <16 mmHg on no medication) could be achieved in 85% eyes in study group while it was 60% in control group (P = 0.04).', 'IOP reduced by 71.1% in study group from 41.9 ± 10.6 to 12.1 ± 2.7 mmHg and from 40.5 ± 8.5 to 12.8 ± 4.5 mmHg in control group, a decline of 68.29%.\tIOP reduced by 71.1% in study group from 41.9 ± 10.6 to 12.1 ± 2.7 mmHg and from 40.5 ± 8.5 to 12.8 ± 4.5 mmHg in control group, a decline of 68.29%.', 'IOP reduced by 71.1% in study group from 41.9 ± 10.6 to 12.1 ± 2.7 mmHg and from 40.5 ± 8.5 to 12.8 ± 4.5 mmHg in control group, a decline of 68.29%.\tBlebs in AMT group showed better bleb morphology in terms of significantly better extent (E3) on day 1 (P = 0.03) and better height (H2 and H3) (P = 0.04), according to the Indiana Bleb Appearance Grading Scale, at all follow-up visits along with normal vascularity.', 'IOP reduced by 71.1% in study group from 41.9 ± 10.6 to 12.1 ± 2.7 mmHg and from 40.5 ± 8.5 to 12.8 ± 4.5 mmHg in control group, a decline of 68.29%.\tThe study group required significantly lesser (P = 0.03) bleb needlings as compared to control group.', 'IOP reduced by 71.1% in study group from 41.9 ± 10.6 to 12.1 ± 2.7 mmHg and from 40.5 ± 8.5 to 12.8 ± 4.5 mmHg in control group, a decline of 68.29%.\tAmnion enhanced the efficacy of MMC-modulated trabeculectomy in terms of eyes with complete success and lesser interventions such as bleb needling.', 'IOP reduced by 71.1% in study group from 41.9 ± 10.6 to 12.1 ± 2.7 mmHg and from 40.5 ± 8.5 to 12.8 ± 4.5 mmHg in control group, a decline of 68.29%.\tThis reiterates the role of amnion as a safe and effective bleb modulator.', 'Blebs in AMT group showed better bleb morphology in terms of significantly better extent (E3) on day 1 (P = 0.03) and better height (H2 and H3) (P = 0.04), according to the Indiana Bleb Appearance Grading Scale, at all follow-up visits along with normal vascularity.\tComplete success (defined as IOP <16 mmHg on no medication) could be achieved in 85% eyes in study group while it was 60% in control group (P = 0.04).', 'Blebs in AMT group showed better bleb morphology in terms of significantly better extent (E3) on day 1 (P = 0.03) and better height (H2 and H3) (P = 0.04), according to the Indiana Bleb Appearance Grading Scale, at all follow-up visits along with normal vascularity.\tIOP reduced by 71.1% in study group from 41.9 ± 10.6 to 12.1 ± 2.7 mmHg and from 40.5 ± 8.5 to 12.8 ± 4.5 mmHg in control group, a decline of 68.29%.', 'Blebs in AMT group showed better bleb morphology in terms of significantly better extent (E3) on day 1 (P = 0.03) and better height (H2 and H3) (P = 0.04), according to the Indiana Bleb Appearance Grading Scale, at all follow-up visits along with normal vascularity.\tBlebs in AMT group showed better bleb morphology in terms of significantly better extent (E3) on day 1 (P = 0.03) and better height (H2 and H3) (P = 0.04), according to the Indiana Bleb Appearance Grading Scale, at all follow-up visits along with normal vascularity.', 'Blebs in AMT group showed better bleb morphology in terms of significantly better extent (E3) on day 1 (P = 0.03) and better height (H2 and H3) (P = 0.04), according to the Indiana Bleb Appearance Grading Scale, at all follow-up visits along with normal vascularity.\tThe study group required significantly lesser (P = 0.03) bleb needlings as compared to control group.', 'Blebs in AMT group showed better bleb morphology in terms of significantly better extent (E3) on day 1 (P = 0.03) and better height (H2 and H3) (P = 0.04), according to the Indiana Bleb Appearance Grading Scale, at all follow-up visits along with normal vascularity.\tAmnion enhanced the efficacy of MMC-modulated trabeculectomy in terms of eyes with complete success and lesser interventions such as bleb needling.', 'Blebs in AMT group showed better bleb morphology in terms of significantly better extent (E3) on day 1 (P = 0.03) and better height (H2 and H3) (P = 0.04), according to the Indiana Bleb Appearance Grading Scale, at all follow-up visits along with normal vascularity.\tThis reiterates the role of amnion as a safe and effective bleb modulator.', 'The study group required significantly lesser (P = 0.03) bleb needlings as compared to control group.\tComplete success (defined as IOP <16 mmHg on no medication) could be achieved in 85% eyes in study group while it was 60% in control group (P = 0.04).', 'The study group required significantly lesser (P = 0.03) bleb needlings as compared to control group.\tIOP reduced by 71.1% in study group from 41.9 ± 10.6 to 12.1 ± 2.7 mmHg and from 40.5 ± 8.5 to 12.8 ± 4.5 mmHg in control group, a decline of 68.29%.', 'The study group required significantly lesser (P = 0.03) bleb needlings as compared to control group.\tBlebs in AMT group showed better bleb morphology in terms of significantly better extent (E3) on day 1 (P = 0.03) and better height (H2 and H3) (P = 0.04), according to the Indiana Bleb Appearance Grading Scale, at all follow-up visits along with normal vascularity.', 'The study group required significantly lesser (P = 0.03) bleb needlings as compared to control group.\tThe study group required significantly lesser (P = 0.03) bleb needlings as compared to control group.', 'The study group required significantly lesser (P = 0.03) bleb needlings as compared to control group.\tAmnion enhanced the efficacy of MMC-modulated trabeculectomy in terms of eyes with complete success and lesser interventions such as bleb needling.', 'The study group required significantly lesser (P = 0.03) bleb needlings as compared to control group.\tThis reiterates the role of amnion as a safe and effective bleb modulator.', 'Amnion enhanced the efficacy of MMC-modulated trabeculectomy in terms of eyes with complete success and lesser interventions such as bleb needling.\tComplete success (defined as IOP <16 mmHg on no medication) could be achieved in 85% eyes in study group while it was 60% in control group (P = 0.04).', 'Amnion enhanced the efficacy of MMC-modulated trabeculectomy in terms of eyes with complete success and lesser interventions such as bleb needling.\tIOP reduced by 71.1% in study group from 41.9 ± 10.6 to 12.1 ± 2.7 mmHg and from 40.5 ± 8.5 to 12.8 ± 4.5 mmHg in control group, a decline of 68.29%.', 'Amnion enhanced the efficacy of MMC-modulated trabeculectomy in terms of eyes with complete success and lesser interventions such as bleb needling.\tBlebs in AMT group showed better bleb morphology in terms of significantly better extent (E3) on day 1 (P = 0.03) and better height (H2 and H3) (P = 0.04), according to the Indiana Bleb Appearance Grading Scale, at all follow-up visits along with normal vascularity.', 'Amnion enhanced the efficacy of MMC-modulated trabeculectomy in terms of eyes with complete success and lesser interventions such as bleb needling.\tThe study group required significantly lesser (P = 0.03) bleb needlings as compared to control group.', 'Amnion enhanced the efficacy of MMC-modulated trabeculectomy in terms of eyes with complete success and lesser interventions such as bleb needling.\tAmnion enhanced the efficacy of MMC-modulated trabeculectomy in terms of eyes with complete success and lesser interventions such as bleb needling.', 'Amnion enhanced the efficacy of MMC-modulated trabeculectomy in terms of eyes with complete success and lesser interventions such as bleb needling.\tThis reiterates the role of amnion as a safe and effective bleb modulator.', 'This reiterates the role of amnion as a safe and effective bleb modulator.\tComplete success (defined as IOP <16 mmHg on no medication) could be achieved in 85% eyes in study group while it was 60% in control group (P = 0.04).', 'This reiterates the role of amnion as a safe and effective bleb modulator.\tIOP reduced by 71.1% in study group from 41.9 ± 10.6 to 12.1 ± 2.7 mmHg and from 40.5 ± 8.5 to 12.8 ± 4.5 mmHg in control group, a decline of 68.29%.', 'This reiterates the role of amnion as a safe and effective bleb modulator.\tBlebs in AMT group showed better bleb morphology in terms of significantly better extent (E3) on day 1 (P = 0.03) and better height (H2 and H3) (P = 0.04), according to the Indiana Bleb Appearance Grading Scale, at all follow-up visits along with normal vascularity.', 'This reiterates the role of amnion as a safe and effective bleb modulator.\tThe study group required significantly lesser (P = 0.03) bleb needlings as compared to control group.', 'This reiterates the role of amnion as a safe and effective bleb modulator.\tAmnion enhanced the efficacy of MMC-modulated trabeculectomy in terms of eyes with complete success and lesser interventions such as bleb needling.', 'This reiterates the role of amnion as a safe and effective bleb modulator.\tThis reiterates the role of amnion as a safe and effective bleb modulator.']","[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['In conclusion, co-infected patients with elevated HBV-replication at ART-initiation are more susceptible to HIV-related morbidity, especially invasive bacterial diseases, during treatment interruption.\tIn conclusion, co-infected patients with elevated HBV-replication at ART-initiation are more susceptible to HIV-related morbidity, especially invasive bacterial diseases, during treatment interruption.', 'In conclusion, co-infected patients with elevated HBV-replication at ART-initiation are more susceptible to HIV-related morbidity, especially invasive bacterial diseases, during treatment interruption.\tNo increase in the incidence of non-HIV-related morbidity was observed for co-infected patients (P = 0.5), even at HBV-replication levels > 10,000 copies/mL (P = 0.7).', 'In conclusion, co-infected patients with elevated HBV-replication at ART-initiation are more susceptible to HIV-related morbidity, especially invasive bacterial diseases, during treatment interruption.\tThe relative effect of CD4GT or 2/4-ART versus C-ART was not different between infection groups (P for interaction = 0.4).', 'In conclusion, co-infected patients with elevated HBV-replication at ART-initiation are more susceptible to HIV-related morbidity, especially invasive bacterial diseases, during treatment interruption.\tIncidence of bacterial infections was also highest in the co-infected group with HBV-replication > 10,000 copies/mL (IR = 12.9 versus 3.3/100 person/years in HIV mono-infected patients, P = 0.001).', 'In conclusion, co-infected patients with elevated HBV-replication at ART-initiation are more susceptible to HIV-related morbidity, especially invasive bacterial diseases, during treatment interruption.\tAfter a median 2.0 year (range = 0.2-3.1) follow-up, ≥ 1 serious HIV-related events occurred in 101 HIV mono-infected and 15 HIV-HBV co-infected patients (IR = 10.0 versus 13.2/100 person/years, respectively, P = 0.3)', 'No increase in the incidence of non-HIV-related morbidity was observed for co-infected patients (P = 0.5), even at HBV-replication levels > 10,000 copies/mL (P = 0.7).\tIn conclusion, co-infected patients with elevated HBV-replication at ART-initiation are more susceptible to HIV-related morbidity, especially invasive bacterial diseases, during treatment interruption.', 'No increase in the incidence of non-HIV-related morbidity was observed for co-infected patients (P = 0.5), even at HBV-replication levels > 10,000 copies/mL (P = 0.7).\tNo increase in the incidence of non-HIV-related morbidity was observed for co-infected patients (P = 0.5), even at HBV-replication levels > 10,000 copies/mL (P = 0.7).', 'No increase in the incidence of non-HIV-related morbidity was observed for co-infected patients (P = 0.5), even at HBV-replication levels > 10,000 copies/mL (P = 0.7).\tThe relative effect of CD4GT or 2/4-ART versus C-ART was not different between infection groups (P for interaction = 0.4).', 'No increase in the incidence of non-HIV-related morbidity was observed for co-infected patients (P = 0.5), even at HBV-replication levels > 10,000 copies/mL (P = 0.7).\tIncidence of bacterial infections was also highest in the co-infected group with HBV-replication > 10,000 copies/mL (IR = 12.9 versus 3.3/100 person/years in HIV mono-infected patients, P = 0.001).', 'No increase in the incidence of non-HIV-related morbidity was observed for co-infected patients (P = 0.5), even at HBV-replication levels > 10,000 copies/mL (P = 0.7).\tAfter a median 2.0 year (range = 0.2-3.1) follow-up, ≥ 1 serious HIV-related events occurred in 101 HIV mono-infected and 15 HIV-HBV co-infected patients (IR = 10.0 versus 13.2/100 person/years, respectively, P = 0.3)', 'The relative effect of CD4GT or 2/4-ART versus C-ART was not different between infection groups (P for interaction = 0.4).\tIn conclusion, co-infected patients with elevated HBV-replication at ART-initiation are more susceptible to HIV-related morbidity, especially invasive bacterial diseases, during treatment interruption.', 'The relative effect of CD4GT or 2/4-ART versus C-ART was not different between infection groups (P for interaction = 0.4).\tNo increase in the incidence of non-HIV-related morbidity was observed for co-infected patients (P = 0.5), even at HBV-replication levels > 10,000 copies/mL (P = 0.7).', 'The relative effect of CD4GT or 2/4-ART versus C-ART was not different between infection groups (P for interaction = 0.4).\tThe relative effect of CD4GT or 2/4-ART versus C-ART was not different between infection groups (P for interaction = 0.4).', 'The relative effect of CD4GT or 2/4-ART versus C-ART was not different between infection groups (P for interaction = 0.4).\tIncidence of bacterial infections was also highest in the co-infected group with HBV-replication > 10,000 copies/mL (IR = 12.9 versus 3.3/100 person/years in HIV mono-infected patients, P = 0.001).', 'The relative effect of CD4GT or 2/4-ART versus C-ART was not different between infection groups (P for interaction = 0.4).\tAfter a median 2.0 year (range = 0.2-3.1) follow-up, ≥ 1 serious HIV-related events occurred in 101 HIV mono-infected and 15 HIV-HBV co-infected patients (IR = 10.0 versus 13.2/100 person/years, respectively, P = 0.3)', 'Incidence of bacterial infections was also highest in the co-infected group with HBV-replication > 10,000 copies/mL (IR = 12.9 versus 3.3/100 person/years in HIV mono-infected patients, P = 0.001).\tIn conclusion, co-infected patients with elevated HBV-replication at ART-initiation are more susceptible to HIV-related morbidity, especially invasive bacterial diseases, during treatment interruption.', 'Incidence of bacterial infections was also highest in the co-infected group with HBV-replication > 10,000 copies/mL (IR = 12.9 versus 3.3/100 person/years in HIV mono-infected patients, P = 0.001).\tNo increase in the incidence of non-HIV-related morbidity was observed for co-infected patients (P = 0.5), even at HBV-replication levels > 10,000 copies/mL (P = 0.7).', 'Incidence of bacterial infections was also highest in the co-infected group with HBV-replication > 10,000 copies/mL (IR = 12.9 versus 3.3/100 person/years in HIV mono-infected patients, P = 0.001).\tThe relative effect of CD4GT or 2/4-ART versus C-ART was not different between infection groups (P for interaction = 0.4).', 'Incidence of bacterial infections was also highest in the co-infected group with HBV-replication > 10,000 copies/mL (IR = 12.9 versus 3.3/100 person/years in HIV mono-infected patients, P = 0.001).\tIncidence of bacterial infections was also highest in the co-infected group with HBV-replication > 10,000 copies/mL (IR = 12.9 versus 3.3/100 person/years in HIV mono-infected patients, P = 0.001).', 'Incidence of bacterial infections was also highest in the co-infected group with HBV-replication > 10,000 copies/mL (IR = 12.9 versus 3.3/100 person/years in HIV mono-infected patients, P = 0.001).\tAfter a median 2.0 year (range = 0.2-3.1) follow-up, ≥ 1 serious HIV-related events occurred in 101 HIV mono-infected and 15 HIV-HBV co-infected patients (IR = 10.0 versus 13.2/100 person/years, respectively, P = 0.3)', 'After a median 2.0 year (range = 0.2-3.1) follow-up, ≥ 1 serious HIV-related events occurred in 101 HIV mono-infected and 15 HIV-HBV co-infected patients (IR = 10.0 versus 13.2/100 person/years, respectively, P = 0.3)\tIn conclusion, co-infected patients with elevated HBV-replication at ART-initiation are more susceptible to HIV-related morbidity, especially invasive bacterial diseases, during treatment interruption.', 'After a median 2.0 year (range = 0.2-3.1) follow-up, ≥ 1 serious HIV-related events occurred in 101 HIV mono-infected and 15 HIV-HBV co-infected patients (IR = 10.0 versus 13.2/100 person/years, respectively, P = 0.3)\tNo increase in the incidence of non-HIV-related morbidity was observed for co-infected patients (P = 0.5), even at HBV-replication levels > 10,000 copies/mL (P = 0.7).', 'After a median 2.0 year (range = 0.2-3.1) follow-up, ≥ 1 serious HIV-related events occurred in 101 HIV mono-infected and 15 HIV-HBV co-infected patients (IR = 10.0 versus 13.2/100 person/years, respectively, P = 0.3)\tThe relative effect of CD4GT or 2/4-ART versus C-ART was not different between infection groups (P for interaction = 0.4).', 'After a median 2.0 year (range = 0.2-3.1) follow-up, ≥ 1 serious HIV-related events occurred in 101 HIV mono-infected and 15 HIV-HBV co-infected patients (IR = 10.0 versus 13.2/100 person/years, respectively, P = 0.3)\tIncidence of bacterial infections was also highest in the co-infected group with HBV-replication > 10,000 copies/mL (IR = 12.9 versus 3.3/100 person/years in HIV mono-infected patients, P = 0.001).', 'After a median 2.0 year (range = 0.2-3.1) follow-up, ≥ 1 serious HIV-related events occurred in 101 HIV mono-infected and 15 HIV-HBV co-infected patients (IR = 10.0 versus 13.2/100 person/years, respectively, P = 0.3)\tAfter a median 2.0 year (range = 0.2-3.1) follow-up, ≥ 1 serious HIV-related events occurred in 101 HIV mono-infected and 15 HIV-HBV co-infected patients (IR = 10.0 versus 13.2/100 person/years, respectively, P = 0.3)']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0]"
"['valsartan/cilnidipine combination would suppress the home morning blood pressure (BP) surge (HMBPS) more effectively than a valsartan/hydrochlorothiazide combination in patients with morning hypertension\tvalsartan/cilnidipine combination would suppress the home morning blood pressure (BP) surge (HMBPS) more effectively than a valsartan/hydrochlorothiazide combination in patients with morning hypertension', 'valsartan/cilnidipine combination would suppress the home morning blood pressure (BP) surge (HMBPS) more effectively than a valsartan/hydrochlorothiazide combination in patients with morning hypertension\tAt the end of the treatment period, the changes in nocturnal SBP and morning SBP from baseline were significant in both the valsartan/cilnidipine and valsartan/hydrochlorothiazide groups (P < .001): -5.0 vs -10.0 mm Hg (P = .035) and -10.7 vs -13.6 mm Hg (P = .142), respectively.', 'valsartan/cilnidipine combination would suppress the home morning blood pressure (BP) surge (HMBPS) more effectively than a valsartan/hydrochlorothiazide combination in patients with morning hypertension\tHMBPS was significantly decreased from baseline in both groups (P < .001), but there was no significant difference between the two groups: 14.4 mm Hg vs 14.0 mm Hg, respectively (P = .892).', 'valsartan/cilnidipine combination would suppress the home morning blood pressure (BP) surge (HMBPS) more effectively than a valsartan/hydrochlorothiazide combination in patients with morning hypertension\tValsartan/cilnidipine could not significantly suppress HMBPS compared with valsartan/hydrochlorothiazide.', 'At the end of the treatment period, the changes in nocturnal SBP and morning SBP from baseline were significant in both the valsartan/cilnidipine and valsartan/hydrochlorothiazide groups (P < .001): -5.0 vs -10.0 mm Hg (P = .035) and -10.7 vs -13.6 mm Hg (P = .142), respectively.\tvalsartan/cilnidipine combination would suppress the home morning blood pressure (BP) surge (HMBPS) more effectively than a valsartan/hydrochlorothiazide combination in patients with morning hypertension', 'At the end of the treatment period, the changes in nocturnal SBP and morning SBP from baseline were significant in both the valsartan/cilnidipine and valsartan/hydrochlorothiazide groups (P < .001): -5.0 vs -10.0 mm Hg (P = .035) and -10.7 vs -13.6 mm Hg (P = .142), respectively.\tAt the end of the treatment period, the changes in nocturnal SBP and morning SBP from baseline were significant in both the valsartan/cilnidipine and valsartan/hydrochlorothiazide groups (P < .001): -5.0 vs -10.0 mm Hg (P = .035) and -10.7 vs -13.6 mm Hg (P = .142), respectively.', 'At the end of the treatment period, the changes in nocturnal SBP and morning SBP from baseline were significant in both the valsartan/cilnidipine and valsartan/hydrochlorothiazide groups (P < .001): -5.0 vs -10.0 mm Hg (P = .035) and -10.7 vs -13.6 mm Hg (P = .142), respectively.\tHMBPS was significantly decreased from baseline in both groups (P < .001), but there was no significant difference between the two groups: 14.4 mm Hg vs 14.0 mm Hg, respectively (P = .892).', 'At the end of the treatment period, the changes in nocturnal SBP and morning SBP from baseline were significant in both the valsartan/cilnidipine and valsartan/hydrochlorothiazide groups (P < .001): -5.0 vs -10.0 mm Hg (P = .035) and -10.7 vs -13.6 mm Hg (P = .142), respectively.\tValsartan/cilnidipine could not significantly suppress HMBPS compared with valsartan/hydrochlorothiazide.', 'HMBPS was significantly decreased from baseline in both groups (P < .001), but there was no significant difference between the two groups: 14.4 mm Hg vs 14.0 mm Hg, respectively (P = .892).\tvalsartan/cilnidipine combination would suppress the home morning blood pressure (BP) surge (HMBPS) more effectively than a valsartan/hydrochlorothiazide combination in patients with morning hypertension', 'HMBPS was significantly decreased from baseline in both groups (P < .001), but there was no significant difference between the two groups: 14.4 mm Hg vs 14.0 mm Hg, respectively (P = .892).\tAt the end of the treatment period, the changes in nocturnal SBP and morning SBP from baseline were significant in both the valsartan/cilnidipine and valsartan/hydrochlorothiazide groups (P < .001): -5.0 vs -10.0 mm Hg (P = .035) and -10.7 vs -13.6 mm Hg (P = .142), respectively.', 'HMBPS was significantly decreased from baseline in both groups (P < .001), but there was no significant difference between the two groups: 14.4 mm Hg vs 14.0 mm Hg, respectively (P = .892).\tHMBPS was significantly decreased from baseline in both groups (P < .001), but there was no significant difference between the two groups: 14.4 mm Hg vs 14.0 mm Hg, respectively (P = .892).', 'HMBPS was significantly decreased from baseline in both groups (P < .001), but there was no significant difference between the two groups: 14.4 mm Hg vs 14.0 mm Hg, respectively (P = .892).\tValsartan/cilnidipine could not significantly suppress HMBPS compared with valsartan/hydrochlorothiazide.', 'Valsartan/cilnidipine could not significantly suppress HMBPS compared with valsartan/hydrochlorothiazide.\tvalsartan/cilnidipine combination would suppress the home morning blood pressure (BP) surge (HMBPS) more effectively than a valsartan/hydrochlorothiazide combination in patients with morning hypertension', 'Valsartan/cilnidipine could not significantly suppress HMBPS compared with valsartan/hydrochlorothiazide.\tAt the end of the treatment period, the changes in nocturnal SBP and morning SBP from baseline were significant in both the valsartan/cilnidipine and valsartan/hydrochlorothiazide groups (P < .001): -5.0 vs -10.0 mm Hg (P = .035) and -10.7 vs -13.6 mm Hg (P = .142), respectively.', 'Valsartan/cilnidipine could not significantly suppress HMBPS compared with valsartan/hydrochlorothiazide.\tHMBPS was significantly decreased from baseline in both groups (P < .001), but there was no significant difference between the two groups: 14.4 mm Hg vs 14.0 mm Hg, respectively (P = .892).', 'Valsartan/cilnidipine could not significantly suppress HMBPS compared with valsartan/hydrochlorothiazide.\tValsartan/cilnidipine could not significantly suppress HMBPS compared with valsartan/hydrochlorothiazide.']","[0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 1, 2, 0, 0, 0]"
"['After a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).\tAfter a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).', 'After a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).\tNone of the subjects in either group experienced viral reactivation based on per protocol analysis.', 'After a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).\tNo serious adverse reactions were observed.', 'After a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).\tIn the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).', 'After a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).\tStable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.', 'After a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).\tHowever, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.', 'After a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).\tThe efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.', 'None of the subjects in either group experienced viral reactivation based on per protocol analysis.\tAfter a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).', 'None of the subjects in either group experienced viral reactivation based on per protocol analysis.\tNone of the subjects in either group experienced viral reactivation based on per protocol analysis.', 'None of the subjects in either group experienced viral reactivation based on per protocol analysis.\tNo serious adverse reactions were observed.', 'None of the subjects in either group experienced viral reactivation based on per protocol analysis.\tIn the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).', 'None of the subjects in either group experienced viral reactivation based on per protocol analysis.\tStable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.', 'None of the subjects in either group experienced viral reactivation based on per protocol analysis.\tHowever, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.', 'None of the subjects in either group experienced viral reactivation based on per protocol analysis.\tThe efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.', 'No serious adverse reactions were observed.\tAfter a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).', 'No serious adverse reactions were observed.\tNone of the subjects in either group experienced viral reactivation based on per protocol analysis.', 'No serious adverse reactions were observed.\tNo serious adverse reactions were observed.', 'No serious adverse reactions were observed.\tIn the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).', 'No serious adverse reactions were observed.\tStable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.', 'No serious adverse reactions were observed.\tHowever, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.', 'No serious adverse reactions were observed.\tThe efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.', 'In the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).\tAfter a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).', 'In the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).\tNone of the subjects in either group experienced viral reactivation based on per protocol analysis.', 'In the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).\tNo serious adverse reactions were observed.', 'In the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).\tIn the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).', 'In the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).\tStable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.', 'In the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).\tHowever, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.', 'In the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).\tThe efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.', 'Stable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.\tAfter a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).', 'Stable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.\tNone of the subjects in either group experienced viral reactivation based on per protocol analysis.', 'Stable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.\tNo serious adverse reactions were observed.', 'Stable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.\tIn the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).', 'Stable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.\tStable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.', 'Stable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.\tHowever, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.', 'Stable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.\tThe efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.', 'However, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.\tAfter a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).', 'However, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.\tNone of the subjects in either group experienced viral reactivation based on per protocol analysis.', 'However, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.\tNo serious adverse reactions were observed.', 'However, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.\tIn the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).', 'However, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.\tStable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.', 'However, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.\tHowever, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.', 'However, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.\tThe efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.', 'The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.\tAfter a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).', 'The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.\tNone of the subjects in either group experienced viral reactivation based on per protocol analysis.', 'The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.\tNo serious adverse reactions were observed.', 'The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.\tIn the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).', 'The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.\tStable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.', 'The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.\tHowever, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.', 'The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.\tThe efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.']","[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['Multivariate analysis indicated a positive relationship between 6MWD and the Physical Composite Score for QoL (p=0.004),\tMultivariate analysis indicated a positive relationship between 6MWD and the Physical Composite Score for QoL (p=0.004),', 'Multivariate analysis indicated a positive relationship between 6MWD and the Physical Composite Score for QoL (p=0.004),\tnegative relationship between delta SPO2 and the Mental Composite Score (p=0.02), irrespective of other known prognostic factors (such as haemodynamics at right heart catheterization).', 'Multivariate analysis indicated a positive relationship between 6MWD and the Physical Composite Score for QoL (p=0.004),\tDepression and Trait-Anxiety were associated with a lower physical (p=0.001) and mental (p<0.001) QoL, respectively.', 'Multivariate analysis indicated a positive relationship between 6MWD and the Physical Composite Score for QoL (p=0.004),\tPsychological factors impact the HRQoL of treated patients.', 'Multivariate analysis indicated a positive relationship between 6MWD and the Physical Composite Score for QoL (p=0.004),\tA longitudinal and qualitative study should refine these results.', 'negative relationship between delta SPO2 and the Mental Composite Score (p=0.02), irrespective of other known prognostic factors (such as haemodynamics at right heart catheterization).\tMultivariate analysis indicated a positive relationship between 6MWD and the Physical Composite Score for QoL (p=0.004),', 'negative relationship between delta SPO2 and the Mental Composite Score (p=0.02), irrespective of other known prognostic factors (such as haemodynamics at right heart catheterization).\tnegative relationship between delta SPO2 and the Mental Composite Score (p=0.02), irrespective of other known prognostic factors (such as haemodynamics at right heart catheterization).', 'negative relationship between delta SPO2 and the Mental Composite Score (p=0.02), irrespective of other known prognostic factors (such as haemodynamics at right heart catheterization).\tDepression and Trait-Anxiety were associated with a lower physical (p=0.001) and mental (p<0.001) QoL, respectively.', 'negative relationship between delta SPO2 and the Mental Composite Score (p=0.02), irrespective of other known prognostic factors (such as haemodynamics at right heart catheterization).\tPsychological factors impact the HRQoL of treated patients.', 'negative relationship between delta SPO2 and the Mental Composite Score (p=0.02), irrespective of other known prognostic factors (such as haemodynamics at right heart catheterization).\tA longitudinal and qualitative study should refine these results.', 'Depression and Trait-Anxiety were associated with a lower physical (p=0.001) and mental (p<0.001) QoL, respectively.\tMultivariate analysis indicated a positive relationship between 6MWD and the Physical Composite Score for QoL (p=0.004),', 'Depression and Trait-Anxiety were associated with a lower physical (p=0.001) and mental (p<0.001) QoL, respectively.\tnegative relationship between delta SPO2 and the Mental Composite Score (p=0.02), irrespective of other known prognostic factors (such as haemodynamics at right heart catheterization).', 'Depression and Trait-Anxiety were associated with a lower physical (p=0.001) and mental (p<0.001) QoL, respectively.\tDepression and Trait-Anxiety were associated with a lower physical (p=0.001) and mental (p<0.001) QoL, respectively.', 'Depression and Trait-Anxiety were associated with a lower physical (p=0.001) and mental (p<0.001) QoL, respectively.\tPsychological factors impact the HRQoL of treated patients.', 'Depression and Trait-Anxiety were associated with a lower physical (p=0.001) and mental (p<0.001) QoL, respectively.\tA longitudinal and qualitative study should refine these results.', 'Psychological factors impact the HRQoL of treated patients.\tMultivariate analysis indicated a positive relationship between 6MWD and the Physical Composite Score for QoL (p=0.004),', 'Psychological factors impact the HRQoL of treated patients.\tnegative relationship between delta SPO2 and the Mental Composite Score (p=0.02), irrespective of other known prognostic factors (such as haemodynamics at right heart catheterization).', 'Psychological factors impact the HRQoL of treated patients.\tDepression and Trait-Anxiety were associated with a lower physical (p=0.001) and mental (p<0.001) QoL, respectively.', 'Psychological factors impact the HRQoL of treated patients.\tPsychological factors impact the HRQoL of treated patients.', 'Psychological factors impact the HRQoL of treated patients.\tA longitudinal and qualitative study should refine these results.', 'A longitudinal and qualitative study should refine these results.\tMultivariate analysis indicated a positive relationship between 6MWD and the Physical Composite Score for QoL (p=0.004),', 'A longitudinal and qualitative study should refine these results.\tnegative relationship between delta SPO2 and the Mental Composite Score (p=0.02), irrespective of other known prognostic factors (such as haemodynamics at right heart catheterization).', 'A longitudinal and qualitative study should refine these results.\tDepression and Trait-Anxiety were associated with a lower physical (p=0.001) and mental (p<0.001) QoL, respectively.', 'A longitudinal and qualitative study should refine these results.\tPsychological factors impact the HRQoL of treated patients.', 'A longitudinal and qualitative study should refine these results.\tA longitudinal and qualitative study should refine these results.']","[0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0]"
"['There were no obvious differences in the normalization rate of ALT, negative conversion rate of HBV DNA and HBeAg, as well as improvement in Child-Pugh scores among the combination therapy group, 12-week optimized therapy group, and ETV monotherapy group.\tThere were no obvious differences in the normalization rate of ALT, negative conversion rate of HBV DNA and HBeAg, as well as improvement in Child-Pugh scores among the combination therapy group, 12-week optimized therapy group, and ETV monotherapy group.', 'There were no obvious differences in the normalization rate of ALT, negative conversion rate of HBV DNA and HBeAg, as well as improvement in Child-Pugh scores among the combination therapy group, 12-week optimized therapy group, and ETV monotherapy group.\tFor the 24-week optimized therapy group, only ALT levels revealed a significant improvement.', 'There were no obvious differences in the normalization rate of ALT, negative conversion rate of HBV DNA and HBeAg, as well as improvement in Child-Pugh scores among the combination therapy group, 12-week optimized therapy group, and ETV monotherapy group.\tAt the end of the treatment, the level of alanine amino-transferase (ALT), albumin (ALB) and total bilirubin (TBIL) in the combination therapy group and 12-week optimized therapy group were significantly improved.', 'There were no obvious differences in the normalization rate of ALT, negative conversion rate of HBV DNA and HBeAg, as well as improvement in Child-Pugh scores among the combination therapy group, 12-week optimized therapy group, and ETV monotherapy group.\tHowever, the difference among these three groups and the 24-week optimized therapy group were significant.', 'There were no obvious differences in the normalization rate of ALT, negative conversion rate of HBV DNA and HBeAg, as well as improvement in Child-Pugh scores among the combination therapy group, 12-week optimized therapy group, and ETV monotherapy group.\tDifferences were not observed in the HBeAg seroconversion between each group.', 'There were no obvious differences in the normalization rate of ALT, negative conversion rate of HBV DNA and HBeAg, as well as improvement in Child-Pugh scores among the combination therapy group, 12-week optimized therapy group, and ETV monotherapy group.\tDifferences in blood urea nitrogen, serum creatinine, creatine kinase, or other serious adverse effects were not observed in each group at the end of the 96-week treatment.', 'There were no obvious differences in the normalization rate of ALT, negative conversion rate of HBV DNA and HBeAg, as well as improvement in Child-Pugh scores among the combination therapy group, 12-week optimized therapy group, and ETV monotherapy group.\tCombination therapy and early ADV addition were the preferred approaches in the antiviral strategy for the treatment of hepatitis B-induced decompensated cirrhosis.', 'For the 24-week optimized therapy group, only ALT levels revealed a significant improvement.\tThere were no obvious differences in the normalization rate of ALT, negative conversion rate of HBV DNA and HBeAg, as well as improvement in Child-Pugh scores among the combination therapy group, 12-week optimized therapy group, and ETV monotherapy group.', 'For the 24-week optimized therapy group, only ALT levels revealed a significant improvement.\tFor the 24-week optimized therapy group, only ALT levels revealed a significant improvement.', 'For the 24-week optimized therapy group, only ALT levels revealed a significant improvement.\tAt the end of the treatment, the level of alanine amino-transferase (ALT), albumin (ALB) and total bilirubin (TBIL) in the combination therapy group and 12-week optimized therapy group were significantly improved.', 'For the 24-week optimized therapy group, only ALT levels revealed a significant improvement.\tHowever, the difference among these three groups and the 24-week optimized therapy group were significant.', 'For the 24-week optimized therapy group, only ALT levels revealed a significant improvement.\tDifferences were not observed in the HBeAg seroconversion between each group.', 'For the 24-week optimized therapy group, only ALT levels revealed a significant improvement.\tDifferences in blood urea nitrogen, serum creatinine, creatine kinase, or other serious adverse effects were not observed in each group at the end of the 96-week treatment.', 'For the 24-week optimized therapy group, only ALT levels revealed a significant improvement.\tCombination therapy and early ADV addition were the preferred approaches in the antiviral strategy for the treatment of hepatitis B-induced decompensated cirrhosis.', 'At the end of the treatment, the level of alanine amino-transferase (ALT), albumin (ALB) and total bilirubin (TBIL) in the combination therapy group and 12-week optimized therapy group were significantly improved.\tThere were no obvious differences in the normalization rate of ALT, negative conversion rate of HBV DNA and HBeAg, as well as improvement in Child-Pugh scores among the combination therapy group, 12-week optimized therapy group, and ETV monotherapy group.', 'At the end of the treatment, the level of alanine amino-transferase (ALT), albumin (ALB) and total bilirubin (TBIL) in the combination therapy group and 12-week optimized therapy group were significantly improved.\tFor the 24-week optimized therapy group, only ALT levels revealed a significant improvement.', 'At the end of the treatment, the level of alanine amino-transferase (ALT), albumin (ALB) and total bilirubin (TBIL) in the combination therapy group and 12-week optimized therapy group were significantly improved.\tAt the end of the treatment, the level of alanine amino-transferase (ALT), albumin (ALB) and total bilirubin (TBIL) in the combination therapy group and 12-week optimized therapy group were significantly improved.', 'At the end of the treatment, the level of alanine amino-transferase (ALT), albumin (ALB) and total bilirubin (TBIL) in the combination therapy group and 12-week optimized therapy group were significantly improved.\tHowever, the difference among these three groups and the 24-week optimized therapy group were significant.', 'At the end of the treatment, the level of alanine amino-transferase (ALT), albumin (ALB) and total bilirubin (TBIL) in the combination therapy group and 12-week optimized therapy group were significantly improved.\tDifferences were not observed in the HBeAg seroconversion between each group.', 'At the end of the treatment, the level of alanine amino-transferase (ALT), albumin (ALB) and total bilirubin (TBIL) in the combination therapy group and 12-week optimized therapy group were significantly improved.\tDifferences in blood urea nitrogen, serum creatinine, creatine kinase, or other serious adverse effects were not observed in each group at the end of the 96-week treatment.', 'At the end of the treatment, the level of alanine amino-transferase (ALT), albumin (ALB) and total bilirubin (TBIL) in the combination therapy group and 12-week optimized therapy group were significantly improved.\tCombination therapy and early ADV addition were the preferred approaches in the antiviral strategy for the treatment of hepatitis B-induced decompensated cirrhosis.', 'However, the difference among these three groups and the 24-week optimized therapy group were significant.\tThere were no obvious differences in the normalization rate of ALT, negative conversion rate of HBV DNA and HBeAg, as well as improvement in Child-Pugh scores among the combination therapy group, 12-week optimized therapy group, and ETV monotherapy group.', 'However, the difference among these three groups and the 24-week optimized therapy group were significant.\tFor the 24-week optimized therapy group, only ALT levels revealed a significant improvement.', 'However, the difference among these three groups and the 24-week optimized therapy group were significant.\tAt the end of the treatment, the level of alanine amino-transferase (ALT), albumin (ALB) and total bilirubin (TBIL) in the combination therapy group and 12-week optimized therapy group were significantly improved.', 'However, the difference among these three groups and the 24-week optimized therapy group were significant.\tHowever, the difference among these three groups and the 24-week optimized therapy group were significant.', 'However, the difference among these three groups and the 24-week optimized therapy group were significant.\tDifferences were not observed in the HBeAg seroconversion between each group.', 'However, the difference among these three groups and the 24-week optimized therapy group were significant.\tDifferences in blood urea nitrogen, serum creatinine, creatine kinase, or other serious adverse effects were not observed in each group at the end of the 96-week treatment.', 'However, the difference among these three groups and the 24-week optimized therapy group were significant.\tCombination therapy and early ADV addition were the preferred approaches in the antiviral strategy for the treatment of hepatitis B-induced decompensated cirrhosis.', 'Differences were not observed in the HBeAg seroconversion between each group.\tThere were no obvious differences in the normalization rate of ALT, negative conversion rate of HBV DNA and HBeAg, as well as improvement in Child-Pugh scores among the combination therapy group, 12-week optimized therapy group, and ETV monotherapy group.', 'Differences were not observed in the HBeAg seroconversion between each group.\tFor the 24-week optimized therapy group, only ALT levels revealed a significant improvement.', 'Differences were not observed in the HBeAg seroconversion between each group.\tAt the end of the treatment, the level of alanine amino-transferase (ALT), albumin (ALB) and total bilirubin (TBIL) in the combination therapy group and 12-week optimized therapy group were significantly improved.', 'Differences were not observed in the HBeAg seroconversion between each group.\tHowever, the difference among these three groups and the 24-week optimized therapy group were significant.', 'Differences were not observed in the HBeAg seroconversion between each group.\tDifferences were not observed in the HBeAg seroconversion between each group.', 'Differences were not observed in the HBeAg seroconversion between each group.\tDifferences in blood urea nitrogen, serum creatinine, creatine kinase, or other serious adverse effects were not observed in each group at the end of the 96-week treatment.', 'Differences were not observed in the HBeAg seroconversion between each group.\tCombination therapy and early ADV addition were the preferred approaches in the antiviral strategy for the treatment of hepatitis B-induced decompensated cirrhosis.', 'Differences in blood urea nitrogen, serum creatinine, creatine kinase, or other serious adverse effects were not observed in each group at the end of the 96-week treatment.\tThere were no obvious differences in the normalization rate of ALT, negative conversion rate of HBV DNA and HBeAg, as well as improvement in Child-Pugh scores among the combination therapy group, 12-week optimized therapy group, and ETV monotherapy group.', 'Differences in blood urea nitrogen, serum creatinine, creatine kinase, or other serious adverse effects were not observed in each group at the end of the 96-week treatment.\tFor the 24-week optimized therapy group, only ALT levels revealed a significant improvement.', 'Differences in blood urea nitrogen, serum creatinine, creatine kinase, or other serious adverse effects were not observed in each group at the end of the 96-week treatment.\tAt the end of the treatment, the level of alanine amino-transferase (ALT), albumin (ALB) and total bilirubin (TBIL) in the combination therapy group and 12-week optimized therapy group were significantly improved.', 'Differences in blood urea nitrogen, serum creatinine, creatine kinase, or other serious adverse effects were not observed in each group at the end of the 96-week treatment.\tHowever, the difference among these three groups and the 24-week optimized therapy group were significant.', 'Differences in blood urea nitrogen, serum creatinine, creatine kinase, or other serious adverse effects were not observed in each group at the end of the 96-week treatment.\tDifferences were not observed in the HBeAg seroconversion between each group.', 'Differences in blood urea nitrogen, serum creatinine, creatine kinase, or other serious adverse effects were not observed in each group at the end of the 96-week treatment.\tDifferences in blood urea nitrogen, serum creatinine, creatine kinase, or other serious adverse effects were not observed in each group at the end of the 96-week treatment.', 'Differences in blood urea nitrogen, serum creatinine, creatine kinase, or other serious adverse effects were not observed in each group at the end of the 96-week treatment.\tCombination therapy and early ADV addition were the preferred approaches in the antiviral strategy for the treatment of hepatitis B-induced decompensated cirrhosis.', 'Combination therapy and early ADV addition were the preferred approaches in the antiviral strategy for the treatment of hepatitis B-induced decompensated cirrhosis.\tThere were no obvious differences in the normalization rate of ALT, negative conversion rate of HBV DNA and HBeAg, as well as improvement in Child-Pugh scores among the combination therapy group, 12-week optimized therapy group, and ETV monotherapy group.', 'Combination therapy and early ADV addition were the preferred approaches in the antiviral strategy for the treatment of hepatitis B-induced decompensated cirrhosis.\tFor the 24-week optimized therapy group, only ALT levels revealed a significant improvement.', 'Combination therapy and early ADV addition were the preferred approaches in the antiviral strategy for the treatment of hepatitis B-induced decompensated cirrhosis.\tAt the end of the treatment, the level of alanine amino-transferase (ALT), albumin (ALB) and total bilirubin (TBIL) in the combination therapy group and 12-week optimized therapy group were significantly improved.', 'Combination therapy and early ADV addition were the preferred approaches in the antiviral strategy for the treatment of hepatitis B-induced decompensated cirrhosis.\tHowever, the difference among these three groups and the 24-week optimized therapy group were significant.', 'Combination therapy and early ADV addition were the preferred approaches in the antiviral strategy for the treatment of hepatitis B-induced decompensated cirrhosis.\tDifferences were not observed in the HBeAg seroconversion between each group.', 'Combination therapy and early ADV addition were the preferred approaches in the antiviral strategy for the treatment of hepatitis B-induced decompensated cirrhosis.\tDifferences in blood urea nitrogen, serum creatinine, creatine kinase, or other serious adverse effects were not observed in each group at the end of the 96-week treatment.', 'Combination therapy and early ADV addition were the preferred approaches in the antiviral strategy for the treatment of hepatitis B-induced decompensated cirrhosis.\tCombination therapy and early ADV addition were the preferred approaches in the antiviral strategy for the treatment of hepatitis B-induced decompensated cirrhosis.']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['Spironolactone could be used as the fourth-line therapy in patients with resistant hypertension.\tSpironolactone could be used as the fourth-line therapy in patients with resistant hypertension.', 'Spironolactone could be used as the fourth-line therapy in patients with resistant hypertension.\tSystolic BP was reduced from 143.5 ± 8.2 mmHg to 137.10 ± 7.57 mmHg in the intervention group, while it did not change significantly in control (between group treatment difference = -4.5 mmHg, p = 0.004).', 'Spironolactone could be used as the fourth-line therapy in patients with resistant hypertension.\tThere was no significant reduction of diastolic BP in the intervention group in comparison to placebo group (between group treatment difference = -1.3 mmHg, p = 0.099).', 'Spironolactone could be used as the fourth-line therapy in patients with resistant hypertension.\tShort course monotherapy with low dose spironolactone is effective in reducing systolic BP in patients with stage I essential hypertension.', 'Systolic BP was reduced from 143.5 ± 8.2 mmHg to 137.10 ± 7.57 mmHg in the intervention group, while it did not change significantly in control (between group treatment difference = -4.5 mmHg, p = 0.004).\tSpironolactone could be used as the fourth-line therapy in patients with resistant hypertension.', 'Systolic BP was reduced from 143.5 ± 8.2 mmHg to 137.10 ± 7.57 mmHg in the intervention group, while it did not change significantly in control (between group treatment difference = -4.5 mmHg, p = 0.004).\tSystolic BP was reduced from 143.5 ± 8.2 mmHg to 137.10 ± 7.57 mmHg in the intervention group, while it did not change significantly in control (between group treatment difference = -4.5 mmHg, p = 0.004).', 'Systolic BP was reduced from 143.5 ± 8.2 mmHg to 137.10 ± 7.57 mmHg in the intervention group, while it did not change significantly in control (between group treatment difference = -4.5 mmHg, p = 0.004).\tThere was no significant reduction of diastolic BP in the intervention group in comparison to placebo group (between group treatment difference = -1.3 mmHg, p = 0.099).', 'Systolic BP was reduced from 143.5 ± 8.2 mmHg to 137.10 ± 7.57 mmHg in the intervention group, while it did not change significantly in control (between group treatment difference = -4.5 mmHg, p = 0.004).\tShort course monotherapy with low dose spironolactone is effective in reducing systolic BP in patients with stage I essential hypertension.', 'There was no significant reduction of diastolic BP in the intervention group in comparison to placebo group (between group treatment difference = -1.3 mmHg, p = 0.099).\tSpironolactone could be used as the fourth-line therapy in patients with resistant hypertension.', 'There was no significant reduction of diastolic BP in the intervention group in comparison to placebo group (between group treatment difference = -1.3 mmHg, p = 0.099).\tSystolic BP was reduced from 143.5 ± 8.2 mmHg to 137.10 ± 7.57 mmHg in the intervention group, while it did not change significantly in control (between group treatment difference = -4.5 mmHg, p = 0.004).', 'There was no significant reduction of diastolic BP in the intervention group in comparison to placebo group (between group treatment difference = -1.3 mmHg, p = 0.099).\tThere was no significant reduction of diastolic BP in the intervention group in comparison to placebo group (between group treatment difference = -1.3 mmHg, p = 0.099).', 'There was no significant reduction of diastolic BP in the intervention group in comparison to placebo group (between group treatment difference = -1.3 mmHg, p = 0.099).\tShort course monotherapy with low dose spironolactone is effective in reducing systolic BP in patients with stage I essential hypertension.', 'Short course monotherapy with low dose spironolactone is effective in reducing systolic BP in patients with stage I essential hypertension.\tSpironolactone could be used as the fourth-line therapy in patients with resistant hypertension.', 'Short course monotherapy with low dose spironolactone is effective in reducing systolic BP in patients with stage I essential hypertension.\tSystolic BP was reduced from 143.5 ± 8.2 mmHg to 137.10 ± 7.57 mmHg in the intervention group, while it did not change significantly in control (between group treatment difference = -4.5 mmHg, p = 0.004).', 'Short course monotherapy with low dose spironolactone is effective in reducing systolic BP in patients with stage I essential hypertension.\tThere was no significant reduction of diastolic BP in the intervention group in comparison to placebo group (between group treatment difference = -1.3 mmHg, p = 0.099).', 'Short course monotherapy with low dose spironolactone is effective in reducing systolic BP in patients with stage I essential hypertension.\tShort course monotherapy with low dose spironolactone is effective in reducing systolic BP in patients with stage I essential hypertension.']","[0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 1, 0, 0, 0, 0]"
"['GS-9620 might therefore be included in therapies to increase the immune response to HBV.\tGS-9620 might therefore be included in therapies to increase the immune response to HBV.', 'GS-9620 might therefore be included in therapies to increase the immune response to HBV.\tT cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.', 'GS-9620 might therefore be included in therapies to increase the immune response to HBV.\tHowever, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.', 'GS-9620 might therefore be included in therapies to increase the immune response to HBV.\tNK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.', 'GS-9620 might therefore be included in therapies to increase the immune response to HBV.\tChanges in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.', 'GS-9620 might therefore be included in therapies to increase the immune response to HBV.\tSerum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.', 'GS-9620 might therefore be included in therapies to increase the immune response to HBV.\tTwelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.', 'T cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.\tGS-9620 might therefore be included in therapies to increase the immune response to HBV.', 'T cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.\tT cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.', 'T cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.\tHowever, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.', 'T cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.\tNK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.', 'T cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.\tChanges in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.', 'T cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.\tSerum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.', 'T cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.\tTwelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.', 'However, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.\tGS-9620 might therefore be included in therapies to increase the immune response to HBV.', 'However, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.\tT cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.', 'However, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.\tHowever, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.', 'However, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.\tNK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.', 'However, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.\tChanges in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.', 'However, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.\tSerum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.', 'However, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.\tTwelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.', 'NK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.\tGS-9620 might therefore be included in therapies to increase the immune response to HBV.', 'NK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.\tT cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.', 'NK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.\tHowever, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.', 'NK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.\tNK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.', 'NK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.\tChanges in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.', 'NK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.\tSerum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.', 'NK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.\tTwelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.', 'Changes in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.\tGS-9620 might therefore be included in therapies to increase the immune response to HBV.', 'Changes in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.\tT cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.', 'Changes in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.\tHowever, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.', 'Changes in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.\tNK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.', 'Changes in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.\tChanges in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.', 'Changes in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.\tSerum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.', 'Changes in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.\tTwelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.', 'Serum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.\tGS-9620 might therefore be included in therapies to increase the immune response to HBV.', 'Serum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.\tT cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.', 'Serum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.\tHowever, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.', 'Serum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.\tNK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.', 'Serum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.\tChanges in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.', 'Serum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.\tSerum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.', 'Serum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.\tTwelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.', 'Twelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.\tGS-9620 might therefore be included in therapies to increase the immune response to HBV.', 'Twelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.\tT cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.', 'Twelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.\tHowever, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.', 'Twelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.\tNK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.', 'Twelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.\tChanges in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.', 'Twelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.\tSerum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.', 'Twelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.\tTwelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0]"
"['Severely immunosuppressed individuals with raised pretreatment AST/ALT or HBsAg seropositivity need closer monitoring for hepatotoxicity.\tSeverely immunosuppressed individuals with raised pretreatment AST/ALT or HBsAg seropositivity need closer monitoring for hepatotoxicity.', 'Severely immunosuppressed individuals with raised pretreatment AST/ALT or HBsAg seropositivity need closer monitoring for hepatotoxicity.\tAmong 426 participants (53% male, median age 35 years, median CD4 count 19 cells/µL), 31 developed hepatotoxicity (7.3%).', 'Severely immunosuppressed individuals with raised pretreatment AST/ALT or HBsAg seropositivity need closer monitoring for hepatotoxicity.\tRaised pretreatment AST/ALT (odds ratio [OR] 3.6, 95% confidence interval [CI]: 1.7 to 7.7) and hepatitis B surface antigen (HBsAg) seropositivity at baseline (OR 4.7, 95% CI: 1.7 to 12.9) were significantly associated with an increased risk of developing hepatotoxicity.', 'Severely immunosuppressed individuals with raised pretreatment AST/ALT or HBsAg seropositivity need closer monitoring for hepatotoxicity.\tParticipants with both raised AST/ALT and positive HBsAg had a higher risk (OR 19.9, 95% CI: 5.3 to 74.3) and earlier onset of hepatotoxicity than participants who did not have these conditions at baseline.', 'Severely immunosuppressed individuals with raised pretreatment AST/ALT or HBsAg seropositivity need closer monitoring for hepatotoxicity.\tThe incidence of hepatotoxicity during IPT and ART was high.', 'Among 426 participants (53% male, median age 35 years, median CD4 count 19 cells/µL), 31 developed hepatotoxicity (7.3%).\tSeverely immunosuppressed individuals with raised pretreatment AST/ALT or HBsAg seropositivity need closer monitoring for hepatotoxicity.', 'Among 426 participants (53% male, median age 35 years, median CD4 count 19 cells/µL), 31 developed hepatotoxicity (7.3%).\tAmong 426 participants (53% male, median age 35 years, median CD4 count 19 cells/µL), 31 developed hepatotoxicity (7.3%).', 'Among 426 participants (53% male, median age 35 years, median CD4 count 19 cells/µL), 31 developed hepatotoxicity (7.3%).\tRaised pretreatment AST/ALT (odds ratio [OR] 3.6, 95% confidence interval [CI]: 1.7 to 7.7) and hepatitis B surface antigen (HBsAg) seropositivity at baseline (OR 4.7, 95% CI: 1.7 to 12.9) were significantly associated with an increased risk of developing hepatotoxicity.', 'Among 426 participants (53% male, median age 35 years, median CD4 count 19 cells/µL), 31 developed hepatotoxicity (7.3%).\tParticipants with both raised AST/ALT and positive HBsAg had a higher risk (OR 19.9, 95% CI: 5.3 to 74.3) and earlier onset of hepatotoxicity than participants who did not have these conditions at baseline.', 'Among 426 participants (53% male, median age 35 years, median CD4 count 19 cells/µL), 31 developed hepatotoxicity (7.3%).\tThe incidence of hepatotoxicity during IPT and ART was high.', 'Raised pretreatment AST/ALT (odds ratio [OR] 3.6, 95% confidence interval [CI]: 1.7 to 7.7) and hepatitis B surface antigen (HBsAg) seropositivity at baseline (OR 4.7, 95% CI: 1.7 to 12.9) were significantly associated with an increased risk of developing hepatotoxicity.\tSeverely immunosuppressed individuals with raised pretreatment AST/ALT or HBsAg seropositivity need closer monitoring for hepatotoxicity.', 'Raised pretreatment AST/ALT (odds ratio [OR] 3.6, 95% confidence interval [CI]: 1.7 to 7.7) and hepatitis B surface antigen (HBsAg) seropositivity at baseline (OR 4.7, 95% CI: 1.7 to 12.9) were significantly associated with an increased risk of developing hepatotoxicity.\tAmong 426 participants (53% male, median age 35 years, median CD4 count 19 cells/µL), 31 developed hepatotoxicity (7.3%).', 'Raised pretreatment AST/ALT (odds ratio [OR] 3.6, 95% confidence interval [CI]: 1.7 to 7.7) and hepatitis B surface antigen (HBsAg) seropositivity at baseline (OR 4.7, 95% CI: 1.7 to 12.9) were significantly associated with an increased risk of developing hepatotoxicity.\tRaised pretreatment AST/ALT (odds ratio [OR] 3.6, 95% confidence interval [CI]: 1.7 to 7.7) and hepatitis B surface antigen (HBsAg) seropositivity at baseline (OR 4.7, 95% CI: 1.7 to 12.9) were significantly associated with an increased risk of developing hepatotoxicity.', 'Raised pretreatment AST/ALT (odds ratio [OR] 3.6, 95% confidence interval [CI]: 1.7 to 7.7) and hepatitis B surface antigen (HBsAg) seropositivity at baseline (OR 4.7, 95% CI: 1.7 to 12.9) were significantly associated with an increased risk of developing hepatotoxicity.\tParticipants with both raised AST/ALT and positive HBsAg had a higher risk (OR 19.9, 95% CI: 5.3 to 74.3) and earlier onset of hepatotoxicity than participants who did not have these conditions at baseline.', 'Raised pretreatment AST/ALT (odds ratio [OR] 3.6, 95% confidence interval [CI]: 1.7 to 7.7) and hepatitis B surface antigen (HBsAg) seropositivity at baseline (OR 4.7, 95% CI: 1.7 to 12.9) were significantly associated with an increased risk of developing hepatotoxicity.\tThe incidence of hepatotoxicity during IPT and ART was high.', 'Participants with both raised AST/ALT and positive HBsAg had a higher risk (OR 19.9, 95% CI: 5.3 to 74.3) and earlier onset of hepatotoxicity than participants who did not have these conditions at baseline.\tSeverely immunosuppressed individuals with raised pretreatment AST/ALT or HBsAg seropositivity need closer monitoring for hepatotoxicity.', 'Participants with both raised AST/ALT and positive HBsAg had a higher risk (OR 19.9, 95% CI: 5.3 to 74.3) and earlier onset of hepatotoxicity than participants who did not have these conditions at baseline.\tAmong 426 participants (53% male, median age 35 years, median CD4 count 19 cells/µL), 31 developed hepatotoxicity (7.3%).', 'Participants with both raised AST/ALT and positive HBsAg had a higher risk (OR 19.9, 95% CI: 5.3 to 74.3) and earlier onset of hepatotoxicity than participants who did not have these conditions at baseline.\tRaised pretreatment AST/ALT (odds ratio [OR] 3.6, 95% confidence interval [CI]: 1.7 to 7.7) and hepatitis B surface antigen (HBsAg) seropositivity at baseline (OR 4.7, 95% CI: 1.7 to 12.9) were significantly associated with an increased risk of developing hepatotoxicity.', 'Participants with both raised AST/ALT and positive HBsAg had a higher risk (OR 19.9, 95% CI: 5.3 to 74.3) and earlier onset of hepatotoxicity than participants who did not have these conditions at baseline.\tParticipants with both raised AST/ALT and positive HBsAg had a higher risk (OR 19.9, 95% CI: 5.3 to 74.3) and earlier onset of hepatotoxicity than participants who did not have these conditions at baseline.', 'Participants with both raised AST/ALT and positive HBsAg had a higher risk (OR 19.9, 95% CI: 5.3 to 74.3) and earlier onset of hepatotoxicity than participants who did not have these conditions at baseline.\tThe incidence of hepatotoxicity during IPT and ART was high.', 'The incidence of hepatotoxicity during IPT and ART was high.\tSeverely immunosuppressed individuals with raised pretreatment AST/ALT or HBsAg seropositivity need closer monitoring for hepatotoxicity.', 'The incidence of hepatotoxicity during IPT and ART was high.\tAmong 426 participants (53% male, median age 35 years, median CD4 count 19 cells/µL), 31 developed hepatotoxicity (7.3%).', 'The incidence of hepatotoxicity during IPT and ART was high.\tRaised pretreatment AST/ALT (odds ratio [OR] 3.6, 95% confidence interval [CI]: 1.7 to 7.7) and hepatitis B surface antigen (HBsAg) seropositivity at baseline (OR 4.7, 95% CI: 1.7 to 12.9) were significantly associated with an increased risk of developing hepatotoxicity.', 'The incidence of hepatotoxicity during IPT and ART was high.\tParticipants with both raised AST/ALT and positive HBsAg had a higher risk (OR 19.9, 95% CI: 5.3 to 74.3) and earlier onset of hepatotoxicity than participants who did not have these conditions at baseline.', 'The incidence of hepatotoxicity during IPT and ART was high.\tThe incidence of hepatotoxicity during IPT and ART was high.']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0]"
"['Results revealed that during daily consumption of fermented milk for 5 wk, systolic [(116.55 ± 12.26 mmHg vs. 124.77 ± 11.04 mmHg) and diastolic blood pressure (80.7 ± 9 vs. 84.5 ± 8.5 mmHg)] from the fermented milk group was lower than the control group.\tResults revealed that during daily consumption of fermented milk for 5 wk, systolic [(116.55 ± 12.26 mmHg vs. 124.77 ± 11.04 mmHg) and diastolic blood pressure (80.7 ± 9 vs. 84.5 ± 8.5 mmHg)] from the fermented milk group was lower than the control group.', 'Results revealed that during daily consumption of fermented milk for 5 wk, systolic [(116.55 ± 12.26 mmHg vs. 124.77 ± 11.04 mmHg) and diastolic blood pressure (80.7 ± 9 vs. 84.5 ± 8.5 mmHg)] from the fermented milk group was lower than the control group.\tAdditionally, triglyceride, total cholesterol, and low-density lipoprotein in blood serum were lower in the fermented milk group than in the control group.', 'Results revealed that during daily consumption of fermented milk for 5 wk, systolic [(116.55 ± 12.26 mmHg vs. 124.77 ± 11.04 mmHg) and diastolic blood pressure (80.7 ± 9 vs. 84.5 ± 8.5 mmHg)] from the fermented milk group was lower than the control group.\tResults demonstrated that daily consumption of fermented milk with Lactococcus lactis (NRRL B-50571) had a blood pressure-lowering effect on prehypertensive subjects.', 'Results revealed that during daily consumption of fermented milk for 5 wk, systolic [(116.55 ± 12.26 mmHg vs. 124.77 ± 11.04 mmHg) and diastolic blood pressure (80.7 ± 9 vs. 84.5 ± 8.5 mmHg)] from the fermented milk group was lower than the control group.\tRegular consumption of this product may be used as a potential functional food.', 'Additionally, triglyceride, total cholesterol, and low-density lipoprotein in blood serum were lower in the fermented milk group than in the control group.\tResults revealed that during daily consumption of fermented milk for 5 wk, systolic [(116.55 ± 12.26 mmHg vs. 124.77 ± 11.04 mmHg) and diastolic blood pressure (80.7 ± 9 vs. 84.5 ± 8.5 mmHg)] from the fermented milk group was lower than the control group.', 'Additionally, triglyceride, total cholesterol, and low-density lipoprotein in blood serum were lower in the fermented milk group than in the control group.\tAdditionally, triglyceride, total cholesterol, and low-density lipoprotein in blood serum were lower in the fermented milk group than in the control group.', 'Additionally, triglyceride, total cholesterol, and low-density lipoprotein in blood serum were lower in the fermented milk group than in the control group.\tResults demonstrated that daily consumption of fermented milk with Lactococcus lactis (NRRL B-50571) had a blood pressure-lowering effect on prehypertensive subjects.', 'Additionally, triglyceride, total cholesterol, and low-density lipoprotein in blood serum were lower in the fermented milk group than in the control group.\tRegular consumption of this product may be used as a potential functional food.', 'Results demonstrated that daily consumption of fermented milk with Lactococcus lactis (NRRL B-50571) had a blood pressure-lowering effect on prehypertensive subjects.\tResults revealed that during daily consumption of fermented milk for 5 wk, systolic [(116.55 ± 12.26 mmHg vs. 124.77 ± 11.04 mmHg) and diastolic blood pressure (80.7 ± 9 vs. 84.5 ± 8.5 mmHg)] from the fermented milk group was lower than the control group.', 'Results demonstrated that daily consumption of fermented milk with Lactococcus lactis (NRRL B-50571) had a blood pressure-lowering effect on prehypertensive subjects.\tAdditionally, triglyceride, total cholesterol, and low-density lipoprotein in blood serum were lower in the fermented milk group than in the control group.', 'Results demonstrated that daily consumption of fermented milk with Lactococcus lactis (NRRL B-50571) had a blood pressure-lowering effect on prehypertensive subjects.\tResults demonstrated that daily consumption of fermented milk with Lactococcus lactis (NRRL B-50571) had a blood pressure-lowering effect on prehypertensive subjects.', 'Results demonstrated that daily consumption of fermented milk with Lactococcus lactis (NRRL B-50571) had a blood pressure-lowering effect on prehypertensive subjects.\tRegular consumption of this product may be used as a potential functional food.', 'Regular consumption of this product may be used as a potential functional food.\tResults revealed that during daily consumption of fermented milk for 5 wk, systolic [(116.55 ± 12.26 mmHg vs. 124.77 ± 11.04 mmHg) and diastolic blood pressure (80.7 ± 9 vs. 84.5 ± 8.5 mmHg)] from the fermented milk group was lower than the control group.', 'Regular consumption of this product may be used as a potential functional food.\tAdditionally, triglyceride, total cholesterol, and low-density lipoprotein in blood serum were lower in the fermented milk group than in the control group.', 'Regular consumption of this product may be used as a potential functional food.\tResults demonstrated that daily consumption of fermented milk with Lactococcus lactis (NRRL B-50571) had a blood pressure-lowering effect on prehypertensive subjects.', 'Regular consumption of this product may be used as a potential functional food.\tRegular consumption of this product may be used as a potential functional food.']","[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]"
"['iron-containing multiple micronutrient may reduce the risk of pregnancy-induced hypertension including gestational hypertension or preeclampsia.\tiron-containing multiple micronutrient may reduce the risk of pregnancy-induced hypertension including gestational hypertension or preeclampsia.', 'iron-containing multiple micronutrient may reduce the risk of pregnancy-induced hypertension including gestational hypertension or preeclampsia.\tThe incidence of pregnancy-induced hypertension was 7.1% (423/5923), 6.3% (374/5933) and 6.3% (372/5914) among the pregnant women who took folic acid only, iron-folic acid and multiple micronutrient supplements, respectively.', 'iron-containing multiple micronutrient may reduce the risk of pregnancy-induced hypertension including gestational hypertension or preeclampsia.\tThe adjusted odds ratios associated with iron-folic acid supplements and multiple micronutrient supplements for pregnancy-induced hypertension were both nearly 0.88 (95% confidence interval, 0.76-1.02), compared with folic acid supplements only.', 'iron-containing multiple micronutrient may reduce the risk of pregnancy-induced hypertension including gestational hypertension or preeclampsia.\tamong pregnant women aged 20-24 years, iron-containing multiple micronutrient supplementation was associated with a reduced risk of pregnancy-induced hypertension compared with folic acid supplements only.', 'iron-containing multiple micronutrient may reduce the risk of pregnancy-induced hypertension including gestational hypertension or preeclampsia.\tAmong pregnant women aged 20-24 years, iron-folic acid (adjusted odds ratios: 0.81, 95% confidence interval: 0.67-0.96) or multiple micronutrient supplementation (adjusted odds ratios: 0.83, 95% confidence interval: 0.70-0.99) can significantly reduce the risk of pregnancy-induced hypertension compared to folic acid supplementation.', 'The incidence of pregnancy-induced hypertension was 7.1% (423/5923), 6.3% (374/5933) and 6.3% (372/5914) among the pregnant women who took folic acid only, iron-folic acid and multiple micronutrient supplements, respectively.\tiron-containing multiple micronutrient may reduce the risk of pregnancy-induced hypertension including gestational hypertension or preeclampsia.', 'The incidence of pregnancy-induced hypertension was 7.1% (423/5923), 6.3% (374/5933) and 6.3% (372/5914) among the pregnant women who took folic acid only, iron-folic acid and multiple micronutrient supplements, respectively.\tThe incidence of pregnancy-induced hypertension was 7.1% (423/5923), 6.3% (374/5933) and 6.3% (372/5914) among the pregnant women who took folic acid only, iron-folic acid and multiple micronutrient supplements, respectively.', 'The incidence of pregnancy-induced hypertension was 7.1% (423/5923), 6.3% (374/5933) and 6.3% (372/5914) among the pregnant women who took folic acid only, iron-folic acid and multiple micronutrient supplements, respectively.\tThe adjusted odds ratios associated with iron-folic acid supplements and multiple micronutrient supplements for pregnancy-induced hypertension were both nearly 0.88 (95% confidence interval, 0.76-1.02), compared with folic acid supplements only.', 'The incidence of pregnancy-induced hypertension was 7.1% (423/5923), 6.3% (374/5933) and 6.3% (372/5914) among the pregnant women who took folic acid only, iron-folic acid and multiple micronutrient supplements, respectively.\tamong pregnant women aged 20-24 years, iron-containing multiple micronutrient supplementation was associated with a reduced risk of pregnancy-induced hypertension compared with folic acid supplements only.', 'The incidence of pregnancy-induced hypertension was 7.1% (423/5923), 6.3% (374/5933) and 6.3% (372/5914) among the pregnant women who took folic acid only, iron-folic acid and multiple micronutrient supplements, respectively.\tAmong pregnant women aged 20-24 years, iron-folic acid (adjusted odds ratios: 0.81, 95% confidence interval: 0.67-0.96) or multiple micronutrient supplementation (adjusted odds ratios: 0.83, 95% confidence interval: 0.70-0.99) can significantly reduce the risk of pregnancy-induced hypertension compared to folic acid supplementation.', 'The adjusted odds ratios associated with iron-folic acid supplements and multiple micronutrient supplements for pregnancy-induced hypertension were both nearly 0.88 (95% confidence interval, 0.76-1.02), compared with folic acid supplements only.\tiron-containing multiple micronutrient may reduce the risk of pregnancy-induced hypertension including gestational hypertension or preeclampsia.', 'The adjusted odds ratios associated with iron-folic acid supplements and multiple micronutrient supplements for pregnancy-induced hypertension were both nearly 0.88 (95% confidence interval, 0.76-1.02), compared with folic acid supplements only.\tThe incidence of pregnancy-induced hypertension was 7.1% (423/5923), 6.3% (374/5933) and 6.3% (372/5914) among the pregnant women who took folic acid only, iron-folic acid and multiple micronutrient supplements, respectively.', 'The adjusted odds ratios associated with iron-folic acid supplements and multiple micronutrient supplements for pregnancy-induced hypertension were both nearly 0.88 (95% confidence interval, 0.76-1.02), compared with folic acid supplements only.\tThe adjusted odds ratios associated with iron-folic acid supplements and multiple micronutrient supplements for pregnancy-induced hypertension were both nearly 0.88 (95% confidence interval, 0.76-1.02), compared with folic acid supplements only.', 'The adjusted odds ratios associated with iron-folic acid supplements and multiple micronutrient supplements for pregnancy-induced hypertension were both nearly 0.88 (95% confidence interval, 0.76-1.02), compared with folic acid supplements only.\tamong pregnant women aged 20-24 years, iron-containing multiple micronutrient supplementation was associated with a reduced risk of pregnancy-induced hypertension compared with folic acid supplements only.', 'The adjusted odds ratios associated with iron-folic acid supplements and multiple micronutrient supplements for pregnancy-induced hypertension were both nearly 0.88 (95% confidence interval, 0.76-1.02), compared with folic acid supplements only.\tAmong pregnant women aged 20-24 years, iron-folic acid (adjusted odds ratios: 0.81, 95% confidence interval: 0.67-0.96) or multiple micronutrient supplementation (adjusted odds ratios: 0.83, 95% confidence interval: 0.70-0.99) can significantly reduce the risk of pregnancy-induced hypertension compared to folic acid supplementation.', 'among pregnant women aged 20-24 years, iron-containing multiple micronutrient supplementation was associated with a reduced risk of pregnancy-induced hypertension compared with folic acid supplements only.\tiron-containing multiple micronutrient may reduce the risk of pregnancy-induced hypertension including gestational hypertension or preeclampsia.', 'among pregnant women aged 20-24 years, iron-containing multiple micronutrient supplementation was associated with a reduced risk of pregnancy-induced hypertension compared with folic acid supplements only.\tThe incidence of pregnancy-induced hypertension was 7.1% (423/5923), 6.3% (374/5933) and 6.3% (372/5914) among the pregnant women who took folic acid only, iron-folic acid and multiple micronutrient supplements, respectively.', 'among pregnant women aged 20-24 years, iron-containing multiple micronutrient supplementation was associated with a reduced risk of pregnancy-induced hypertension compared with folic acid supplements only.\tThe adjusted odds ratios associated with iron-folic acid supplements and multiple micronutrient supplements for pregnancy-induced hypertension were both nearly 0.88 (95% confidence interval, 0.76-1.02), compared with folic acid supplements only.', 'among pregnant women aged 20-24 years, iron-containing multiple micronutrient supplementation was associated with a reduced risk of pregnancy-induced hypertension compared with folic acid supplements only.\tamong pregnant women aged 20-24 years, iron-containing multiple micronutrient supplementation was associated with a reduced risk of pregnancy-induced hypertension compared with folic acid supplements only.', 'among pregnant women aged 20-24 years, iron-containing multiple micronutrient supplementation was associated with a reduced risk of pregnancy-induced hypertension compared with folic acid supplements only.\tAmong pregnant women aged 20-24 years, iron-folic acid (adjusted odds ratios: 0.81, 95% confidence interval: 0.67-0.96) or multiple micronutrient supplementation (adjusted odds ratios: 0.83, 95% confidence interval: 0.70-0.99) can significantly reduce the risk of pregnancy-induced hypertension compared to folic acid supplementation.', 'Among pregnant women aged 20-24 years, iron-folic acid (adjusted odds ratios: 0.81, 95% confidence interval: 0.67-0.96) or multiple micronutrient supplementation (adjusted odds ratios: 0.83, 95% confidence interval: 0.70-0.99) can significantly reduce the risk of pregnancy-induced hypertension compared to folic acid supplementation.\tiron-containing multiple micronutrient may reduce the risk of pregnancy-induced hypertension including gestational hypertension or preeclampsia.', 'Among pregnant women aged 20-24 years, iron-folic acid (adjusted odds ratios: 0.81, 95% confidence interval: 0.67-0.96) or multiple micronutrient supplementation (adjusted odds ratios: 0.83, 95% confidence interval: 0.70-0.99) can significantly reduce the risk of pregnancy-induced hypertension compared to folic acid supplementation.\tThe incidence of pregnancy-induced hypertension was 7.1% (423/5923), 6.3% (374/5933) and 6.3% (372/5914) among the pregnant women who took folic acid only, iron-folic acid and multiple micronutrient supplements, respectively.', 'Among pregnant women aged 20-24 years, iron-folic acid (adjusted odds ratios: 0.81, 95% confidence interval: 0.67-0.96) or multiple micronutrient supplementation (adjusted odds ratios: 0.83, 95% confidence interval: 0.70-0.99) can significantly reduce the risk of pregnancy-induced hypertension compared to folic acid supplementation.\tThe adjusted odds ratios associated with iron-folic acid supplements and multiple micronutrient supplements for pregnancy-induced hypertension were both nearly 0.88 (95% confidence interval, 0.76-1.02), compared with folic acid supplements only.', 'Among pregnant women aged 20-24 years, iron-folic acid (adjusted odds ratios: 0.81, 95% confidence interval: 0.67-0.96) or multiple micronutrient supplementation (adjusted odds ratios: 0.83, 95% confidence interval: 0.70-0.99) can significantly reduce the risk of pregnancy-induced hypertension compared to folic acid supplementation.\tamong pregnant women aged 20-24 years, iron-containing multiple micronutrient supplementation was associated with a reduced risk of pregnancy-induced hypertension compared with folic acid supplements only.', 'Among pregnant women aged 20-24 years, iron-folic acid (adjusted odds ratios: 0.81, 95% confidence interval: 0.67-0.96) or multiple micronutrient supplementation (adjusted odds ratios: 0.83, 95% confidence interval: 0.70-0.99) can significantly reduce the risk of pregnancy-induced hypertension compared to folic acid supplementation.\tAmong pregnant women aged 20-24 years, iron-folic acid (adjusted odds ratios: 0.81, 95% confidence interval: 0.67-0.96) or multiple micronutrient supplementation (adjusted odds ratios: 0.83, 95% confidence interval: 0.70-0.99) can significantly reduce the risk of pregnancy-induced hypertension compared to folic acid supplementation.']","[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0]"
"['Synbiotic is effective in reducing of blood pressure in women with GDM.\tSynbiotic is effective in reducing of blood pressure in women with GDM.', 'Synbiotic is effective in reducing of blood pressure in women with GDM.\tNo significant changes in FPG, insulin resistance/sensitivity, lipid profile and TAC indices were seen in synbiotic group compared to the placebo one (p\u202f>\u202f0.05).', 'Synbiotic is effective in reducing of blood pressure in women with GDM.\tSignificant within group increases for HDL-C and TAC levels in synbiotic group were observed (p\u202f<\u202f0.05).', 'Synbiotic is effective in reducing of blood pressure in women with GDM.\tLDL-C showed significant increment in the placebo group compared to the baseline of the study (6.9\u202fmg/dL, p\u202f<\u202f0.05).', 'Synbiotic is effective in reducing of blood pressure in women with GDM.\tBetween group comparison showed significant decrease in SBP and DBP in synbiotic group compared to placebo (-2.5 vs. 8.6\u202fmmHg, and -1.8 vs. 2.1\u202fmmHg, p\u202f<\u202f0.05).', 'Synbiotic is effective in reducing of blood pressure in women with GDM.\tThe results showed that, in women with GDM, synbiotic supplementation had no effect on FPG and insulin resistance/sensitivity indices.', 'Synbiotic is effective in reducing of blood pressure in women with GDM.\tLipid profile and TAC status may be affected by synbiotic supplementation.', 'No significant changes in FPG, insulin resistance/sensitivity, lipid profile and TAC indices were seen in synbiotic group compared to the placebo one (p\u202f>\u202f0.05).\tSynbiotic is effective in reducing of blood pressure in women with GDM.', 'No significant changes in FPG, insulin resistance/sensitivity, lipid profile and TAC indices were seen in synbiotic group compared to the placebo one (p\u202f>\u202f0.05).\tNo significant changes in FPG, insulin resistance/sensitivity, lipid profile and TAC indices were seen in synbiotic group compared to the placebo one (p\u202f>\u202f0.05).', 'No significant changes in FPG, insulin resistance/sensitivity, lipid profile and TAC indices were seen in synbiotic group compared to the placebo one (p\u202f>\u202f0.05).\tSignificant within group increases for HDL-C and TAC levels in synbiotic group were observed (p\u202f<\u202f0.05).', 'No significant changes in FPG, insulin resistance/sensitivity, lipid profile and TAC indices were seen in synbiotic group compared to the placebo one (p\u202f>\u202f0.05).\tLDL-C showed significant increment in the placebo group compared to the baseline of the study (6.9\u202fmg/dL, p\u202f<\u202f0.05).', 'No significant changes in FPG, insulin resistance/sensitivity, lipid profile and TAC indices were seen in synbiotic group compared to the placebo one (p\u202f>\u202f0.05).\tBetween group comparison showed significant decrease in SBP and DBP in synbiotic group compared to placebo (-2.5 vs. 8.6\u202fmmHg, and -1.8 vs. 2.1\u202fmmHg, p\u202f<\u202f0.05).', 'No significant changes in FPG, insulin resistance/sensitivity, lipid profile and TAC indices were seen in synbiotic group compared to the placebo one (p\u202f>\u202f0.05).\tThe results showed that, in women with GDM, synbiotic supplementation had no effect on FPG and insulin resistance/sensitivity indices.', 'No significant changes in FPG, insulin resistance/sensitivity, lipid profile and TAC indices were seen in synbiotic group compared to the placebo one (p\u202f>\u202f0.05).\tLipid profile and TAC status may be affected by synbiotic supplementation.', 'Significant within group increases for HDL-C and TAC levels in synbiotic group were observed (p\u202f<\u202f0.05).\tSynbiotic is effective in reducing of blood pressure in women with GDM.', 'Significant within group increases for HDL-C and TAC levels in synbiotic group were observed (p\u202f<\u202f0.05).\tNo significant changes in FPG, insulin resistance/sensitivity, lipid profile and TAC indices were seen in synbiotic group compared to the placebo one (p\u202f>\u202f0.05).', 'Significant within group increases for HDL-C and TAC levels in synbiotic group were observed (p\u202f<\u202f0.05).\tSignificant within group increases for HDL-C and TAC levels in synbiotic group were observed (p\u202f<\u202f0.05).', 'Significant within group increases for HDL-C and TAC levels in synbiotic group were observed (p\u202f<\u202f0.05).\tLDL-C showed significant increment in the placebo group compared to the baseline of the study (6.9\u202fmg/dL, p\u202f<\u202f0.05).', 'Significant within group increases for HDL-C and TAC levels in synbiotic group were observed (p\u202f<\u202f0.05).\tBetween group comparison showed significant decrease in SBP and DBP in synbiotic group compared to placebo (-2.5 vs. 8.6\u202fmmHg, and -1.8 vs. 2.1\u202fmmHg, p\u202f<\u202f0.05).', 'Significant within group increases for HDL-C and TAC levels in synbiotic group were observed (p\u202f<\u202f0.05).\tThe results showed that, in women with GDM, synbiotic supplementation had no effect on FPG and insulin resistance/sensitivity indices.', 'Significant within group increases for HDL-C and TAC levels in synbiotic group were observed (p\u202f<\u202f0.05).\tLipid profile and TAC status may be affected by synbiotic supplementation.', 'LDL-C showed significant increment in the placebo group compared to the baseline of the study (6.9\u202fmg/dL, p\u202f<\u202f0.05).\tSynbiotic is effective in reducing of blood pressure in women with GDM.', 'LDL-C showed significant increment in the placebo group compared to the baseline of the study (6.9\u202fmg/dL, p\u202f<\u202f0.05).\tNo significant changes in FPG, insulin resistance/sensitivity, lipid profile and TAC indices were seen in synbiotic group compared to the placebo one (p\u202f>\u202f0.05).', 'LDL-C showed significant increment in the placebo group compared to the baseline of the study (6.9\u202fmg/dL, p\u202f<\u202f0.05).\tSignificant within group increases for HDL-C and TAC levels in synbiotic group were observed (p\u202f<\u202f0.05).', 'LDL-C showed significant increment in the placebo group compared to the baseline of the study (6.9\u202fmg/dL, p\u202f<\u202f0.05).\tLDL-C showed significant increment in the placebo group compared to the baseline of the study (6.9\u202fmg/dL, p\u202f<\u202f0.05).', 'LDL-C showed significant increment in the placebo group compared to the baseline of the study (6.9\u202fmg/dL, p\u202f<\u202f0.05).\tBetween group comparison showed significant decrease in SBP and DBP in synbiotic group compared to placebo (-2.5 vs. 8.6\u202fmmHg, and -1.8 vs. 2.1\u202fmmHg, p\u202f<\u202f0.05).', 'LDL-C showed significant increment in the placebo group compared to the baseline of the study (6.9\u202fmg/dL, p\u202f<\u202f0.05).\tThe results showed that, in women with GDM, synbiotic supplementation had no effect on FPG and insulin resistance/sensitivity indices.', 'LDL-C showed significant increment in the placebo group compared to the baseline of the study (6.9\u202fmg/dL, p\u202f<\u202f0.05).\tLipid profile and TAC status may be affected by synbiotic supplementation.', 'Between group comparison showed significant decrease in SBP and DBP in synbiotic group compared to placebo (-2.5 vs. 8.6\u202fmmHg, and -1.8 vs. 2.1\u202fmmHg, p\u202f<\u202f0.05).\tSynbiotic is effective in reducing of blood pressure in women with GDM.', 'Between group comparison showed significant decrease in SBP and DBP in synbiotic group compared to placebo (-2.5 vs. 8.6\u202fmmHg, and -1.8 vs. 2.1\u202fmmHg, p\u202f<\u202f0.05).\tNo significant changes in FPG, insulin resistance/sensitivity, lipid profile and TAC indices were seen in synbiotic group compared to the placebo one (p\u202f>\u202f0.05).', 'Between group comparison showed significant decrease in SBP and DBP in synbiotic group compared to placebo (-2.5 vs. 8.6\u202fmmHg, and -1.8 vs. 2.1\u202fmmHg, p\u202f<\u202f0.05).\tSignificant within group increases for HDL-C and TAC levels in synbiotic group were observed (p\u202f<\u202f0.05).', 'Between group comparison showed significant decrease in SBP and DBP in synbiotic group compared to placebo (-2.5 vs. 8.6\u202fmmHg, and -1.8 vs. 2.1\u202fmmHg, p\u202f<\u202f0.05).\tLDL-C showed significant increment in the placebo group compared to the baseline of the study (6.9\u202fmg/dL, p\u202f<\u202f0.05).', 'Between group comparison showed significant decrease in SBP and DBP in synbiotic group compared to placebo (-2.5 vs. 8.6\u202fmmHg, and -1.8 vs. 2.1\u202fmmHg, p\u202f<\u202f0.05).\tBetween group comparison showed significant decrease in SBP and DBP in synbiotic group compared to placebo (-2.5 vs. 8.6\u202fmmHg, and -1.8 vs. 2.1\u202fmmHg, p\u202f<\u202f0.05).', 'Between group comparison showed significant decrease in SBP and DBP in synbiotic group compared to placebo (-2.5 vs. 8.6\u202fmmHg, and -1.8 vs. 2.1\u202fmmHg, p\u202f<\u202f0.05).\tThe results showed that, in women with GDM, synbiotic supplementation had no effect on FPG and insulin resistance/sensitivity indices.', 'Between group comparison showed significant decrease in SBP and DBP in synbiotic group compared to placebo (-2.5 vs. 8.6\u202fmmHg, and -1.8 vs. 2.1\u202fmmHg, p\u202f<\u202f0.05).\tLipid profile and TAC status may be affected by synbiotic supplementation.', 'The results showed that, in women with GDM, synbiotic supplementation had no effect on FPG and insulin resistance/sensitivity indices.\tSynbiotic is effective in reducing of blood pressure in women with GDM.', 'The results showed that, in women with GDM, synbiotic supplementation had no effect on FPG and insulin resistance/sensitivity indices.\tNo significant changes in FPG, insulin resistance/sensitivity, lipid profile and TAC indices were seen in synbiotic group compared to the placebo one (p\u202f>\u202f0.05).', 'The results showed that, in women with GDM, synbiotic supplementation had no effect on FPG and insulin resistance/sensitivity indices.\tSignificant within group increases for HDL-C and TAC levels in synbiotic group were observed (p\u202f<\u202f0.05).', 'The results showed that, in women with GDM, synbiotic supplementation had no effect on FPG and insulin resistance/sensitivity indices.\tLDL-C showed significant increment in the placebo group compared to the baseline of the study (6.9\u202fmg/dL, p\u202f<\u202f0.05).', 'The results showed that, in women with GDM, synbiotic supplementation had no effect on FPG and insulin resistance/sensitivity indices.\tBetween group comparison showed significant decrease in SBP and DBP in synbiotic group compared to placebo (-2.5 vs. 8.6\u202fmmHg, and -1.8 vs. 2.1\u202fmmHg, p\u202f<\u202f0.05).', 'The results showed that, in women with GDM, synbiotic supplementation had no effect on FPG and insulin resistance/sensitivity indices.\tThe results showed that, in women with GDM, synbiotic supplementation had no effect on FPG and insulin resistance/sensitivity indices.', 'The results showed that, in women with GDM, synbiotic supplementation had no effect on FPG and insulin resistance/sensitivity indices.\tLipid profile and TAC status may be affected by synbiotic supplementation.', 'Lipid profile and TAC status may be affected by synbiotic supplementation.\tSynbiotic is effective in reducing of blood pressure in women with GDM.', 'Lipid profile and TAC status may be affected by synbiotic supplementation.\tNo significant changes in FPG, insulin resistance/sensitivity, lipid profile and TAC indices were seen in synbiotic group compared to the placebo one (p\u202f>\u202f0.05).', 'Lipid profile and TAC status may be affected by synbiotic supplementation.\tSignificant within group increases for HDL-C and TAC levels in synbiotic group were observed (p\u202f<\u202f0.05).', 'Lipid profile and TAC status may be affected by synbiotic supplementation.\tLDL-C showed significant increment in the placebo group compared to the baseline of the study (6.9\u202fmg/dL, p\u202f<\u202f0.05).', 'Lipid profile and TAC status may be affected by synbiotic supplementation.\tBetween group comparison showed significant decrease in SBP and DBP in synbiotic group compared to placebo (-2.5 vs. 8.6\u202fmmHg, and -1.8 vs. 2.1\u202fmmHg, p\u202f<\u202f0.05).', 'Lipid profile and TAC status may be affected by synbiotic supplementation.\tThe results showed that, in women with GDM, synbiotic supplementation had no effect on FPG and insulin resistance/sensitivity indices.', 'Lipid profile and TAC status may be affected by synbiotic supplementation.\tLipid profile and TAC status may be affected by synbiotic supplementation.']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['Symptomatic hypotension did not develop in any of the patients during the wet session, compared to 4 (40%) during the dry session.\tSymptomatic hypotension did not develop in any of the patients during the wet session, compared to 4 (40%) during the dry session.', 'Symptomatic hypotension did not develop in any of the patients during the wet session, compared to 4 (40%) during the dry session.\tSystolic blood pressure adjusted to ultrafiltration was stable during the wet session, 0.22 mmHg/15 min (95% CI -0.27 to 0.70), P\u2009=\u20090.38, and significantly decreased during the dry session, -0.68 mmHg/15 min (95%CI -1.24 to -0.11), P\u2009=\u20090.02.', 'Symptomatic hypotension did not develop in any of the patients during the wet session, compared to 4 (40%) during the dry session.\tDiastolic blood pressure did not change during the sessions.', 'Symptomatic hypotension did not develop in any of the patients during the wet session, compared to 4 (40%) during the dry session.\tMean atrial natriuretic peptide significantly increased in the wet session, by 31.36 pgr/mL (95%CI 8.73-53.99), P\u2009=\u20090.007, and slightly and insignificantly decreased in the dry session, by 21.66 pgr/mL (95% CI -52.59 to 9.25), P\u2009=\u20090.167.', 'Symptomatic hypotension did not develop in any of the patients during the wet session, compared to 4 (40%) during the dry session.\tReduced effective circulating volume is a major cause for IDH, which can be prevented using head-out water immersion facilitated redistribution.', 'Symptomatic hypotension did not develop in any of the patients during the wet session, compared to 4 (40%) during the dry session.\tAldosterone blood levels did not change.', 'Systolic blood pressure adjusted to ultrafiltration was stable during the wet session, 0.22 mmHg/15 min (95% CI -0.27 to 0.70), P\u2009=\u20090.38, and significantly decreased during the dry session, -0.68 mmHg/15 min (95%CI -1.24 to -0.11), P\u2009=\u20090.02.\tSymptomatic hypotension did not develop in any of the patients during the wet session, compared to 4 (40%) during the dry session.', 'Systolic blood pressure adjusted to ultrafiltration was stable during the wet session, 0.22 mmHg/15 min (95% CI -0.27 to 0.70), P\u2009=\u20090.38, and significantly decreased during the dry session, -0.68 mmHg/15 min (95%CI -1.24 to -0.11), P\u2009=\u20090.02.\tSystolic blood pressure adjusted to ultrafiltration was stable during the wet session, 0.22 mmHg/15 min (95% CI -0.27 to 0.70), P\u2009=\u20090.38, and significantly decreased during the dry session, -0.68 mmHg/15 min (95%CI -1.24 to -0.11), P\u2009=\u20090.02.', 'Systolic blood pressure adjusted to ultrafiltration was stable during the wet session, 0.22 mmHg/15 min (95% CI -0.27 to 0.70), P\u2009=\u20090.38, and significantly decreased during the dry session, -0.68 mmHg/15 min (95%CI -1.24 to -0.11), P\u2009=\u20090.02.\tDiastolic blood pressure did not change during the sessions.', 'Systolic blood pressure adjusted to ultrafiltration was stable during the wet session, 0.22 mmHg/15 min (95% CI -0.27 to 0.70), P\u2009=\u20090.38, and significantly decreased during the dry session, -0.68 mmHg/15 min (95%CI -1.24 to -0.11), P\u2009=\u20090.02.\tMean atrial natriuretic peptide significantly increased in the wet session, by 31.36 pgr/mL (95%CI 8.73-53.99), P\u2009=\u20090.007, and slightly and insignificantly decreased in the dry session, by 21.66 pgr/mL (95% CI -52.59 to 9.25), P\u2009=\u20090.167.', 'Systolic blood pressure adjusted to ultrafiltration was stable during the wet session, 0.22 mmHg/15 min (95% CI -0.27 to 0.70), P\u2009=\u20090.38, and significantly decreased during the dry session, -0.68 mmHg/15 min (95%CI -1.24 to -0.11), P\u2009=\u20090.02.\tReduced effective circulating volume is a major cause for IDH, which can be prevented using head-out water immersion facilitated redistribution.', 'Systolic blood pressure adjusted to ultrafiltration was stable during the wet session, 0.22 mmHg/15 min (95% CI -0.27 to 0.70), P\u2009=\u20090.38, and significantly decreased during the dry session, -0.68 mmHg/15 min (95%CI -1.24 to -0.11), P\u2009=\u20090.02.\tAldosterone blood levels did not change.', 'Diastolic blood pressure did not change during the sessions.\tSymptomatic hypotension did not develop in any of the patients during the wet session, compared to 4 (40%) during the dry session.', 'Diastolic blood pressure did not change during the sessions.\tSystolic blood pressure adjusted to ultrafiltration was stable during the wet session, 0.22 mmHg/15 min (95% CI -0.27 to 0.70), P\u2009=\u20090.38, and significantly decreased during the dry session, -0.68 mmHg/15 min (95%CI -1.24 to -0.11), P\u2009=\u20090.02.', 'Diastolic blood pressure did not change during the sessions.\tDiastolic blood pressure did not change during the sessions.', 'Diastolic blood pressure did not change during the sessions.\tMean atrial natriuretic peptide significantly increased in the wet session, by 31.36 pgr/mL (95%CI 8.73-53.99), P\u2009=\u20090.007, and slightly and insignificantly decreased in the dry session, by 21.66 pgr/mL (95% CI -52.59 to 9.25), P\u2009=\u20090.167.', 'Diastolic blood pressure did not change during the sessions.\tReduced effective circulating volume is a major cause for IDH, which can be prevented using head-out water immersion facilitated redistribution.', 'Diastolic blood pressure did not change during the sessions.\tAldosterone blood levels did not change.', 'Mean atrial natriuretic peptide significantly increased in the wet session, by 31.36 pgr/mL (95%CI 8.73-53.99), P\u2009=\u20090.007, and slightly and insignificantly decreased in the dry session, by 21.66 pgr/mL (95% CI -52.59 to 9.25), P\u2009=\u20090.167.\tSymptomatic hypotension did not develop in any of the patients during the wet session, compared to 4 (40%) during the dry session.', 'Mean atrial natriuretic peptide significantly increased in the wet session, by 31.36 pgr/mL (95%CI 8.73-53.99), P\u2009=\u20090.007, and slightly and insignificantly decreased in the dry session, by 21.66 pgr/mL (95% CI -52.59 to 9.25), P\u2009=\u20090.167.\tSystolic blood pressure adjusted to ultrafiltration was stable during the wet session, 0.22 mmHg/15 min (95% CI -0.27 to 0.70), P\u2009=\u20090.38, and significantly decreased during the dry session, -0.68 mmHg/15 min (95%CI -1.24 to -0.11), P\u2009=\u20090.02.', 'Mean atrial natriuretic peptide significantly increased in the wet session, by 31.36 pgr/mL (95%CI 8.73-53.99), P\u2009=\u20090.007, and slightly and insignificantly decreased in the dry session, by 21.66 pgr/mL (95% CI -52.59 to 9.25), P\u2009=\u20090.167.\tDiastolic blood pressure did not change during the sessions.', 'Mean atrial natriuretic peptide significantly increased in the wet session, by 31.36 pgr/mL (95%CI 8.73-53.99), P\u2009=\u20090.007, and slightly and insignificantly decreased in the dry session, by 21.66 pgr/mL (95% CI -52.59 to 9.25), P\u2009=\u20090.167.\tMean atrial natriuretic peptide significantly increased in the wet session, by 31.36 pgr/mL (95%CI 8.73-53.99), P\u2009=\u20090.007, and slightly and insignificantly decreased in the dry session, by 21.66 pgr/mL (95% CI -52.59 to 9.25), P\u2009=\u20090.167.', 'Mean atrial natriuretic peptide significantly increased in the wet session, by 31.36 pgr/mL (95%CI 8.73-53.99), P\u2009=\u20090.007, and slightly and insignificantly decreased in the dry session, by 21.66 pgr/mL (95% CI -52.59 to 9.25), P\u2009=\u20090.167.\tReduced effective circulating volume is a major cause for IDH, which can be prevented using head-out water immersion facilitated redistribution.', 'Mean atrial natriuretic peptide significantly increased in the wet session, by 31.36 pgr/mL (95%CI 8.73-53.99), P\u2009=\u20090.007, and slightly and insignificantly decreased in the dry session, by 21.66 pgr/mL (95% CI -52.59 to 9.25), P\u2009=\u20090.167.\tAldosterone blood levels did not change.', 'Reduced effective circulating volume is a major cause for IDH, which can be prevented using head-out water immersion facilitated redistribution.\tSymptomatic hypotension did not develop in any of the patients during the wet session, compared to 4 (40%) during the dry session.', 'Reduced effective circulating volume is a major cause for IDH, which can be prevented using head-out water immersion facilitated redistribution.\tSystolic blood pressure adjusted to ultrafiltration was stable during the wet session, 0.22 mmHg/15 min (95% CI -0.27 to 0.70), P\u2009=\u20090.38, and significantly decreased during the dry session, -0.68 mmHg/15 min (95%CI -1.24 to -0.11), P\u2009=\u20090.02.', 'Reduced effective circulating volume is a major cause for IDH, which can be prevented using head-out water immersion facilitated redistribution.\tDiastolic blood pressure did not change during the sessions.', 'Reduced effective circulating volume is a major cause for IDH, which can be prevented using head-out water immersion facilitated redistribution.\tMean atrial natriuretic peptide significantly increased in the wet session, by 31.36 pgr/mL (95%CI 8.73-53.99), P\u2009=\u20090.007, and slightly and insignificantly decreased in the dry session, by 21.66 pgr/mL (95% CI -52.59 to 9.25), P\u2009=\u20090.167.', 'Reduced effective circulating volume is a major cause for IDH, which can be prevented using head-out water immersion facilitated redistribution.\tReduced effective circulating volume is a major cause for IDH, which can be prevented using head-out water immersion facilitated redistribution.', 'Reduced effective circulating volume is a major cause for IDH, which can be prevented using head-out water immersion facilitated redistribution.\tAldosterone blood levels did not change.', 'Aldosterone blood levels did not change.\tSymptomatic hypotension did not develop in any of the patients during the wet session, compared to 4 (40%) during the dry session.', 'Aldosterone blood levels did not change.\tSystolic blood pressure adjusted to ultrafiltration was stable during the wet session, 0.22 mmHg/15 min (95% CI -0.27 to 0.70), P\u2009=\u20090.38, and significantly decreased during the dry session, -0.68 mmHg/15 min (95%CI -1.24 to -0.11), P\u2009=\u20090.02.', 'Aldosterone blood levels did not change.\tDiastolic blood pressure did not change during the sessions.', 'Aldosterone blood levels did not change.\tMean atrial natriuretic peptide significantly increased in the wet session, by 31.36 pgr/mL (95%CI 8.73-53.99), P\u2009=\u20090.007, and slightly and insignificantly decreased in the dry session, by 21.66 pgr/mL (95% CI -52.59 to 9.25), P\u2009=\u20090.167.', 'Aldosterone blood levels did not change.\tReduced effective circulating volume is a major cause for IDH, which can be prevented using head-out water immersion facilitated redistribution.', 'Aldosterone blood levels did not change.\tAldosterone blood levels did not change.']","[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['It shows that a sequential combination of interferon-α and lamivudine was beneficial.\tIt shows that a sequential combination of interferon-α and lamivudine was beneficial.', 'It shows that a sequential combination of interferon-α and lamivudine was beneficial.\tOf the 46 patients in the treatment group, 73.91% had undetectable serum HBV DNA, 32.61% achieved HBeAg seroconversion and 21.74% lost hepatitis B surface antigen (HBsAg) at the endpoint.', 'It shows that a sequential combination of interferon-α and lamivudine was beneficial.\tNo LAM resistance emerged at week 96.', 'It shows that a sequential combination of interferon-α and lamivudine was beneficial.\tIn the control group, only one (4.35%) patient underwent spontaneous HBeAg seroconversion and had undetectable serum HBV DNA during observation, and moreover, none developed HBsAg clearance.', 'It shows that a sequential combination of interferon-α and lamivudine was beneficial.\tFor all patients, no serious adverse events were observed.', 'It shows that a sequential combination of interferon-α and lamivudine was beneficial.\tAntiviral treatment with a sequential combination of IFN and LAM resulted in a significant improvement in the rates of undetectable serum HBV DNA, HBeAg seroconversion and HBsAg loss in children with chronic HBV infection and immune-tolerant characteristics.', 'It shows that a sequential combination of interferon-α and lamivudine was beneficial.\tIt remains unresolved how children with immune-tolerant CHB should be treated.', 'Of the 46 patients in the treatment group, 73.91% had undetectable serum HBV DNA, 32.61% achieved HBeAg seroconversion and 21.74% lost hepatitis B surface antigen (HBsAg) at the endpoint.\tIt shows that a sequential combination of interferon-α and lamivudine was beneficial.', 'Of the 46 patients in the treatment group, 73.91% had undetectable serum HBV DNA, 32.61% achieved HBeAg seroconversion and 21.74% lost hepatitis B surface antigen (HBsAg) at the endpoint.\tOf the 46 patients in the treatment group, 73.91% had undetectable serum HBV DNA, 32.61% achieved HBeAg seroconversion and 21.74% lost hepatitis B surface antigen (HBsAg) at the endpoint.', 'Of the 46 patients in the treatment group, 73.91% had undetectable serum HBV DNA, 32.61% achieved HBeAg seroconversion and 21.74% lost hepatitis B surface antigen (HBsAg) at the endpoint.\tNo LAM resistance emerged at week 96.', 'Of the 46 patients in the treatment group, 73.91% had undetectable serum HBV DNA, 32.61% achieved HBeAg seroconversion and 21.74% lost hepatitis B surface antigen (HBsAg) at the endpoint.\tIn the control group, only one (4.35%) patient underwent spontaneous HBeAg seroconversion and had undetectable serum HBV DNA during observation, and moreover, none developed HBsAg clearance.', 'Of the 46 patients in the treatment group, 73.91% had undetectable serum HBV DNA, 32.61% achieved HBeAg seroconversion and 21.74% lost hepatitis B surface antigen (HBsAg) at the endpoint.\tFor all patients, no serious adverse events were observed.', 'Of the 46 patients in the treatment group, 73.91% had undetectable serum HBV DNA, 32.61% achieved HBeAg seroconversion and 21.74% lost hepatitis B surface antigen (HBsAg) at the endpoint.\tAntiviral treatment with a sequential combination of IFN and LAM resulted in a significant improvement in the rates of undetectable serum HBV DNA, HBeAg seroconversion and HBsAg loss in children with chronic HBV infection and immune-tolerant characteristics.', 'Of the 46 patients in the treatment group, 73.91% had undetectable serum HBV DNA, 32.61% achieved HBeAg seroconversion and 21.74% lost hepatitis B surface antigen (HBsAg) at the endpoint.\tIt remains unresolved how children with immune-tolerant CHB should be treated.', 'No LAM resistance emerged at week 96.\tIt shows that a sequential combination of interferon-α and lamivudine was beneficial.', 'No LAM resistance emerged at week 96.\tOf the 46 patients in the treatment group, 73.91% had undetectable serum HBV DNA, 32.61% achieved HBeAg seroconversion and 21.74% lost hepatitis B surface antigen (HBsAg) at the endpoint.', 'No LAM resistance emerged at week 96.\tNo LAM resistance emerged at week 96.', 'No LAM resistance emerged at week 96.\tIn the control group, only one (4.35%) patient underwent spontaneous HBeAg seroconversion and had undetectable serum HBV DNA during observation, and moreover, none developed HBsAg clearance.', 'No LAM resistance emerged at week 96.\tFor all patients, no serious adverse events were observed.', 'No LAM resistance emerged at week 96.\tAntiviral treatment with a sequential combination of IFN and LAM resulted in a significant improvement in the rates of undetectable serum HBV DNA, HBeAg seroconversion and HBsAg loss in children with chronic HBV infection and immune-tolerant characteristics.', 'No LAM resistance emerged at week 96.\tIt remains unresolved how children with immune-tolerant CHB should be treated.', 'In the control group, only one (4.35%) patient underwent spontaneous HBeAg seroconversion and had undetectable serum HBV DNA during observation, and moreover, none developed HBsAg clearance.\tIt shows that a sequential combination of interferon-α and lamivudine was beneficial.', 'In the control group, only one (4.35%) patient underwent spontaneous HBeAg seroconversion and had undetectable serum HBV DNA during observation, and moreover, none developed HBsAg clearance.\tOf the 46 patients in the treatment group, 73.91% had undetectable serum HBV DNA, 32.61% achieved HBeAg seroconversion and 21.74% lost hepatitis B surface antigen (HBsAg) at the endpoint.', 'In the control group, only one (4.35%) patient underwent spontaneous HBeAg seroconversion and had undetectable serum HBV DNA during observation, and moreover, none developed HBsAg clearance.\tNo LAM resistance emerged at week 96.', 'In the control group, only one (4.35%) patient underwent spontaneous HBeAg seroconversion and had undetectable serum HBV DNA during observation, and moreover, none developed HBsAg clearance.\tIn the control group, only one (4.35%) patient underwent spontaneous HBeAg seroconversion and had undetectable serum HBV DNA during observation, and moreover, none developed HBsAg clearance.', 'In the control group, only one (4.35%) patient underwent spontaneous HBeAg seroconversion and had undetectable serum HBV DNA during observation, and moreover, none developed HBsAg clearance.\tFor all patients, no serious adverse events were observed.', 'In the control group, only one (4.35%) patient underwent spontaneous HBeAg seroconversion and had undetectable serum HBV DNA during observation, and moreover, none developed HBsAg clearance.\tAntiviral treatment with a sequential combination of IFN and LAM resulted in a significant improvement in the rates of undetectable serum HBV DNA, HBeAg seroconversion and HBsAg loss in children with chronic HBV infection and immune-tolerant characteristics.', 'In the control group, only one (4.35%) patient underwent spontaneous HBeAg seroconversion and had undetectable serum HBV DNA during observation, and moreover, none developed HBsAg clearance.\tIt remains unresolved how children with immune-tolerant CHB should be treated.', 'For all patients, no serious adverse events were observed.\tIt shows that a sequential combination of interferon-α and lamivudine was beneficial.', 'For all patients, no serious adverse events were observed.\tOf the 46 patients in the treatment group, 73.91% had undetectable serum HBV DNA, 32.61% achieved HBeAg seroconversion and 21.74% lost hepatitis B surface antigen (HBsAg) at the endpoint.', 'For all patients, no serious adverse events were observed.\tNo LAM resistance emerged at week 96.', 'For all patients, no serious adverse events were observed.\tIn the control group, only one (4.35%) patient underwent spontaneous HBeAg seroconversion and had undetectable serum HBV DNA during observation, and moreover, none developed HBsAg clearance.', 'For all patients, no serious adverse events were observed.\tFor all patients, no serious adverse events were observed.', 'For all patients, no serious adverse events were observed.\tAntiviral treatment with a sequential combination of IFN and LAM resulted in a significant improvement in the rates of undetectable serum HBV DNA, HBeAg seroconversion and HBsAg loss in children with chronic HBV infection and immune-tolerant characteristics.', 'For all patients, no serious adverse events were observed.\tIt remains unresolved how children with immune-tolerant CHB should be treated.', 'Antiviral treatment with a sequential combination of IFN and LAM resulted in a significant improvement in the rates of undetectable serum HBV DNA, HBeAg seroconversion and HBsAg loss in children with chronic HBV infection and immune-tolerant characteristics.\tIt shows that a sequential combination of interferon-α and lamivudine was beneficial.', 'Antiviral treatment with a sequential combination of IFN and LAM resulted in a significant improvement in the rates of undetectable serum HBV DNA, HBeAg seroconversion and HBsAg loss in children with chronic HBV infection and immune-tolerant characteristics.\tOf the 46 patients in the treatment group, 73.91% had undetectable serum HBV DNA, 32.61% achieved HBeAg seroconversion and 21.74% lost hepatitis B surface antigen (HBsAg) at the endpoint.', 'Antiviral treatment with a sequential combination of IFN and LAM resulted in a significant improvement in the rates of undetectable serum HBV DNA, HBeAg seroconversion and HBsAg loss in children with chronic HBV infection and immune-tolerant characteristics.\tNo LAM resistance emerged at week 96.', 'Antiviral treatment with a sequential combination of IFN and LAM resulted in a significant improvement in the rates of undetectable serum HBV DNA, HBeAg seroconversion and HBsAg loss in children with chronic HBV infection and immune-tolerant characteristics.\tIn the control group, only one (4.35%) patient underwent spontaneous HBeAg seroconversion and had undetectable serum HBV DNA during observation, and moreover, none developed HBsAg clearance.', 'Antiviral treatment with a sequential combination of IFN and LAM resulted in a significant improvement in the rates of undetectable serum HBV DNA, HBeAg seroconversion and HBsAg loss in children with chronic HBV infection and immune-tolerant characteristics.\tFor all patients, no serious adverse events were observed.', 'Antiviral treatment with a sequential combination of IFN and LAM resulted in a significant improvement in the rates of undetectable serum HBV DNA, HBeAg seroconversion and HBsAg loss in children with chronic HBV infection and immune-tolerant characteristics.\tAntiviral treatment with a sequential combination of IFN and LAM resulted in a significant improvement in the rates of undetectable serum HBV DNA, HBeAg seroconversion and HBsAg loss in children with chronic HBV infection and immune-tolerant characteristics.', 'Antiviral treatment with a sequential combination of IFN and LAM resulted in a significant improvement in the rates of undetectable serum HBV DNA, HBeAg seroconversion and HBsAg loss in children with chronic HBV infection and immune-tolerant characteristics.\tIt remains unresolved how children with immune-tolerant CHB should be treated.', 'It remains unresolved how children with immune-tolerant CHB should be treated.\tIt shows that a sequential combination of interferon-α and lamivudine was beneficial.', 'It remains unresolved how children with immune-tolerant CHB should be treated.\tOf the 46 patients in the treatment group, 73.91% had undetectable serum HBV DNA, 32.61% achieved HBeAg seroconversion and 21.74% lost hepatitis B surface antigen (HBsAg) at the endpoint.', 'It remains unresolved how children with immune-tolerant CHB should be treated.\tNo LAM resistance emerged at week 96.', 'It remains unresolved how children with immune-tolerant CHB should be treated.\tIn the control group, only one (4.35%) patient underwent spontaneous HBeAg seroconversion and had undetectable serum HBV DNA during observation, and moreover, none developed HBsAg clearance.', 'It remains unresolved how children with immune-tolerant CHB should be treated.\tFor all patients, no serious adverse events were observed.', 'It remains unresolved how children with immune-tolerant CHB should be treated.\tAntiviral treatment with a sequential combination of IFN and LAM resulted in a significant improvement in the rates of undetectable serum HBV DNA, HBeAg seroconversion and HBsAg loss in children with chronic HBV infection and immune-tolerant characteristics.', 'It remains unresolved how children with immune-tolerant CHB should be treated.\tIt remains unresolved how children with immune-tolerant CHB should be treated.']","[0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['No significant differences were observed among groups for HBeAg seroconversion (PEG-IFN alfa-2a+placebo, 36.3%; PEG-IFN alfa-2a+ETV, 29.5%; and PEG-IFN alfa-2a+ADV, 27.4%), HBeAg loss (37.4%, 32.2%, and 28.6%, respectively) or change in hepatitis B surface antigen (HBsAg) levels from baseline (-0.56 IU/mL, -0.60 IU/mL, and -0.41 IU/mL, respectively).\tNo significant differences were observed among groups for HBeAg seroconversion (PEG-IFN alfa-2a+placebo, 36.3%; PEG-IFN alfa-2a+ETV, 29.5%; and PEG-IFN alfa-2a+ADV, 27.4%), HBeAg loss (37.4%, 32.2%, and 28.6%, respectively) or change in hepatitis B surface antigen (HBsAg) levels from baseline (-0.56 IU/mL, -0.60 IU/mL, and -0.41 IU/mL, respectively).', 'No significant differences were observed among groups for HBeAg seroconversion (PEG-IFN alfa-2a+placebo, 36.3%; PEG-IFN alfa-2a+ETV, 29.5%; and PEG-IFN alfa-2a+ADV, 27.4%), HBeAg loss (37.4%, 32.2%, and 28.6%, respectively) or change in hepatitis B surface antigen (HBsAg) levels from baseline (-0.56 IU/mL, -0.60 IU/mL, and -0.41 IU/mL, respectively).\tHowever, hepatitis B virus DNA levels were higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa+ETV at week 64 (p = 0.0412), 76 (p = 0.0311), and 88 (p = 0.0113), and alanine aminotransferase (ALT) normalization rate was higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa-2a+ADV (p = 0.0283) or PEG-IFN alfa-2a+ETV (p = 0.0369) at week 88.', 'No significant differences were observed among groups for HBeAg seroconversion (PEG-IFN alfa-2a+placebo, 36.3%; PEG-IFN alfa-2a+ETV, 29.5%; and PEG-IFN alfa-2a+ADV, 27.4%), HBeAg loss (37.4%, 32.2%, and 28.6%, respectively) or change in hepatitis B surface antigen (HBsAg) levels from baseline (-0.56 IU/mL, -0.60 IU/mL, and -0.41 IU/mL, respectively).\tSub-analysis of results revealed an association between on-treatment HBsAg and ALT levels and efficacy 48 weeks post-treatment.', 'No significant differences were observed among groups for HBeAg seroconversion (PEG-IFN alfa-2a+placebo, 36.3%; PEG-IFN alfa-2a+ETV, 29.5%; and PEG-IFN alfa-2a+ADV, 27.4%), HBeAg loss (37.4%, 32.2%, and 28.6%, respectively) or change in hepatitis B surface antigen (HBsAg) levels from baseline (-0.56 IU/mL, -0.60 IU/mL, and -0.41 IU/mL, respectively).\tSafety was comparable among treatment groups.', 'No significant differences were observed among groups for HBeAg seroconversion (PEG-IFN alfa-2a+placebo, 36.3%; PEG-IFN alfa-2a+ETV, 29.5%; and PEG-IFN alfa-2a+ADV, 27.4%), HBeAg loss (37.4%, 32.2%, and 28.6%, respectively) or change in hepatitis B surface antigen (HBsAg) levels from baseline (-0.56 IU/mL, -0.60 IU/mL, and -0.41 IU/mL, respectively).\tPre-therapy with ADV or ETV followed by PEG-IFN alfa-2a is not superior to PEG-IFN alfa-2a monotherapy in Taiwanese patients with HBeAg-positive CHB.', 'However, hepatitis B virus DNA levels were higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa+ETV at week 64 (p = 0.0412), 76 (p = 0.0311), and 88 (p = 0.0113), and alanine aminotransferase (ALT) normalization rate was higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa-2a+ADV (p = 0.0283) or PEG-IFN alfa-2a+ETV (p = 0.0369) at week 88.\tNo significant differences were observed among groups for HBeAg seroconversion (PEG-IFN alfa-2a+placebo, 36.3%; PEG-IFN alfa-2a+ETV, 29.5%; and PEG-IFN alfa-2a+ADV, 27.4%), HBeAg loss (37.4%, 32.2%, and 28.6%, respectively) or change in hepatitis B surface antigen (HBsAg) levels from baseline (-0.56 IU/mL, -0.60 IU/mL, and -0.41 IU/mL, respectively).', 'However, hepatitis B virus DNA levels were higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa+ETV at week 64 (p = 0.0412), 76 (p = 0.0311), and 88 (p = 0.0113), and alanine aminotransferase (ALT) normalization rate was higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa-2a+ADV (p = 0.0283) or PEG-IFN alfa-2a+ETV (p = 0.0369) at week 88.\tHowever, hepatitis B virus DNA levels were higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa+ETV at week 64 (p = 0.0412), 76 (p = 0.0311), and 88 (p = 0.0113), and alanine aminotransferase (ALT) normalization rate was higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa-2a+ADV (p = 0.0283) or PEG-IFN alfa-2a+ETV (p = 0.0369) at week 88.', 'However, hepatitis B virus DNA levels were higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa+ETV at week 64 (p = 0.0412), 76 (p = 0.0311), and 88 (p = 0.0113), and alanine aminotransferase (ALT) normalization rate was higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa-2a+ADV (p = 0.0283) or PEG-IFN alfa-2a+ETV (p = 0.0369) at week 88.\tSub-analysis of results revealed an association between on-treatment HBsAg and ALT levels and efficacy 48 weeks post-treatment.', 'However, hepatitis B virus DNA levels were higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa+ETV at week 64 (p = 0.0412), 76 (p = 0.0311), and 88 (p = 0.0113), and alanine aminotransferase (ALT) normalization rate was higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa-2a+ADV (p = 0.0283) or PEG-IFN alfa-2a+ETV (p = 0.0369) at week 88.\tSafety was comparable among treatment groups.', 'However, hepatitis B virus DNA levels were higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa+ETV at week 64 (p = 0.0412), 76 (p = 0.0311), and 88 (p = 0.0113), and alanine aminotransferase (ALT) normalization rate was higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa-2a+ADV (p = 0.0283) or PEG-IFN alfa-2a+ETV (p = 0.0369) at week 88.\tPre-therapy with ADV or ETV followed by PEG-IFN alfa-2a is not superior to PEG-IFN alfa-2a monotherapy in Taiwanese patients with HBeAg-positive CHB.', 'Sub-analysis of results revealed an association between on-treatment HBsAg and ALT levels and efficacy 48 weeks post-treatment.\tNo significant differences were observed among groups for HBeAg seroconversion (PEG-IFN alfa-2a+placebo, 36.3%; PEG-IFN alfa-2a+ETV, 29.5%; and PEG-IFN alfa-2a+ADV, 27.4%), HBeAg loss (37.4%, 32.2%, and 28.6%, respectively) or change in hepatitis B surface antigen (HBsAg) levels from baseline (-0.56 IU/mL, -0.60 IU/mL, and -0.41 IU/mL, respectively).', 'Sub-analysis of results revealed an association between on-treatment HBsAg and ALT levels and efficacy 48 weeks post-treatment.\tHowever, hepatitis B virus DNA levels were higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa+ETV at week 64 (p = 0.0412), 76 (p = 0.0311), and 88 (p = 0.0113), and alanine aminotransferase (ALT) normalization rate was higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa-2a+ADV (p = 0.0283) or PEG-IFN alfa-2a+ETV (p = 0.0369) at week 88.', 'Sub-analysis of results revealed an association between on-treatment HBsAg and ALT levels and efficacy 48 weeks post-treatment.\tSub-analysis of results revealed an association between on-treatment HBsAg and ALT levels and efficacy 48 weeks post-treatment.', 'Sub-analysis of results revealed an association between on-treatment HBsAg and ALT levels and efficacy 48 weeks post-treatment.\tSafety was comparable among treatment groups.', 'Sub-analysis of results revealed an association between on-treatment HBsAg and ALT levels and efficacy 48 weeks post-treatment.\tPre-therapy with ADV or ETV followed by PEG-IFN alfa-2a is not superior to PEG-IFN alfa-2a monotherapy in Taiwanese patients with HBeAg-positive CHB.', 'Safety was comparable among treatment groups.\tNo significant differences were observed among groups for HBeAg seroconversion (PEG-IFN alfa-2a+placebo, 36.3%; PEG-IFN alfa-2a+ETV, 29.5%; and PEG-IFN alfa-2a+ADV, 27.4%), HBeAg loss (37.4%, 32.2%, and 28.6%, respectively) or change in hepatitis B surface antigen (HBsAg) levels from baseline (-0.56 IU/mL, -0.60 IU/mL, and -0.41 IU/mL, respectively).', 'Safety was comparable among treatment groups.\tHowever, hepatitis B virus DNA levels were higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa+ETV at week 64 (p = 0.0412), 76 (p = 0.0311), and 88 (p = 0.0113), and alanine aminotransferase (ALT) normalization rate was higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa-2a+ADV (p = 0.0283) or PEG-IFN alfa-2a+ETV (p = 0.0369) at week 88.', 'Safety was comparable among treatment groups.\tSub-analysis of results revealed an association between on-treatment HBsAg and ALT levels and efficacy 48 weeks post-treatment.', 'Safety was comparable among treatment groups.\tSafety was comparable among treatment groups.', 'Safety was comparable among treatment groups.\tPre-therapy with ADV or ETV followed by PEG-IFN alfa-2a is not superior to PEG-IFN alfa-2a monotherapy in Taiwanese patients with HBeAg-positive CHB.', 'Pre-therapy with ADV or ETV followed by PEG-IFN alfa-2a is not superior to PEG-IFN alfa-2a monotherapy in Taiwanese patients with HBeAg-positive CHB.\tNo significant differences were observed among groups for HBeAg seroconversion (PEG-IFN alfa-2a+placebo, 36.3%; PEG-IFN alfa-2a+ETV, 29.5%; and PEG-IFN alfa-2a+ADV, 27.4%), HBeAg loss (37.4%, 32.2%, and 28.6%, respectively) or change in hepatitis B surface antigen (HBsAg) levels from baseline (-0.56 IU/mL, -0.60 IU/mL, and -0.41 IU/mL, respectively).', 'Pre-therapy with ADV or ETV followed by PEG-IFN alfa-2a is not superior to PEG-IFN alfa-2a monotherapy in Taiwanese patients with HBeAg-positive CHB.\tHowever, hepatitis B virus DNA levels were higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa+ETV at week 64 (p = 0.0412), 76 (p = 0.0311), and 88 (p = 0.0113), and alanine aminotransferase (ALT) normalization rate was higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa-2a+ADV (p = 0.0283) or PEG-IFN alfa-2a+ETV (p = 0.0369) at week 88.', 'Pre-therapy with ADV or ETV followed by PEG-IFN alfa-2a is not superior to PEG-IFN alfa-2a monotherapy in Taiwanese patients with HBeAg-positive CHB.\tSub-analysis of results revealed an association between on-treatment HBsAg and ALT levels and efficacy 48 weeks post-treatment.', 'Pre-therapy with ADV or ETV followed by PEG-IFN alfa-2a is not superior to PEG-IFN alfa-2a monotherapy in Taiwanese patients with HBeAg-positive CHB.\tSafety was comparable among treatment groups.', 'Pre-therapy with ADV or ETV followed by PEG-IFN alfa-2a is not superior to PEG-IFN alfa-2a monotherapy in Taiwanese patients with HBeAg-positive CHB.\tPre-therapy with ADV or ETV followed by PEG-IFN alfa-2a is not superior to PEG-IFN alfa-2a monotherapy in Taiwanese patients with HBeAg-positive CHB.']","[0, 0, 0, 0, 1, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0]"
"['Compared with the spironolactone group (n=95), the clonidine group (n=92) presented similar rates of achieving the primary end point (20.5% versus 20.8%, respectively; relative risk, 1.01 [0.55-1.88]; P=1.00).\tCompared with the spironolactone group (n=95), the clonidine group (n=92) presented similar rates of achieving the primary end point (20.5% versus 20.8%, respectively; relative risk, 1.01 [0.55-1.88]; P=1.00).', 'Compared with the spironolactone group (n=95), the clonidine group (n=92) presented similar rates of achieving the primary end point (20.5% versus 20.8%, respectively; relative risk, 1.01 [0.55-1.88]; P=1.00).\tSecondary end point analysis showed similar office BP (33.3% versus 29.3%) and ambulatory BP monitoring (44% versus 46.2%) control for spironolactone and clonidine, respectively.', 'Compared with the spironolactone group (n=95), the clonidine group (n=92) presented similar rates of achieving the primary end point (20.5% versus 20.8%, respectively; relative risk, 1.01 [0.55-1.88]; P=1.00).\tspironolactone promoted greater decrease in 24-h systolic and diastolic BP and diastolic daytime ambulatory BP than clonidine.', 'Compared with the spironolactone group (n=95), the clonidine group (n=92) presented similar rates of achieving the primary end point (20.5% versus 20.8%, respectively; relative risk, 1.01 [0.55-1.88]; P=1.00).\tclonidine was not superior to spironolactone in true resistant hypertensive patients, but the overall BP control was low (≈21%).', 'Compared with the spironolactone group (n=95), the clonidine group (n=92) presented similar rates of achieving the primary end point (20.5% versus 20.8%, respectively; relative risk, 1.01 [0.55-1.88]; P=1.00).\tspironolactone is preferable for the fourth-drug therapy.', 'Secondary end point analysis showed similar office BP (33.3% versus 29.3%) and ambulatory BP monitoring (44% versus 46.2%) control for spironolactone and clonidine, respectively.\tCompared with the spironolactone group (n=95), the clonidine group (n=92) presented similar rates of achieving the primary end point (20.5% versus 20.8%, respectively; relative risk, 1.01 [0.55-1.88]; P=1.00).', 'Secondary end point analysis showed similar office BP (33.3% versus 29.3%) and ambulatory BP monitoring (44% versus 46.2%) control for spironolactone and clonidine, respectively.\tSecondary end point analysis showed similar office BP (33.3% versus 29.3%) and ambulatory BP monitoring (44% versus 46.2%) control for spironolactone and clonidine, respectively.', 'Secondary end point analysis showed similar office BP (33.3% versus 29.3%) and ambulatory BP monitoring (44% versus 46.2%) control for spironolactone and clonidine, respectively.\tspironolactone promoted greater decrease in 24-h systolic and diastolic BP and diastolic daytime ambulatory BP than clonidine.', 'Secondary end point analysis showed similar office BP (33.3% versus 29.3%) and ambulatory BP monitoring (44% versus 46.2%) control for spironolactone and clonidine, respectively.\tclonidine was not superior to spironolactone in true resistant hypertensive patients, but the overall BP control was low (≈21%).', 'Secondary end point analysis showed similar office BP (33.3% versus 29.3%) and ambulatory BP monitoring (44% versus 46.2%) control for spironolactone and clonidine, respectively.\tspironolactone is preferable for the fourth-drug therapy.', 'spironolactone promoted greater decrease in 24-h systolic and diastolic BP and diastolic daytime ambulatory BP than clonidine.\tCompared with the spironolactone group (n=95), the clonidine group (n=92) presented similar rates of achieving the primary end point (20.5% versus 20.8%, respectively; relative risk, 1.01 [0.55-1.88]; P=1.00).', 'spironolactone promoted greater decrease in 24-h systolic and diastolic BP and diastolic daytime ambulatory BP than clonidine.\tSecondary end point analysis showed similar office BP (33.3% versus 29.3%) and ambulatory BP monitoring (44% versus 46.2%) control for spironolactone and clonidine, respectively.', 'spironolactone promoted greater decrease in 24-h systolic and diastolic BP and diastolic daytime ambulatory BP than clonidine.\tspironolactone promoted greater decrease in 24-h systolic and diastolic BP and diastolic daytime ambulatory BP than clonidine.', 'spironolactone promoted greater decrease in 24-h systolic and diastolic BP and diastolic daytime ambulatory BP than clonidine.\tclonidine was not superior to spironolactone in true resistant hypertensive patients, but the overall BP control was low (≈21%).', 'spironolactone promoted greater decrease in 24-h systolic and diastolic BP and diastolic daytime ambulatory BP than clonidine.\tspironolactone is preferable for the fourth-drug therapy.', 'clonidine was not superior to spironolactone in true resistant hypertensive patients, but the overall BP control was low (≈21%).\tCompared with the spironolactone group (n=95), the clonidine group (n=92) presented similar rates of achieving the primary end point (20.5% versus 20.8%, respectively; relative risk, 1.01 [0.55-1.88]; P=1.00).', 'clonidine was not superior to spironolactone in true resistant hypertensive patients, but the overall BP control was low (≈21%).\tSecondary end point analysis showed similar office BP (33.3% versus 29.3%) and ambulatory BP monitoring (44% versus 46.2%) control for spironolactone and clonidine, respectively.', 'clonidine was not superior to spironolactone in true resistant hypertensive patients, but the overall BP control was low (≈21%).\tspironolactone promoted greater decrease in 24-h systolic and diastolic BP and diastolic daytime ambulatory BP than clonidine.', 'clonidine was not superior to spironolactone in true resistant hypertensive patients, but the overall BP control was low (≈21%).\tclonidine was not superior to spironolactone in true resistant hypertensive patients, but the overall BP control was low (≈21%).', 'clonidine was not superior to spironolactone in true resistant hypertensive patients, but the overall BP control was low (≈21%).\tspironolactone is preferable for the fourth-drug therapy.', 'spironolactone is preferable for the fourth-drug therapy.\tCompared with the spironolactone group (n=95), the clonidine group (n=92) presented similar rates of achieving the primary end point (20.5% versus 20.8%, respectively; relative risk, 1.01 [0.55-1.88]; P=1.00).', 'spironolactone is preferable for the fourth-drug therapy.\tSecondary end point analysis showed similar office BP (33.3% versus 29.3%) and ambulatory BP monitoring (44% versus 46.2%) control for spironolactone and clonidine, respectively.', 'spironolactone is preferable for the fourth-drug therapy.\tspironolactone promoted greater decrease in 24-h systolic and diastolic BP and diastolic daytime ambulatory BP than clonidine.', 'spironolactone is preferable for the fourth-drug therapy.\tclonidine was not superior to spironolactone in true resistant hypertensive patients, but the overall BP control was low (≈21%).', 'spironolactone is preferable for the fourth-drug therapy.\tspironolactone is preferable for the fourth-drug therapy.']","[0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0]"
"['The cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).\tThe cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).', 'The cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).\tPostoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).', 'The cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).\tSerious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).', 'The cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).\tTrabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.', 'The cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).\tThe frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.', 'The cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).\tLower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.', 'The cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).\tMean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).', 'Postoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).\tThe cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).', 'Postoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).\tPostoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).', 'Postoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).\tSerious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).', 'Postoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).\tTrabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.', 'Postoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).\tThe frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.', 'Postoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).\tLower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.', 'Postoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).\tMean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).', 'Serious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).\tThe cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).', 'Serious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).\tPostoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).', 'Serious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).\tSerious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).', 'Serious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).\tTrabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.', 'Serious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).\tThe frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.', 'Serious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).\tLower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.', 'Serious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).\tMean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).', 'Trabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.\tThe cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).', 'Trabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.\tPostoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).', 'Trabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.\tSerious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).', 'Trabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.\tTrabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.', 'Trabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.\tThe frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.', 'Trabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.\tLower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.', 'Trabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.\tMean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).', 'The frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.\tThe cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).', 'The frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.\tPostoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).', 'The frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.\tSerious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).', 'The frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.\tTrabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.', 'The frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.\tThe frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.', 'The frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.\tLower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.', 'The frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.\tMean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).', 'Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.\tThe cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).', 'Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.\tPostoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).', 'Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.\tSerious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).', 'Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.\tTrabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.', 'Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.\tThe frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.', 'Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.\tLower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.', 'Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.\tMean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).', 'Mean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).\tThe cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).', 'Mean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).\tPostoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).', 'Mean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).\tSerious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).', 'Mean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).\tTrabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.', 'Mean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).\tThe frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.', 'Mean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).\tLower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.', 'Mean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).\tMean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).']","[0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0]"
"['Larger studies using physiologically standardized ginseng preparations are warranted to substantiate the present findings and to demonstrate therapeutic effectiveness of AG.\tLarger studies using physiologically standardized ginseng preparations are warranted to substantiate the present findings and to demonstrate therapeutic effectiveness of AG.', 'Larger studies using physiologically standardized ginseng preparations are warranted to substantiate the present findings and to demonstrate therapeutic effectiveness of AG.\tAG extract added to conventional treatment provided an effective and safe adjunct in the management of T2DM.', 'Larger studies using physiologically standardized ginseng preparations are warranted to substantiate the present findings and to demonstrate therapeutic effectiveness of AG.\tCompared to placebo, AG significantly reduced HbA1c (- 0.29%; p\u2009=\u20090.041) and fasting blood glucose (- 0.71 mmol/L; p\u2009=\u20090.008).', 'Larger studies using physiologically standardized ginseng preparations are warranted to substantiate the present findings and to demonstrate therapeutic effectiveness of AG.\tAG lowered systolic blood pressure (- 5.6\u2009±\u20092.7 mmHg; p\u2009<\u20090.001), increased NOx (+\u20091.85\u2009±\u20092.13 µmol/L; p\u2009<\u20090.03), and produced a mean percent end-difference of - 12.3\u2009±\u20093.9% in LDL-C and -\u200913.9\u2009±\u20095.8% in LDL-C/HDL.', 'AG extract added to conventional treatment provided an effective and safe adjunct in the management of T2DM.\tLarger studies using physiologically standardized ginseng preparations are warranted to substantiate the present findings and to demonstrate therapeutic effectiveness of AG.', 'AG extract added to conventional treatment provided an effective and safe adjunct in the management of T2DM.\tAG extract added to conventional treatment provided an effective and safe adjunct in the management of T2DM.', 'AG extract added to conventional treatment provided an effective and safe adjunct in the management of T2DM.\tCompared to placebo, AG significantly reduced HbA1c (- 0.29%; p\u2009=\u20090.041) and fasting blood glucose (- 0.71 mmol/L; p\u2009=\u20090.008).', 'AG extract added to conventional treatment provided an effective and safe adjunct in the management of T2DM.\tAG lowered systolic blood pressure (- 5.6\u2009±\u20092.7 mmHg; p\u2009<\u20090.001), increased NOx (+\u20091.85\u2009±\u20092.13 µmol/L; p\u2009<\u20090.03), and produced a mean percent end-difference of - 12.3\u2009±\u20093.9% in LDL-C and -\u200913.9\u2009±\u20095.8% in LDL-C/HDL.', 'Compared to placebo, AG significantly reduced HbA1c (- 0.29%; p\u2009=\u20090.041) and fasting blood glucose (- 0.71 mmol/L; p\u2009=\u20090.008).\tLarger studies using physiologically standardized ginseng preparations are warranted to substantiate the present findings and to demonstrate therapeutic effectiveness of AG.', 'Compared to placebo, AG significantly reduced HbA1c (- 0.29%; p\u2009=\u20090.041) and fasting blood glucose (- 0.71 mmol/L; p\u2009=\u20090.008).\tAG extract added to conventional treatment provided an effective and safe adjunct in the management of T2DM.', 'Compared to placebo, AG significantly reduced HbA1c (- 0.29%; p\u2009=\u20090.041) and fasting blood glucose (- 0.71 mmol/L; p\u2009=\u20090.008).\tCompared to placebo, AG significantly reduced HbA1c (- 0.29%; p\u2009=\u20090.041) and fasting blood glucose (- 0.71 mmol/L; p\u2009=\u20090.008).', 'Compared to placebo, AG significantly reduced HbA1c (- 0.29%; p\u2009=\u20090.041) and fasting blood glucose (- 0.71 mmol/L; p\u2009=\u20090.008).\tAG lowered systolic blood pressure (- 5.6\u2009±\u20092.7 mmHg; p\u2009<\u20090.001), increased NOx (+\u20091.85\u2009±\u20092.13 µmol/L; p\u2009<\u20090.03), and produced a mean percent end-difference of - 12.3\u2009±\u20093.9% in LDL-C and -\u200913.9\u2009±\u20095.8% in LDL-C/HDL.', 'AG lowered systolic blood pressure (- 5.6\u2009±\u20092.7 mmHg; p\u2009<\u20090.001), increased NOx (+\u20091.85\u2009±\u20092.13 µmol/L; p\u2009<\u20090.03), and produced a mean percent end-difference of - 12.3\u2009±\u20093.9% in LDL-C and -\u200913.9\u2009±\u20095.8% in LDL-C/HDL.\tLarger studies using physiologically standardized ginseng preparations are warranted to substantiate the present findings and to demonstrate therapeutic effectiveness of AG.', 'AG lowered systolic blood pressure (- 5.6\u2009±\u20092.7 mmHg; p\u2009<\u20090.001), increased NOx (+\u20091.85\u2009±\u20092.13 µmol/L; p\u2009<\u20090.03), and produced a mean percent end-difference of - 12.3\u2009±\u20093.9% in LDL-C and -\u200913.9\u2009±\u20095.8% in LDL-C/HDL.\tAG extract added to conventional treatment provided an effective and safe adjunct in the management of T2DM.', 'AG lowered systolic blood pressure (- 5.6\u2009±\u20092.7 mmHg; p\u2009<\u20090.001), increased NOx (+\u20091.85\u2009±\u20092.13 µmol/L; p\u2009<\u20090.03), and produced a mean percent end-difference of - 12.3\u2009±\u20093.9% in LDL-C and -\u200913.9\u2009±\u20095.8% in LDL-C/HDL.\tCompared to placebo, AG significantly reduced HbA1c (- 0.29%; p\u2009=\u20090.041) and fasting blood glucose (- 0.71 mmol/L; p\u2009=\u20090.008).', 'AG lowered systolic blood pressure (- 5.6\u2009±\u20092.7 mmHg; p\u2009<\u20090.001), increased NOx (+\u20091.85\u2009±\u20092.13 µmol/L; p\u2009<\u20090.03), and produced a mean percent end-difference of - 12.3\u2009±\u20093.9% in LDL-C and -\u200913.9\u2009±\u20095.8% in LDL-C/HDL.\tAG lowered systolic blood pressure (- 5.6\u2009±\u20092.7 mmHg; p\u2009<\u20090.001), increased NOx (+\u20091.85\u2009±\u20092.13 µmol/L; p\u2009<\u20090.03), and produced a mean percent end-difference of - 12.3\u2009±\u20093.9% in LDL-C and -\u200913.9\u2009±\u20095.8% in LDL-C/HDL.']","[0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 1, 0, 0]"
"['Ca consumption during the study was equivalent to 1200 mg/d during MD and 525 mg/d during CD.\tCa consumption during the study was equivalent to 1200 mg/d during MD and 525 mg/d during CD.', 'Ca consumption during the study was equivalent to 1200 mg/d during MD and 525 mg/d during CD.\tThere was a greater reduction in WC, SBP, DBP and LAP index after MD compared with CD.', 'Ca consumption during the study was equivalent to 1200 mg/d during MD and 525 mg/d during CD.\tHDL:LDL ratio increased and total cholesterol, LDL-cholesterol, SBP, DBP and LAP index decreased only in MD.', 'Ca consumption during the study was equivalent to 1200 mg/d during MD and 525 mg/d during CD.\tThe consumption of approximately 1200 mg of Ca/d (700 mg from fat-free milk+500mg from other dietary sources) associated with an energy-restricted diet decreased some of the MetS components and cardiometabolic measures in adults with T2DM.', 'There was a greater reduction in WC, SBP, DBP and LAP index after MD compared with CD.\tCa consumption during the study was equivalent to 1200 mg/d during MD and 525 mg/d during CD.', 'There was a greater reduction in WC, SBP, DBP and LAP index after MD compared with CD.\tThere was a greater reduction in WC, SBP, DBP and LAP index after MD compared with CD.', 'There was a greater reduction in WC, SBP, DBP and LAP index after MD compared with CD.\tHDL:LDL ratio increased and total cholesterol, LDL-cholesterol, SBP, DBP and LAP index decreased only in MD.', 'There was a greater reduction in WC, SBP, DBP and LAP index after MD compared with CD.\tThe consumption of approximately 1200 mg of Ca/d (700 mg from fat-free milk+500mg from other dietary sources) associated with an energy-restricted diet decreased some of the MetS components and cardiometabolic measures in adults with T2DM.', 'HDL:LDL ratio increased and total cholesterol, LDL-cholesterol, SBP, DBP and LAP index decreased only in MD.\tCa consumption during the study was equivalent to 1200 mg/d during MD and 525 mg/d during CD.', 'HDL:LDL ratio increased and total cholesterol, LDL-cholesterol, SBP, DBP and LAP index decreased only in MD.\tThere was a greater reduction in WC, SBP, DBP and LAP index after MD compared with CD.', 'HDL:LDL ratio increased and total cholesterol, LDL-cholesterol, SBP, DBP and LAP index decreased only in MD.\tHDL:LDL ratio increased and total cholesterol, LDL-cholesterol, SBP, DBP and LAP index decreased only in MD.', 'HDL:LDL ratio increased and total cholesterol, LDL-cholesterol, SBP, DBP and LAP index decreased only in MD.\tThe consumption of approximately 1200 mg of Ca/d (700 mg from fat-free milk+500mg from other dietary sources) associated with an energy-restricted diet decreased some of the MetS components and cardiometabolic measures in adults with T2DM.', 'The consumption of approximately 1200 mg of Ca/d (700 mg from fat-free milk+500mg from other dietary sources) associated with an energy-restricted diet decreased some of the MetS components and cardiometabolic measures in adults with T2DM.\tCa consumption during the study was equivalent to 1200 mg/d during MD and 525 mg/d during CD.', 'The consumption of approximately 1200 mg of Ca/d (700 mg from fat-free milk+500mg from other dietary sources) associated with an energy-restricted diet decreased some of the MetS components and cardiometabolic measures in adults with T2DM.\tThere was a greater reduction in WC, SBP, DBP and LAP index after MD compared with CD.', 'The consumption of approximately 1200 mg of Ca/d (700 mg from fat-free milk+500mg from other dietary sources) associated with an energy-restricted diet decreased some of the MetS components and cardiometabolic measures in adults with T2DM.\tHDL:LDL ratio increased and total cholesterol, LDL-cholesterol, SBP, DBP and LAP index decreased only in MD.', 'The consumption of approximately 1200 mg of Ca/d (700 mg from fat-free milk+500mg from other dietary sources) associated with an energy-restricted diet decreased some of the MetS components and cardiometabolic measures in adults with T2DM.\tThe consumption of approximately 1200 mg of Ca/d (700 mg from fat-free milk+500mg from other dietary sources) associated with an energy-restricted diet decreased some of the MetS components and cardiometabolic measures in adults with T2DM.']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['Larger sample size is presumably needed to assess the effect of RIPC for patients with diabetes mellitus.\tLarger sample size is presumably needed to assess the effect of RIPC for patients with diabetes mellitus.', 'Larger sample size is presumably needed to assess the effect of RIPC for patients with diabetes mellitus.\tRemote ischemic preconditioning significantly reduces the incidence of acute kidney injury in non-diabetic patients undergoing PCI.', 'Larger sample size is presumably needed to assess the effect of RIPC for patients with diabetes mellitus.\tRIPC significantly reduced CIN incidence in the overall population (12.1% vs. 26.1%, p=0.01, with a NNT=9) and in non-diabetic patients (9.2% vs. 25.0%, p=0.02), but showed no benefit in diabetics (16.7% vs. 28.2%, p=0.21).', 'Larger sample size is presumably needed to assess the effect of RIPC for patients with diabetes mellitus.\tA trend for lower PMI was seen in the intervention arm (creatine kinase - muscle brain >5 URL; 8.4% vs. 16.4%, p=0.07; troponin T >5 URL; 27% vs. 38%, p=0.21).', 'Remote ischemic preconditioning significantly reduces the incidence of acute kidney injury in non-diabetic patients undergoing PCI.\tLarger sample size is presumably needed to assess the effect of RIPC for patients with diabetes mellitus.', 'Remote ischemic preconditioning significantly reduces the incidence of acute kidney injury in non-diabetic patients undergoing PCI.\tRemote ischemic preconditioning significantly reduces the incidence of acute kidney injury in non-diabetic patients undergoing PCI.', 'Remote ischemic preconditioning significantly reduces the incidence of acute kidney injury in non-diabetic patients undergoing PCI.\tRIPC significantly reduced CIN incidence in the overall population (12.1% vs. 26.1%, p=0.01, with a NNT=9) and in non-diabetic patients (9.2% vs. 25.0%, p=0.02), but showed no benefit in diabetics (16.7% vs. 28.2%, p=0.21).', 'Remote ischemic preconditioning significantly reduces the incidence of acute kidney injury in non-diabetic patients undergoing PCI.\tA trend for lower PMI was seen in the intervention arm (creatine kinase - muscle brain >5 URL; 8.4% vs. 16.4%, p=0.07; troponin T >5 URL; 27% vs. 38%, p=0.21).', 'RIPC significantly reduced CIN incidence in the overall population (12.1% vs. 26.1%, p=0.01, with a NNT=9) and in non-diabetic patients (9.2% vs. 25.0%, p=0.02), but showed no benefit in diabetics (16.7% vs. 28.2%, p=0.21).\tLarger sample size is presumably needed to assess the effect of RIPC for patients with diabetes mellitus.', 'RIPC significantly reduced CIN incidence in the overall population (12.1% vs. 26.1%, p=0.01, with a NNT=9) and in non-diabetic patients (9.2% vs. 25.0%, p=0.02), but showed no benefit in diabetics (16.7% vs. 28.2%, p=0.21).\tRemote ischemic preconditioning significantly reduces the incidence of acute kidney injury in non-diabetic patients undergoing PCI.', 'RIPC significantly reduced CIN incidence in the overall population (12.1% vs. 26.1%, p=0.01, with a NNT=9) and in non-diabetic patients (9.2% vs. 25.0%, p=0.02), but showed no benefit in diabetics (16.7% vs. 28.2%, p=0.21).\tRIPC significantly reduced CIN incidence in the overall population (12.1% vs. 26.1%, p=0.01, with a NNT=9) and in non-diabetic patients (9.2% vs. 25.0%, p=0.02), but showed no benefit in diabetics (16.7% vs. 28.2%, p=0.21).', 'RIPC significantly reduced CIN incidence in the overall population (12.1% vs. 26.1%, p=0.01, with a NNT=9) and in non-diabetic patients (9.2% vs. 25.0%, p=0.02), but showed no benefit in diabetics (16.7% vs. 28.2%, p=0.21).\tA trend for lower PMI was seen in the intervention arm (creatine kinase - muscle brain >5 URL; 8.4% vs. 16.4%, p=0.07; troponin T >5 URL; 27% vs. 38%, p=0.21).', 'A trend for lower PMI was seen in the intervention arm (creatine kinase - muscle brain >5 URL; 8.4% vs. 16.4%, p=0.07; troponin T >5 URL; 27% vs. 38%, p=0.21).\tLarger sample size is presumably needed to assess the effect of RIPC for patients with diabetes mellitus.', 'A trend for lower PMI was seen in the intervention arm (creatine kinase - muscle brain >5 URL; 8.4% vs. 16.4%, p=0.07; troponin T >5 URL; 27% vs. 38%, p=0.21).\tRemote ischemic preconditioning significantly reduces the incidence of acute kidney injury in non-diabetic patients undergoing PCI.', 'A trend for lower PMI was seen in the intervention arm (creatine kinase - muscle brain >5 URL; 8.4% vs. 16.4%, p=0.07; troponin T >5 URL; 27% vs. 38%, p=0.21).\tRIPC significantly reduced CIN incidence in the overall population (12.1% vs. 26.1%, p=0.01, with a NNT=9) and in non-diabetic patients (9.2% vs. 25.0%, p=0.02), but showed no benefit in diabetics (16.7% vs. 28.2%, p=0.21).', 'A trend for lower PMI was seen in the intervention arm (creatine kinase - muscle brain >5 URL; 8.4% vs. 16.4%, p=0.07; troponin T >5 URL; 27% vs. 38%, p=0.21).\tA trend for lower PMI was seen in the intervention arm (creatine kinase - muscle brain >5 URL; 8.4% vs. 16.4%, p=0.07; troponin T >5 URL; 27% vs. 38%, p=0.21).']","[0, 2, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 1, 0, 0]"
"['Available data indicate that dietary sodium (as salt) relates directly to blood pressure (BP).\tAvailable data indicate that dietary sodium (as salt) relates directly to blood pressure (BP).', 'Available data indicate that dietary sodium (as salt) relates directly to blood pressure (BP).\tNormal weight and obese participants manifested significant positive relations to BP of urinary sodium; relations were weaker for overweight people.', 'Available data indicate that dietary sodium (as salt) relates directly to blood pressure (BP).\tAt lower but not higher levels of 24-hour sodium excretion, potassium intake blunted the sodium-BP relation.', 'Available data indicate that dietary sodium (as salt) relates directly to blood pressure (BP).\tThe adverse association of dietary sodium with BP is minimally attenuated by other dietary constituents;', 'Available data indicate that dietary sodium (as salt) relates directly to blood pressure (BP).\tthese findings underscore the importance of reducing salt intake for the prevention and control of prehypertension and hypertension.', 'Normal weight and obese participants manifested significant positive relations to BP of urinary sodium; relations were weaker for overweight people.\tAvailable data indicate that dietary sodium (as salt) relates directly to blood pressure (BP).', 'Normal weight and obese participants manifested significant positive relations to BP of urinary sodium; relations were weaker for overweight people.\tNormal weight and obese participants manifested significant positive relations to BP of urinary sodium; relations were weaker for overweight people.', 'Normal weight and obese participants manifested significant positive relations to BP of urinary sodium; relations were weaker for overweight people.\tAt lower but not higher levels of 24-hour sodium excretion, potassium intake blunted the sodium-BP relation.', 'Normal weight and obese participants manifested significant positive relations to BP of urinary sodium; relations were weaker for overweight people.\tThe adverse association of dietary sodium with BP is minimally attenuated by other dietary constituents;', 'Normal weight and obese participants manifested significant positive relations to BP of urinary sodium; relations were weaker for overweight people.\tthese findings underscore the importance of reducing salt intake for the prevention and control of prehypertension and hypertension.', 'At lower but not higher levels of 24-hour sodium excretion, potassium intake blunted the sodium-BP relation.\tAvailable data indicate that dietary sodium (as salt) relates directly to blood pressure (BP).', 'At lower but not higher levels of 24-hour sodium excretion, potassium intake blunted the sodium-BP relation.\tNormal weight and obese participants manifested significant positive relations to BP of urinary sodium; relations were weaker for overweight people.', 'At lower but not higher levels of 24-hour sodium excretion, potassium intake blunted the sodium-BP relation.\tAt lower but not higher levels of 24-hour sodium excretion, potassium intake blunted the sodium-BP relation.', 'At lower but not higher levels of 24-hour sodium excretion, potassium intake blunted the sodium-BP relation.\tThe adverse association of dietary sodium with BP is minimally attenuated by other dietary constituents;', 'At lower but not higher levels of 24-hour sodium excretion, potassium intake blunted the sodium-BP relation.\tthese findings underscore the importance of reducing salt intake for the prevention and control of prehypertension and hypertension.', 'The adverse association of dietary sodium with BP is minimally attenuated by other dietary constituents;\tAvailable data indicate that dietary sodium (as salt) relates directly to blood pressure (BP).', 'The adverse association of dietary sodium with BP is minimally attenuated by other dietary constituents;\tNormal weight and obese participants manifested significant positive relations to BP of urinary sodium; relations were weaker for overweight people.', 'The adverse association of dietary sodium with BP is minimally attenuated by other dietary constituents;\tAt lower but not higher levels of 24-hour sodium excretion, potassium intake blunted the sodium-BP relation.', 'The adverse association of dietary sodium with BP is minimally attenuated by other dietary constituents;\tThe adverse association of dietary sodium with BP is minimally attenuated by other dietary constituents;', 'The adverse association of dietary sodium with BP is minimally attenuated by other dietary constituents;\tthese findings underscore the importance of reducing salt intake for the prevention and control of prehypertension and hypertension.', 'these findings underscore the importance of reducing salt intake for the prevention and control of prehypertension and hypertension.\tAvailable data indicate that dietary sodium (as salt) relates directly to blood pressure (BP).', 'these findings underscore the importance of reducing salt intake for the prevention and control of prehypertension and hypertension.\tNormal weight and obese participants manifested significant positive relations to BP of urinary sodium; relations were weaker for overweight people.', 'these findings underscore the importance of reducing salt intake for the prevention and control of prehypertension and hypertension.\tAt lower but not higher levels of 24-hour sodium excretion, potassium intake blunted the sodium-BP relation.', 'these findings underscore the importance of reducing salt intake for the prevention and control of prehypertension and hypertension.\tThe adverse association of dietary sodium with BP is minimally attenuated by other dietary constituents;', 'these findings underscore the importance of reducing salt intake for the prevention and control of prehypertension and hypertension.\tthese findings underscore the importance of reducing salt intake for the prevention and control of prehypertension and hypertension.']","[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['The mean (SD) systolic BP decreased by 8 (12) mm Hg in the standard group and by 27 (17) mm Hg in the intensive group (P\u2009<\u2009.001), with mean (SD) achieved pressures of 141 (13) and 126 (10) mm Hg, respectively.\tThe mean (SD) systolic BP decreased by 8 (12) mm Hg in the standard group and by 27 (17) mm Hg in the intensive group (P\u2009<\u2009.001), with mean (SD) achieved pressures of 141 (13) and 126 (10) mm Hg, respectively.', 'The mean (SD) systolic BP decreased by 8 (12) mm Hg in the standard group and by 27 (17) mm Hg in the intensive group (P\u2009<\u2009.001), with mean (SD) achieved pressures of 141 (13) and 126 (10) mm Hg, respectively.\tChange in global perfusion did not differ between treatment groups: the mean (SD) change was -0.5 (9.4) mL/min/100 g in the standard group vs 0.7 (8.6) mL/min/100 g in the intensive group (partial η2, 0.004; 95% CI, -3.551 to 5.818; P\u2009=\u2009.63).', 'The mean (SD) systolic BP decreased by 8 (12) mm Hg in the standard group and by 27 (17) mm Hg in the intensive group (P\u2009<\u2009.001), with mean (SD) achieved pressures of 141 (13) and 126 (10) mm Hg, respectively.\tNo differences were observed when the analysis examined gray or white matter only or was confined to those achieving target BP.', 'The mean (SD) systolic BP decreased by 8 (12) mm Hg in the standard group and by 27 (17) mm Hg in the intensive group (P\u2009<\u2009.001), with mean (SD) achieved pressures of 141 (13) and 126 (10) mm Hg, respectively.\tIntensive BP lowering did not reduce cerebral perfusion in severe small vessel disease.', 'The mean (SD) systolic BP decreased by 8 (12) mm Hg in the standard group and by 27 (17) mm Hg in the intensive group (P\u2009<\u2009.001), with mean (SD) achieved pressures of 141 (13) and 126 (10) mm Hg, respectively.\tThe number of adverse events did not differ between treatment groups, with a mean (SD) of 0.21 (0.65) for the standard group and 0.32 (0.75) for the intensive group (P\u2009=\u2009.44).', 'Change in global perfusion did not differ between treatment groups: the mean (SD) change was -0.5 (9.4) mL/min/100 g in the standard group vs 0.7 (8.6) mL/min/100 g in the intensive group (partial η2, 0.004; 95% CI, -3.551 to 5.818; P\u2009=\u2009.63).\tThe mean (SD) systolic BP decreased by 8 (12) mm Hg in the standard group and by 27 (17) mm Hg in the intensive group (P\u2009<\u2009.001), with mean (SD) achieved pressures of 141 (13) and 126 (10) mm Hg, respectively.', 'Change in global perfusion did not differ between treatment groups: the mean (SD) change was -0.5 (9.4) mL/min/100 g in the standard group vs 0.7 (8.6) mL/min/100 g in the intensive group (partial η2, 0.004; 95% CI, -3.551 to 5.818; P\u2009=\u2009.63).\tChange in global perfusion did not differ between treatment groups: the mean (SD) change was -0.5 (9.4) mL/min/100 g in the standard group vs 0.7 (8.6) mL/min/100 g in the intensive group (partial η2, 0.004; 95% CI, -3.551 to 5.818; P\u2009=\u2009.63).', 'Change in global perfusion did not differ between treatment groups: the mean (SD) change was -0.5 (9.4) mL/min/100 g in the standard group vs 0.7 (8.6) mL/min/100 g in the intensive group (partial η2, 0.004; 95% CI, -3.551 to 5.818; P\u2009=\u2009.63).\tNo differences were observed when the analysis examined gray or white matter only or was confined to those achieving target BP.', 'Change in global perfusion did not differ between treatment groups: the mean (SD) change was -0.5 (9.4) mL/min/100 g in the standard group vs 0.7 (8.6) mL/min/100 g in the intensive group (partial η2, 0.004; 95% CI, -3.551 to 5.818; P\u2009=\u2009.63).\tIntensive BP lowering did not reduce cerebral perfusion in severe small vessel disease.', 'Change in global perfusion did not differ between treatment groups: the mean (SD) change was -0.5 (9.4) mL/min/100 g in the standard group vs 0.7 (8.6) mL/min/100 g in the intensive group (partial η2, 0.004; 95% CI, -3.551 to 5.818; P\u2009=\u2009.63).\tThe number of adverse events did not differ between treatment groups, with a mean (SD) of 0.21 (0.65) for the standard group and 0.32 (0.75) for the intensive group (P\u2009=\u2009.44).', 'No differences were observed when the analysis examined gray or white matter only or was confined to those achieving target BP.\tThe mean (SD) systolic BP decreased by 8 (12) mm Hg in the standard group and by 27 (17) mm Hg in the intensive group (P\u2009<\u2009.001), with mean (SD) achieved pressures of 141 (13) and 126 (10) mm Hg, respectively.', 'No differences were observed when the analysis examined gray or white matter only or was confined to those achieving target BP.\tChange in global perfusion did not differ between treatment groups: the mean (SD) change was -0.5 (9.4) mL/min/100 g in the standard group vs 0.7 (8.6) mL/min/100 g in the intensive group (partial η2, 0.004; 95% CI, -3.551 to 5.818; P\u2009=\u2009.63).', 'No differences were observed when the analysis examined gray or white matter only or was confined to those achieving target BP.\tNo differences were observed when the analysis examined gray or white matter only or was confined to those achieving target BP.', 'No differences were observed when the analysis examined gray or white matter only or was confined to those achieving target BP.\tIntensive BP lowering did not reduce cerebral perfusion in severe small vessel disease.', 'No differences were observed when the analysis examined gray or white matter only or was confined to those achieving target BP.\tThe number of adverse events did not differ between treatment groups, with a mean (SD) of 0.21 (0.65) for the standard group and 0.32 (0.75) for the intensive group (P\u2009=\u2009.44).', 'Intensive BP lowering did not reduce cerebral perfusion in severe small vessel disease.\tThe mean (SD) systolic BP decreased by 8 (12) mm Hg in the standard group and by 27 (17) mm Hg in the intensive group (P\u2009<\u2009.001), with mean (SD) achieved pressures of 141 (13) and 126 (10) mm Hg, respectively.', 'Intensive BP lowering did not reduce cerebral perfusion in severe small vessel disease.\tChange in global perfusion did not differ between treatment groups: the mean (SD) change was -0.5 (9.4) mL/min/100 g in the standard group vs 0.7 (8.6) mL/min/100 g in the intensive group (partial η2, 0.004; 95% CI, -3.551 to 5.818; P\u2009=\u2009.63).', 'Intensive BP lowering did not reduce cerebral perfusion in severe small vessel disease.\tNo differences were observed when the analysis examined gray or white matter only or was confined to those achieving target BP.', 'Intensive BP lowering did not reduce cerebral perfusion in severe small vessel disease.\tIntensive BP lowering did not reduce cerebral perfusion in severe small vessel disease.', 'Intensive BP lowering did not reduce cerebral perfusion in severe small vessel disease.\tThe number of adverse events did not differ between treatment groups, with a mean (SD) of 0.21 (0.65) for the standard group and 0.32 (0.75) for the intensive group (P\u2009=\u2009.44).', 'The number of adverse events did not differ between treatment groups, with a mean (SD) of 0.21 (0.65) for the standard group and 0.32 (0.75) for the intensive group (P\u2009=\u2009.44).\tThe mean (SD) systolic BP decreased by 8 (12) mm Hg in the standard group and by 27 (17) mm Hg in the intensive group (P\u2009<\u2009.001), with mean (SD) achieved pressures of 141 (13) and 126 (10) mm Hg, respectively.', 'The number of adverse events did not differ between treatment groups, with a mean (SD) of 0.21 (0.65) for the standard group and 0.32 (0.75) for the intensive group (P\u2009=\u2009.44).\tChange in global perfusion did not differ between treatment groups: the mean (SD) change was -0.5 (9.4) mL/min/100 g in the standard group vs 0.7 (8.6) mL/min/100 g in the intensive group (partial η2, 0.004; 95% CI, -3.551 to 5.818; P\u2009=\u2009.63).', 'The number of adverse events did not differ between treatment groups, with a mean (SD) of 0.21 (0.65) for the standard group and 0.32 (0.75) for the intensive group (P\u2009=\u2009.44).\tNo differences were observed when the analysis examined gray or white matter only or was confined to those achieving target BP.', 'The number of adverse events did not differ between treatment groups, with a mean (SD) of 0.21 (0.65) for the standard group and 0.32 (0.75) for the intensive group (P\u2009=\u2009.44).\tIntensive BP lowering did not reduce cerebral perfusion in severe small vessel disease.', 'The number of adverse events did not differ between treatment groups, with a mean (SD) of 0.21 (0.65) for the standard group and 0.32 (0.75) for the intensive group (P\u2009=\u2009.44).\tThe number of adverse events did not differ between treatment groups, with a mean (SD) of 0.21 (0.65) for the standard group and 0.32 (0.75) for the intensive group (P\u2009=\u2009.44).']","[0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['Aortic systolic pressure and augmentation index, assessed by radial artery oscillatory tonometry, were unaffected by CPAP but decreased after AZT and AZT plus CPAP (RM-ANOVA P = .030 and .031, respectively).\tAortic systolic pressure and augmentation index, assessed by radial artery oscillatory tonometry, were unaffected by CPAP but decreased after AZT and AZT plus CPAP (RM-ANOVA P = .030 and .031, respectively).', 'Aortic systolic pressure and augmentation index, assessed by radial artery oscillatory tonometry, were unaffected by CPAP but decreased after AZT and AZT plus CPAP (RM-ANOVA P = .030 and .031, respectively).\tThe apnea-hypopnea index was significantly reduced in all three treatment arms, most prominently by AZT plus CPAP (RM-ANOVA P = .003).', 'Aortic systolic pressure and augmentation index, assessed by radial artery oscillatory tonometry, were unaffected by CPAP but decreased after AZT and AZT plus CPAP (RM-ANOVA P = .030 and .031, respectively).\tThe reduction of venous bicarbonate concentration following AZT was correlated with the change of apnea-hypopnea index (r = 0.66, P = .013).', 'Aortic systolic pressure and augmentation index, assessed by radial artery oscillatory tonometry, were unaffected by CPAP but decreased after AZT and AZT plus CPAP (RM-ANOVA P = .030 and .031, respectively).\tAZT reduced blood pressure, vascular stiffness, and sleep-disordered breathing in patients with OSA and comorbid hypertension.', 'Aortic systolic pressure and augmentation index, assessed by radial artery oscillatory tonometry, were unaffected by CPAP but decreased after AZT and AZT plus CPAP (RM-ANOVA P = .030 and .031, respectively).\tCarbonic anhydrase inhibition may constitute a potential target for drug therapy in patients with sleep apnea and comorbid hypertension.', 'The apnea-hypopnea index was significantly reduced in all three treatment arms, most prominently by AZT plus CPAP (RM-ANOVA P = .003).\tAortic systolic pressure and augmentation index, assessed by radial artery oscillatory tonometry, were unaffected by CPAP but decreased after AZT and AZT plus CPAP (RM-ANOVA P = .030 and .031, respectively).', 'The apnea-hypopnea index was significantly reduced in all three treatment arms, most prominently by AZT plus CPAP (RM-ANOVA P = .003).\tThe apnea-hypopnea index was significantly reduced in all three treatment arms, most prominently by AZT plus CPAP (RM-ANOVA P = .003).', 'The apnea-hypopnea index was significantly reduced in all three treatment arms, most prominently by AZT plus CPAP (RM-ANOVA P = .003).\tThe reduction of venous bicarbonate concentration following AZT was correlated with the change of apnea-hypopnea index (r = 0.66, P = .013).', 'The apnea-hypopnea index was significantly reduced in all three treatment arms, most prominently by AZT plus CPAP (RM-ANOVA P = .003).\tAZT reduced blood pressure, vascular stiffness, and sleep-disordered breathing in patients with OSA and comorbid hypertension.', 'The apnea-hypopnea index was significantly reduced in all three treatment arms, most prominently by AZT plus CPAP (RM-ANOVA P = .003).\tCarbonic anhydrase inhibition may constitute a potential target for drug therapy in patients with sleep apnea and comorbid hypertension.', 'The reduction of venous bicarbonate concentration following AZT was correlated with the change of apnea-hypopnea index (r = 0.66, P = .013).\tAortic systolic pressure and augmentation index, assessed by radial artery oscillatory tonometry, were unaffected by CPAP but decreased after AZT and AZT plus CPAP (RM-ANOVA P = .030 and .031, respectively).', 'The reduction of venous bicarbonate concentration following AZT was correlated with the change of apnea-hypopnea index (r = 0.66, P = .013).\tThe apnea-hypopnea index was significantly reduced in all three treatment arms, most prominently by AZT plus CPAP (RM-ANOVA P = .003).', 'The reduction of venous bicarbonate concentration following AZT was correlated with the change of apnea-hypopnea index (r = 0.66, P = .013).\tThe reduction of venous bicarbonate concentration following AZT was correlated with the change of apnea-hypopnea index (r = 0.66, P = .013).', 'The reduction of venous bicarbonate concentration following AZT was correlated with the change of apnea-hypopnea index (r = 0.66, P = .013).\tAZT reduced blood pressure, vascular stiffness, and sleep-disordered breathing in patients with OSA and comorbid hypertension.', 'The reduction of venous bicarbonate concentration following AZT was correlated with the change of apnea-hypopnea index (r = 0.66, P = .013).\tCarbonic anhydrase inhibition may constitute a potential target for drug therapy in patients with sleep apnea and comorbid hypertension.', 'AZT reduced blood pressure, vascular stiffness, and sleep-disordered breathing in patients with OSA and comorbid hypertension.\tAortic systolic pressure and augmentation index, assessed by radial artery oscillatory tonometry, were unaffected by CPAP but decreased after AZT and AZT plus CPAP (RM-ANOVA P = .030 and .031, respectively).', 'AZT reduced blood pressure, vascular stiffness, and sleep-disordered breathing in patients with OSA and comorbid hypertension.\tThe apnea-hypopnea index was significantly reduced in all three treatment arms, most prominently by AZT plus CPAP (RM-ANOVA P = .003).', 'AZT reduced blood pressure, vascular stiffness, and sleep-disordered breathing in patients with OSA and comorbid hypertension.\tThe reduction of venous bicarbonate concentration following AZT was correlated with the change of apnea-hypopnea index (r = 0.66, P = .013).', 'AZT reduced blood pressure, vascular stiffness, and sleep-disordered breathing in patients with OSA and comorbid hypertension.\tAZT reduced blood pressure, vascular stiffness, and sleep-disordered breathing in patients with OSA and comorbid hypertension.', 'AZT reduced blood pressure, vascular stiffness, and sleep-disordered breathing in patients with OSA and comorbid hypertension.\tCarbonic anhydrase inhibition may constitute a potential target for drug therapy in patients with sleep apnea and comorbid hypertension.', 'Carbonic anhydrase inhibition may constitute a potential target for drug therapy in patients with sleep apnea and comorbid hypertension.\tAortic systolic pressure and augmentation index, assessed by radial artery oscillatory tonometry, were unaffected by CPAP but decreased after AZT and AZT plus CPAP (RM-ANOVA P = .030 and .031, respectively).', 'Carbonic anhydrase inhibition may constitute a potential target for drug therapy in patients with sleep apnea and comorbid hypertension.\tThe apnea-hypopnea index was significantly reduced in all three treatment arms, most prominently by AZT plus CPAP (RM-ANOVA P = .003).', 'Carbonic anhydrase inhibition may constitute a potential target for drug therapy in patients with sleep apnea and comorbid hypertension.\tThe reduction of venous bicarbonate concentration following AZT was correlated with the change of apnea-hypopnea index (r = 0.66, P = .013).', 'Carbonic anhydrase inhibition may constitute a potential target for drug therapy in patients with sleep apnea and comorbid hypertension.\tAZT reduced blood pressure, vascular stiffness, and sleep-disordered breathing in patients with OSA and comorbid hypertension.', 'Carbonic anhydrase inhibition may constitute a potential target for drug therapy in patients with sleep apnea and comorbid hypertension.\tCarbonic anhydrase inhibition may constitute a potential target for drug therapy in patients with sleep apnea and comorbid hypertension.']","[0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0]"
"['In a setting in which the rate of mother-to-child HBV transmission was low with the administration of hepatitis B immune globulin and hepatitis B vaccine in infants born to HBeAg-positive mothers, the additional maternal use of TDF did not result in a significantly lower rate of transmission.\tIn a setting in which the rate of mother-to-child HBV transmission was low with the administration of hepatitis B immune globulin and hepatitis B vaccine in infants born to HBeAg-positive mothers, the additional maternal use of TDF did not result in a significantly lower rate of transmission.', 'In a setting in which the rate of mother-to-child HBV transmission was low with the administration of hepatitis B immune globulin and hepatitis B vaccine in infants born to HBeAg-positive mothers, the additional maternal use of TDF did not result in a significantly lower rate of transmission.\tIn the primary analysis, none of the 147 infants (0%; 95% confidence interval [CI], 0 to 2) in the TDF group were infected, as compared with 3 of 147 (2%; 95% CI, 0 to 6) in the placebo group (P=0.12).', 'In a setting in which the rate of mother-to-child HBV transmission was low with the administration of hepatitis B immune globulin and hepatitis B vaccine in infants born to HBeAg-positive mothers, the additional maternal use of TDF did not result in a significantly lower rate of transmission.\tThe rate of adverse events did not differ significantly between groups.', 'In a setting in which the rate of mother-to-child HBV transmission was low with the administration of hepatitis B immune globulin and hepatitis B vaccine in infants born to HBeAg-positive mothers, the additional maternal use of TDF did not result in a significantly lower rate of transmission.\tThe incidence of a maternal alanine aminotransferase level of more than 300 IU per liter after discontinuation of the trial regimen was 6% in the TDF group and 3% in the placebo group (P=0.29).', 'In the primary analysis, none of the 147 infants (0%; 95% confidence interval [CI], 0 to 2) in the TDF group were infected, as compared with 3 of 147 (2%; 95% CI, 0 to 6) in the placebo group (P=0.12).\tIn a setting in which the rate of mother-to-child HBV transmission was low with the administration of hepatitis B immune globulin and hepatitis B vaccine in infants born to HBeAg-positive mothers, the additional maternal use of TDF did not result in a significantly lower rate of transmission.', 'In the primary analysis, none of the 147 infants (0%; 95% confidence interval [CI], 0 to 2) in the TDF group were infected, as compared with 3 of 147 (2%; 95% CI, 0 to 6) in the placebo group (P=0.12).\tIn the primary analysis, none of the 147 infants (0%; 95% confidence interval [CI], 0 to 2) in the TDF group were infected, as compared with 3 of 147 (2%; 95% CI, 0 to 6) in the placebo group (P=0.12).', 'In the primary analysis, none of the 147 infants (0%; 95% confidence interval [CI], 0 to 2) in the TDF group were infected, as compared with 3 of 147 (2%; 95% CI, 0 to 6) in the placebo group (P=0.12).\tThe rate of adverse events did not differ significantly between groups.', 'In the primary analysis, none of the 147 infants (0%; 95% confidence interval [CI], 0 to 2) in the TDF group were infected, as compared with 3 of 147 (2%; 95% CI, 0 to 6) in the placebo group (P=0.12).\tThe incidence of a maternal alanine aminotransferase level of more than 300 IU per liter after discontinuation of the trial regimen was 6% in the TDF group and 3% in the placebo group (P=0.29).', 'The rate of adverse events did not differ significantly between groups.\tIn a setting in which the rate of mother-to-child HBV transmission was low with the administration of hepatitis B immune globulin and hepatitis B vaccine in infants born to HBeAg-positive mothers, the additional maternal use of TDF did not result in a significantly lower rate of transmission.', 'The rate of adverse events did not differ significantly between groups.\tIn the primary analysis, none of the 147 infants (0%; 95% confidence interval [CI], 0 to 2) in the TDF group were infected, as compared with 3 of 147 (2%; 95% CI, 0 to 6) in the placebo group (P=0.12).', 'The rate of adverse events did not differ significantly between groups.\tThe rate of adverse events did not differ significantly between groups.', 'The rate of adverse events did not differ significantly between groups.\tThe incidence of a maternal alanine aminotransferase level of more than 300 IU per liter after discontinuation of the trial regimen was 6% in the TDF group and 3% in the placebo group (P=0.29).', 'The incidence of a maternal alanine aminotransferase level of more than 300 IU per liter after discontinuation of the trial regimen was 6% in the TDF group and 3% in the placebo group (P=0.29).\tIn a setting in which the rate of mother-to-child HBV transmission was low with the administration of hepatitis B immune globulin and hepatitis B vaccine in infants born to HBeAg-positive mothers, the additional maternal use of TDF did not result in a significantly lower rate of transmission.', 'The incidence of a maternal alanine aminotransferase level of more than 300 IU per liter after discontinuation of the trial regimen was 6% in the TDF group and 3% in the placebo group (P=0.29).\tIn the primary analysis, none of the 147 infants (0%; 95% confidence interval [CI], 0 to 2) in the TDF group were infected, as compared with 3 of 147 (2%; 95% CI, 0 to 6) in the placebo group (P=0.12).', 'The incidence of a maternal alanine aminotransferase level of more than 300 IU per liter after discontinuation of the trial regimen was 6% in the TDF group and 3% in the placebo group (P=0.29).\tThe rate of adverse events did not differ significantly between groups.', 'The incidence of a maternal alanine aminotransferase level of more than 300 IU per liter after discontinuation of the trial regimen was 6% in the TDF group and 3% in the placebo group (P=0.29).\tThe incidence of a maternal alanine aminotransferase level of more than 300 IU per liter after discontinuation of the trial regimen was 6% in the TDF group and 3% in the placebo group (P=0.29).']","[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0]"
"['At 6 months, the mean systolic blood pressure fell by 27.0 mm Hg (to 125.8 mm Hg) in the intervention group and by 9.3 mm Hg (to 145.4 mm Hg) in the control group; the mean reduction was 21.6 mm Hg greater with the intervention (95% confidence interval, 14.7 to 28.4; P<0.001).\tAt 6 months, the mean systolic blood pressure fell by 27.0 mm Hg (to 125.8 mm Hg) in the intervention group and by 9.3 mm Hg (to 145.4 mm Hg) in the control group; the mean reduction was 21.6 mm Hg greater with the intervention (95% confidence interval, 14.7 to 28.4; P<0.001).', 'At 6 months, the mean systolic blood pressure fell by 27.0 mm Hg (to 125.8 mm Hg) in the intervention group and by 9.3 mm Hg (to 145.4 mm Hg) in the control group; the mean reduction was 21.6 mm Hg greater with the intervention (95% confidence interval, 14.7 to 28.4; P<0.001).\tA blood-pressure level of less than 130/80 mm Hg was achieved among 63.6% of the participants in the intervention group versus 11.7% of the participants in the control group (P<0.001).', 'At 6 months, the mean systolic blood pressure fell by 27.0 mm Hg (to 125.8 mm Hg) in the intervention group and by 9.3 mm Hg (to 145.4 mm Hg) in the control group; the mean reduction was 21.6 mm Hg greater with the intervention (95% confidence interval, 14.7 to 28.4; P<0.001).\tIn the intervention group, the rate of cohort retention was 95%, and there were few adverse events (three cases of acute kidney injury).', 'At 6 months, the mean systolic blood pressure fell by 27.0 mm Hg (to 125.8 mm Hg) in the intervention group and by 9.3 mm Hg (to 145.4 mm Hg) in the control group; the mean reduction was 21.6 mm Hg greater with the intervention (95% confidence interval, 14.7 to 28.4; P<0.001).\tAmong black male barbershop patrons with uncontrolled hypertension, health promotion by barbers resulted in larger blood-pressure reduction when coupled with medication management in barbershops by specialty-trained pharmacists.', 'A blood-pressure level of less than 130/80 mm Hg was achieved among 63.6% of the participants in the intervention group versus 11.7% of the participants in the control group (P<0.001).\tAt 6 months, the mean systolic blood pressure fell by 27.0 mm Hg (to 125.8 mm Hg) in the intervention group and by 9.3 mm Hg (to 145.4 mm Hg) in the control group; the mean reduction was 21.6 mm Hg greater with the intervention (95% confidence interval, 14.7 to 28.4; P<0.001).', 'A blood-pressure level of less than 130/80 mm Hg was achieved among 63.6% of the participants in the intervention group versus 11.7% of the participants in the control group (P<0.001).\tA blood-pressure level of less than 130/80 mm Hg was achieved among 63.6% of the participants in the intervention group versus 11.7% of the participants in the control group (P<0.001).', 'A blood-pressure level of less than 130/80 mm Hg was achieved among 63.6% of the participants in the intervention group versus 11.7% of the participants in the control group (P<0.001).\tIn the intervention group, the rate of cohort retention was 95%, and there were few adverse events (three cases of acute kidney injury).', 'A blood-pressure level of less than 130/80 mm Hg was achieved among 63.6% of the participants in the intervention group versus 11.7% of the participants in the control group (P<0.001).\tAmong black male barbershop patrons with uncontrolled hypertension, health promotion by barbers resulted in larger blood-pressure reduction when coupled with medication management in barbershops by specialty-trained pharmacists.', 'In the intervention group, the rate of cohort retention was 95%, and there were few adverse events (three cases of acute kidney injury).\tAt 6 months, the mean systolic blood pressure fell by 27.0 mm Hg (to 125.8 mm Hg) in the intervention group and by 9.3 mm Hg (to 145.4 mm Hg) in the control group; the mean reduction was 21.6 mm Hg greater with the intervention (95% confidence interval, 14.7 to 28.4; P<0.001).', 'In the intervention group, the rate of cohort retention was 95%, and there were few adverse events (three cases of acute kidney injury).\tA blood-pressure level of less than 130/80 mm Hg was achieved among 63.6% of the participants in the intervention group versus 11.7% of the participants in the control group (P<0.001).', 'In the intervention group, the rate of cohort retention was 95%, and there were few adverse events (three cases of acute kidney injury).\tIn the intervention group, the rate of cohort retention was 95%, and there were few adverse events (three cases of acute kidney injury).', 'In the intervention group, the rate of cohort retention was 95%, and there were few adverse events (three cases of acute kidney injury).\tAmong black male barbershop patrons with uncontrolled hypertension, health promotion by barbers resulted in larger blood-pressure reduction when coupled with medication management in barbershops by specialty-trained pharmacists.', 'Among black male barbershop patrons with uncontrolled hypertension, health promotion by barbers resulted in larger blood-pressure reduction when coupled with medication management in barbershops by specialty-trained pharmacists.\tAt 6 months, the mean systolic blood pressure fell by 27.0 mm Hg (to 125.8 mm Hg) in the intervention group and by 9.3 mm Hg (to 145.4 mm Hg) in the control group; the mean reduction was 21.6 mm Hg greater with the intervention (95% confidence interval, 14.7 to 28.4; P<0.001).', 'Among black male barbershop patrons with uncontrolled hypertension, health promotion by barbers resulted in larger blood-pressure reduction when coupled with medication management in barbershops by specialty-trained pharmacists.\tA blood-pressure level of less than 130/80 mm Hg was achieved among 63.6% of the participants in the intervention group versus 11.7% of the participants in the control group (P<0.001).', 'Among black male barbershop patrons with uncontrolled hypertension, health promotion by barbers resulted in larger blood-pressure reduction when coupled with medication management in barbershops by specialty-trained pharmacists.\tIn the intervention group, the rate of cohort retention was 95%, and there were few adverse events (three cases of acute kidney injury).', 'Among black male barbershop patrons with uncontrolled hypertension, health promotion by barbers resulted in larger blood-pressure reduction when coupled with medication management in barbershops by specialty-trained pharmacists.\tAmong black male barbershop patrons with uncontrolled hypertension, health promotion by barbers resulted in larger blood-pressure reduction when coupled with medication management in barbershops by specialty-trained pharmacists.']","[0, 0, 0, 1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]"
"['Hypertension is a generally accepted atherogenic risk factor.\tHypertension is a generally accepted atherogenic risk factor.', 'Hypertension is a generally accepted atherogenic risk factor.\tThe results showed that mean c-IMT z-scores increased significantly during 4 years (0.002 ± 0.003, p < 0.001) as well as carotid-femoral PWV (13.99 ± 2.74, p < 0.01) and total cholesterol (6.97 ± 1.08, p < 0.001).', 'Hypertension is a generally accepted atherogenic risk factor.\tLinear regression showed statistically significant associations between systolic blood pressure, diastolic blood pressure, C-reactive protein, lip-line, and heart rate with c-IMT z-scores of >1.5SD in the fully adjusted models and the p values were 0.000, 0.000, 0.017, 0.001, and 0.044, respectively .', 'Hypertension is a generally accepted atherogenic risk factor.\tIn a full-model logistic regression, significant risk factors for an increase in IMT of ≥1.5 z-scores were carotid-femoral PWV (odds ratio: 1.119, confidence interval: 1.018, 1.230, p = 0.020 < 0.05) at first measurement.', 'Hypertension is a generally accepted atherogenic risk factor.\tThe conclusion of the study was that longitudinal c-IMT measurements revealed progression in subclinical atherosclerosis during a four-year period in a hypertensive old-aged cohort.', 'Hypertension is a generally accepted atherogenic risk factor.\tSystolic or diastolic blood pressure, homocysteine, carotid-femoral PWV, and waistline were significantly related to c-IMT increment.', 'Hypertension is a generally accepted atherogenic risk factor.\tBy lifestyle and medical intervention to control these risk factors may prevent progression of c-IMT in old-aged cohort with hypertension.', 'The results showed that mean c-IMT z-scores increased significantly during 4 years (0.002 ± 0.003, p < 0.001) as well as carotid-femoral PWV (13.99 ± 2.74, p < 0.01) and total cholesterol (6.97 ± 1.08, p < 0.001).\tHypertension is a generally accepted atherogenic risk factor.', 'The results showed that mean c-IMT z-scores increased significantly during 4 years (0.002 ± 0.003, p < 0.001) as well as carotid-femoral PWV (13.99 ± 2.74, p < 0.01) and total cholesterol (6.97 ± 1.08, p < 0.001).\tThe results showed that mean c-IMT z-scores increased significantly during 4 years (0.002 ± 0.003, p < 0.001) as well as carotid-femoral PWV (13.99 ± 2.74, p < 0.01) and total cholesterol (6.97 ± 1.08, p < 0.001).', 'The results showed that mean c-IMT z-scores increased significantly during 4 years (0.002 ± 0.003, p < 0.001) as well as carotid-femoral PWV (13.99 ± 2.74, p < 0.01) and total cholesterol (6.97 ± 1.08, p < 0.001).\tLinear regression showed statistically significant associations between systolic blood pressure, diastolic blood pressure, C-reactive protein, lip-line, and heart rate with c-IMT z-scores of >1.5SD in the fully adjusted models and the p values were 0.000, 0.000, 0.017, 0.001, and 0.044, respectively .', 'The results showed that mean c-IMT z-scores increased significantly during 4 years (0.002 ± 0.003, p < 0.001) as well as carotid-femoral PWV (13.99 ± 2.74, p < 0.01) and total cholesterol (6.97 ± 1.08, p < 0.001).\tIn a full-model logistic regression, significant risk factors for an increase in IMT of ≥1.5 z-scores were carotid-femoral PWV (odds ratio: 1.119, confidence interval: 1.018, 1.230, p = 0.020 < 0.05) at first measurement.', 'The results showed that mean c-IMT z-scores increased significantly during 4 years (0.002 ± 0.003, p < 0.001) as well as carotid-femoral PWV (13.99 ± 2.74, p < 0.01) and total cholesterol (6.97 ± 1.08, p < 0.001).\tThe conclusion of the study was that longitudinal c-IMT measurements revealed progression in subclinical atherosclerosis during a four-year period in a hypertensive old-aged cohort.', 'The results showed that mean c-IMT z-scores increased significantly during 4 years (0.002 ± 0.003, p < 0.001) as well as carotid-femoral PWV (13.99 ± 2.74, p < 0.01) and total cholesterol (6.97 ± 1.08, p < 0.001).\tSystolic or diastolic blood pressure, homocysteine, carotid-femoral PWV, and waistline were significantly related to c-IMT increment.', 'The results showed that mean c-IMT z-scores increased significantly during 4 years (0.002 ± 0.003, p < 0.001) as well as carotid-femoral PWV (13.99 ± 2.74, p < 0.01) and total cholesterol (6.97 ± 1.08, p < 0.001).\tBy lifestyle and medical intervention to control these risk factors may prevent progression of c-IMT in old-aged cohort with hypertension.', 'Linear regression showed statistically significant associations between systolic blood pressure, diastolic blood pressure, C-reactive protein, lip-line, and heart rate with c-IMT z-scores of >1.5SD in the fully adjusted models and the p values were 0.000, 0.000, 0.017, 0.001, and 0.044, respectively .\tHypertension is a generally accepted atherogenic risk factor.', 'Linear regression showed statistically significant associations between systolic blood pressure, diastolic blood pressure, C-reactive protein, lip-line, and heart rate with c-IMT z-scores of >1.5SD in the fully adjusted models and the p values were 0.000, 0.000, 0.017, 0.001, and 0.044, respectively .\tThe results showed that mean c-IMT z-scores increased significantly during 4 years (0.002 ± 0.003, p < 0.001) as well as carotid-femoral PWV (13.99 ± 2.74, p < 0.01) and total cholesterol (6.97 ± 1.08, p < 0.001).', 'Linear regression showed statistically significant associations between systolic blood pressure, diastolic blood pressure, C-reactive protein, lip-line, and heart rate with c-IMT z-scores of >1.5SD in the fully adjusted models and the p values were 0.000, 0.000, 0.017, 0.001, and 0.044, respectively .\tLinear regression showed statistically significant associations between systolic blood pressure, diastolic blood pressure, C-reactive protein, lip-line, and heart rate with c-IMT z-scores of >1.5SD in the fully adjusted models and the p values were 0.000, 0.000, 0.017, 0.001, and 0.044, respectively .', 'Linear regression showed statistically significant associations between systolic blood pressure, diastolic blood pressure, C-reactive protein, lip-line, and heart rate with c-IMT z-scores of >1.5SD in the fully adjusted models and the p values were 0.000, 0.000, 0.017, 0.001, and 0.044, respectively .\tIn a full-model logistic regression, significant risk factors for an increase in IMT of ≥1.5 z-scores were carotid-femoral PWV (odds ratio: 1.119, confidence interval: 1.018, 1.230, p = 0.020 < 0.05) at first measurement.', 'Linear regression showed statistically significant associations between systolic blood pressure, diastolic blood pressure, C-reactive protein, lip-line, and heart rate with c-IMT z-scores of >1.5SD in the fully adjusted models and the p values were 0.000, 0.000, 0.017, 0.001, and 0.044, respectively .\tThe conclusion of the study was that longitudinal c-IMT measurements revealed progression in subclinical atherosclerosis during a four-year period in a hypertensive old-aged cohort.', 'Linear regression showed statistically significant associations between systolic blood pressure, diastolic blood pressure, C-reactive protein, lip-line, and heart rate with c-IMT z-scores of >1.5SD in the fully adjusted models and the p values were 0.000, 0.000, 0.017, 0.001, and 0.044, respectively .\tSystolic or diastolic blood pressure, homocysteine, carotid-femoral PWV, and waistline were significantly related to c-IMT increment.', 'Linear regression showed statistically significant associations between systolic blood pressure, diastolic blood pressure, C-reactive protein, lip-line, and heart rate with c-IMT z-scores of >1.5SD in the fully adjusted models and the p values were 0.000, 0.000, 0.017, 0.001, and 0.044, respectively .\tBy lifestyle and medical intervention to control these risk factors may prevent progression of c-IMT in old-aged cohort with hypertension.', 'In a full-model logistic regression, significant risk factors for an increase in IMT of ≥1.5 z-scores were carotid-femoral PWV (odds ratio: 1.119, confidence interval: 1.018, 1.230, p = 0.020 < 0.05) at first measurement.\tHypertension is a generally accepted atherogenic risk factor.', 'In a full-model logistic regression, significant risk factors for an increase in IMT of ≥1.5 z-scores were carotid-femoral PWV (odds ratio: 1.119, confidence interval: 1.018, 1.230, p = 0.020 < 0.05) at first measurement.\tThe results showed that mean c-IMT z-scores increased significantly during 4 years (0.002 ± 0.003, p < 0.001) as well as carotid-femoral PWV (13.99 ± 2.74, p < 0.01) and total cholesterol (6.97 ± 1.08, p < 0.001).', 'In a full-model logistic regression, significant risk factors for an increase in IMT of ≥1.5 z-scores were carotid-femoral PWV (odds ratio: 1.119, confidence interval: 1.018, 1.230, p = 0.020 < 0.05) at first measurement.\tLinear regression showed statistically significant associations between systolic blood pressure, diastolic blood pressure, C-reactive protein, lip-line, and heart rate with c-IMT z-scores of >1.5SD in the fully adjusted models and the p values were 0.000, 0.000, 0.017, 0.001, and 0.044, respectively .', 'In a full-model logistic regression, significant risk factors for an increase in IMT of ≥1.5 z-scores were carotid-femoral PWV (odds ratio: 1.119, confidence interval: 1.018, 1.230, p = 0.020 < 0.05) at first measurement.\tIn a full-model logistic regression, significant risk factors for an increase in IMT of ≥1.5 z-scores were carotid-femoral PWV (odds ratio: 1.119, confidence interval: 1.018, 1.230, p = 0.020 < 0.05) at first measurement.', 'In a full-model logistic regression, significant risk factors for an increase in IMT of ≥1.5 z-scores were carotid-femoral PWV (odds ratio: 1.119, confidence interval: 1.018, 1.230, p = 0.020 < 0.05) at first measurement.\tThe conclusion of the study was that longitudinal c-IMT measurements revealed progression in subclinical atherosclerosis during a four-year period in a hypertensive old-aged cohort.', 'In a full-model logistic regression, significant risk factors for an increase in IMT of ≥1.5 z-scores were carotid-femoral PWV (odds ratio: 1.119, confidence interval: 1.018, 1.230, p = 0.020 < 0.05) at first measurement.\tSystolic or diastolic blood pressure, homocysteine, carotid-femoral PWV, and waistline were significantly related to c-IMT increment.', 'In a full-model logistic regression, significant risk factors for an increase in IMT of ≥1.5 z-scores were carotid-femoral PWV (odds ratio: 1.119, confidence interval: 1.018, 1.230, p = 0.020 < 0.05) at first measurement.\tBy lifestyle and medical intervention to control these risk factors may prevent progression of c-IMT in old-aged cohort with hypertension.', 'The conclusion of the study was that longitudinal c-IMT measurements revealed progression in subclinical atherosclerosis during a four-year period in a hypertensive old-aged cohort.\tHypertension is a generally accepted atherogenic risk factor.', 'The conclusion of the study was that longitudinal c-IMT measurements revealed progression in subclinical atherosclerosis during a four-year period in a hypertensive old-aged cohort.\tThe results showed that mean c-IMT z-scores increased significantly during 4 years (0.002 ± 0.003, p < 0.001) as well as carotid-femoral PWV (13.99 ± 2.74, p < 0.01) and total cholesterol (6.97 ± 1.08, p < 0.001).', 'The conclusion of the study was that longitudinal c-IMT measurements revealed progression in subclinical atherosclerosis during a four-year period in a hypertensive old-aged cohort.\tLinear regression showed statistically significant associations between systolic blood pressure, diastolic blood pressure, C-reactive protein, lip-line, and heart rate with c-IMT z-scores of >1.5SD in the fully adjusted models and the p values were 0.000, 0.000, 0.017, 0.001, and 0.044, respectively .', 'The conclusion of the study was that longitudinal c-IMT measurements revealed progression in subclinical atherosclerosis during a four-year period in a hypertensive old-aged cohort.\tIn a full-model logistic regression, significant risk factors for an increase in IMT of ≥1.5 z-scores were carotid-femoral PWV (odds ratio: 1.119, confidence interval: 1.018, 1.230, p = 0.020 < 0.05) at first measurement.', 'The conclusion of the study was that longitudinal c-IMT measurements revealed progression in subclinical atherosclerosis during a four-year period in a hypertensive old-aged cohort.\tThe conclusion of the study was that longitudinal c-IMT measurements revealed progression in subclinical atherosclerosis during a four-year period in a hypertensive old-aged cohort.', 'The conclusion of the study was that longitudinal c-IMT measurements revealed progression in subclinical atherosclerosis during a four-year period in a hypertensive old-aged cohort.\tSystolic or diastolic blood pressure, homocysteine, carotid-femoral PWV, and waistline were significantly related to c-IMT increment.', 'The conclusion of the study was that longitudinal c-IMT measurements revealed progression in subclinical atherosclerosis during a four-year period in a hypertensive old-aged cohort.\tBy lifestyle and medical intervention to control these risk factors may prevent progression of c-IMT in old-aged cohort with hypertension.', 'Systolic or diastolic blood pressure, homocysteine, carotid-femoral PWV, and waistline were significantly related to c-IMT increment.\tHypertension is a generally accepted atherogenic risk factor.', 'Systolic or diastolic blood pressure, homocysteine, carotid-femoral PWV, and waistline were significantly related to c-IMT increment.\tThe results showed that mean c-IMT z-scores increased significantly during 4 years (0.002 ± 0.003, p < 0.001) as well as carotid-femoral PWV (13.99 ± 2.74, p < 0.01) and total cholesterol (6.97 ± 1.08, p < 0.001).', 'Systolic or diastolic blood pressure, homocysteine, carotid-femoral PWV, and waistline were significantly related to c-IMT increment.\tLinear regression showed statistically significant associations between systolic blood pressure, diastolic blood pressure, C-reactive protein, lip-line, and heart rate with c-IMT z-scores of >1.5SD in the fully adjusted models and the p values were 0.000, 0.000, 0.017, 0.001, and 0.044, respectively .', 'Systolic or diastolic blood pressure, homocysteine, carotid-femoral PWV, and waistline were significantly related to c-IMT increment.\tIn a full-model logistic regression, significant risk factors for an increase in IMT of ≥1.5 z-scores were carotid-femoral PWV (odds ratio: 1.119, confidence interval: 1.018, 1.230, p = 0.020 < 0.05) at first measurement.', 'Systolic or diastolic blood pressure, homocysteine, carotid-femoral PWV, and waistline were significantly related to c-IMT increment.\tThe conclusion of the study was that longitudinal c-IMT measurements revealed progression in subclinical atherosclerosis during a four-year period in a hypertensive old-aged cohort.', 'Systolic or diastolic blood pressure, homocysteine, carotid-femoral PWV, and waistline were significantly related to c-IMT increment.\tSystolic or diastolic blood pressure, homocysteine, carotid-femoral PWV, and waistline were significantly related to c-IMT increment.', 'Systolic or diastolic blood pressure, homocysteine, carotid-femoral PWV, and waistline were significantly related to c-IMT increment.\tBy lifestyle and medical intervention to control these risk factors may prevent progression of c-IMT in old-aged cohort with hypertension.', 'By lifestyle and medical intervention to control these risk factors may prevent progression of c-IMT in old-aged cohort with hypertension.\tHypertension is a generally accepted atherogenic risk factor.', 'By lifestyle and medical intervention to control these risk factors may prevent progression of c-IMT in old-aged cohort with hypertension.\tThe results showed that mean c-IMT z-scores increased significantly during 4 years (0.002 ± 0.003, p < 0.001) as well as carotid-femoral PWV (13.99 ± 2.74, p < 0.01) and total cholesterol (6.97 ± 1.08, p < 0.001).', 'By lifestyle and medical intervention to control these risk factors may prevent progression of c-IMT in old-aged cohort with hypertension.\tLinear regression showed statistically significant associations between systolic blood pressure, diastolic blood pressure, C-reactive protein, lip-line, and heart rate with c-IMT z-scores of >1.5SD in the fully adjusted models and the p values were 0.000, 0.000, 0.017, 0.001, and 0.044, respectively .', 'By lifestyle and medical intervention to control these risk factors may prevent progression of c-IMT in old-aged cohort with hypertension.\tIn a full-model logistic regression, significant risk factors for an increase in IMT of ≥1.5 z-scores were carotid-femoral PWV (odds ratio: 1.119, confidence interval: 1.018, 1.230, p = 0.020 < 0.05) at first measurement.', 'By lifestyle and medical intervention to control these risk factors may prevent progression of c-IMT in old-aged cohort with hypertension.\tThe conclusion of the study was that longitudinal c-IMT measurements revealed progression in subclinical atherosclerosis during a four-year period in a hypertensive old-aged cohort.', 'By lifestyle and medical intervention to control these risk factors may prevent progression of c-IMT in old-aged cohort with hypertension.\tSystolic or diastolic blood pressure, homocysteine, carotid-femoral PWV, and waistline were significantly related to c-IMT increment.', 'By lifestyle and medical intervention to control these risk factors may prevent progression of c-IMT in old-aged cohort with hypertension.\tBy lifestyle and medical intervention to control these risk factors may prevent progression of c-IMT in old-aged cohort with hypertension.']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['At two year follow-up there was a significant group by time interaction showing lower Center for Epidemiological Studies-Depression (CESD) scores in the SSRI + CCB group, F(1,291) = 4.13, p = 0.043, η2 p = 0.014.\tAt two year follow-up there was a significant group by time interaction showing lower Center for Epidemiological Studies-Depression (CESD) scores in the SSRI + CCB group, F(1,291) = 4.13, p = 0.043, η2 p = 0.014.', 'At two year follow-up there was a significant group by time interaction showing lower Center for Epidemiological Studies-Depression (CESD) scores in the SSRI + CCB group, F(1,291) = 4.13, p = 0.043, η2 p = 0.014.\tOver ten-years follow-up, SSRI + CCB use was associated with improved general cognitive function (Mini-Mental State Examination: β = 0.97; 95% CI 0.14 to 1.81, p = 0.023) and immediate visual memory (Boston Visual Retention Test: β = 0.69; 95% CI 0.06 to 1.32, p = 0.033).', 'At two year follow-up there was a significant group by time interaction showing lower Center for Epidemiological Studies-Depression (CESD) scores in the SSRI + CCB group, F(1,291) = 4.13, p = 0.043, η2 p = 0.014.\tThe findings provide general population evidence that SSRI augmentation with CCB may improve depression and cognitive function.', 'Over ten-years follow-up, SSRI + CCB use was associated with improved general cognitive function (Mini-Mental State Examination: β = 0.97; 95% CI 0.14 to 1.81, p = 0.023) and immediate visual memory (Boston Visual Retention Test: β = 0.69; 95% CI 0.06 to 1.32, p = 0.033).\tAt two year follow-up there was a significant group by time interaction showing lower Center for Epidemiological Studies-Depression (CESD) scores in the SSRI + CCB group, F(1,291) = 4.13, p = 0.043, η2 p = 0.014.', 'Over ten-years follow-up, SSRI + CCB use was associated with improved general cognitive function (Mini-Mental State Examination: β = 0.97; 95% CI 0.14 to 1.81, p = 0.023) and immediate visual memory (Boston Visual Retention Test: β = 0.69; 95% CI 0.06 to 1.32, p = 0.033).\tOver ten-years follow-up, SSRI + CCB use was associated with improved general cognitive function (Mini-Mental State Examination: β = 0.97; 95% CI 0.14 to 1.81, p = 0.023) and immediate visual memory (Boston Visual Retention Test: β = 0.69; 95% CI 0.06 to 1.32, p = 0.033).', 'Over ten-years follow-up, SSRI + CCB use was associated with improved general cognitive function (Mini-Mental State Examination: β = 0.97; 95% CI 0.14 to 1.81, p = 0.023) and immediate visual memory (Boston Visual Retention Test: β = 0.69; 95% CI 0.06 to 1.32, p = 0.033).\tThe findings provide general population evidence that SSRI augmentation with CCB may improve depression and cognitive function.', 'The findings provide general population evidence that SSRI augmentation with CCB may improve depression and cognitive function.\tAt two year follow-up there was a significant group by time interaction showing lower Center for Epidemiological Studies-Depression (CESD) scores in the SSRI + CCB group, F(1,291) = 4.13, p = 0.043, η2 p = 0.014.', 'The findings provide general population evidence that SSRI augmentation with CCB may improve depression and cognitive function.\tOver ten-years follow-up, SSRI + CCB use was associated with improved general cognitive function (Mini-Mental State Examination: β = 0.97; 95% CI 0.14 to 1.81, p = 0.023) and immediate visual memory (Boston Visual Retention Test: β = 0.69; 95% CI 0.06 to 1.32, p = 0.033).', 'The findings provide general population evidence that SSRI augmentation with CCB may improve depression and cognitive function.\tThe findings provide general population evidence that SSRI augmentation with CCB may improve depression and cognitive function.']","[0, 0, 1, 0, 0, 1, 0, 0, 0]"
"['Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.\tSodium nitrite has been reported to be effective in reducing chronic peripheral pain.', 'Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.\tThere were no reports of treatment-related headaches.', 'Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.\tThe number of subjects reporting adverse events and the number of adverse events did not change with dose.', 'Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.\tIn the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.', 'Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.\tthe 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,', 'Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.\tthe mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.', 'Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.\tPatients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.', 'Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.\tNo changes were observed in HbA1c levels or PulseOx.', 'Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.\tIn a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.', 'Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.\tThe ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.', 'Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.\tThe 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.', 'Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.\tSustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.', 'There were no reports of treatment-related headaches.\tSodium nitrite has been reported to be effective in reducing chronic peripheral pain.', 'There were no reports of treatment-related headaches.\tThere were no reports of treatment-related headaches.', 'There were no reports of treatment-related headaches.\tThe number of subjects reporting adverse events and the number of adverse events did not change with dose.', 'There were no reports of treatment-related headaches.\tIn the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.', 'There were no reports of treatment-related headaches.\tthe 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,', 'There were no reports of treatment-related headaches.\tthe mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.', 'There were no reports of treatment-related headaches.\tPatients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.', 'There were no reports of treatment-related headaches.\tNo changes were observed in HbA1c levels or PulseOx.', 'There were no reports of treatment-related headaches.\tIn a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.', 'There were no reports of treatment-related headaches.\tThe ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.', 'There were no reports of treatment-related headaches.\tThe 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.', 'There were no reports of treatment-related headaches.\tSustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.', 'The number of subjects reporting adverse events and the number of adverse events did not change with dose.\tSodium nitrite has been reported to be effective in reducing chronic peripheral pain.', 'The number of subjects reporting adverse events and the number of adverse events did not change with dose.\tThere were no reports of treatment-related headaches.', 'The number of subjects reporting adverse events and the number of adverse events did not change with dose.\tThe number of subjects reporting adverse events and the number of adverse events did not change with dose.', 'The number of subjects reporting adverse events and the number of adverse events did not change with dose.\tIn the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.', 'The number of subjects reporting adverse events and the number of adverse events did not change with dose.\tthe 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,', 'The number of subjects reporting adverse events and the number of adverse events did not change with dose.\tthe mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.', 'The number of subjects reporting adverse events and the number of adverse events did not change with dose.\tPatients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.', 'The number of subjects reporting adverse events and the number of adverse events did not change with dose.\tNo changes were observed in HbA1c levels or PulseOx.', 'The number of subjects reporting adverse events and the number of adverse events did not change with dose.\tIn a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.', 'The number of subjects reporting adverse events and the number of adverse events did not change with dose.\tThe ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.', 'The number of subjects reporting adverse events and the number of adverse events did not change with dose.\tThe 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.', 'The number of subjects reporting adverse events and the number of adverse events did not change with dose.\tSustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.', 'In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.\tSodium nitrite has been reported to be effective in reducing chronic peripheral pain.', 'In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.\tThere were no reports of treatment-related headaches.', 'In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.\tThe number of subjects reporting adverse events and the number of adverse events did not change with dose.', 'In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.\tIn the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.', 'In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.\tthe 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,', 'In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.\tthe mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.', 'In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.\tPatients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.', 'In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.\tNo changes were observed in HbA1c levels or PulseOx.', 'In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.\tIn a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.', 'In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.\tThe ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.', 'In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.\tThe 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.', 'In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.\tSustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.', 'the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,\tSodium nitrite has been reported to be effective in reducing chronic peripheral pain.', 'the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,\tThere were no reports of treatment-related headaches.', 'the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,\tThe number of subjects reporting adverse events and the number of adverse events did not change with dose.', 'the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,\tIn the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.', 'the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,\tthe 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,', 'the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,\tthe mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.', 'the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,\tPatients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.', 'the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,\tNo changes were observed in HbA1c levels or PulseOx.', 'the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,\tIn a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.', 'the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,\tThe ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.', 'the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,\tThe 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.', 'the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,\tSustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.', 'the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.\tSodium nitrite has been reported to be effective in reducing chronic peripheral pain.', 'the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.\tThere were no reports of treatment-related headaches.', 'the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.\tThe number of subjects reporting adverse events and the number of adverse events did not change with dose.', 'the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.\tIn the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.', 'the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.\tthe 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,', 'the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.\tthe mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.', 'the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.\tPatients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.', 'the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.\tNo changes were observed in HbA1c levels or PulseOx.', 'the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.\tIn a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.', 'the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.\tThe ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.', 'the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.\tThe 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.', 'the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.\tSustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.', 'Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.\tSodium nitrite has been reported to be effective in reducing chronic peripheral pain.', 'Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.\tThere were no reports of treatment-related headaches.', 'Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.\tThe number of subjects reporting adverse events and the number of adverse events did not change with dose.', 'Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.\tIn the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.', 'Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.\tthe 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,', 'Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.\tthe mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.', 'Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.\tPatients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.', 'Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.\tNo changes were observed in HbA1c levels or PulseOx.', 'Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.\tIn a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.', 'Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.\tThe ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.', 'Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.\tThe 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.', 'Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.\tSustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.', 'No changes were observed in HbA1c levels or PulseOx.\tSodium nitrite has been reported to be effective in reducing chronic peripheral pain.', 'No changes were observed in HbA1c levels or PulseOx.\tThere were no reports of treatment-related headaches.', 'No changes were observed in HbA1c levels or PulseOx.\tThe number of subjects reporting adverse events and the number of adverse events did not change with dose.', 'No changes were observed in HbA1c levels or PulseOx.\tIn the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.', 'No changes were observed in HbA1c levels or PulseOx.\tthe 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,', 'No changes were observed in HbA1c levels or PulseOx.\tthe mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.', 'No changes were observed in HbA1c levels or PulseOx.\tPatients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.', 'No changes were observed in HbA1c levels or PulseOx.\tNo changes were observed in HbA1c levels or PulseOx.', 'No changes were observed in HbA1c levels or PulseOx.\tIn a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.', 'No changes were observed in HbA1c levels or PulseOx.\tThe ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.', 'No changes were observed in HbA1c levels or PulseOx.\tThe 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.', 'No changes were observed in HbA1c levels or PulseOx.\tSustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.', 'In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.\tSodium nitrite has been reported to be effective in reducing chronic peripheral pain.', 'In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.\tThere were no reports of treatment-related headaches.', 'In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.\tThe number of subjects reporting adverse events and the number of adverse events did not change with dose.', 'In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.\tIn the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.', 'In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.\tthe 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,', 'In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.\tthe mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.', 'In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.\tPatients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.', 'In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.\tNo changes were observed in HbA1c levels or PulseOx.', 'In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.\tIn a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.', 'In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.\tThe ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.', 'In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.\tThe 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.', 'In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.\tSustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.', 'The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.\tSodium nitrite has been reported to be effective in reducing chronic peripheral pain.', 'The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.\tThere were no reports of treatment-related headaches.', 'The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.\tThe number of subjects reporting adverse events and the number of adverse events did not change with dose.', 'The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.\tIn the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.', 'The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.\tthe 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,', 'The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.\tthe mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.', 'The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.\tPatients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.', 'The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.\tNo changes were observed in HbA1c levels or PulseOx.', 'The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.\tIn a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.', 'The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.\tThe ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.', 'The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.\tThe 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.', 'The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.\tSustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.', 'The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.\tSodium nitrite has been reported to be effective in reducing chronic peripheral pain.', 'The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.\tThere were no reports of treatment-related headaches.', 'The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.\tThe number of subjects reporting adverse events and the number of adverse events did not change with dose.', 'The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.\tIn the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.', 'The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.\tthe 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,', 'The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.\tthe mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.', 'The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.\tPatients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.', 'The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.\tNo changes were observed in HbA1c levels or PulseOx.', 'The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.\tIn a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.', 'The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.\tThe ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.', 'The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.\tThe 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.', 'The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.\tSustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.', 'Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.\tSodium nitrite has been reported to be effective in reducing chronic peripheral pain.', 'Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.\tThere were no reports of treatment-related headaches.', 'Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.\tThe number of subjects reporting adverse events and the number of adverse events did not change with dose.', 'Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.\tIn the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.', 'Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.\tthe 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,', 'Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.\tthe mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.', 'Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.\tPatients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.', 'Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.\tNo changes were observed in HbA1c levels or PulseOx.', 'Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.\tIn a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.', 'Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.\tThe ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.', 'Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.\tThe 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.', 'Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.\tSustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['vitamin C and/or E improve fasting blood sugar (FBS), HbA1c, lipid profile, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), reduced glutathione (GSH); and Quantitative Insulin Sensitivity Check Index (QISCI) compared with diabetic patients group that received placebo.\tvitamin C and/or E improve fasting blood sugar (FBS), HbA1c, lipid profile, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), reduced glutathione (GSH); and Quantitative Insulin Sensitivity Check Index (QISCI) compared with diabetic patients group that received placebo.', 'vitamin C and/or E improve fasting blood sugar (FBS), HbA1c, lipid profile, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), reduced glutathione (GSH); and Quantitative Insulin Sensitivity Check Index (QISCI) compared with diabetic patients group that received placebo.\tthere has been an increasing interest in the influence of antioxidant vitamins on the efficacy of oral hypoglycemic therapy in type 2 diabetic patients (T2DM).', 'vitamin C and/or E improve fasting blood sugar (FBS), HbA1c, lipid profile, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), reduced glutathione (GSH); and Quantitative Insulin Sensitivity Check Index (QISCI) compared with diabetic patients group that received placebo.\tThis study provided additional evidence on the beneficial effects of supplementing antioxidant vitamins in T2DM which could improve the clinical condition and attenuate or prevent diabetic pathogenesis and complications that, secondly to poor glycemic control, could attribute to the imbalance between the decline in the endogenous antioxidants and increasing production of the reactive oxygen species leading to the oxidant-mediated damage present in the diabetic context.', 'there has been an increasing interest in the influence of antioxidant vitamins on the efficacy of oral hypoglycemic therapy in type 2 diabetic patients (T2DM).\tvitamin C and/or E improve fasting blood sugar (FBS), HbA1c, lipid profile, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), reduced glutathione (GSH); and Quantitative Insulin Sensitivity Check Index (QISCI) compared with diabetic patients group that received placebo.', 'there has been an increasing interest in the influence of antioxidant vitamins on the efficacy of oral hypoglycemic therapy in type 2 diabetic patients (T2DM).\tthere has been an increasing interest in the influence of antioxidant vitamins on the efficacy of oral hypoglycemic therapy in type 2 diabetic patients (T2DM).', 'there has been an increasing interest in the influence of antioxidant vitamins on the efficacy of oral hypoglycemic therapy in type 2 diabetic patients (T2DM).\tThis study provided additional evidence on the beneficial effects of supplementing antioxidant vitamins in T2DM which could improve the clinical condition and attenuate or prevent diabetic pathogenesis and complications that, secondly to poor glycemic control, could attribute to the imbalance between the decline in the endogenous antioxidants and increasing production of the reactive oxygen species leading to the oxidant-mediated damage present in the diabetic context.', 'This study provided additional evidence on the beneficial effects of supplementing antioxidant vitamins in T2DM which could improve the clinical condition and attenuate or prevent diabetic pathogenesis and complications that, secondly to poor glycemic control, could attribute to the imbalance between the decline in the endogenous antioxidants and increasing production of the reactive oxygen species leading to the oxidant-mediated damage present in the diabetic context.\tvitamin C and/or E improve fasting blood sugar (FBS), HbA1c, lipid profile, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), reduced glutathione (GSH); and Quantitative Insulin Sensitivity Check Index (QISCI) compared with diabetic patients group that received placebo.', 'This study provided additional evidence on the beneficial effects of supplementing antioxidant vitamins in T2DM which could improve the clinical condition and attenuate or prevent diabetic pathogenesis and complications that, secondly to poor glycemic control, could attribute to the imbalance between the decline in the endogenous antioxidants and increasing production of the reactive oxygen species leading to the oxidant-mediated damage present in the diabetic context.\tthere has been an increasing interest in the influence of antioxidant vitamins on the efficacy of oral hypoglycemic therapy in type 2 diabetic patients (T2DM).', 'This study provided additional evidence on the beneficial effects of supplementing antioxidant vitamins in T2DM which could improve the clinical condition and attenuate or prevent diabetic pathogenesis and complications that, secondly to poor glycemic control, could attribute to the imbalance between the decline in the endogenous antioxidants and increasing production of the reactive oxygen species leading to the oxidant-mediated damage present in the diabetic context.\tThis study provided additional evidence on the beneficial effects of supplementing antioxidant vitamins in T2DM which could improve the clinical condition and attenuate or prevent diabetic pathogenesis and complications that, secondly to poor glycemic control, could attribute to the imbalance between the decline in the endogenous antioxidants and increasing production of the reactive oxygen species leading to the oxidant-mediated damage present in the diabetic context.']","[0, 0, 1, 0, 0, 0, 0, 0, 0]"
"['Observational data support a role for vitamin D in type 2 diabetes,\tObservational data support a role for vitamin D in type 2 diabetes,', 'Observational data support a role for vitamin D in type 2 diabetes,\tbut evidence from trials is inconclusive.', 'Observational data support a role for vitamin D in type 2 diabetes,\tAt week 24, mean 25(OH)D changed by 20.5 and -1.6 ng/mL in the vitamin D and placebo groups, respectively (P < 0.001).', 'Observational data support a role for vitamin D in type 2 diabetes,\tThe vitamin D and placebo groups did not differ in change in ISR or HbA1c.', 'Observational data support a role for vitamin D in type 2 diabetes,\tAmong patients treated with lifestyle only (n = 28), vitamin D supplementation reduced HbA1c compared with placebo (-0.1% vs 0.3%, respectively; P = 0.034) at week 24.', 'Observational data support a role for vitamin D in type 2 diabetes,\tVitamin D3 at 4000 IU/d did not change ISR or HbA1c in patients with well-controlled type 2 diabetes on metformin not selected for vitamin D deficiency.', 'but evidence from trials is inconclusive.\tObservational data support a role for vitamin D in type 2 diabetes,', 'but evidence from trials is inconclusive.\tbut evidence from trials is inconclusive.', 'but evidence from trials is inconclusive.\tAt week 24, mean 25(OH)D changed by 20.5 and -1.6 ng/mL in the vitamin D and placebo groups, respectively (P < 0.001).', 'but evidence from trials is inconclusive.\tThe vitamin D and placebo groups did not differ in change in ISR or HbA1c.', 'but evidence from trials is inconclusive.\tAmong patients treated with lifestyle only (n = 28), vitamin D supplementation reduced HbA1c compared with placebo (-0.1% vs 0.3%, respectively; P = 0.034) at week 24.', 'but evidence from trials is inconclusive.\tVitamin D3 at 4000 IU/d did not change ISR or HbA1c in patients with well-controlled type 2 diabetes on metformin not selected for vitamin D deficiency.', 'At week 24, mean 25(OH)D changed by 20.5 and -1.6 ng/mL in the vitamin D and placebo groups, respectively (P < 0.001).\tObservational data support a role for vitamin D in type 2 diabetes,', 'At week 24, mean 25(OH)D changed by 20.5 and -1.6 ng/mL in the vitamin D and placebo groups, respectively (P < 0.001).\tbut evidence from trials is inconclusive.', 'At week 24, mean 25(OH)D changed by 20.5 and -1.6 ng/mL in the vitamin D and placebo groups, respectively (P < 0.001).\tAt week 24, mean 25(OH)D changed by 20.5 and -1.6 ng/mL in the vitamin D and placebo groups, respectively (P < 0.001).', 'At week 24, mean 25(OH)D changed by 20.5 and -1.6 ng/mL in the vitamin D and placebo groups, respectively (P < 0.001).\tThe vitamin D and placebo groups did not differ in change in ISR or HbA1c.', 'At week 24, mean 25(OH)D changed by 20.5 and -1.6 ng/mL in the vitamin D and placebo groups, respectively (P < 0.001).\tAmong patients treated with lifestyle only (n = 28), vitamin D supplementation reduced HbA1c compared with placebo (-0.1% vs 0.3%, respectively; P = 0.034) at week 24.', 'At week 24, mean 25(OH)D changed by 20.5 and -1.6 ng/mL in the vitamin D and placebo groups, respectively (P < 0.001).\tVitamin D3 at 4000 IU/d did not change ISR or HbA1c in patients with well-controlled type 2 diabetes on metformin not selected for vitamin D deficiency.', 'The vitamin D and placebo groups did not differ in change in ISR or HbA1c.\tObservational data support a role for vitamin D in type 2 diabetes,', 'The vitamin D and placebo groups did not differ in change in ISR or HbA1c.\tbut evidence from trials is inconclusive.', 'The vitamin D and placebo groups did not differ in change in ISR or HbA1c.\tAt week 24, mean 25(OH)D changed by 20.5 and -1.6 ng/mL in the vitamin D and placebo groups, respectively (P < 0.001).', 'The vitamin D and placebo groups did not differ in change in ISR or HbA1c.\tThe vitamin D and placebo groups did not differ in change in ISR or HbA1c.', 'The vitamin D and placebo groups did not differ in change in ISR or HbA1c.\tAmong patients treated with lifestyle only (n = 28), vitamin D supplementation reduced HbA1c compared with placebo (-0.1% vs 0.3%, respectively; P = 0.034) at week 24.', 'The vitamin D and placebo groups did not differ in change in ISR or HbA1c.\tVitamin D3 at 4000 IU/d did not change ISR or HbA1c in patients with well-controlled type 2 diabetes on metformin not selected for vitamin D deficiency.', 'Among patients treated with lifestyle only (n = 28), vitamin D supplementation reduced HbA1c compared with placebo (-0.1% vs 0.3%, respectively; P = 0.034) at week 24.\tObservational data support a role for vitamin D in type 2 diabetes,', 'Among patients treated with lifestyle only (n = 28), vitamin D supplementation reduced HbA1c compared with placebo (-0.1% vs 0.3%, respectively; P = 0.034) at week 24.\tbut evidence from trials is inconclusive.', 'Among patients treated with lifestyle only (n = 28), vitamin D supplementation reduced HbA1c compared with placebo (-0.1% vs 0.3%, respectively; P = 0.034) at week 24.\tAt week 24, mean 25(OH)D changed by 20.5 and -1.6 ng/mL in the vitamin D and placebo groups, respectively (P < 0.001).', 'Among patients treated with lifestyle only (n = 28), vitamin D supplementation reduced HbA1c compared with placebo (-0.1% vs 0.3%, respectively; P = 0.034) at week 24.\tThe vitamin D and placebo groups did not differ in change in ISR or HbA1c.', 'Among patients treated with lifestyle only (n = 28), vitamin D supplementation reduced HbA1c compared with placebo (-0.1% vs 0.3%, respectively; P = 0.034) at week 24.\tAmong patients treated with lifestyle only (n = 28), vitamin D supplementation reduced HbA1c compared with placebo (-0.1% vs 0.3%, respectively; P = 0.034) at week 24.', 'Among patients treated with lifestyle only (n = 28), vitamin D supplementation reduced HbA1c compared with placebo (-0.1% vs 0.3%, respectively; P = 0.034) at week 24.\tVitamin D3 at 4000 IU/d did not change ISR or HbA1c in patients with well-controlled type 2 diabetes on metformin not selected for vitamin D deficiency.', 'Vitamin D3 at 4000 IU/d did not change ISR or HbA1c in patients with well-controlled type 2 diabetes on metformin not selected for vitamin D deficiency.\tObservational data support a role for vitamin D in type 2 diabetes,', 'Vitamin D3 at 4000 IU/d did not change ISR or HbA1c in patients with well-controlled type 2 diabetes on metformin not selected for vitamin D deficiency.\tbut evidence from trials is inconclusive.', 'Vitamin D3 at 4000 IU/d did not change ISR or HbA1c in patients with well-controlled type 2 diabetes on metformin not selected for vitamin D deficiency.\tAt week 24, mean 25(OH)D changed by 20.5 and -1.6 ng/mL in the vitamin D and placebo groups, respectively (P < 0.001).', 'Vitamin D3 at 4000 IU/d did not change ISR or HbA1c in patients with well-controlled type 2 diabetes on metformin not selected for vitamin D deficiency.\tThe vitamin D and placebo groups did not differ in change in ISR or HbA1c.', 'Vitamin D3 at 4000 IU/d did not change ISR or HbA1c in patients with well-controlled type 2 diabetes on metformin not selected for vitamin D deficiency.\tAmong patients treated with lifestyle only (n = 28), vitamin D supplementation reduced HbA1c compared with placebo (-0.1% vs 0.3%, respectively; P = 0.034) at week 24.', 'Vitamin D3 at 4000 IU/d did not change ISR or HbA1c in patients with well-controlled type 2 diabetes on metformin not selected for vitamin D deficiency.\tVitamin D3 at 4000 IU/d did not change ISR or HbA1c in patients with well-controlled type 2 diabetes on metformin not selected for vitamin D deficiency.']","[0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['Methionine aminopeptidase 2 (MetAP2) inhibition has been shown to result in significant weight loss and improved glucose control.\tMethionine aminopeptidase 2 (MetAP2) inhibition has been shown to result in significant weight loss and improved glucose control.', 'Methionine aminopeptidase 2 (MetAP2) inhibition has been shown to result in significant weight loss and improved glucose control.\tZGN-1061 was well tolerated across all doses with most frequent adverse events of mild headache and procedural-related irritation.', 'Methionine aminopeptidase 2 (MetAP2) inhibition has been shown to result in significant weight loss and improved glucose control.\tAll doses of ZGN-1061 were rapidly absorbed and cleared, resulting in short duration of exposure that is anticipated to minimize potential off-drug target risks.', 'Methionine aminopeptidase 2 (MetAP2) inhibition has been shown to result in significant weight loss and improved glucose control.\tSafety observations were consistent with SAD findings.', 'Methionine aminopeptidase 2 (MetAP2) inhibition has been shown to result in significant weight loss and improved glucose control.\tEfficacy measures in the MAD phase indicated trends for weight change (-1.5 kg total ZGN-1061 vs -0.2 kg placebo) and other biomarker changes.', 'Methionine aminopeptidase 2 (MetAP2) inhibition has been shown to result in significant weight loss and improved glucose control.\tZGN-1061 was well tolerated with no safety signals in all doses tested.', 'Methionine aminopeptidase 2 (MetAP2) inhibition has been shown to result in significant weight loss and improved glucose control.\tthe desired pharmacokinetic profile and preliminary efficacy observations with ZGN-1061 support evaluation in larger and longer clinical trials.', 'ZGN-1061 was well tolerated across all doses with most frequent adverse events of mild headache and procedural-related irritation.\tMethionine aminopeptidase 2 (MetAP2) inhibition has been shown to result in significant weight loss and improved glucose control.', 'ZGN-1061 was well tolerated across all doses with most frequent adverse events of mild headache and procedural-related irritation.\tZGN-1061 was well tolerated across all doses with most frequent adverse events of mild headache and procedural-related irritation.', 'ZGN-1061 was well tolerated across all doses with most frequent adverse events of mild headache and procedural-related irritation.\tAll doses of ZGN-1061 were rapidly absorbed and cleared, resulting in short duration of exposure that is anticipated to minimize potential off-drug target risks.', 'ZGN-1061 was well tolerated across all doses with most frequent adverse events of mild headache and procedural-related irritation.\tSafety observations were consistent with SAD findings.', 'ZGN-1061 was well tolerated across all doses with most frequent adverse events of mild headache and procedural-related irritation.\tEfficacy measures in the MAD phase indicated trends for weight change (-1.5 kg total ZGN-1061 vs -0.2 kg placebo) and other biomarker changes.', 'ZGN-1061 was well tolerated across all doses with most frequent adverse events of mild headache and procedural-related irritation.\tZGN-1061 was well tolerated with no safety signals in all doses tested.', 'ZGN-1061 was well tolerated across all doses with most frequent adverse events of mild headache and procedural-related irritation.\tthe desired pharmacokinetic profile and preliminary efficacy observations with ZGN-1061 support evaluation in larger and longer clinical trials.', 'All doses of ZGN-1061 were rapidly absorbed and cleared, resulting in short duration of exposure that is anticipated to minimize potential off-drug target risks.\tMethionine aminopeptidase 2 (MetAP2) inhibition has been shown to result in significant weight loss and improved glucose control.', 'All doses of ZGN-1061 were rapidly absorbed and cleared, resulting in short duration of exposure that is anticipated to minimize potential off-drug target risks.\tZGN-1061 was well tolerated across all doses with most frequent adverse events of mild headache and procedural-related irritation.', 'All doses of ZGN-1061 were rapidly absorbed and cleared, resulting in short duration of exposure that is anticipated to minimize potential off-drug target risks.\tAll doses of ZGN-1061 were rapidly absorbed and cleared, resulting in short duration of exposure that is anticipated to minimize potential off-drug target risks.', 'All doses of ZGN-1061 were rapidly absorbed and cleared, resulting in short duration of exposure that is anticipated to minimize potential off-drug target risks.\tSafety observations were consistent with SAD findings.', 'All doses of ZGN-1061 were rapidly absorbed and cleared, resulting in short duration of exposure that is anticipated to minimize potential off-drug target risks.\tEfficacy measures in the MAD phase indicated trends for weight change (-1.5 kg total ZGN-1061 vs -0.2 kg placebo) and other biomarker changes.', 'All doses of ZGN-1061 were rapidly absorbed and cleared, resulting in short duration of exposure that is anticipated to minimize potential off-drug target risks.\tZGN-1061 was well tolerated with no safety signals in all doses tested.', 'All doses of ZGN-1061 were rapidly absorbed and cleared, resulting in short duration of exposure that is anticipated to minimize potential off-drug target risks.\tthe desired pharmacokinetic profile and preliminary efficacy observations with ZGN-1061 support evaluation in larger and longer clinical trials.', 'Safety observations were consistent with SAD findings.\tMethionine aminopeptidase 2 (MetAP2) inhibition has been shown to result in significant weight loss and improved glucose control.', 'Safety observations were consistent with SAD findings.\tZGN-1061 was well tolerated across all doses with most frequent adverse events of mild headache and procedural-related irritation.', 'Safety observations were consistent with SAD findings.\tAll doses of ZGN-1061 were rapidly absorbed and cleared, resulting in short duration of exposure that is anticipated to minimize potential off-drug target risks.', 'Safety observations were consistent with SAD findings.\tSafety observations were consistent with SAD findings.', 'Safety observations were consistent with SAD findings.\tEfficacy measures in the MAD phase indicated trends for weight change (-1.5 kg total ZGN-1061 vs -0.2 kg placebo) and other biomarker changes.', 'Safety observations were consistent with SAD findings.\tZGN-1061 was well tolerated with no safety signals in all doses tested.', 'Safety observations were consistent with SAD findings.\tthe desired pharmacokinetic profile and preliminary efficacy observations with ZGN-1061 support evaluation in larger and longer clinical trials.', 'Efficacy measures in the MAD phase indicated trends for weight change (-1.5 kg total ZGN-1061 vs -0.2 kg placebo) and other biomarker changes.\tMethionine aminopeptidase 2 (MetAP2) inhibition has been shown to result in significant weight loss and improved glucose control.', 'Efficacy measures in the MAD phase indicated trends for weight change (-1.5 kg total ZGN-1061 vs -0.2 kg placebo) and other biomarker changes.\tZGN-1061 was well tolerated across all doses with most frequent adverse events of mild headache and procedural-related irritation.', 'Efficacy measures in the MAD phase indicated trends for weight change (-1.5 kg total ZGN-1061 vs -0.2 kg placebo) and other biomarker changes.\tAll doses of ZGN-1061 were rapidly absorbed and cleared, resulting in short duration of exposure that is anticipated to minimize potential off-drug target risks.', 'Efficacy measures in the MAD phase indicated trends for weight change (-1.5 kg total ZGN-1061 vs -0.2 kg placebo) and other biomarker changes.\tSafety observations were consistent with SAD findings.', 'Efficacy measures in the MAD phase indicated trends for weight change (-1.5 kg total ZGN-1061 vs -0.2 kg placebo) and other biomarker changes.\tEfficacy measures in the MAD phase indicated trends for weight change (-1.5 kg total ZGN-1061 vs -0.2 kg placebo) and other biomarker changes.', 'Efficacy measures in the MAD phase indicated trends for weight change (-1.5 kg total ZGN-1061 vs -0.2 kg placebo) and other biomarker changes.\tZGN-1061 was well tolerated with no safety signals in all doses tested.', 'Efficacy measures in the MAD phase indicated trends for weight change (-1.5 kg total ZGN-1061 vs -0.2 kg placebo) and other biomarker changes.\tthe desired pharmacokinetic profile and preliminary efficacy observations with ZGN-1061 support evaluation in larger and longer clinical trials.', 'ZGN-1061 was well tolerated with no safety signals in all doses tested.\tMethionine aminopeptidase 2 (MetAP2) inhibition has been shown to result in significant weight loss and improved glucose control.', 'ZGN-1061 was well tolerated with no safety signals in all doses tested.\tZGN-1061 was well tolerated across all doses with most frequent adverse events of mild headache and procedural-related irritation.', 'ZGN-1061 was well tolerated with no safety signals in all doses tested.\tAll doses of ZGN-1061 were rapidly absorbed and cleared, resulting in short duration of exposure that is anticipated to minimize potential off-drug target risks.', 'ZGN-1061 was well tolerated with no safety signals in all doses tested.\tSafety observations were consistent with SAD findings.', 'ZGN-1061 was well tolerated with no safety signals in all doses tested.\tEfficacy measures in the MAD phase indicated trends for weight change (-1.5 kg total ZGN-1061 vs -0.2 kg placebo) and other biomarker changes.', 'ZGN-1061 was well tolerated with no safety signals in all doses tested.\tZGN-1061 was well tolerated with no safety signals in all doses tested.', 'ZGN-1061 was well tolerated with no safety signals in all doses tested.\tthe desired pharmacokinetic profile and preliminary efficacy observations with ZGN-1061 support evaluation in larger and longer clinical trials.', 'the desired pharmacokinetic profile and preliminary efficacy observations with ZGN-1061 support evaluation in larger and longer clinical trials.\tMethionine aminopeptidase 2 (MetAP2) inhibition has been shown to result in significant weight loss and improved glucose control.', 'the desired pharmacokinetic profile and preliminary efficacy observations with ZGN-1061 support evaluation in larger and longer clinical trials.\tZGN-1061 was well tolerated across all doses with most frequent adverse events of mild headache and procedural-related irritation.', 'the desired pharmacokinetic profile and preliminary efficacy observations with ZGN-1061 support evaluation in larger and longer clinical trials.\tAll doses of ZGN-1061 were rapidly absorbed and cleared, resulting in short duration of exposure that is anticipated to minimize potential off-drug target risks.', 'the desired pharmacokinetic profile and preliminary efficacy observations with ZGN-1061 support evaluation in larger and longer clinical trials.\tSafety observations were consistent with SAD findings.', 'the desired pharmacokinetic profile and preliminary efficacy observations with ZGN-1061 support evaluation in larger and longer clinical trials.\tEfficacy measures in the MAD phase indicated trends for weight change (-1.5 kg total ZGN-1061 vs -0.2 kg placebo) and other biomarker changes.', 'the desired pharmacokinetic profile and preliminary efficacy observations with ZGN-1061 support evaluation in larger and longer clinical trials.\tZGN-1061 was well tolerated with no safety signals in all doses tested.', 'the desired pharmacokinetic profile and preliminary efficacy observations with ZGN-1061 support evaluation in larger and longer clinical trials.\tthe desired pharmacokinetic profile and preliminary efficacy observations with ZGN-1061 support evaluation in larger and longer clinical trials.']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['In CHEST-1, riociguat significantly improved RRS (p < 0.0001) and risk stratum (p < 0.001) vs placebo from baseline to Week 16.\tIn CHEST-1, riociguat significantly improved RRS (p < 0.0001) and risk stratum (p < 0.001) vs placebo from baseline to Week 16.', 'In CHEST-1, riociguat significantly improved RRS (p < 0.0001) and risk stratum (p < 0.001) vs placebo from baseline to Week 16.\tRRS at baseline, and at Week 16, and change in RRS during CHEST-1 were significantly associated with survival (hazard ratios for a 1-point reduction in RRS: 0.702, 0.692, and 0.682, respectively) and clinical worsening-free survival (hazard ratios: 0.697, 0.719, and 0.754, respectively) over 2 years in CHEST-2.', 'In CHEST-1, riociguat significantly improved RRS (p < 0.0001) and risk stratum (p < 0.001) vs placebo from baseline to Week 16.\tRiociguat improved RRS in patients with inoperable and persistent/recurrent CTEPH.', 'In CHEST-1, riociguat significantly improved RRS (p < 0.0001) and risk stratum (p < 0.001) vs placebo from baseline to Week 16.\tRRS at baseline and Week 16, and change in RRS from baseline, predicted survival and clinical worsening-free survival.', 'In CHEST-1, riociguat significantly improved RRS (p < 0.0001) and risk stratum (p < 0.001) vs placebo from baseline to Week 16.\tThis analysis of RRS in patients with inoperable or persistent/recurrent CTEPH suggests utility for the RRS in indications beyond PAH.', 'RRS at baseline, and at Week 16, and change in RRS during CHEST-1 were significantly associated with survival (hazard ratios for a 1-point reduction in RRS: 0.702, 0.692, and 0.682, respectively) and clinical worsening-free survival (hazard ratios: 0.697, 0.719, and 0.754, respectively) over 2 years in CHEST-2.\tIn CHEST-1, riociguat significantly improved RRS (p < 0.0001) and risk stratum (p < 0.001) vs placebo from baseline to Week 16.', 'RRS at baseline, and at Week 16, and change in RRS during CHEST-1 were significantly associated with survival (hazard ratios for a 1-point reduction in RRS: 0.702, 0.692, and 0.682, respectively) and clinical worsening-free survival (hazard ratios: 0.697, 0.719, and 0.754, respectively) over 2 years in CHEST-2.\tRRS at baseline, and at Week 16, and change in RRS during CHEST-1 were significantly associated with survival (hazard ratios for a 1-point reduction in RRS: 0.702, 0.692, and 0.682, respectively) and clinical worsening-free survival (hazard ratios: 0.697, 0.719, and 0.754, respectively) over 2 years in CHEST-2.', 'RRS at baseline, and at Week 16, and change in RRS during CHEST-1 were significantly associated with survival (hazard ratios for a 1-point reduction in RRS: 0.702, 0.692, and 0.682, respectively) and clinical worsening-free survival (hazard ratios: 0.697, 0.719, and 0.754, respectively) over 2 years in CHEST-2.\tRiociguat improved RRS in patients with inoperable and persistent/recurrent CTEPH.', 'RRS at baseline, and at Week 16, and change in RRS during CHEST-1 were significantly associated with survival (hazard ratios for a 1-point reduction in RRS: 0.702, 0.692, and 0.682, respectively) and clinical worsening-free survival (hazard ratios: 0.697, 0.719, and 0.754, respectively) over 2 years in CHEST-2.\tRRS at baseline and Week 16, and change in RRS from baseline, predicted survival and clinical worsening-free survival.', 'RRS at baseline, and at Week 16, and change in RRS during CHEST-1 were significantly associated with survival (hazard ratios for a 1-point reduction in RRS: 0.702, 0.692, and 0.682, respectively) and clinical worsening-free survival (hazard ratios: 0.697, 0.719, and 0.754, respectively) over 2 years in CHEST-2.\tThis analysis of RRS in patients with inoperable or persistent/recurrent CTEPH suggests utility for the RRS in indications beyond PAH.', 'Riociguat improved RRS in patients with inoperable and persistent/recurrent CTEPH.\tIn CHEST-1, riociguat significantly improved RRS (p < 0.0001) and risk stratum (p < 0.001) vs placebo from baseline to Week 16.', 'Riociguat improved RRS in patients with inoperable and persistent/recurrent CTEPH.\tRRS at baseline, and at Week 16, and change in RRS during CHEST-1 were significantly associated with survival (hazard ratios for a 1-point reduction in RRS: 0.702, 0.692, and 0.682, respectively) and clinical worsening-free survival (hazard ratios: 0.697, 0.719, and 0.754, respectively) over 2 years in CHEST-2.', 'Riociguat improved RRS in patients with inoperable and persistent/recurrent CTEPH.\tRiociguat improved RRS in patients with inoperable and persistent/recurrent CTEPH.', 'Riociguat improved RRS in patients with inoperable and persistent/recurrent CTEPH.\tRRS at baseline and Week 16, and change in RRS from baseline, predicted survival and clinical worsening-free survival.', 'Riociguat improved RRS in patients with inoperable and persistent/recurrent CTEPH.\tThis analysis of RRS in patients with inoperable or persistent/recurrent CTEPH suggests utility for the RRS in indications beyond PAH.', 'RRS at baseline and Week 16, and change in RRS from baseline, predicted survival and clinical worsening-free survival.\tIn CHEST-1, riociguat significantly improved RRS (p < 0.0001) and risk stratum (p < 0.001) vs placebo from baseline to Week 16.', 'RRS at baseline and Week 16, and change in RRS from baseline, predicted survival and clinical worsening-free survival.\tRRS at baseline, and at Week 16, and change in RRS during CHEST-1 were significantly associated with survival (hazard ratios for a 1-point reduction in RRS: 0.702, 0.692, and 0.682, respectively) and clinical worsening-free survival (hazard ratios: 0.697, 0.719, and 0.754, respectively) over 2 years in CHEST-2.', 'RRS at baseline and Week 16, and change in RRS from baseline, predicted survival and clinical worsening-free survival.\tRiociguat improved RRS in patients with inoperable and persistent/recurrent CTEPH.', 'RRS at baseline and Week 16, and change in RRS from baseline, predicted survival and clinical worsening-free survival.\tRRS at baseline and Week 16, and change in RRS from baseline, predicted survival and clinical worsening-free survival.', 'RRS at baseline and Week 16, and change in RRS from baseline, predicted survival and clinical worsening-free survival.\tThis analysis of RRS in patients with inoperable or persistent/recurrent CTEPH suggests utility for the RRS in indications beyond PAH.', 'This analysis of RRS in patients with inoperable or persistent/recurrent CTEPH suggests utility for the RRS in indications beyond PAH.\tIn CHEST-1, riociguat significantly improved RRS (p < 0.0001) and risk stratum (p < 0.001) vs placebo from baseline to Week 16.', 'This analysis of RRS in patients with inoperable or persistent/recurrent CTEPH suggests utility for the RRS in indications beyond PAH.\tRRS at baseline, and at Week 16, and change in RRS during CHEST-1 were significantly associated with survival (hazard ratios for a 1-point reduction in RRS: 0.702, 0.692, and 0.682, respectively) and clinical worsening-free survival (hazard ratios: 0.697, 0.719, and 0.754, respectively) over 2 years in CHEST-2.', 'This analysis of RRS in patients with inoperable or persistent/recurrent CTEPH suggests utility for the RRS in indications beyond PAH.\tRiociguat improved RRS in patients with inoperable and persistent/recurrent CTEPH.', 'This analysis of RRS in patients with inoperable or persistent/recurrent CTEPH suggests utility for the RRS in indications beyond PAH.\tRRS at baseline and Week 16, and change in RRS from baseline, predicted survival and clinical worsening-free survival.', 'This analysis of RRS in patients with inoperable or persistent/recurrent CTEPH suggests utility for the RRS in indications beyond PAH.\tThis analysis of RRS in patients with inoperable or persistent/recurrent CTEPH suggests utility for the RRS in indications beyond PAH.']","[0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0]"
"['Low serum vitamin D has been associated with metabolic syndrome and Non-alcoholic fatty liver disease (NAFLD).\tLow serum vitamin D has been associated with metabolic syndrome and Non-alcoholic fatty liver disease (NAFLD).', 'Low serum vitamin D has been associated with metabolic syndrome and Non-alcoholic fatty liver disease (NAFLD).\tsignificant reduction of serum alkaline phosphatase and GGT were seen with vitamin D and calcitriol supplementation from baseline levels,', 'Low serum vitamin D has been associated with metabolic syndrome and Non-alcoholic fatty liver disease (NAFLD).\tno beneficial effects was seen when comparing vitamin D, calcitriol and placebo groups at the end of trial.', 'Low serum vitamin D has been associated with metabolic syndrome and Non-alcoholic fatty liver disease (NAFLD).\tThere was no statistically significant difference between placebo, calcitriol, vitamin D groups in terms of serum aminotransferase, alkaline phosphatase, serum GGT and lipid profile (P\u202f>\u202f0.05).', 'Low serum vitamin D has been associated with metabolic syndrome and Non-alcoholic fatty liver disease (NAFLD).\tSerum and gamma glutamyl transferase (GGT) level was also significantly decreased compared to the baseline levels after 12 weeks of treatment with vitamin D.', 'Low serum vitamin D has been associated with metabolic syndrome and Non-alcoholic fatty liver disease (NAFLD).\tAfter 12 weeks of treatment, serum alkaline phosphatase levels was significantly decreased from baseline levels in vitamin D and calcitriol treated groups (P\u202f<\u202f0.05).', 'significant reduction of serum alkaline phosphatase and GGT were seen with vitamin D and calcitriol supplementation from baseline levels,\tLow serum vitamin D has been associated with metabolic syndrome and Non-alcoholic fatty liver disease (NAFLD).', 'significant reduction of serum alkaline phosphatase and GGT were seen with vitamin D and calcitriol supplementation from baseline levels,\tsignificant reduction of serum alkaline phosphatase and GGT were seen with vitamin D and calcitriol supplementation from baseline levels,', 'significant reduction of serum alkaline phosphatase and GGT were seen with vitamin D and calcitriol supplementation from baseline levels,\tno beneficial effects was seen when comparing vitamin D, calcitriol and placebo groups at the end of trial.', 'significant reduction of serum alkaline phosphatase and GGT were seen with vitamin D and calcitriol supplementation from baseline levels,\tThere was no statistically significant difference between placebo, calcitriol, vitamin D groups in terms of serum aminotransferase, alkaline phosphatase, serum GGT and lipid profile (P\u202f>\u202f0.05).', 'significant reduction of serum alkaline phosphatase and GGT were seen with vitamin D and calcitriol supplementation from baseline levels,\tSerum and gamma glutamyl transferase (GGT) level was also significantly decreased compared to the baseline levels after 12 weeks of treatment with vitamin D.', 'significant reduction of serum alkaline phosphatase and GGT were seen with vitamin D and calcitriol supplementation from baseline levels,\tAfter 12 weeks of treatment, serum alkaline phosphatase levels was significantly decreased from baseline levels in vitamin D and calcitriol treated groups (P\u202f<\u202f0.05).', 'no beneficial effects was seen when comparing vitamin D, calcitriol and placebo groups at the end of trial.\tLow serum vitamin D has been associated with metabolic syndrome and Non-alcoholic fatty liver disease (NAFLD).', 'no beneficial effects was seen when comparing vitamin D, calcitriol and placebo groups at the end of trial.\tsignificant reduction of serum alkaline phosphatase and GGT were seen with vitamin D and calcitriol supplementation from baseline levels,', 'no beneficial effects was seen when comparing vitamin D, calcitriol and placebo groups at the end of trial.\tno beneficial effects was seen when comparing vitamin D, calcitriol and placebo groups at the end of trial.', 'no beneficial effects was seen when comparing vitamin D, calcitriol and placebo groups at the end of trial.\tThere was no statistically significant difference between placebo, calcitriol, vitamin D groups in terms of serum aminotransferase, alkaline phosphatase, serum GGT and lipid profile (P\u202f>\u202f0.05).', 'no beneficial effects was seen when comparing vitamin D, calcitriol and placebo groups at the end of trial.\tSerum and gamma glutamyl transferase (GGT) level was also significantly decreased compared to the baseline levels after 12 weeks of treatment with vitamin D.', 'no beneficial effects was seen when comparing vitamin D, calcitriol and placebo groups at the end of trial.\tAfter 12 weeks of treatment, serum alkaline phosphatase levels was significantly decreased from baseline levels in vitamin D and calcitriol treated groups (P\u202f<\u202f0.05).', 'There was no statistically significant difference between placebo, calcitriol, vitamin D groups in terms of serum aminotransferase, alkaline phosphatase, serum GGT and lipid profile (P\u202f>\u202f0.05).\tLow serum vitamin D has been associated with metabolic syndrome and Non-alcoholic fatty liver disease (NAFLD).', 'There was no statistically significant difference between placebo, calcitriol, vitamin D groups in terms of serum aminotransferase, alkaline phosphatase, serum GGT and lipid profile (P\u202f>\u202f0.05).\tsignificant reduction of serum alkaline phosphatase and GGT were seen with vitamin D and calcitriol supplementation from baseline levels,', 'There was no statistically significant difference between placebo, calcitriol, vitamin D groups in terms of serum aminotransferase, alkaline phosphatase, serum GGT and lipid profile (P\u202f>\u202f0.05).\tno beneficial effects was seen when comparing vitamin D, calcitriol and placebo groups at the end of trial.', 'There was no statistically significant difference between placebo, calcitriol, vitamin D groups in terms of serum aminotransferase, alkaline phosphatase, serum GGT and lipid profile (P\u202f>\u202f0.05).\tThere was no statistically significant difference between placebo, calcitriol, vitamin D groups in terms of serum aminotransferase, alkaline phosphatase, serum GGT and lipid profile (P\u202f>\u202f0.05).', 'There was no statistically significant difference between placebo, calcitriol, vitamin D groups in terms of serum aminotransferase, alkaline phosphatase, serum GGT and lipid profile (P\u202f>\u202f0.05).\tSerum and gamma glutamyl transferase (GGT) level was also significantly decreased compared to the baseline levels after 12 weeks of treatment with vitamin D.', 'There was no statistically significant difference between placebo, calcitriol, vitamin D groups in terms of serum aminotransferase, alkaline phosphatase, serum GGT and lipid profile (P\u202f>\u202f0.05).\tAfter 12 weeks of treatment, serum alkaline phosphatase levels was significantly decreased from baseline levels in vitamin D and calcitriol treated groups (P\u202f<\u202f0.05).', 'Serum and gamma glutamyl transferase (GGT) level was also significantly decreased compared to the baseline levels after 12 weeks of treatment with vitamin D.\tLow serum vitamin D has been associated with metabolic syndrome and Non-alcoholic fatty liver disease (NAFLD).', 'Serum and gamma glutamyl transferase (GGT) level was also significantly decreased compared to the baseline levels after 12 weeks of treatment with vitamin D.\tsignificant reduction of serum alkaline phosphatase and GGT were seen with vitamin D and calcitriol supplementation from baseline levels,', 'Serum and gamma glutamyl transferase (GGT) level was also significantly decreased compared to the baseline levels after 12 weeks of treatment with vitamin D.\tno beneficial effects was seen when comparing vitamin D, calcitriol and placebo groups at the end of trial.', 'Serum and gamma glutamyl transferase (GGT) level was also significantly decreased compared to the baseline levels after 12 weeks of treatment with vitamin D.\tThere was no statistically significant difference between placebo, calcitriol, vitamin D groups in terms of serum aminotransferase, alkaline phosphatase, serum GGT and lipid profile (P\u202f>\u202f0.05).', 'Serum and gamma glutamyl transferase (GGT) level was also significantly decreased compared to the baseline levels after 12 weeks of treatment with vitamin D.\tSerum and gamma glutamyl transferase (GGT) level was also significantly decreased compared to the baseline levels after 12 weeks of treatment with vitamin D.', 'Serum and gamma glutamyl transferase (GGT) level was also significantly decreased compared to the baseline levels after 12 weeks of treatment with vitamin D.\tAfter 12 weeks of treatment, serum alkaline phosphatase levels was significantly decreased from baseline levels in vitamin D and calcitriol treated groups (P\u202f<\u202f0.05).', 'After 12 weeks of treatment, serum alkaline phosphatase levels was significantly decreased from baseline levels in vitamin D and calcitriol treated groups (P\u202f<\u202f0.05).\tLow serum vitamin D has been associated with metabolic syndrome and Non-alcoholic fatty liver disease (NAFLD).', 'After 12 weeks of treatment, serum alkaline phosphatase levels was significantly decreased from baseline levels in vitamin D and calcitriol treated groups (P\u202f<\u202f0.05).\tsignificant reduction of serum alkaline phosphatase and GGT were seen with vitamin D and calcitriol supplementation from baseline levels,', 'After 12 weeks of treatment, serum alkaline phosphatase levels was significantly decreased from baseline levels in vitamin D and calcitriol treated groups (P\u202f<\u202f0.05).\tno beneficial effects was seen when comparing vitamin D, calcitriol and placebo groups at the end of trial.', 'After 12 weeks of treatment, serum alkaline phosphatase levels was significantly decreased from baseline levels in vitamin D and calcitriol treated groups (P\u202f<\u202f0.05).\tThere was no statistically significant difference between placebo, calcitriol, vitamin D groups in terms of serum aminotransferase, alkaline phosphatase, serum GGT and lipid profile (P\u202f>\u202f0.05).', 'After 12 weeks of treatment, serum alkaline phosphatase levels was significantly decreased from baseline levels in vitamin D and calcitriol treated groups (P\u202f<\u202f0.05).\tSerum and gamma glutamyl transferase (GGT) level was also significantly decreased compared to the baseline levels after 12 weeks of treatment with vitamin D.', 'After 12 weeks of treatment, serum alkaline phosphatase levels was significantly decreased from baseline levels in vitamin D and calcitriol treated groups (P\u202f<\u202f0.05).\tAfter 12 weeks of treatment, serum alkaline phosphatase levels was significantly decreased from baseline levels in vitamin D and calcitriol treated groups (P\u202f<\u202f0.05).']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]"
"['Cardiovascular complications are one of main cause of increased mortality and morbidity among Diabetes Mellitus (DM) patients.\tCardiovascular complications are one of main cause of increased mortality and morbidity among Diabetes Mellitus (DM) patients.', 'Cardiovascular complications are one of main cause of increased mortality and morbidity among Diabetes Mellitus (DM) patients.\tEight weeks supplementation with EPA led to significant reductions in Met (p\u202f<\u202f0.002) and Cys (p\u202f<\u202f0.001) compared with the placebo (p\u202f<\u202f0.06).', 'Cardiovascular complications are one of main cause of increased mortality and morbidity among Diabetes Mellitus (DM) patients.\tAltered metabolism of sulphur amino acids in diabetes reflected as increases in concentration of methionine and cysteine/cystine in the blood which known as a markers of Cardiovascular Diseases (CVD).', 'Cardiovascular complications are one of main cause of increased mortality and morbidity among Diabetes Mellitus (DM) patients.\tcompared to placebo a significant reduction in AIP were seen after taking EPA (p\u202f<\u202f0.04).', 'Cardiovascular complications are one of main cause of increased mortality and morbidity among Diabetes Mellitus (DM) patients.\tEPA supplementation in patients with T2DM for eight weeks had beneficial effects on Met, Cys and AIP, which may attribute to the prevention of vascular complications in the T2DM patients.', 'Eight weeks supplementation with EPA led to significant reductions in Met (p\u202f<\u202f0.002) and Cys (p\u202f<\u202f0.001) compared with the placebo (p\u202f<\u202f0.06).\tCardiovascular complications are one of main cause of increased mortality and morbidity among Diabetes Mellitus (DM) patients.', 'Eight weeks supplementation with EPA led to significant reductions in Met (p\u202f<\u202f0.002) and Cys (p\u202f<\u202f0.001) compared with the placebo (p\u202f<\u202f0.06).\tEight weeks supplementation with EPA led to significant reductions in Met (p\u202f<\u202f0.002) and Cys (p\u202f<\u202f0.001) compared with the placebo (p\u202f<\u202f0.06).', 'Eight weeks supplementation with EPA led to significant reductions in Met (p\u202f<\u202f0.002) and Cys (p\u202f<\u202f0.001) compared with the placebo (p\u202f<\u202f0.06).\tAltered metabolism of sulphur amino acids in diabetes reflected as increases in concentration of methionine and cysteine/cystine in the blood which known as a markers of Cardiovascular Diseases (CVD).', 'Eight weeks supplementation with EPA led to significant reductions in Met (p\u202f<\u202f0.002) and Cys (p\u202f<\u202f0.001) compared with the placebo (p\u202f<\u202f0.06).\tcompared to placebo a significant reduction in AIP were seen after taking EPA (p\u202f<\u202f0.04).', 'Eight weeks supplementation with EPA led to significant reductions in Met (p\u202f<\u202f0.002) and Cys (p\u202f<\u202f0.001) compared with the placebo (p\u202f<\u202f0.06).\tEPA supplementation in patients with T2DM for eight weeks had beneficial effects on Met, Cys and AIP, which may attribute to the prevention of vascular complications in the T2DM patients.', 'Altered metabolism of sulphur amino acids in diabetes reflected as increases in concentration of methionine and cysteine/cystine in the blood which known as a markers of Cardiovascular Diseases (CVD).\tCardiovascular complications are one of main cause of increased mortality and morbidity among Diabetes Mellitus (DM) patients.', 'Altered metabolism of sulphur amino acids in diabetes reflected as increases in concentration of methionine and cysteine/cystine in the blood which known as a markers of Cardiovascular Diseases (CVD).\tEight weeks supplementation with EPA led to significant reductions in Met (p\u202f<\u202f0.002) and Cys (p\u202f<\u202f0.001) compared with the placebo (p\u202f<\u202f0.06).', 'Altered metabolism of sulphur amino acids in diabetes reflected as increases in concentration of methionine and cysteine/cystine in the blood which known as a markers of Cardiovascular Diseases (CVD).\tAltered metabolism of sulphur amino acids in diabetes reflected as increases in concentration of methionine and cysteine/cystine in the blood which known as a markers of Cardiovascular Diseases (CVD).', 'Altered metabolism of sulphur amino acids in diabetes reflected as increases in concentration of methionine and cysteine/cystine in the blood which known as a markers of Cardiovascular Diseases (CVD).\tcompared to placebo a significant reduction in AIP were seen after taking EPA (p\u202f<\u202f0.04).', 'Altered metabolism of sulphur amino acids in diabetes reflected as increases in concentration of methionine and cysteine/cystine in the blood which known as a markers of Cardiovascular Diseases (CVD).\tEPA supplementation in patients with T2DM for eight weeks had beneficial effects on Met, Cys and AIP, which may attribute to the prevention of vascular complications in the T2DM patients.', 'compared to placebo a significant reduction in AIP were seen after taking EPA (p\u202f<\u202f0.04).\tCardiovascular complications are one of main cause of increased mortality and morbidity among Diabetes Mellitus (DM) patients.', 'compared to placebo a significant reduction in AIP were seen after taking EPA (p\u202f<\u202f0.04).\tEight weeks supplementation with EPA led to significant reductions in Met (p\u202f<\u202f0.002) and Cys (p\u202f<\u202f0.001) compared with the placebo (p\u202f<\u202f0.06).', 'compared to placebo a significant reduction in AIP were seen after taking EPA (p\u202f<\u202f0.04).\tAltered metabolism of sulphur amino acids in diabetes reflected as increases in concentration of methionine and cysteine/cystine in the blood which known as a markers of Cardiovascular Diseases (CVD).', 'compared to placebo a significant reduction in AIP were seen after taking EPA (p\u202f<\u202f0.04).\tcompared to placebo a significant reduction in AIP were seen after taking EPA (p\u202f<\u202f0.04).', 'compared to placebo a significant reduction in AIP were seen after taking EPA (p\u202f<\u202f0.04).\tEPA supplementation in patients with T2DM for eight weeks had beneficial effects on Met, Cys and AIP, which may attribute to the prevention of vascular complications in the T2DM patients.', 'EPA supplementation in patients with T2DM for eight weeks had beneficial effects on Met, Cys and AIP, which may attribute to the prevention of vascular complications in the T2DM patients.\tCardiovascular complications are one of main cause of increased mortality and morbidity among Diabetes Mellitus (DM) patients.', 'EPA supplementation in patients with T2DM for eight weeks had beneficial effects on Met, Cys and AIP, which may attribute to the prevention of vascular complications in the T2DM patients.\tEight weeks supplementation with EPA led to significant reductions in Met (p\u202f<\u202f0.002) and Cys (p\u202f<\u202f0.001) compared with the placebo (p\u202f<\u202f0.06).', 'EPA supplementation in patients with T2DM for eight weeks had beneficial effects on Met, Cys and AIP, which may attribute to the prevention of vascular complications in the T2DM patients.\tAltered metabolism of sulphur amino acids in diabetes reflected as increases in concentration of methionine and cysteine/cystine in the blood which known as a markers of Cardiovascular Diseases (CVD).', 'EPA supplementation in patients with T2DM for eight weeks had beneficial effects on Met, Cys and AIP, which may attribute to the prevention of vascular complications in the T2DM patients.\tcompared to placebo a significant reduction in AIP were seen after taking EPA (p\u202f<\u202f0.04).', 'EPA supplementation in patients with T2DM for eight weeks had beneficial effects on Met, Cys and AIP, which may attribute to the prevention of vascular complications in the T2DM patients.\tEPA supplementation in patients with T2DM for eight weeks had beneficial effects on Met, Cys and AIP, which may attribute to the prevention of vascular complications in the T2DM patients.']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0]"
"['In the primary intention-to-treat analysis, the effect of GLI encouragement was 0.95% weight loss at six months (95% confidence interval [CI], 0.13-1.77%; P\u202f=\u202f0.02), and 1.20% weight loss at 12\u202fmonths (95% CI, 0.05-2.36%; P\u202f=\u202f0.04).\tIn the primary intention-to-treat analysis, the effect of GLI encouragement was 0.95% weight loss at six months (95% confidence interval [CI], 0.13-1.77%; P\u202f=\u202f0.02), and 1.20% weight loss at 12\u202fmonths (95% CI, 0.05-2.36%; P\u202f=\u202f0.04).', 'In the primary intention-to-treat analysis, the effect of GLI encouragement was 0.95% weight loss at six months (95% confidence interval [CI], 0.13-1.77%; P\u202f=\u202f0.02), and 1.20% weight loss at 12\u202fmonths (95% CI, 0.05-2.36%; P\u202f=\u202f0.04).\tAt 12\u202fmonths, there was a 0.30% (3.3\u202fmmol/mol) reduction in hemoglobin A1c,', 'In the primary intention-to-treat analysis, the effect of GLI encouragement was 0.95% weight loss at six months (95% confidence interval [CI], 0.13-1.77%; P\u202f=\u202f0.02), and 1.20% weight loss at 12\u202fmonths (95% CI, 0.05-2.36%; P\u202f=\u202f0.04).\tbut this result did not achieve statistical significance (P\u202f=\u202f0.054).', 'In the primary intention-to-treat analysis, the effect of GLI encouragement was 0.95% weight loss at six months (95% confidence interval [CI], 0.13-1.77%; P\u202f=\u202f0.02), and 1.20% weight loss at 12\u202fmonths (95% CI, 0.05-2.36%; P\u202f=\u202f0.04).\tIn instrumental variable analysis estimating effects among the subgroup of participants who attended any GLI visits, the effect of GLI attendance was 2.30% weight loss at six months (95% CI, 0.30-4.30%; P\u202f=\u202f0.02), and 2.07% weight loss at 12\u202fmonths (95% CI, 0.25-3.88%; P\u202f=\u202f0.02).', 'In the primary intention-to-treat analysis, the effect of GLI encouragement was 0.95% weight loss at six months (95% confidence interval [CI], 0.13-1.77%; P\u202f=\u202f0.02), and 1.20% weight loss at 12\u202fmonths (95% CI, 0.05-2.36%; P\u202f=\u202f0.04).\tAmong adults with type 2 diabetes, a group-based lifestyle intervention in a community-based setting achieved modest weight loss at 6 and 12\u202fmonths.', 'At 12\u202fmonths, there was a 0.30% (3.3\u202fmmol/mol) reduction in hemoglobin A1c,\tIn the primary intention-to-treat analysis, the effect of GLI encouragement was 0.95% weight loss at six months (95% confidence interval [CI], 0.13-1.77%; P\u202f=\u202f0.02), and 1.20% weight loss at 12\u202fmonths (95% CI, 0.05-2.36%; P\u202f=\u202f0.04).', 'At 12\u202fmonths, there was a 0.30% (3.3\u202fmmol/mol) reduction in hemoglobin A1c,\tAt 12\u202fmonths, there was a 0.30% (3.3\u202fmmol/mol) reduction in hemoglobin A1c,', 'At 12\u202fmonths, there was a 0.30% (3.3\u202fmmol/mol) reduction in hemoglobin A1c,\tbut this result did not achieve statistical significance (P\u202f=\u202f0.054).', 'At 12\u202fmonths, there was a 0.30% (3.3\u202fmmol/mol) reduction in hemoglobin A1c,\tIn instrumental variable analysis estimating effects among the subgroup of participants who attended any GLI visits, the effect of GLI attendance was 2.30% weight loss at six months (95% CI, 0.30-4.30%; P\u202f=\u202f0.02), and 2.07% weight loss at 12\u202fmonths (95% CI, 0.25-3.88%; P\u202f=\u202f0.02).', 'At 12\u202fmonths, there was a 0.30% (3.3\u202fmmol/mol) reduction in hemoglobin A1c,\tAmong adults with type 2 diabetes, a group-based lifestyle intervention in a community-based setting achieved modest weight loss at 6 and 12\u202fmonths.', 'but this result did not achieve statistical significance (P\u202f=\u202f0.054).\tIn the primary intention-to-treat analysis, the effect of GLI encouragement was 0.95% weight loss at six months (95% confidence interval [CI], 0.13-1.77%; P\u202f=\u202f0.02), and 1.20% weight loss at 12\u202fmonths (95% CI, 0.05-2.36%; P\u202f=\u202f0.04).', 'but this result did not achieve statistical significance (P\u202f=\u202f0.054).\tAt 12\u202fmonths, there was a 0.30% (3.3\u202fmmol/mol) reduction in hemoglobin A1c,', 'but this result did not achieve statistical significance (P\u202f=\u202f0.054).\tbut this result did not achieve statistical significance (P\u202f=\u202f0.054).', 'but this result did not achieve statistical significance (P\u202f=\u202f0.054).\tIn instrumental variable analysis estimating effects among the subgroup of participants who attended any GLI visits, the effect of GLI attendance was 2.30% weight loss at six months (95% CI, 0.30-4.30%; P\u202f=\u202f0.02), and 2.07% weight loss at 12\u202fmonths (95% CI, 0.25-3.88%; P\u202f=\u202f0.02).', 'but this result did not achieve statistical significance (P\u202f=\u202f0.054).\tAmong adults with type 2 diabetes, a group-based lifestyle intervention in a community-based setting achieved modest weight loss at 6 and 12\u202fmonths.', 'In instrumental variable analysis estimating effects among the subgroup of participants who attended any GLI visits, the effect of GLI attendance was 2.30% weight loss at six months (95% CI, 0.30-4.30%; P\u202f=\u202f0.02), and 2.07% weight loss at 12\u202fmonths (95% CI, 0.25-3.88%; P\u202f=\u202f0.02).\tIn the primary intention-to-treat analysis, the effect of GLI encouragement was 0.95% weight loss at six months (95% confidence interval [CI], 0.13-1.77%; P\u202f=\u202f0.02), and 1.20% weight loss at 12\u202fmonths (95% CI, 0.05-2.36%; P\u202f=\u202f0.04).', 'In instrumental variable analysis estimating effects among the subgroup of participants who attended any GLI visits, the effect of GLI attendance was 2.30% weight loss at six months (95% CI, 0.30-4.30%; P\u202f=\u202f0.02), and 2.07% weight loss at 12\u202fmonths (95% CI, 0.25-3.88%; P\u202f=\u202f0.02).\tAt 12\u202fmonths, there was a 0.30% (3.3\u202fmmol/mol) reduction in hemoglobin A1c,', 'In instrumental variable analysis estimating effects among the subgroup of participants who attended any GLI visits, the effect of GLI attendance was 2.30% weight loss at six months (95% CI, 0.30-4.30%; P\u202f=\u202f0.02), and 2.07% weight loss at 12\u202fmonths (95% CI, 0.25-3.88%; P\u202f=\u202f0.02).\tbut this result did not achieve statistical significance (P\u202f=\u202f0.054).', 'In instrumental variable analysis estimating effects among the subgroup of participants who attended any GLI visits, the effect of GLI attendance was 2.30% weight loss at six months (95% CI, 0.30-4.30%; P\u202f=\u202f0.02), and 2.07% weight loss at 12\u202fmonths (95% CI, 0.25-3.88%; P\u202f=\u202f0.02).\tIn instrumental variable analysis estimating effects among the subgroup of participants who attended any GLI visits, the effect of GLI attendance was 2.30% weight loss at six months (95% CI, 0.30-4.30%; P\u202f=\u202f0.02), and 2.07% weight loss at 12\u202fmonths (95% CI, 0.25-3.88%; P\u202f=\u202f0.02).', 'In instrumental variable analysis estimating effects among the subgroup of participants who attended any GLI visits, the effect of GLI attendance was 2.30% weight loss at six months (95% CI, 0.30-4.30%; P\u202f=\u202f0.02), and 2.07% weight loss at 12\u202fmonths (95% CI, 0.25-3.88%; P\u202f=\u202f0.02).\tAmong adults with type 2 diabetes, a group-based lifestyle intervention in a community-based setting achieved modest weight loss at 6 and 12\u202fmonths.', 'Among adults with type 2 diabetes, a group-based lifestyle intervention in a community-based setting achieved modest weight loss at 6 and 12\u202fmonths.\tIn the primary intention-to-treat analysis, the effect of GLI encouragement was 0.95% weight loss at six months (95% confidence interval [CI], 0.13-1.77%; P\u202f=\u202f0.02), and 1.20% weight loss at 12\u202fmonths (95% CI, 0.05-2.36%; P\u202f=\u202f0.04).', 'Among adults with type 2 diabetes, a group-based lifestyle intervention in a community-based setting achieved modest weight loss at 6 and 12\u202fmonths.\tAt 12\u202fmonths, there was a 0.30% (3.3\u202fmmol/mol) reduction in hemoglobin A1c,', 'Among adults with type 2 diabetes, a group-based lifestyle intervention in a community-based setting achieved modest weight loss at 6 and 12\u202fmonths.\tbut this result did not achieve statistical significance (P\u202f=\u202f0.054).', 'Among adults with type 2 diabetes, a group-based lifestyle intervention in a community-based setting achieved modest weight loss at 6 and 12\u202fmonths.\tIn instrumental variable analysis estimating effects among the subgroup of participants who attended any GLI visits, the effect of GLI attendance was 2.30% weight loss at six months (95% CI, 0.30-4.30%; P\u202f=\u202f0.02), and 2.07% weight loss at 12\u202fmonths (95% CI, 0.25-3.88%; P\u202f=\u202f0.02).', 'Among adults with type 2 diabetes, a group-based lifestyle intervention in a community-based setting achieved modest weight loss at 6 and 12\u202fmonths.\tAmong adults with type 2 diabetes, a group-based lifestyle intervention in a community-based setting achieved modest weight loss at 6 and 12\u202fmonths.']","[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0]"
"['Risk of all three outcomes was higher for participants with chronic kidney disease or frailty.\tRisk of all three outcomes was higher for participants with chronic kidney disease or frailty.', 'Risk of all three outcomes was higher for participants with chronic kidney disease or frailty.\tOlder age was also associated with greater risk of syncope, hypotension, and falls, but there was no age-by-treatment interaction for any of the SAE outcomes.', 'Risk of all three outcomes was higher for participants with chronic kidney disease or frailty.\tParticipants randomized to intensive SBP control had greater risk of hypotension and possibly syncope, but not falls.', 'Risk of all three outcomes was higher for participants with chronic kidney disease or frailty.\tRandomization to intensive SBP control was associated with greater risk of an SAE involving hypotension (hazard ratio (HR) = 1.67, 95% confidence interval (CI) = 1.21-2.32, P = .002), and possibly syncope (HR = 1.32, 95% CI = 0.98-1.79, P = .07), but not falls (HR = 0.98, 95% CI = 0.75-1.29, P = .90).', 'Older age was also associated with greater risk of syncope, hypotension, and falls, but there was no age-by-treatment interaction for any of the SAE outcomes.\tRisk of all three outcomes was higher for participants with chronic kidney disease or frailty.', 'Older age was also associated with greater risk of syncope, hypotension, and falls, but there was no age-by-treatment interaction for any of the SAE outcomes.\tOlder age was also associated with greater risk of syncope, hypotension, and falls, but there was no age-by-treatment interaction for any of the SAE outcomes.', 'Older age was also associated with greater risk of syncope, hypotension, and falls, but there was no age-by-treatment interaction for any of the SAE outcomes.\tParticipants randomized to intensive SBP control had greater risk of hypotension and possibly syncope, but not falls.', 'Older age was also associated with greater risk of syncope, hypotension, and falls, but there was no age-by-treatment interaction for any of the SAE outcomes.\tRandomization to intensive SBP control was associated with greater risk of an SAE involving hypotension (hazard ratio (HR) = 1.67, 95% confidence interval (CI) = 1.21-2.32, P = .002), and possibly syncope (HR = 1.32, 95% CI = 0.98-1.79, P = .07), but not falls (HR = 0.98, 95% CI = 0.75-1.29, P = .90).', 'Participants randomized to intensive SBP control had greater risk of hypotension and possibly syncope, but not falls.\tRisk of all three outcomes was higher for participants with chronic kidney disease or frailty.', 'Participants randomized to intensive SBP control had greater risk of hypotension and possibly syncope, but not falls.\tOlder age was also associated with greater risk of syncope, hypotension, and falls, but there was no age-by-treatment interaction for any of the SAE outcomes.', 'Participants randomized to intensive SBP control had greater risk of hypotension and possibly syncope, but not falls.\tParticipants randomized to intensive SBP control had greater risk of hypotension and possibly syncope, but not falls.', 'Participants randomized to intensive SBP control had greater risk of hypotension and possibly syncope, but not falls.\tRandomization to intensive SBP control was associated with greater risk of an SAE involving hypotension (hazard ratio (HR) = 1.67, 95% confidence interval (CI) = 1.21-2.32, P = .002), and possibly syncope (HR = 1.32, 95% CI = 0.98-1.79, P = .07), but not falls (HR = 0.98, 95% CI = 0.75-1.29, P = .90).', 'Randomization to intensive SBP control was associated with greater risk of an SAE involving hypotension (hazard ratio (HR) = 1.67, 95% confidence interval (CI) = 1.21-2.32, P = .002), and possibly syncope (HR = 1.32, 95% CI = 0.98-1.79, P = .07), but not falls (HR = 0.98, 95% CI = 0.75-1.29, P = .90).\tRisk of all three outcomes was higher for participants with chronic kidney disease or frailty.', 'Randomization to intensive SBP control was associated with greater risk of an SAE involving hypotension (hazard ratio (HR) = 1.67, 95% confidence interval (CI) = 1.21-2.32, P = .002), and possibly syncope (HR = 1.32, 95% CI = 0.98-1.79, P = .07), but not falls (HR = 0.98, 95% CI = 0.75-1.29, P = .90).\tOlder age was also associated with greater risk of syncope, hypotension, and falls, but there was no age-by-treatment interaction for any of the SAE outcomes.', 'Randomization to intensive SBP control was associated with greater risk of an SAE involving hypotension (hazard ratio (HR) = 1.67, 95% confidence interval (CI) = 1.21-2.32, P = .002), and possibly syncope (HR = 1.32, 95% CI = 0.98-1.79, P = .07), but not falls (HR = 0.98, 95% CI = 0.75-1.29, P = .90).\tParticipants randomized to intensive SBP control had greater risk of hypotension and possibly syncope, but not falls.', 'Randomization to intensive SBP control was associated with greater risk of an SAE involving hypotension (hazard ratio (HR) = 1.67, 95% confidence interval (CI) = 1.21-2.32, P = .002), and possibly syncope (HR = 1.32, 95% CI = 0.98-1.79, P = .07), but not falls (HR = 0.98, 95% CI = 0.75-1.29, P = .90).\tRandomization to intensive SBP control was associated with greater risk of an SAE involving hypotension (hazard ratio (HR) = 1.67, 95% confidence interval (CI) = 1.21-2.32, P = .002), and possibly syncope (HR = 1.32, 95% CI = 0.98-1.79, P = .07), but not falls (HR = 0.98, 95% CI = 0.75-1.29, P = .90).']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0]"
"['Multiple studies have evaluated the hypoglycemic effect of cinnamon in patients with diabetes mellitus (DM) type II, with conflicting results.\tMultiple studies have evaluated the hypoglycemic effect of cinnamon in patients with diabetes mellitus (DM) type II, with conflicting results.', 'Multiple studies have evaluated the hypoglycemic effect of cinnamon in patients with diabetes mellitus (DM) type II, with conflicting results.\tCinnamon supplementation led to improvement of all anthropometric (BMI, body fat, and visceral fat), glycemic (FPG, 2hpp, HbA1C, Fasting Insulin, and Insulin Resistance), and lipids (Cholesterol Total, LDL-c and HDL-c) outcomes (except for triglycerides level).', 'Multiple studies have evaluated the hypoglycemic effect of cinnamon in patients with diabetes mellitus (DM) type II, with conflicting results.\tAll observed changes (except for Cholesterol Total and LDL-c) were significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).', 'Multiple studies have evaluated the hypoglycemic effect of cinnamon in patients with diabetes mellitus (DM) type II, with conflicting results.\tBased on the study findings, cinnamon may improve anthropometric parameters, glycemic indices and lipid profile of patients with type II diabetes.', 'Multiple studies have evaluated the hypoglycemic effect of cinnamon in patients with diabetes mellitus (DM) type II, with conflicting results.\tThese benefits are significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).', 'Cinnamon supplementation led to improvement of all anthropometric (BMI, body fat, and visceral fat), glycemic (FPG, 2hpp, HbA1C, Fasting Insulin, and Insulin Resistance), and lipids (Cholesterol Total, LDL-c and HDL-c) outcomes (except for triglycerides level).\tMultiple studies have evaluated the hypoglycemic effect of cinnamon in patients with diabetes mellitus (DM) type II, with conflicting results.', 'Cinnamon supplementation led to improvement of all anthropometric (BMI, body fat, and visceral fat), glycemic (FPG, 2hpp, HbA1C, Fasting Insulin, and Insulin Resistance), and lipids (Cholesterol Total, LDL-c and HDL-c) outcomes (except for triglycerides level).\tCinnamon supplementation led to improvement of all anthropometric (BMI, body fat, and visceral fat), glycemic (FPG, 2hpp, HbA1C, Fasting Insulin, and Insulin Resistance), and lipids (Cholesterol Total, LDL-c and HDL-c) outcomes (except for triglycerides level).', 'Cinnamon supplementation led to improvement of all anthropometric (BMI, body fat, and visceral fat), glycemic (FPG, 2hpp, HbA1C, Fasting Insulin, and Insulin Resistance), and lipids (Cholesterol Total, LDL-c and HDL-c) outcomes (except for triglycerides level).\tAll observed changes (except for Cholesterol Total and LDL-c) were significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).', 'Cinnamon supplementation led to improvement of all anthropometric (BMI, body fat, and visceral fat), glycemic (FPG, 2hpp, HbA1C, Fasting Insulin, and Insulin Resistance), and lipids (Cholesterol Total, LDL-c and HDL-c) outcomes (except for triglycerides level).\tBased on the study findings, cinnamon may improve anthropometric parameters, glycemic indices and lipid profile of patients with type II diabetes.', 'Cinnamon supplementation led to improvement of all anthropometric (BMI, body fat, and visceral fat), glycemic (FPG, 2hpp, HbA1C, Fasting Insulin, and Insulin Resistance), and lipids (Cholesterol Total, LDL-c and HDL-c) outcomes (except for triglycerides level).\tThese benefits are significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).', 'All observed changes (except for Cholesterol Total and LDL-c) were significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).\tMultiple studies have evaluated the hypoglycemic effect of cinnamon in patients with diabetes mellitus (DM) type II, with conflicting results.', 'All observed changes (except for Cholesterol Total and LDL-c) were significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).\tCinnamon supplementation led to improvement of all anthropometric (BMI, body fat, and visceral fat), glycemic (FPG, 2hpp, HbA1C, Fasting Insulin, and Insulin Resistance), and lipids (Cholesterol Total, LDL-c and HDL-c) outcomes (except for triglycerides level).', 'All observed changes (except for Cholesterol Total and LDL-c) were significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).\tAll observed changes (except for Cholesterol Total and LDL-c) were significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).', 'All observed changes (except for Cholesterol Total and LDL-c) were significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).\tBased on the study findings, cinnamon may improve anthropometric parameters, glycemic indices and lipid profile of patients with type II diabetes.', 'All observed changes (except for Cholesterol Total and LDL-c) were significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).\tThese benefits are significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).', 'Based on the study findings, cinnamon may improve anthropometric parameters, glycemic indices and lipid profile of patients with type II diabetes.\tMultiple studies have evaluated the hypoglycemic effect of cinnamon in patients with diabetes mellitus (DM) type II, with conflicting results.', 'Based on the study findings, cinnamon may improve anthropometric parameters, glycemic indices and lipid profile of patients with type II diabetes.\tCinnamon supplementation led to improvement of all anthropometric (BMI, body fat, and visceral fat), glycemic (FPG, 2hpp, HbA1C, Fasting Insulin, and Insulin Resistance), and lipids (Cholesterol Total, LDL-c and HDL-c) outcomes (except for triglycerides level).', 'Based on the study findings, cinnamon may improve anthropometric parameters, glycemic indices and lipid profile of patients with type II diabetes.\tAll observed changes (except for Cholesterol Total and LDL-c) were significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).', 'Based on the study findings, cinnamon may improve anthropometric parameters, glycemic indices and lipid profile of patients with type II diabetes.\tBased on the study findings, cinnamon may improve anthropometric parameters, glycemic indices and lipid profile of patients with type II diabetes.', 'Based on the study findings, cinnamon may improve anthropometric parameters, glycemic indices and lipid profile of patients with type II diabetes.\tThese benefits are significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).', 'These benefits are significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).\tMultiple studies have evaluated the hypoglycemic effect of cinnamon in patients with diabetes mellitus (DM) type II, with conflicting results.', 'These benefits are significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).\tCinnamon supplementation led to improvement of all anthropometric (BMI, body fat, and visceral fat), glycemic (FPG, 2hpp, HbA1C, Fasting Insulin, and Insulin Resistance), and lipids (Cholesterol Total, LDL-c and HDL-c) outcomes (except for triglycerides level).', 'These benefits are significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).\tAll observed changes (except for Cholesterol Total and LDL-c) were significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).', 'These benefits are significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).\tBased on the study findings, cinnamon may improve anthropometric parameters, glycemic indices and lipid profile of patients with type II diabetes.', 'These benefits are significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).\tThese benefits are significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).']","[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['Time with nocturnal hypoglycemia, glucose levels <70\u2009mg/dL was reduced by 48% (10.2 vs. 19.6\u2009min each night, P\u2009<\u20090.001) and glucose levels <54\u2009mg/dL by 65%. (3.1 vs. 8.9\u2009min, P\u2009<\u20090.001).\tTime with nocturnal hypoglycemia, glucose levels <70\u2009mg/dL was reduced by 48% (10.2 vs. 19.6\u2009min each night, P\u2009<\u20090.001) and glucose levels <54\u2009mg/dL by 65%. (3.1 vs. 8.9\u2009min, P\u2009<\u20090.001).', 'Time with nocturnal hypoglycemia, glucose levels <70\u2009mg/dL was reduced by 48% (10.2 vs. 19.6\u2009min each night, P\u2009<\u20090.001) and glucose levels <54\u2009mg/dL by 65%. (3.1 vs. 8.9\u2009min, P\u2009<\u20090.001).\tFor the corresponding glucose cutoffs, daytime hypoglycemia was reduced by 40% (29 vs. 49\u2009min, P\u2009<\u20090.001) and 54% (8 vs. 18\u2009min., P\u2009<\u20090.001), respectively.', 'Time with nocturnal hypoglycemia, glucose levels <70\u2009mg/dL was reduced by 48% (10.2 vs. 19.6\u2009min each night, P\u2009<\u20090.001) and glucose levels <54\u2009mg/dL by 65%. (3.1 vs. 8.9\u2009min, P\u2009<\u20090.001).\tCompared with SMBG, CGM use improved hypoglycemia-related confidence in social situations (P\u2009=\u20090.016) and confidence in more broadly avoiding serious problems due to hypoglycemia (P\u2009=\u20090.0020).', 'Time with nocturnal hypoglycemia, glucose levels <70\u2009mg/dL was reduced by 48% (10.2 vs. 19.6\u2009min each night, P\u2009<\u20090.001) and glucose levels <54\u2009mg/dL by 65%. (3.1 vs. 8.9\u2009min, P\u2009<\u20090.001).\tPersons also reported greater confidence in detecting and responding to decreasing blood glucose levels (thereby avoiding hypoglycemia) during CGM use (P\u2009=\u20090.0033)', 'Time with nocturnal hypoglycemia, glucose levels <70\u2009mg/dL was reduced by 48% (10.2 vs. 19.6\u2009min each night, P\u2009<\u20090.001) and glucose levels <54\u2009mg/dL by 65%. (3.1 vs. 8.9\u2009min, P\u2009<\u20090.001).\tindicated greater conviction that they could more freely live their lives despite the risk of hypoglycemia (P\u2009=\u20090.022).', 'Time with nocturnal hypoglycemia, glucose levels <70\u2009mg/dL was reduced by 48% (10.2 vs. 19.6\u2009min each night, P\u2009<\u20090.001) and glucose levels <54\u2009mg/dL by 65%. (3.1 vs. 8.9\u2009min, P\u2009<\u20090.001).\tCGM reduced time in both nocturnal and daytime hypoglycemia in persons with type 1 diabetes treated with MDI and improved hypoglycemia-related confidence, especially in social situations, thus contributing to greater well-being and quality of life.', 'For the corresponding glucose cutoffs, daytime hypoglycemia was reduced by 40% (29 vs. 49\u2009min, P\u2009<\u20090.001) and 54% (8 vs. 18\u2009min., P\u2009<\u20090.001), respectively.\tTime with nocturnal hypoglycemia, glucose levels <70\u2009mg/dL was reduced by 48% (10.2 vs. 19.6\u2009min each night, P\u2009<\u20090.001) and glucose levels <54\u2009mg/dL by 65%. (3.1 vs. 8.9\u2009min, P\u2009<\u20090.001).', 'For the corresponding glucose cutoffs, daytime hypoglycemia was reduced by 40% (29 vs. 49\u2009min, P\u2009<\u20090.001) and 54% (8 vs. 18\u2009min., P\u2009<\u20090.001), respectively.\tFor the corresponding glucose cutoffs, daytime hypoglycemia was reduced by 40% (29 vs. 49\u2009min, P\u2009<\u20090.001) and 54% (8 vs. 18\u2009min., P\u2009<\u20090.001), respectively.', 'For the corresponding glucose cutoffs, daytime hypoglycemia was reduced by 40% (29 vs. 49\u2009min, P\u2009<\u20090.001) and 54% (8 vs. 18\u2009min., P\u2009<\u20090.001), respectively.\tCompared with SMBG, CGM use improved hypoglycemia-related confidence in social situations (P\u2009=\u20090.016) and confidence in more broadly avoiding serious problems due to hypoglycemia (P\u2009=\u20090.0020).', 'For the corresponding glucose cutoffs, daytime hypoglycemia was reduced by 40% (29 vs. 49\u2009min, P\u2009<\u20090.001) and 54% (8 vs. 18\u2009min., P\u2009<\u20090.001), respectively.\tPersons also reported greater confidence in detecting and responding to decreasing blood glucose levels (thereby avoiding hypoglycemia) during CGM use (P\u2009=\u20090.0033)', 'For the corresponding glucose cutoffs, daytime hypoglycemia was reduced by 40% (29 vs. 49\u2009min, P\u2009<\u20090.001) and 54% (8 vs. 18\u2009min., P\u2009<\u20090.001), respectively.\tindicated greater conviction that they could more freely live their lives despite the risk of hypoglycemia (P\u2009=\u20090.022).', 'For the corresponding glucose cutoffs, daytime hypoglycemia was reduced by 40% (29 vs. 49\u2009min, P\u2009<\u20090.001) and 54% (8 vs. 18\u2009min., P\u2009<\u20090.001), respectively.\tCGM reduced time in both nocturnal and daytime hypoglycemia in persons with type 1 diabetes treated with MDI and improved hypoglycemia-related confidence, especially in social situations, thus contributing to greater well-being and quality of life.', 'Compared with SMBG, CGM use improved hypoglycemia-related confidence in social situations (P\u2009=\u20090.016) and confidence in more broadly avoiding serious problems due to hypoglycemia (P\u2009=\u20090.0020).\tTime with nocturnal hypoglycemia, glucose levels <70\u2009mg/dL was reduced by 48% (10.2 vs. 19.6\u2009min each night, P\u2009<\u20090.001) and glucose levels <54\u2009mg/dL by 65%. (3.1 vs. 8.9\u2009min, P\u2009<\u20090.001).', 'Compared with SMBG, CGM use improved hypoglycemia-related confidence in social situations (P\u2009=\u20090.016) and confidence in more broadly avoiding serious problems due to hypoglycemia (P\u2009=\u20090.0020).\tFor the corresponding glucose cutoffs, daytime hypoglycemia was reduced by 40% (29 vs. 49\u2009min, P\u2009<\u20090.001) and 54% (8 vs. 18\u2009min., P\u2009<\u20090.001), respectively.', 'Compared with SMBG, CGM use improved hypoglycemia-related confidence in social situations (P\u2009=\u20090.016) and confidence in more broadly avoiding serious problems due to hypoglycemia (P\u2009=\u20090.0020).\tCompared with SMBG, CGM use improved hypoglycemia-related confidence in social situations (P\u2009=\u20090.016) and confidence in more broadly avoiding serious problems due to hypoglycemia (P\u2009=\u20090.0020).', 'Compared with SMBG, CGM use improved hypoglycemia-related confidence in social situations (P\u2009=\u20090.016) and confidence in more broadly avoiding serious problems due to hypoglycemia (P\u2009=\u20090.0020).\tPersons also reported greater confidence in detecting and responding to decreasing blood glucose levels (thereby avoiding hypoglycemia) during CGM use (P\u2009=\u20090.0033)', 'Compared with SMBG, CGM use improved hypoglycemia-related confidence in social situations (P\u2009=\u20090.016) and confidence in more broadly avoiding serious problems due to hypoglycemia (P\u2009=\u20090.0020).\tindicated greater conviction that they could more freely live their lives despite the risk of hypoglycemia (P\u2009=\u20090.022).', 'Compared with SMBG, CGM use improved hypoglycemia-related confidence in social situations (P\u2009=\u20090.016) and confidence in more broadly avoiding serious problems due to hypoglycemia (P\u2009=\u20090.0020).\tCGM reduced time in both nocturnal and daytime hypoglycemia in persons with type 1 diabetes treated with MDI and improved hypoglycemia-related confidence, especially in social situations, thus contributing to greater well-being and quality of life.', 'Persons also reported greater confidence in detecting and responding to decreasing blood glucose levels (thereby avoiding hypoglycemia) during CGM use (P\u2009=\u20090.0033)\tTime with nocturnal hypoglycemia, glucose levels <70\u2009mg/dL was reduced by 48% (10.2 vs. 19.6\u2009min each night, P\u2009<\u20090.001) and glucose levels <54\u2009mg/dL by 65%. (3.1 vs. 8.9\u2009min, P\u2009<\u20090.001).', 'Persons also reported greater confidence in detecting and responding to decreasing blood glucose levels (thereby avoiding hypoglycemia) during CGM use (P\u2009=\u20090.0033)\tFor the corresponding glucose cutoffs, daytime hypoglycemia was reduced by 40% (29 vs. 49\u2009min, P\u2009<\u20090.001) and 54% (8 vs. 18\u2009min., P\u2009<\u20090.001), respectively.', 'Persons also reported greater confidence in detecting and responding to decreasing blood glucose levels (thereby avoiding hypoglycemia) during CGM use (P\u2009=\u20090.0033)\tCompared with SMBG, CGM use improved hypoglycemia-related confidence in social situations (P\u2009=\u20090.016) and confidence in more broadly avoiding serious problems due to hypoglycemia (P\u2009=\u20090.0020).', 'Persons also reported greater confidence in detecting and responding to decreasing blood glucose levels (thereby avoiding hypoglycemia) during CGM use (P\u2009=\u20090.0033)\tPersons also reported greater confidence in detecting and responding to decreasing blood glucose levels (thereby avoiding hypoglycemia) during CGM use (P\u2009=\u20090.0033)', 'Persons also reported greater confidence in detecting and responding to decreasing blood glucose levels (thereby avoiding hypoglycemia) during CGM use (P\u2009=\u20090.0033)\tindicated greater conviction that they could more freely live their lives despite the risk of hypoglycemia (P\u2009=\u20090.022).', 'Persons also reported greater confidence in detecting and responding to decreasing blood glucose levels (thereby avoiding hypoglycemia) during CGM use (P\u2009=\u20090.0033)\tCGM reduced time in both nocturnal and daytime hypoglycemia in persons with type 1 diabetes treated with MDI and improved hypoglycemia-related confidence, especially in social situations, thus contributing to greater well-being and quality of life.', 'indicated greater conviction that they could more freely live their lives despite the risk of hypoglycemia (P\u2009=\u20090.022).\tTime with nocturnal hypoglycemia, glucose levels <70\u2009mg/dL was reduced by 48% (10.2 vs. 19.6\u2009min each night, P\u2009<\u20090.001) and glucose levels <54\u2009mg/dL by 65%. (3.1 vs. 8.9\u2009min, P\u2009<\u20090.001).', 'indicated greater conviction that they could more freely live their lives despite the risk of hypoglycemia (P\u2009=\u20090.022).\tFor the corresponding glucose cutoffs, daytime hypoglycemia was reduced by 40% (29 vs. 49\u2009min, P\u2009<\u20090.001) and 54% (8 vs. 18\u2009min., P\u2009<\u20090.001), respectively.', 'indicated greater conviction that they could more freely live their lives despite the risk of hypoglycemia (P\u2009=\u20090.022).\tCompared with SMBG, CGM use improved hypoglycemia-related confidence in social situations (P\u2009=\u20090.016) and confidence in more broadly avoiding serious problems due to hypoglycemia (P\u2009=\u20090.0020).', 'indicated greater conviction that they could more freely live their lives despite the risk of hypoglycemia (P\u2009=\u20090.022).\tPersons also reported greater confidence in detecting and responding to decreasing blood glucose levels (thereby avoiding hypoglycemia) during CGM use (P\u2009=\u20090.0033)', 'indicated greater conviction that they could more freely live their lives despite the risk of hypoglycemia (P\u2009=\u20090.022).\tindicated greater conviction that they could more freely live their lives despite the risk of hypoglycemia (P\u2009=\u20090.022).', 'indicated greater conviction that they could more freely live their lives despite the risk of hypoglycemia (P\u2009=\u20090.022).\tCGM reduced time in both nocturnal and daytime hypoglycemia in persons with type 1 diabetes treated with MDI and improved hypoglycemia-related confidence, especially in social situations, thus contributing to greater well-being and quality of life.', 'CGM reduced time in both nocturnal and daytime hypoglycemia in persons with type 1 diabetes treated with MDI and improved hypoglycemia-related confidence, especially in social situations, thus contributing to greater well-being and quality of life.\tTime with nocturnal hypoglycemia, glucose levels <70\u2009mg/dL was reduced by 48% (10.2 vs. 19.6\u2009min each night, P\u2009<\u20090.001) and glucose levels <54\u2009mg/dL by 65%. (3.1 vs. 8.9\u2009min, P\u2009<\u20090.001).', 'CGM reduced time in both nocturnal and daytime hypoglycemia in persons with type 1 diabetes treated with MDI and improved hypoglycemia-related confidence, especially in social situations, thus contributing to greater well-being and quality of life.\tFor the corresponding glucose cutoffs, daytime hypoglycemia was reduced by 40% (29 vs. 49\u2009min, P\u2009<\u20090.001) and 54% (8 vs. 18\u2009min., P\u2009<\u20090.001), respectively.', 'CGM reduced time in both nocturnal and daytime hypoglycemia in persons with type 1 diabetes treated with MDI and improved hypoglycemia-related confidence, especially in social situations, thus contributing to greater well-being and quality of life.\tCompared with SMBG, CGM use improved hypoglycemia-related confidence in social situations (P\u2009=\u20090.016) and confidence in more broadly avoiding serious problems due to hypoglycemia (P\u2009=\u20090.0020).', 'CGM reduced time in both nocturnal and daytime hypoglycemia in persons with type 1 diabetes treated with MDI and improved hypoglycemia-related confidence, especially in social situations, thus contributing to greater well-being and quality of life.\tPersons also reported greater confidence in detecting and responding to decreasing blood glucose levels (thereby avoiding hypoglycemia) during CGM use (P\u2009=\u20090.0033)', 'CGM reduced time in both nocturnal and daytime hypoglycemia in persons with type 1 diabetes treated with MDI and improved hypoglycemia-related confidence, especially in social situations, thus contributing to greater well-being and quality of life.\tindicated greater conviction that they could more freely live their lives despite the risk of hypoglycemia (P\u2009=\u20090.022).', 'CGM reduced time in both nocturnal and daytime hypoglycemia in persons with type 1 diabetes treated with MDI and improved hypoglycemia-related confidence, especially in social situations, thus contributing to greater well-being and quality of life.\tCGM reduced time in both nocturnal and daytime hypoglycemia in persons with type 1 diabetes treated with MDI and improved hypoglycemia-related confidence, especially in social situations, thus contributing to greater well-being and quality of life.']","[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['There was a significant difference in post-intervention levels of urea, creatinine, sodium, potassium, calcium, and phosphorus between the two groups.\tThere was a significant difference in post-intervention levels of urea, creatinine, sodium, potassium, calcium, and phosphorus between the two groups.', 'There was a significant difference in post-intervention levels of urea, creatinine, sodium, potassium, calcium, and phosphorus between the two groups.\tAppropriate nutrition training via small-group method for patients on hemodialysis can impose positive effects on laboratory parameters.', 'Appropriate nutrition training via small-group method for patients on hemodialysis can impose positive effects on laboratory parameters.\tThere was a significant difference in post-intervention levels of urea, creatinine, sodium, potassium, calcium, and phosphorus between the two groups.', 'Appropriate nutrition training via small-group method for patients on hemodialysis can impose positive effects on laboratory parameters.\tAppropriate nutrition training via small-group method for patients on hemodialysis can impose positive effects on laboratory parameters.']","[0, 0, 0, 0]"
"['Survival advantage was significant with regular surveillance but not with irregular surveillance.\tSurvival advantage was significant with regular surveillance but not with irregular surveillance.', 'Survival advantage was significant with regular surveillance but not with irregular surveillance.\tPatients in the regular surveillance group were diagnosed at earlier stages ([very] early stage, 64.4%) than the irregular surveillance (40.4%) or nonsurveillance (26.9%) groups and had more chance for curative treatments (52.4%) than the irregular surveillance (39.4%) or nonsurveillance (23.3%) groups (all P < 0.001).', 'Survival advantage was significant with regular surveillance but not with irregular surveillance.\tMortality risk was significantly lower in the regular surveillance group (adjusted hazard ratio [aHR], 0.69; 95% [CI], 0.57-0.83) but not in the irregular surveillance group (aHR, 0.94; 95% CI, 0.69-1.28) compared with the nonsurveillance group after adjusting for confounding factors and lead-time.', 'Survival advantage was significant with regular surveillance but not with irregular surveillance.\tWhen the subjects were restricted to cirrhotic patients or Child-Pugh class A/B patients, similar results were obtained for mortality risk reduction between groups.', 'Survival advantage was significant with regular surveillance but not with irregular surveillance.\tHCC surveillance was associated with longer survival owing to earlier diagnosis and curative treatment.', 'Patients in the regular surveillance group were diagnosed at earlier stages ([very] early stage, 64.4%) than the irregular surveillance (40.4%) or nonsurveillance (26.9%) groups and had more chance for curative treatments (52.4%) than the irregular surveillance (39.4%) or nonsurveillance (23.3%) groups (all P < 0.001).\tSurvival advantage was significant with regular surveillance but not with irregular surveillance.', 'Patients in the regular surveillance group were diagnosed at earlier stages ([very] early stage, 64.4%) than the irregular surveillance (40.4%) or nonsurveillance (26.9%) groups and had more chance for curative treatments (52.4%) than the irregular surveillance (39.4%) or nonsurveillance (23.3%) groups (all P < 0.001).\tPatients in the regular surveillance group were diagnosed at earlier stages ([very] early stage, 64.4%) than the irregular surveillance (40.4%) or nonsurveillance (26.9%) groups and had more chance for curative treatments (52.4%) than the irregular surveillance (39.4%) or nonsurveillance (23.3%) groups (all P < 0.001).', 'Patients in the regular surveillance group were diagnosed at earlier stages ([very] early stage, 64.4%) than the irregular surveillance (40.4%) or nonsurveillance (26.9%) groups and had more chance for curative treatments (52.4%) than the irregular surveillance (39.4%) or nonsurveillance (23.3%) groups (all P < 0.001).\tMortality risk was significantly lower in the regular surveillance group (adjusted hazard ratio [aHR], 0.69; 95% [CI], 0.57-0.83) but not in the irregular surveillance group (aHR, 0.94; 95% CI, 0.69-1.28) compared with the nonsurveillance group after adjusting for confounding factors and lead-time.', 'Patients in the regular surveillance group were diagnosed at earlier stages ([very] early stage, 64.4%) than the irregular surveillance (40.4%) or nonsurveillance (26.9%) groups and had more chance for curative treatments (52.4%) than the irregular surveillance (39.4%) or nonsurveillance (23.3%) groups (all P < 0.001).\tWhen the subjects were restricted to cirrhotic patients or Child-Pugh class A/B patients, similar results were obtained for mortality risk reduction between groups.', 'Patients in the regular surveillance group were diagnosed at earlier stages ([very] early stage, 64.4%) than the irregular surveillance (40.4%) or nonsurveillance (26.9%) groups and had more chance for curative treatments (52.4%) than the irregular surveillance (39.4%) or nonsurveillance (23.3%) groups (all P < 0.001).\tHCC surveillance was associated with longer survival owing to earlier diagnosis and curative treatment.', 'Mortality risk was significantly lower in the regular surveillance group (adjusted hazard ratio [aHR], 0.69; 95% [CI], 0.57-0.83) but not in the irregular surveillance group (aHR, 0.94; 95% CI, 0.69-1.28) compared with the nonsurveillance group after adjusting for confounding factors and lead-time.\tSurvival advantage was significant with regular surveillance but not with irregular surveillance.', 'Mortality risk was significantly lower in the regular surveillance group (adjusted hazard ratio [aHR], 0.69; 95% [CI], 0.57-0.83) but not in the irregular surveillance group (aHR, 0.94; 95% CI, 0.69-1.28) compared with the nonsurveillance group after adjusting for confounding factors and lead-time.\tPatients in the regular surveillance group were diagnosed at earlier stages ([very] early stage, 64.4%) than the irregular surveillance (40.4%) or nonsurveillance (26.9%) groups and had more chance for curative treatments (52.4%) than the irregular surveillance (39.4%) or nonsurveillance (23.3%) groups (all P < 0.001).', 'Mortality risk was significantly lower in the regular surveillance group (adjusted hazard ratio [aHR], 0.69; 95% [CI], 0.57-0.83) but not in the irregular surveillance group (aHR, 0.94; 95% CI, 0.69-1.28) compared with the nonsurveillance group after adjusting for confounding factors and lead-time.\tMortality risk was significantly lower in the regular surveillance group (adjusted hazard ratio [aHR], 0.69; 95% [CI], 0.57-0.83) but not in the irregular surveillance group (aHR, 0.94; 95% CI, 0.69-1.28) compared with the nonsurveillance group after adjusting for confounding factors and lead-time.', 'Mortality risk was significantly lower in the regular surveillance group (adjusted hazard ratio [aHR], 0.69; 95% [CI], 0.57-0.83) but not in the irregular surveillance group (aHR, 0.94; 95% CI, 0.69-1.28) compared with the nonsurveillance group after adjusting for confounding factors and lead-time.\tWhen the subjects were restricted to cirrhotic patients or Child-Pugh class A/B patients, similar results were obtained for mortality risk reduction between groups.', 'Mortality risk was significantly lower in the regular surveillance group (adjusted hazard ratio [aHR], 0.69; 95% [CI], 0.57-0.83) but not in the irregular surveillance group (aHR, 0.94; 95% CI, 0.69-1.28) compared with the nonsurveillance group after adjusting for confounding factors and lead-time.\tHCC surveillance was associated with longer survival owing to earlier diagnosis and curative treatment.', 'When the subjects were restricted to cirrhotic patients or Child-Pugh class A/B patients, similar results were obtained for mortality risk reduction between groups.\tSurvival advantage was significant with regular surveillance but not with irregular surveillance.', 'When the subjects were restricted to cirrhotic patients or Child-Pugh class A/B patients, similar results were obtained for mortality risk reduction between groups.\tPatients in the regular surveillance group were diagnosed at earlier stages ([very] early stage, 64.4%) than the irregular surveillance (40.4%) or nonsurveillance (26.9%) groups and had more chance for curative treatments (52.4%) than the irregular surveillance (39.4%) or nonsurveillance (23.3%) groups (all P < 0.001).', 'When the subjects were restricted to cirrhotic patients or Child-Pugh class A/B patients, similar results were obtained for mortality risk reduction between groups.\tMortality risk was significantly lower in the regular surveillance group (adjusted hazard ratio [aHR], 0.69; 95% [CI], 0.57-0.83) but not in the irregular surveillance group (aHR, 0.94; 95% CI, 0.69-1.28) compared with the nonsurveillance group after adjusting for confounding factors and lead-time.', 'When the subjects were restricted to cirrhotic patients or Child-Pugh class A/B patients, similar results were obtained for mortality risk reduction between groups.\tWhen the subjects were restricted to cirrhotic patients or Child-Pugh class A/B patients, similar results were obtained for mortality risk reduction between groups.', 'When the subjects were restricted to cirrhotic patients or Child-Pugh class A/B patients, similar results were obtained for mortality risk reduction between groups.\tHCC surveillance was associated with longer survival owing to earlier diagnosis and curative treatment.', 'HCC surveillance was associated with longer survival owing to earlier diagnosis and curative treatment.\tSurvival advantage was significant with regular surveillance but not with irregular surveillance.', 'HCC surveillance was associated with longer survival owing to earlier diagnosis and curative treatment.\tPatients in the regular surveillance group were diagnosed at earlier stages ([very] early stage, 64.4%) than the irregular surveillance (40.4%) or nonsurveillance (26.9%) groups and had more chance for curative treatments (52.4%) than the irregular surveillance (39.4%) or nonsurveillance (23.3%) groups (all P < 0.001).', 'HCC surveillance was associated with longer survival owing to earlier diagnosis and curative treatment.\tMortality risk was significantly lower in the regular surveillance group (adjusted hazard ratio [aHR], 0.69; 95% [CI], 0.57-0.83) but not in the irregular surveillance group (aHR, 0.94; 95% CI, 0.69-1.28) compared with the nonsurveillance group after adjusting for confounding factors and lead-time.', 'HCC surveillance was associated with longer survival owing to earlier diagnosis and curative treatment.\tWhen the subjects were restricted to cirrhotic patients or Child-Pugh class A/B patients, similar results were obtained for mortality risk reduction between groups.', 'HCC surveillance was associated with longer survival owing to earlier diagnosis and curative treatment.\tHCC surveillance was associated with longer survival owing to earlier diagnosis and curative treatment.']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['At the end of the study, the mean systolic blood pressure (SBP) of the ISH LSSalt group had significantly decreased by 10.18 mm Hg (95% confidence interval (CI): 3.13 to 17.2, P\u200a=\u200a.006) compared with that of the ISH NSalt group,\tAt the end of the study, the mean systolic blood pressure (SBP) of the ISH LSSalt group had significantly decreased by 10.18 mm Hg (95% confidence interval (CI): 3.13 to 17.2, P\u200a=\u200a.006) compared with that of the ISH NSalt group,', 'At the end of the study, the mean systolic blood pressure (SBP) of the ISH LSSalt group had significantly decreased by 10.18 mm Hg (95% confidence interval (CI): 3.13 to 17.2, P\u200a=\u200a.006) compared with that of the ISH NSalt group,\tthe mean SBP only decreased by 5.10 mm Hg (95% CI: -2.02 to 12.2, P\u200a=\u200a.158) in the NISH LSSalt group compared with that of the NISH NSalt group.', 'At the end of the study, the mean systolic blood pressure (SBP) of the ISH LSSalt group had significantly decreased by 10.18 mm Hg (95% confidence interval (CI): 3.13 to 17.2, P\u200a=\u200a.006) compared with that of the ISH NSalt group,\tThe mean diastolic blood pressure (DBP) had no significant differences in the ISH and NISH groups.', 'At the end of the study, the mean systolic blood pressure (SBP) of the ISH LSSalt group had significantly decreased by 10.18 mm Hg (95% confidence interval (CI): 3.13 to 17.2, P\u200a=\u200a.006) compared with that of the ISH NSalt group,\tNo obvious renin angiotensin system activation was found after LSSalt intervention.', 'At the end of the study, the mean systolic blood pressure (SBP) of the ISH LSSalt group had significantly decreased by 10.18 mm Hg (95% confidence interval (CI): 3.13 to 17.2, P\u200a=\u200a.006) compared with that of the ISH NSalt group,\tThe present study showed that the SBP of ISH patients was significantly decreased with the LSSalt intervention,', 'At the end of the study, the mean systolic blood pressure (SBP) of the ISH LSSalt group had significantly decreased by 10.18 mm Hg (95% confidence interval (CI): 3.13 to 17.2, P\u200a=\u200a.006) compared with that of the ISH NSalt group,\tneither the SBP of the NISH patients nor the DBP of either group were similarly decreased, which indicated that ISH patients were more sensitive to salt restriction.', 'At the end of the study, the mean systolic blood pressure (SBP) of the ISH LSSalt group had significantly decreased by 10.18 mm Hg (95% confidence interval (CI): 3.13 to 17.2, P\u200a=\u200a.006) compared with that of the ISH NSalt group,\tRegarding the urinary excretion of electrolytes and blood biochemical assays, the LSSalt treatment had the same effects on the ISH group as on the NISH group.', 'At the end of the study, the mean systolic blood pressure (SBP) of the ISH LSSalt group had significantly decreased by 10.18 mm Hg (95% confidence interval (CI): 3.13 to 17.2, P\u200a=\u200a.006) compared with that of the ISH NSalt group,\tEvidence has shown that long-term sodium reduction can not only reduce blood pressure, but also provide cardiovascular benefits.', 'the mean SBP only decreased by 5.10 mm Hg (95% CI: -2.02 to 12.2, P\u200a=\u200a.158) in the NISH LSSalt group compared with that of the NISH NSalt group.\tAt the end of the study, the mean systolic blood pressure (SBP) of the ISH LSSalt group had significantly decreased by 10.18 mm Hg (95% confidence interval (CI): 3.13 to 17.2, P\u200a=\u200a.006) compared with that of the ISH NSalt group,', 'the mean SBP only decreased by 5.10 mm Hg (95% CI: -2.02 to 12.2, P\u200a=\u200a.158) in the NISH LSSalt group compared with that of the NISH NSalt group.\tthe mean SBP only decreased by 5.10 mm Hg (95% CI: -2.02 to 12.2, P\u200a=\u200a.158) in the NISH LSSalt group compared with that of the NISH NSalt group.', 'the mean SBP only decreased by 5.10 mm Hg (95% CI: -2.02 to 12.2, P\u200a=\u200a.158) in the NISH LSSalt group compared with that of the NISH NSalt group.\tThe mean diastolic blood pressure (DBP) had no significant differences in the ISH and NISH groups.', 'the mean SBP only decreased by 5.10 mm Hg (95% CI: -2.02 to 12.2, P\u200a=\u200a.158) in the NISH LSSalt group compared with that of the NISH NSalt group.\tNo obvious renin angiotensin system activation was found after LSSalt intervention.', 'the mean SBP only decreased by 5.10 mm Hg (95% CI: -2.02 to 12.2, P\u200a=\u200a.158) in the NISH LSSalt group compared with that of the NISH NSalt group.\tThe present study showed that the SBP of ISH patients was significantly decreased with the LSSalt intervention,', 'the mean SBP only decreased by 5.10 mm Hg (95% CI: -2.02 to 12.2, P\u200a=\u200a.158) in the NISH LSSalt group compared with that of the NISH NSalt group.\tneither the SBP of the NISH patients nor the DBP of either group were similarly decreased, which indicated that ISH patients were more sensitive to salt restriction.', 'the mean SBP only decreased by 5.10 mm Hg (95% CI: -2.02 to 12.2, P\u200a=\u200a.158) in the NISH LSSalt group compared with that of the NISH NSalt group.\tRegarding the urinary excretion of electrolytes and blood biochemical assays, the LSSalt treatment had the same effects on the ISH group as on the NISH group.', 'the mean SBP only decreased by 5.10 mm Hg (95% CI: -2.02 to 12.2, P\u200a=\u200a.158) in the NISH LSSalt group compared with that of the NISH NSalt group.\tEvidence has shown that long-term sodium reduction can not only reduce blood pressure, but also provide cardiovascular benefits.', 'The mean diastolic blood pressure (DBP) had no significant differences in the ISH and NISH groups.\tAt the end of the study, the mean systolic blood pressure (SBP) of the ISH LSSalt group had significantly decreased by 10.18 mm Hg (95% confidence interval (CI): 3.13 to 17.2, P\u200a=\u200a.006) compared with that of the ISH NSalt group,', 'The mean diastolic blood pressure (DBP) had no significant differences in the ISH and NISH groups.\tthe mean SBP only decreased by 5.10 mm Hg (95% CI: -2.02 to 12.2, P\u200a=\u200a.158) in the NISH LSSalt group compared with that of the NISH NSalt group.', 'The mean diastolic blood pressure (DBP) had no significant differences in the ISH and NISH groups.\tThe mean diastolic blood pressure (DBP) had no significant differences in the ISH and NISH groups.', 'The mean diastolic blood pressure (DBP) had no significant differences in the ISH and NISH groups.\tNo obvious renin angiotensin system activation was found after LSSalt intervention.', 'The mean diastolic blood pressure (DBP) had no significant differences in the ISH and NISH groups.\tThe present study showed that the SBP of ISH patients was significantly decreased with the LSSalt intervention,', 'The mean diastolic blood pressure (DBP) had no significant differences in the ISH and NISH groups.\tneither the SBP of the NISH patients nor the DBP of either group were similarly decreased, which indicated that ISH patients were more sensitive to salt restriction.', 'The mean diastolic blood pressure (DBP) had no significant differences in the ISH and NISH groups.\tRegarding the urinary excretion of electrolytes and blood biochemical assays, the LSSalt treatment had the same effects on the ISH group as on the NISH group.', 'The mean diastolic blood pressure (DBP) had no significant differences in the ISH and NISH groups.\tEvidence has shown that long-term sodium reduction can not only reduce blood pressure, but also provide cardiovascular benefits.', 'No obvious renin angiotensin system activation was found after LSSalt intervention.\tAt the end of the study, the mean systolic blood pressure (SBP) of the ISH LSSalt group had significantly decreased by 10.18 mm Hg (95% confidence interval (CI): 3.13 to 17.2, P\u200a=\u200a.006) compared with that of the ISH NSalt group,', 'No obvious renin angiotensin system activation was found after LSSalt intervention.\tthe mean SBP only decreased by 5.10 mm Hg (95% CI: -2.02 to 12.2, P\u200a=\u200a.158) in the NISH LSSalt group compared with that of the NISH NSalt group.', 'No obvious renin angiotensin system activation was found after LSSalt intervention.\tThe mean diastolic blood pressure (DBP) had no significant differences in the ISH and NISH groups.', 'No obvious renin angiotensin system activation was found after LSSalt intervention.\tNo obvious renin angiotensin system activation was found after LSSalt intervention.', 'No obvious renin angiotensin system activation was found after LSSalt intervention.\tThe present study showed that the SBP of ISH patients was significantly decreased with the LSSalt intervention,', 'No obvious renin angiotensin system activation was found after LSSalt intervention.\tneither the SBP of the NISH patients nor the DBP of either group were similarly decreased, which indicated that ISH patients were more sensitive to salt restriction.', 'No obvious renin angiotensin system activation was found after LSSalt intervention.\tRegarding the urinary excretion of electrolytes and blood biochemical assays, the LSSalt treatment had the same effects on the ISH group as on the NISH group.', 'No obvious renin angiotensin system activation was found after LSSalt intervention.\tEvidence has shown that long-term sodium reduction can not only reduce blood pressure, but also provide cardiovascular benefits.', 'The present study showed that the SBP of ISH patients was significantly decreased with the LSSalt intervention,\tAt the end of the study, the mean systolic blood pressure (SBP) of the ISH LSSalt group had significantly decreased by 10.18 mm Hg (95% confidence interval (CI): 3.13 to 17.2, P\u200a=\u200a.006) compared with that of the ISH NSalt group,', 'The present study showed that the SBP of ISH patients was significantly decreased with the LSSalt intervention,\tthe mean SBP only decreased by 5.10 mm Hg (95% CI: -2.02 to 12.2, P\u200a=\u200a.158) in the NISH LSSalt group compared with that of the NISH NSalt group.', 'The present study showed that the SBP of ISH patients was significantly decreased with the LSSalt intervention,\tThe mean diastolic blood pressure (DBP) had no significant differences in the ISH and NISH groups.', 'The present study showed that the SBP of ISH patients was significantly decreased with the LSSalt intervention,\tNo obvious renin angiotensin system activation was found after LSSalt intervention.', 'The present study showed that the SBP of ISH patients was significantly decreased with the LSSalt intervention,\tThe present study showed that the SBP of ISH patients was significantly decreased with the LSSalt intervention,', 'The present study showed that the SBP of ISH patients was significantly decreased with the LSSalt intervention,\tneither the SBP of the NISH patients nor the DBP of either group were similarly decreased, which indicated that ISH patients were more sensitive to salt restriction.', 'The present study showed that the SBP of ISH patients was significantly decreased with the LSSalt intervention,\tRegarding the urinary excretion of electrolytes and blood biochemical assays, the LSSalt treatment had the same effects on the ISH group as on the NISH group.', 'The present study showed that the SBP of ISH patients was significantly decreased with the LSSalt intervention,\tEvidence has shown that long-term sodium reduction can not only reduce blood pressure, but also provide cardiovascular benefits.', 'neither the SBP of the NISH patients nor the DBP of either group were similarly decreased, which indicated that ISH patients were more sensitive to salt restriction.\tAt the end of the study, the mean systolic blood pressure (SBP) of the ISH LSSalt group had significantly decreased by 10.18 mm Hg (95% confidence interval (CI): 3.13 to 17.2, P\u200a=\u200a.006) compared with that of the ISH NSalt group,', 'neither the SBP of the NISH patients nor the DBP of either group were similarly decreased, which indicated that ISH patients were more sensitive to salt restriction.\tthe mean SBP only decreased by 5.10 mm Hg (95% CI: -2.02 to 12.2, P\u200a=\u200a.158) in the NISH LSSalt group compared with that of the NISH NSalt group.', 'neither the SBP of the NISH patients nor the DBP of either group were similarly decreased, which indicated that ISH patients were more sensitive to salt restriction.\tThe mean diastolic blood pressure (DBP) had no significant differences in the ISH and NISH groups.', 'neither the SBP of the NISH patients nor the DBP of either group were similarly decreased, which indicated that ISH patients were more sensitive to salt restriction.\tNo obvious renin angiotensin system activation was found after LSSalt intervention.', 'neither the SBP of the NISH patients nor the DBP of either group were similarly decreased, which indicated that ISH patients were more sensitive to salt restriction.\tThe present study showed that the SBP of ISH patients was significantly decreased with the LSSalt intervention,', 'neither the SBP of the NISH patients nor the DBP of either group were similarly decreased, which indicated that ISH patients were more sensitive to salt restriction.\tneither the SBP of the NISH patients nor the DBP of either group were similarly decreased, which indicated that ISH patients were more sensitive to salt restriction.', 'neither the SBP of the NISH patients nor the DBP of either group were similarly decreased, which indicated that ISH patients were more sensitive to salt restriction.\tRegarding the urinary excretion of electrolytes and blood biochemical assays, the LSSalt treatment had the same effects on the ISH group as on the NISH group.', 'neither the SBP of the NISH patients nor the DBP of either group were similarly decreased, which indicated that ISH patients were more sensitive to salt restriction.\tEvidence has shown that long-term sodium reduction can not only reduce blood pressure, but also provide cardiovascular benefits.', 'Regarding the urinary excretion of electrolytes and blood biochemical assays, the LSSalt treatment had the same effects on the ISH group as on the NISH group.\tAt the end of the study, the mean systolic blood pressure (SBP) of the ISH LSSalt group had significantly decreased by 10.18 mm Hg (95% confidence interval (CI): 3.13 to 17.2, P\u200a=\u200a.006) compared with that of the ISH NSalt group,', 'Regarding the urinary excretion of electrolytes and blood biochemical assays, the LSSalt treatment had the same effects on the ISH group as on the NISH group.\tthe mean SBP only decreased by 5.10 mm Hg (95% CI: -2.02 to 12.2, P\u200a=\u200a.158) in the NISH LSSalt group compared with that of the NISH NSalt group.', 'Regarding the urinary excretion of electrolytes and blood biochemical assays, the LSSalt treatment had the same effects on the ISH group as on the NISH group.\tThe mean diastolic blood pressure (DBP) had no significant differences in the ISH and NISH groups.', 'Regarding the urinary excretion of electrolytes and blood biochemical assays, the LSSalt treatment had the same effects on the ISH group as on the NISH group.\tNo obvious renin angiotensin system activation was found after LSSalt intervention.', 'Regarding the urinary excretion of electrolytes and blood biochemical assays, the LSSalt treatment had the same effects on the ISH group as on the NISH group.\tThe present study showed that the SBP of ISH patients was significantly decreased with the LSSalt intervention,', 'Regarding the urinary excretion of electrolytes and blood biochemical assays, the LSSalt treatment had the same effects on the ISH group as on the NISH group.\tneither the SBP of the NISH patients nor the DBP of either group were similarly decreased, which indicated that ISH patients were more sensitive to salt restriction.', 'Regarding the urinary excretion of electrolytes and blood biochemical assays, the LSSalt treatment had the same effects on the ISH group as on the NISH group.\tRegarding the urinary excretion of electrolytes and blood biochemical assays, the LSSalt treatment had the same effects on the ISH group as on the NISH group.', 'Regarding the urinary excretion of electrolytes and blood biochemical assays, the LSSalt treatment had the same effects on the ISH group as on the NISH group.\tEvidence has shown that long-term sodium reduction can not only reduce blood pressure, but also provide cardiovascular benefits.', 'Evidence has shown that long-term sodium reduction can not only reduce blood pressure, but also provide cardiovascular benefits.\tAt the end of the study, the mean systolic blood pressure (SBP) of the ISH LSSalt group had significantly decreased by 10.18 mm Hg (95% confidence interval (CI): 3.13 to 17.2, P\u200a=\u200a.006) compared with that of the ISH NSalt group,', 'Evidence has shown that long-term sodium reduction can not only reduce blood pressure, but also provide cardiovascular benefits.\tthe mean SBP only decreased by 5.10 mm Hg (95% CI: -2.02 to 12.2, P\u200a=\u200a.158) in the NISH LSSalt group compared with that of the NISH NSalt group.', 'Evidence has shown that long-term sodium reduction can not only reduce blood pressure, but also provide cardiovascular benefits.\tThe mean diastolic blood pressure (DBP) had no significant differences in the ISH and NISH groups.', 'Evidence has shown that long-term sodium reduction can not only reduce blood pressure, but also provide cardiovascular benefits.\tNo obvious renin angiotensin system activation was found after LSSalt intervention.', 'Evidence has shown that long-term sodium reduction can not only reduce blood pressure, but also provide cardiovascular benefits.\tThe present study showed that the SBP of ISH patients was significantly decreased with the LSSalt intervention,', 'Evidence has shown that long-term sodium reduction can not only reduce blood pressure, but also provide cardiovascular benefits.\tneither the SBP of the NISH patients nor the DBP of either group were similarly decreased, which indicated that ISH patients were more sensitive to salt restriction.', 'Evidence has shown that long-term sodium reduction can not only reduce blood pressure, but also provide cardiovascular benefits.\tRegarding the urinary excretion of electrolytes and blood biochemical assays, the LSSalt treatment had the same effects on the ISH group as on the NISH group.', 'Evidence has shown that long-term sodium reduction can not only reduce blood pressure, but also provide cardiovascular benefits.\tEvidence has shown that long-term sodium reduction can not only reduce blood pressure, but also provide cardiovascular benefits.']","[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['Changes in UACR category were not different among treatment groups at the 52-week visit (global P = 0.29).\tChanges in UACR category were not different among treatment groups at the 52-week visit (global P = 0.29).', 'Changes in UACR category were not different among treatment groups at the 52-week visit (global P = 0.29).\tAverage change in mean arterial pressure from baseline to 2 years was -1.2 ± 15, -1.8 ± 13.5, -2.6 ± 14.4 mm Hg in the aflibercept, bevacizumab, and ranibizumab groups, respectively (global P = 0.69).', 'Changes in UACR category were not different among treatment groups at the 52-week visit (global P = 0.29).\tThere do not appear to be treatment group differences for changes in blood pressure or UACR as a reflection of kidney function in patients with DME treated with aflibercept, bevacizumab, or ranibizumab.', 'Average change in mean arterial pressure from baseline to 2 years was -1.2 ± 15, -1.8 ± 13.5, -2.6 ± 14.4 mm Hg in the aflibercept, bevacizumab, and ranibizumab groups, respectively (global P = 0.69).\tChanges in UACR category were not different among treatment groups at the 52-week visit (global P = 0.29).', 'Average change in mean arterial pressure from baseline to 2 years was -1.2 ± 15, -1.8 ± 13.5, -2.6 ± 14.4 mm Hg in the aflibercept, bevacizumab, and ranibizumab groups, respectively (global P = 0.69).\tAverage change in mean arterial pressure from baseline to 2 years was -1.2 ± 15, -1.8 ± 13.5, -2.6 ± 14.4 mm Hg in the aflibercept, bevacizumab, and ranibizumab groups, respectively (global P = 0.69).', 'Average change in mean arterial pressure from baseline to 2 years was -1.2 ± 15, -1.8 ± 13.5, -2.6 ± 14.4 mm Hg in the aflibercept, bevacizumab, and ranibizumab groups, respectively (global P = 0.69).\tThere do not appear to be treatment group differences for changes in blood pressure or UACR as a reflection of kidney function in patients with DME treated with aflibercept, bevacizumab, or ranibizumab.', 'There do not appear to be treatment group differences for changes in blood pressure or UACR as a reflection of kidney function in patients with DME treated with aflibercept, bevacizumab, or ranibizumab.\tChanges in UACR category were not different among treatment groups at the 52-week visit (global P = 0.29).', 'There do not appear to be treatment group differences for changes in blood pressure or UACR as a reflection of kidney function in patients with DME treated with aflibercept, bevacizumab, or ranibizumab.\tAverage change in mean arterial pressure from baseline to 2 years was -1.2 ± 15, -1.8 ± 13.5, -2.6 ± 14.4 mm Hg in the aflibercept, bevacizumab, and ranibizumab groups, respectively (global P = 0.69).', 'There do not appear to be treatment group differences for changes in blood pressure or UACR as a reflection of kidney function in patients with DME treated with aflibercept, bevacizumab, or ranibizumab.\tThere do not appear to be treatment group differences for changes in blood pressure or UACR as a reflection of kidney function in patients with DME treated with aflibercept, bevacizumab, or ranibizumab.']","[0, 0, 1, 0, 0, 1, 0, 0, 0]"
"['anthracyclines are effective chemotherapeutic agents for treating B-cell lymphoma,\tanthracyclines are effective chemotherapeutic agents for treating B-cell lymphoma,', 'anthracyclines are effective chemotherapeutic agents for treating B-cell lymphoma,\tadverse effects, such as bone marrow suppression and cardiotoxicity, limit their clinical application.', 'anthracyclines are effective chemotherapeutic agents for treating B-cell lymphoma,\tCumulative anthracycline doses of 253-400 mg (HR: 2.35; 95% CI 1.41-3.91; p\u2009=\u20090.0010), 401-504 mg (HR: 2.26; 95% CI 1.26-4.05; p\u2009=\u20090.0063), and\u2009>\u2009504 mg (HR: 2.29; 95% CI 1.25-4.18; p\u2009=\u20090.0072) increased the incidence density of diabetes in a dose-dependent manner (p\u2009=\u20090.0006).', 'anthracyclines are effective chemotherapeutic agents for treating B-cell lymphoma,\tAnthracycline administration was associated with a higher incidence of diabetes (HR: 1.75; 95% CI 1.11-2.75; p\u2009=\u20090.0163) after adjustments for age, gender, cumulative dose of prednisolone, and co-morbidities.', 'anthracyclines are effective chemotherapeutic agents for treating B-cell lymphoma,\tThe annual alteration of adapted diabetes complications severity index score was not significantly different between B-cell lymphoma patients with or without anthracycline treatment (p\u2009=\u20090.4924).', 'anthracyclines are effective chemotherapeutic agents for treating B-cell lymphoma,\tAnthracycline therapy increases diabetes risk in a dose-dependent manner in B-cell lymphoma patients.', 'anthracyclines are effective chemotherapeutic agents for treating B-cell lymphoma,\tIntensive blood glucose monitoring and control should be recommended for B-cell lymphoma patients receiving anthracycline treatment.', 'adverse effects, such as bone marrow suppression and cardiotoxicity, limit their clinical application.\tanthracyclines are effective chemotherapeutic agents for treating B-cell lymphoma,', 'adverse effects, such as bone marrow suppression and cardiotoxicity, limit their clinical application.\tadverse effects, such as bone marrow suppression and cardiotoxicity, limit their clinical application.', 'adverse effects, such as bone marrow suppression and cardiotoxicity, limit their clinical application.\tCumulative anthracycline doses of 253-400 mg (HR: 2.35; 95% CI 1.41-3.91; p\u2009=\u20090.0010), 401-504 mg (HR: 2.26; 95% CI 1.26-4.05; p\u2009=\u20090.0063), and\u2009>\u2009504 mg (HR: 2.29; 95% CI 1.25-4.18; p\u2009=\u20090.0072) increased the incidence density of diabetes in a dose-dependent manner (p\u2009=\u20090.0006).', 'adverse effects, such as bone marrow suppression and cardiotoxicity, limit their clinical application.\tAnthracycline administration was associated with a higher incidence of diabetes (HR: 1.75; 95% CI 1.11-2.75; p\u2009=\u20090.0163) after adjustments for age, gender, cumulative dose of prednisolone, and co-morbidities.', 'adverse effects, such as bone marrow suppression and cardiotoxicity, limit their clinical application.\tThe annual alteration of adapted diabetes complications severity index score was not significantly different between B-cell lymphoma patients with or without anthracycline treatment (p\u2009=\u20090.4924).', 'adverse effects, such as bone marrow suppression and cardiotoxicity, limit their clinical application.\tAnthracycline therapy increases diabetes risk in a dose-dependent manner in B-cell lymphoma patients.', 'adverse effects, such as bone marrow suppression and cardiotoxicity, limit their clinical application.\tIntensive blood glucose monitoring and control should be recommended for B-cell lymphoma patients receiving anthracycline treatment.', 'Cumulative anthracycline doses of 253-400 mg (HR: 2.35; 95% CI 1.41-3.91; p\u2009=\u20090.0010), 401-504 mg (HR: 2.26; 95% CI 1.26-4.05; p\u2009=\u20090.0063), and\u2009>\u2009504 mg (HR: 2.29; 95% CI 1.25-4.18; p\u2009=\u20090.0072) increased the incidence density of diabetes in a dose-dependent manner (p\u2009=\u20090.0006).\tanthracyclines are effective chemotherapeutic agents for treating B-cell lymphoma,', 'Cumulative anthracycline doses of 253-400 mg (HR: 2.35; 95% CI 1.41-3.91; p\u2009=\u20090.0010), 401-504 mg (HR: 2.26; 95% CI 1.26-4.05; p\u2009=\u20090.0063), and\u2009>\u2009504 mg (HR: 2.29; 95% CI 1.25-4.18; p\u2009=\u20090.0072) increased the incidence density of diabetes in a dose-dependent manner (p\u2009=\u20090.0006).\tadverse effects, such as bone marrow suppression and cardiotoxicity, limit their clinical application.', 'Cumulative anthracycline doses of 253-400 mg (HR: 2.35; 95% CI 1.41-3.91; p\u2009=\u20090.0010), 401-504 mg (HR: 2.26; 95% CI 1.26-4.05; p\u2009=\u20090.0063), and\u2009>\u2009504 mg (HR: 2.29; 95% CI 1.25-4.18; p\u2009=\u20090.0072) increased the incidence density of diabetes in a dose-dependent manner (p\u2009=\u20090.0006).\tCumulative anthracycline doses of 253-400 mg (HR: 2.35; 95% CI 1.41-3.91; p\u2009=\u20090.0010), 401-504 mg (HR: 2.26; 95% CI 1.26-4.05; p\u2009=\u20090.0063), and\u2009>\u2009504 mg (HR: 2.29; 95% CI 1.25-4.18; p\u2009=\u20090.0072) increased the incidence density of diabetes in a dose-dependent manner (p\u2009=\u20090.0006).', 'Cumulative anthracycline doses of 253-400 mg (HR: 2.35; 95% CI 1.41-3.91; p\u2009=\u20090.0010), 401-504 mg (HR: 2.26; 95% CI 1.26-4.05; p\u2009=\u20090.0063), and\u2009>\u2009504 mg (HR: 2.29; 95% CI 1.25-4.18; p\u2009=\u20090.0072) increased the incidence density of diabetes in a dose-dependent manner (p\u2009=\u20090.0006).\tAnthracycline administration was associated with a higher incidence of diabetes (HR: 1.75; 95% CI 1.11-2.75; p\u2009=\u20090.0163) after adjustments for age, gender, cumulative dose of prednisolone, and co-morbidities.', 'Cumulative anthracycline doses of 253-400 mg (HR: 2.35; 95% CI 1.41-3.91; p\u2009=\u20090.0010), 401-504 mg (HR: 2.26; 95% CI 1.26-4.05; p\u2009=\u20090.0063), and\u2009>\u2009504 mg (HR: 2.29; 95% CI 1.25-4.18; p\u2009=\u20090.0072) increased the incidence density of diabetes in a dose-dependent manner (p\u2009=\u20090.0006).\tThe annual alteration of adapted diabetes complications severity index score was not significantly different between B-cell lymphoma patients with or without anthracycline treatment (p\u2009=\u20090.4924).', 'Cumulative anthracycline doses of 253-400 mg (HR: 2.35; 95% CI 1.41-3.91; p\u2009=\u20090.0010), 401-504 mg (HR: 2.26; 95% CI 1.26-4.05; p\u2009=\u20090.0063), and\u2009>\u2009504 mg (HR: 2.29; 95% CI 1.25-4.18; p\u2009=\u20090.0072) increased the incidence density of diabetes in a dose-dependent manner (p\u2009=\u20090.0006).\tAnthracycline therapy increases diabetes risk in a dose-dependent manner in B-cell lymphoma patients.', 'Cumulative anthracycline doses of 253-400 mg (HR: 2.35; 95% CI 1.41-3.91; p\u2009=\u20090.0010), 401-504 mg (HR: 2.26; 95% CI 1.26-4.05; p\u2009=\u20090.0063), and\u2009>\u2009504 mg (HR: 2.29; 95% CI 1.25-4.18; p\u2009=\u20090.0072) increased the incidence density of diabetes in a dose-dependent manner (p\u2009=\u20090.0006).\tIntensive blood glucose monitoring and control should be recommended for B-cell lymphoma patients receiving anthracycline treatment.', 'Anthracycline administration was associated with a higher incidence of diabetes (HR: 1.75; 95% CI 1.11-2.75; p\u2009=\u20090.0163) after adjustments for age, gender, cumulative dose of prednisolone, and co-morbidities.\tanthracyclines are effective chemotherapeutic agents for treating B-cell lymphoma,', 'Anthracycline administration was associated with a higher incidence of diabetes (HR: 1.75; 95% CI 1.11-2.75; p\u2009=\u20090.0163) after adjustments for age, gender, cumulative dose of prednisolone, and co-morbidities.\tadverse effects, such as bone marrow suppression and cardiotoxicity, limit their clinical application.', 'Anthracycline administration was associated with a higher incidence of diabetes (HR: 1.75; 95% CI 1.11-2.75; p\u2009=\u20090.0163) after adjustments for age, gender, cumulative dose of prednisolone, and co-morbidities.\tCumulative anthracycline doses of 253-400 mg (HR: 2.35; 95% CI 1.41-3.91; p\u2009=\u20090.0010), 401-504 mg (HR: 2.26; 95% CI 1.26-4.05; p\u2009=\u20090.0063), and\u2009>\u2009504 mg (HR: 2.29; 95% CI 1.25-4.18; p\u2009=\u20090.0072) increased the incidence density of diabetes in a dose-dependent manner (p\u2009=\u20090.0006).', 'Anthracycline administration was associated with a higher incidence of diabetes (HR: 1.75; 95% CI 1.11-2.75; p\u2009=\u20090.0163) after adjustments for age, gender, cumulative dose of prednisolone, and co-morbidities.\tAnthracycline administration was associated with a higher incidence of diabetes (HR: 1.75; 95% CI 1.11-2.75; p\u2009=\u20090.0163) after adjustments for age, gender, cumulative dose of prednisolone, and co-morbidities.', 'Anthracycline administration was associated with a higher incidence of diabetes (HR: 1.75; 95% CI 1.11-2.75; p\u2009=\u20090.0163) after adjustments for age, gender, cumulative dose of prednisolone, and co-morbidities.\tThe annual alteration of adapted diabetes complications severity index score was not significantly different between B-cell lymphoma patients with or without anthracycline treatment (p\u2009=\u20090.4924).', 'Anthracycline administration was associated with a higher incidence of diabetes (HR: 1.75; 95% CI 1.11-2.75; p\u2009=\u20090.0163) after adjustments for age, gender, cumulative dose of prednisolone, and co-morbidities.\tAnthracycline therapy increases diabetes risk in a dose-dependent manner in B-cell lymphoma patients.', 'Anthracycline administration was associated with a higher incidence of diabetes (HR: 1.75; 95% CI 1.11-2.75; p\u2009=\u20090.0163) after adjustments for age, gender, cumulative dose of prednisolone, and co-morbidities.\tIntensive blood glucose monitoring and control should be recommended for B-cell lymphoma patients receiving anthracycline treatment.', 'The annual alteration of adapted diabetes complications severity index score was not significantly different between B-cell lymphoma patients with or without anthracycline treatment (p\u2009=\u20090.4924).\tanthracyclines are effective chemotherapeutic agents for treating B-cell lymphoma,', 'The annual alteration of adapted diabetes complications severity index score was not significantly different between B-cell lymphoma patients with or without anthracycline treatment (p\u2009=\u20090.4924).\tadverse effects, such as bone marrow suppression and cardiotoxicity, limit their clinical application.', 'The annual alteration of adapted diabetes complications severity index score was not significantly different between B-cell lymphoma patients with or without anthracycline treatment (p\u2009=\u20090.4924).\tCumulative anthracycline doses of 253-400 mg (HR: 2.35; 95% CI 1.41-3.91; p\u2009=\u20090.0010), 401-504 mg (HR: 2.26; 95% CI 1.26-4.05; p\u2009=\u20090.0063), and\u2009>\u2009504 mg (HR: 2.29; 95% CI 1.25-4.18; p\u2009=\u20090.0072) increased the incidence density of diabetes in a dose-dependent manner (p\u2009=\u20090.0006).', 'The annual alteration of adapted diabetes complications severity index score was not significantly different between B-cell lymphoma patients with or without anthracycline treatment (p\u2009=\u20090.4924).\tAnthracycline administration was associated with a higher incidence of diabetes (HR: 1.75; 95% CI 1.11-2.75; p\u2009=\u20090.0163) after adjustments for age, gender, cumulative dose of prednisolone, and co-morbidities.', 'The annual alteration of adapted diabetes complications severity index score was not significantly different between B-cell lymphoma patients with or without anthracycline treatment (p\u2009=\u20090.4924).\tThe annual alteration of adapted diabetes complications severity index score was not significantly different between B-cell lymphoma patients with or without anthracycline treatment (p\u2009=\u20090.4924).', 'The annual alteration of adapted diabetes complications severity index score was not significantly different between B-cell lymphoma patients with or without anthracycline treatment (p\u2009=\u20090.4924).\tAnthracycline therapy increases diabetes risk in a dose-dependent manner in B-cell lymphoma patients.', 'The annual alteration of adapted diabetes complications severity index score was not significantly different between B-cell lymphoma patients with or without anthracycline treatment (p\u2009=\u20090.4924).\tIntensive blood glucose monitoring and control should be recommended for B-cell lymphoma patients receiving anthracycline treatment.', 'Anthracycline therapy increases diabetes risk in a dose-dependent manner in B-cell lymphoma patients.\tanthracyclines are effective chemotherapeutic agents for treating B-cell lymphoma,', 'Anthracycline therapy increases diabetes risk in a dose-dependent manner in B-cell lymphoma patients.\tadverse effects, such as bone marrow suppression and cardiotoxicity, limit their clinical application.', 'Anthracycline therapy increases diabetes risk in a dose-dependent manner in B-cell lymphoma patients.\tCumulative anthracycline doses of 253-400 mg (HR: 2.35; 95% CI 1.41-3.91; p\u2009=\u20090.0010), 401-504 mg (HR: 2.26; 95% CI 1.26-4.05; p\u2009=\u20090.0063), and\u2009>\u2009504 mg (HR: 2.29; 95% CI 1.25-4.18; p\u2009=\u20090.0072) increased the incidence density of diabetes in a dose-dependent manner (p\u2009=\u20090.0006).', 'Anthracycline therapy increases diabetes risk in a dose-dependent manner in B-cell lymphoma patients.\tAnthracycline administration was associated with a higher incidence of diabetes (HR: 1.75; 95% CI 1.11-2.75; p\u2009=\u20090.0163) after adjustments for age, gender, cumulative dose of prednisolone, and co-morbidities.', 'Anthracycline therapy increases diabetes risk in a dose-dependent manner in B-cell lymphoma patients.\tThe annual alteration of adapted diabetes complications severity index score was not significantly different between B-cell lymphoma patients with or without anthracycline treatment (p\u2009=\u20090.4924).', 'Anthracycline therapy increases diabetes risk in a dose-dependent manner in B-cell lymphoma patients.\tAnthracycline therapy increases diabetes risk in a dose-dependent manner in B-cell lymphoma patients.', 'Anthracycline therapy increases diabetes risk in a dose-dependent manner in B-cell lymphoma patients.\tIntensive blood glucose monitoring and control should be recommended for B-cell lymphoma patients receiving anthracycline treatment.', 'Intensive blood glucose monitoring and control should be recommended for B-cell lymphoma patients receiving anthracycline treatment.\tanthracyclines are effective chemotherapeutic agents for treating B-cell lymphoma,', 'Intensive blood glucose monitoring and control should be recommended for B-cell lymphoma patients receiving anthracycline treatment.\tadverse effects, such as bone marrow suppression and cardiotoxicity, limit their clinical application.', 'Intensive blood glucose monitoring and control should be recommended for B-cell lymphoma patients receiving anthracycline treatment.\tCumulative anthracycline doses of 253-400 mg (HR: 2.35; 95% CI 1.41-3.91; p\u2009=\u20090.0010), 401-504 mg (HR: 2.26; 95% CI 1.26-4.05; p\u2009=\u20090.0063), and\u2009>\u2009504 mg (HR: 2.29; 95% CI 1.25-4.18; p\u2009=\u20090.0072) increased the incidence density of diabetes in a dose-dependent manner (p\u2009=\u20090.0006).', 'Intensive blood glucose monitoring and control should be recommended for B-cell lymphoma patients receiving anthracycline treatment.\tAnthracycline administration was associated with a higher incidence of diabetes (HR: 1.75; 95% CI 1.11-2.75; p\u2009=\u20090.0163) after adjustments for age, gender, cumulative dose of prednisolone, and co-morbidities.', 'Intensive blood glucose monitoring and control should be recommended for B-cell lymphoma patients receiving anthracycline treatment.\tThe annual alteration of adapted diabetes complications severity index score was not significantly different between B-cell lymphoma patients with or without anthracycline treatment (p\u2009=\u20090.4924).', 'Intensive blood glucose monitoring and control should be recommended for B-cell lymphoma patients receiving anthracycline treatment.\tAnthracycline therapy increases diabetes risk in a dose-dependent manner in B-cell lymphoma patients.', 'Intensive blood glucose monitoring and control should be recommended for B-cell lymphoma patients receiving anthracycline treatment.\tIntensive blood glucose monitoring and control should be recommended for B-cell lymphoma patients receiving anthracycline treatment.']","[0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]"
"['Treatment-related quality of life (QOL) is an important aspect of diabetes management.\tTreatment-related quality of life (QOL) is an important aspect of diabetes management.', 'Treatment-related quality of life (QOL) is an important aspect of diabetes management.\tCompared with baseline data, total DTR-QOL17 scores were significantly higher after 12 weeks of linagliptin and voglibose treatment.', 'Treatment-related quality of life (QOL) is an important aspect of diabetes management.\tThe change in the total DTR-QOL17 score and the score of one domain, burden on social activities and daily activities, was significantly greater in the linagliptin group than in the voglibose group.', 'Treatment-related quality of life (QOL) is an important aspect of diabetes management.\tIn addition, only linagliptin treatment was identified as a factor associated with an increased total DTR-QOL17 score.', 'Treatment-related quality of life (QOL) is an important aspect of diabetes management.\tLinagliptin is superior to voglibose in terms of improving treatment-related QOL in Japanese patients with T2DM.', 'Compared with baseline data, total DTR-QOL17 scores were significantly higher after 12 weeks of linagliptin and voglibose treatment.\tTreatment-related quality of life (QOL) is an important aspect of diabetes management.', 'Compared with baseline data, total DTR-QOL17 scores were significantly higher after 12 weeks of linagliptin and voglibose treatment.\tCompared with baseline data, total DTR-QOL17 scores were significantly higher after 12 weeks of linagliptin and voglibose treatment.', 'Compared with baseline data, total DTR-QOL17 scores were significantly higher after 12 weeks of linagliptin and voglibose treatment.\tThe change in the total DTR-QOL17 score and the score of one domain, burden on social activities and daily activities, was significantly greater in the linagliptin group than in the voglibose group.', 'Compared with baseline data, total DTR-QOL17 scores were significantly higher after 12 weeks of linagliptin and voglibose treatment.\tIn addition, only linagliptin treatment was identified as a factor associated with an increased total DTR-QOL17 score.', 'Compared with baseline data, total DTR-QOL17 scores were significantly higher after 12 weeks of linagliptin and voglibose treatment.\tLinagliptin is superior to voglibose in terms of improving treatment-related QOL in Japanese patients with T2DM.', 'The change in the total DTR-QOL17 score and the score of one domain, burden on social activities and daily activities, was significantly greater in the linagliptin group than in the voglibose group.\tTreatment-related quality of life (QOL) is an important aspect of diabetes management.', 'The change in the total DTR-QOL17 score and the score of one domain, burden on social activities and daily activities, was significantly greater in the linagliptin group than in the voglibose group.\tCompared with baseline data, total DTR-QOL17 scores were significantly higher after 12 weeks of linagliptin and voglibose treatment.', 'The change in the total DTR-QOL17 score and the score of one domain, burden on social activities and daily activities, was significantly greater in the linagliptin group than in the voglibose group.\tThe change in the total DTR-QOL17 score and the score of one domain, burden on social activities and daily activities, was significantly greater in the linagliptin group than in the voglibose group.', 'The change in the total DTR-QOL17 score and the score of one domain, burden on social activities and daily activities, was significantly greater in the linagliptin group than in the voglibose group.\tIn addition, only linagliptin treatment was identified as a factor associated with an increased total DTR-QOL17 score.', 'The change in the total DTR-QOL17 score and the score of one domain, burden on social activities and daily activities, was significantly greater in the linagliptin group than in the voglibose group.\tLinagliptin is superior to voglibose in terms of improving treatment-related QOL in Japanese patients with T2DM.', 'In addition, only linagliptin treatment was identified as a factor associated with an increased total DTR-QOL17 score.\tTreatment-related quality of life (QOL) is an important aspect of diabetes management.', 'In addition, only linagliptin treatment was identified as a factor associated with an increased total DTR-QOL17 score.\tCompared with baseline data, total DTR-QOL17 scores were significantly higher after 12 weeks of linagliptin and voglibose treatment.', 'In addition, only linagliptin treatment was identified as a factor associated with an increased total DTR-QOL17 score.\tThe change in the total DTR-QOL17 score and the score of one domain, burden on social activities and daily activities, was significantly greater in the linagliptin group than in the voglibose group.', 'In addition, only linagliptin treatment was identified as a factor associated with an increased total DTR-QOL17 score.\tIn addition, only linagliptin treatment was identified as a factor associated with an increased total DTR-QOL17 score.', 'In addition, only linagliptin treatment was identified as a factor associated with an increased total DTR-QOL17 score.\tLinagliptin is superior to voglibose in terms of improving treatment-related QOL in Japanese patients with T2DM.', 'Linagliptin is superior to voglibose in terms of improving treatment-related QOL in Japanese patients with T2DM.\tTreatment-related quality of life (QOL) is an important aspect of diabetes management.', 'Linagliptin is superior to voglibose in terms of improving treatment-related QOL in Japanese patients with T2DM.\tCompared with baseline data, total DTR-QOL17 scores were significantly higher after 12 weeks of linagliptin and voglibose treatment.', 'Linagliptin is superior to voglibose in terms of improving treatment-related QOL in Japanese patients with T2DM.\tThe change in the total DTR-QOL17 score and the score of one domain, burden on social activities and daily activities, was significantly greater in the linagliptin group than in the voglibose group.', 'Linagliptin is superior to voglibose in terms of improving treatment-related QOL in Japanese patients with T2DM.\tIn addition, only linagliptin treatment was identified as a factor associated with an increased total DTR-QOL17 score.', 'Linagliptin is superior to voglibose in terms of improving treatment-related QOL in Japanese patients with T2DM.\tLinagliptin is superior to voglibose in terms of improving treatment-related QOL in Japanese patients with T2DM.']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0]"
"['KAMUT khorasan is an ancient grain with widely acclaimed health benefits.\tKAMUT khorasan is an ancient grain with widely acclaimed health benefits.', 'KAMUT khorasan is an ancient grain with widely acclaimed health benefits.\tThis study suggests that a short-term replacement diet with ancient KAMUT khorasan products is most effective in reducing metabolic risk factors and ameliorating the liver profile in patients with NAFLD.', 'KAMUT khorasan is an ancient grain with widely acclaimed health benefits.\tsignificant improvements in the liver steatosis grading, Doppler perfusion index values, and reactive oxygen species (ROS) production were evident after consumption of both the khorasan and control products.', 'KAMUT khorasan is an ancient grain with widely acclaimed health benefits.\tsignificant reductions in circulating proinflammatory tumor necrosis factor-alpha by 50%, interleukin l-receptor antagonist-alpha by 37%, interleukin-8 by 24%, and interferon gamma by 24% were evident only in participants who consumed the khorasan products (p < 0.05 for all).', 'KAMUT khorasan is an ancient grain with widely acclaimed health benefits.\tAfter the implementation of a general linear model for repeated measurements adjusted for baseline demographic details, risk factors, and medication, alanine aminotransferase (ALT) was significantly reduced by 12%, aspartate aminotransferase (AST) by 14%, alkaline phosphatase (ALP) by 8%, and cholesterol by 6% only in the khorasan group (p < 0.05 for all).', 'This study suggests that a short-term replacement diet with ancient KAMUT khorasan products is most effective in reducing metabolic risk factors and ameliorating the liver profile in patients with NAFLD.\tKAMUT khorasan is an ancient grain with widely acclaimed health benefits.', 'This study suggests that a short-term replacement diet with ancient KAMUT khorasan products is most effective in reducing metabolic risk factors and ameliorating the liver profile in patients with NAFLD.\tThis study suggests that a short-term replacement diet with ancient KAMUT khorasan products is most effective in reducing metabolic risk factors and ameliorating the liver profile in patients with NAFLD.', 'This study suggests that a short-term replacement diet with ancient KAMUT khorasan products is most effective in reducing metabolic risk factors and ameliorating the liver profile in patients with NAFLD.\tsignificant improvements in the liver steatosis grading, Doppler perfusion index values, and reactive oxygen species (ROS) production were evident after consumption of both the khorasan and control products.', 'This study suggests that a short-term replacement diet with ancient KAMUT khorasan products is most effective in reducing metabolic risk factors and ameliorating the liver profile in patients with NAFLD.\tsignificant reductions in circulating proinflammatory tumor necrosis factor-alpha by 50%, interleukin l-receptor antagonist-alpha by 37%, interleukin-8 by 24%, and interferon gamma by 24% were evident only in participants who consumed the khorasan products (p < 0.05 for all).', 'This study suggests that a short-term replacement diet with ancient KAMUT khorasan products is most effective in reducing metabolic risk factors and ameliorating the liver profile in patients with NAFLD.\tAfter the implementation of a general linear model for repeated measurements adjusted for baseline demographic details, risk factors, and medication, alanine aminotransferase (ALT) was significantly reduced by 12%, aspartate aminotransferase (AST) by 14%, alkaline phosphatase (ALP) by 8%, and cholesterol by 6% only in the khorasan group (p < 0.05 for all).', 'significant improvements in the liver steatosis grading, Doppler perfusion index values, and reactive oxygen species (ROS) production were evident after consumption of both the khorasan and control products.\tKAMUT khorasan is an ancient grain with widely acclaimed health benefits.', 'significant improvements in the liver steatosis grading, Doppler perfusion index values, and reactive oxygen species (ROS) production were evident after consumption of both the khorasan and control products.\tThis study suggests that a short-term replacement diet with ancient KAMUT khorasan products is most effective in reducing metabolic risk factors and ameliorating the liver profile in patients with NAFLD.', 'significant improvements in the liver steatosis grading, Doppler perfusion index values, and reactive oxygen species (ROS) production were evident after consumption of both the khorasan and control products.\tsignificant improvements in the liver steatosis grading, Doppler perfusion index values, and reactive oxygen species (ROS) production were evident after consumption of both the khorasan and control products.', 'significant improvements in the liver steatosis grading, Doppler perfusion index values, and reactive oxygen species (ROS) production were evident after consumption of both the khorasan and control products.\tsignificant reductions in circulating proinflammatory tumor necrosis factor-alpha by 50%, interleukin l-receptor antagonist-alpha by 37%, interleukin-8 by 24%, and interferon gamma by 24% were evident only in participants who consumed the khorasan products (p < 0.05 for all).', 'significant improvements in the liver steatosis grading, Doppler perfusion index values, and reactive oxygen species (ROS) production were evident after consumption of both the khorasan and control products.\tAfter the implementation of a general linear model for repeated measurements adjusted for baseline demographic details, risk factors, and medication, alanine aminotransferase (ALT) was significantly reduced by 12%, aspartate aminotransferase (AST) by 14%, alkaline phosphatase (ALP) by 8%, and cholesterol by 6% only in the khorasan group (p < 0.05 for all).', 'significant reductions in circulating proinflammatory tumor necrosis factor-alpha by 50%, interleukin l-receptor antagonist-alpha by 37%, interleukin-8 by 24%, and interferon gamma by 24% were evident only in participants who consumed the khorasan products (p < 0.05 for all).\tKAMUT khorasan is an ancient grain with widely acclaimed health benefits.', 'significant reductions in circulating proinflammatory tumor necrosis factor-alpha by 50%, interleukin l-receptor antagonist-alpha by 37%, interleukin-8 by 24%, and interferon gamma by 24% were evident only in participants who consumed the khorasan products (p < 0.05 for all).\tThis study suggests that a short-term replacement diet with ancient KAMUT khorasan products is most effective in reducing metabolic risk factors and ameliorating the liver profile in patients with NAFLD.', 'significant reductions in circulating proinflammatory tumor necrosis factor-alpha by 50%, interleukin l-receptor antagonist-alpha by 37%, interleukin-8 by 24%, and interferon gamma by 24% were evident only in participants who consumed the khorasan products (p < 0.05 for all).\tsignificant improvements in the liver steatosis grading, Doppler perfusion index values, and reactive oxygen species (ROS) production were evident after consumption of both the khorasan and control products.', 'significant reductions in circulating proinflammatory tumor necrosis factor-alpha by 50%, interleukin l-receptor antagonist-alpha by 37%, interleukin-8 by 24%, and interferon gamma by 24% were evident only in participants who consumed the khorasan products (p < 0.05 for all).\tsignificant reductions in circulating proinflammatory tumor necrosis factor-alpha by 50%, interleukin l-receptor antagonist-alpha by 37%, interleukin-8 by 24%, and interferon gamma by 24% were evident only in participants who consumed the khorasan products (p < 0.05 for all).', 'significant reductions in circulating proinflammatory tumor necrosis factor-alpha by 50%, interleukin l-receptor antagonist-alpha by 37%, interleukin-8 by 24%, and interferon gamma by 24% were evident only in participants who consumed the khorasan products (p < 0.05 for all).\tAfter the implementation of a general linear model for repeated measurements adjusted for baseline demographic details, risk factors, and medication, alanine aminotransferase (ALT) was significantly reduced by 12%, aspartate aminotransferase (AST) by 14%, alkaline phosphatase (ALP) by 8%, and cholesterol by 6% only in the khorasan group (p < 0.05 for all).', 'After the implementation of a general linear model for repeated measurements adjusted for baseline demographic details, risk factors, and medication, alanine aminotransferase (ALT) was significantly reduced by 12%, aspartate aminotransferase (AST) by 14%, alkaline phosphatase (ALP) by 8%, and cholesterol by 6% only in the khorasan group (p < 0.05 for all).\tKAMUT khorasan is an ancient grain with widely acclaimed health benefits.', 'After the implementation of a general linear model for repeated measurements adjusted for baseline demographic details, risk factors, and medication, alanine aminotransferase (ALT) was significantly reduced by 12%, aspartate aminotransferase (AST) by 14%, alkaline phosphatase (ALP) by 8%, and cholesterol by 6% only in the khorasan group (p < 0.05 for all).\tThis study suggests that a short-term replacement diet with ancient KAMUT khorasan products is most effective in reducing metabolic risk factors and ameliorating the liver profile in patients with NAFLD.', 'After the implementation of a general linear model for repeated measurements adjusted for baseline demographic details, risk factors, and medication, alanine aminotransferase (ALT) was significantly reduced by 12%, aspartate aminotransferase (AST) by 14%, alkaline phosphatase (ALP) by 8%, and cholesterol by 6% only in the khorasan group (p < 0.05 for all).\tsignificant improvements in the liver steatosis grading, Doppler perfusion index values, and reactive oxygen species (ROS) production were evident after consumption of both the khorasan and control products.', 'After the implementation of a general linear model for repeated measurements adjusted for baseline demographic details, risk factors, and medication, alanine aminotransferase (ALT) was significantly reduced by 12%, aspartate aminotransferase (AST) by 14%, alkaline phosphatase (ALP) by 8%, and cholesterol by 6% only in the khorasan group (p < 0.05 for all).\tsignificant reductions in circulating proinflammatory tumor necrosis factor-alpha by 50%, interleukin l-receptor antagonist-alpha by 37%, interleukin-8 by 24%, and interferon gamma by 24% were evident only in participants who consumed the khorasan products (p < 0.05 for all).', 'After the implementation of a general linear model for repeated measurements adjusted for baseline demographic details, risk factors, and medication, alanine aminotransferase (ALT) was significantly reduced by 12%, aspartate aminotransferase (AST) by 14%, alkaline phosphatase (ALP) by 8%, and cholesterol by 6% only in the khorasan group (p < 0.05 for all).\tAfter the implementation of a general linear model for repeated measurements adjusted for baseline demographic details, risk factors, and medication, alanine aminotransferase (ALT) was significantly reduced by 12%, aspartate aminotransferase (AST) by 14%, alkaline phosphatase (ALP) by 8%, and cholesterol by 6% only in the khorasan group (p < 0.05 for all).']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0]"
"['Large-scale clinical trials have shown that incretin-based therapies mitigate albuminuria\tLarge-scale clinical trials have shown that incretin-based therapies mitigate albuminuria', 'Large-scale clinical trials have shown that incretin-based therapies mitigate albuminuria\tbut have not shown beneficial effects on eGFR.', 'Large-scale clinical trials have shown that incretin-based therapies mitigate albuminuria\tResearch on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).', 'Large-scale clinical trials have shown that incretin-based therapies mitigate albuminuria\tBut in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.', 'Large-scale clinical trials have shown that incretin-based therapies mitigate albuminuria\tThere may be salutary effects of incretin-based treatments on the diabetic kidney,', 'Large-scale clinical trials have shown that incretin-based therapies mitigate albuminuria\tbut the system is complex and not amenable to simple explanation or prior prediction.', 'Large-scale clinical trials have shown that incretin-based therapies mitigate albuminuria\tThis contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.', 'but have not shown beneficial effects on eGFR.\tLarge-scale clinical trials have shown that incretin-based therapies mitigate albuminuria', 'but have not shown beneficial effects on eGFR.\tbut have not shown beneficial effects on eGFR.', 'but have not shown beneficial effects on eGFR.\tResearch on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).', 'but have not shown beneficial effects on eGFR.\tBut in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.', 'but have not shown beneficial effects on eGFR.\tThere may be salutary effects of incretin-based treatments on the diabetic kidney,', 'but have not shown beneficial effects on eGFR.\tbut the system is complex and not amenable to simple explanation or prior prediction.', 'but have not shown beneficial effects on eGFR.\tThis contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.', 'Research on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).\tLarge-scale clinical trials have shown that incretin-based therapies mitigate albuminuria', 'Research on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).\tbut have not shown beneficial effects on eGFR.', 'Research on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).\tResearch on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).', 'Research on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).\tBut in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.', 'Research on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).\tThere may be salutary effects of incretin-based treatments on the diabetic kidney,', 'Research on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).\tbut the system is complex and not amenable to simple explanation or prior prediction.', 'Research on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).\tThis contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.', 'But in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.\tLarge-scale clinical trials have shown that incretin-based therapies mitigate albuminuria', 'But in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.\tbut have not shown beneficial effects on eGFR.', 'But in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.\tResearch on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).', 'But in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.\tBut in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.', 'But in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.\tThere may be salutary effects of incretin-based treatments on the diabetic kidney,', 'But in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.\tbut the system is complex and not amenable to simple explanation or prior prediction.', 'But in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.\tThis contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.', 'There may be salutary effects of incretin-based treatments on the diabetic kidney,\tLarge-scale clinical trials have shown that incretin-based therapies mitigate albuminuria', 'There may be salutary effects of incretin-based treatments on the diabetic kidney,\tbut have not shown beneficial effects on eGFR.', 'There may be salutary effects of incretin-based treatments on the diabetic kidney,\tResearch on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).', 'There may be salutary effects of incretin-based treatments on the diabetic kidney,\tBut in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.', 'There may be salutary effects of incretin-based treatments on the diabetic kidney,\tThere may be salutary effects of incretin-based treatments on the diabetic kidney,', 'There may be salutary effects of incretin-based treatments on the diabetic kidney,\tbut the system is complex and not amenable to simple explanation or prior prediction.', 'There may be salutary effects of incretin-based treatments on the diabetic kidney,\tThis contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.', 'but the system is complex and not amenable to simple explanation or prior prediction.\tLarge-scale clinical trials have shown that incretin-based therapies mitigate albuminuria', 'but the system is complex and not amenable to simple explanation or prior prediction.\tbut have not shown beneficial effects on eGFR.', 'but the system is complex and not amenable to simple explanation or prior prediction.\tResearch on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).', 'but the system is complex and not amenable to simple explanation or prior prediction.\tBut in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.', 'but the system is complex and not amenable to simple explanation or prior prediction.\tThere may be salutary effects of incretin-based treatments on the diabetic kidney,', 'but the system is complex and not amenable to simple explanation or prior prediction.\tbut the system is complex and not amenable to simple explanation or prior prediction.', 'but the system is complex and not amenable to simple explanation or prior prediction.\tThis contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.', 'This contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.\tLarge-scale clinical trials have shown that incretin-based therapies mitigate albuminuria', 'This contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.\tbut have not shown beneficial effects on eGFR.', 'This contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.\tResearch on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).', 'This contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.\tBut in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.', 'This contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.\tThere may be salutary effects of incretin-based treatments on the diabetic kidney,', 'This contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.\tbut the system is complex and not amenable to simple explanation or prior prediction.', 'This contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.\tThis contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.']","[0, 0, 0, 0, 1, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 2, 0]"
"['The immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.\tThe immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.', 'The immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.\tThis treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance.', 'The immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.\tRapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity.', 'The immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.\tHepatic glucose production decreased after rapamycin pre-treatment (-\u20091.1\u2009±\u20091.1 mg/kg/min, p\u2009=\u20090.04) and after ITx (-\u20091.6\u2009±\u20090.6 mg/kg/min, p\u2009=\u20090.015),', 'The immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.\tno changes in peripheral glucose disposal were observed.', 'The immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.\tFasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: -\u20092.1\u2009±\u20091.4%, p\u2009=\u20090.002),', 'The immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.\tfasting C-peptide (+0.5\u2009±\u20090.3 nmol/l, p\u2009=\u20090.002) and SUITO index increased (+57.4\u2009±\u200939.7, p\u2009=\u20090.016), without differences between the two groups.', 'The immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.\tDIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (-\u200937\u2009±\u200915 vs. -\u200919\u2009±\u200913 U/day, p\u2009=\u20090.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta\u2009=\u200918.2\u2009±\u20095.9, p\u2009=\u20090.006).', 'The immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.\tWe found a significant reduction in DIR after rapamycin pre-treatment (-\u20098\u2009±\u20096 U/day, mean\u2009±\u2009SD, p\u2009<\u20090.001) and 1 year after ITx.', 'This treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance.\tThe immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.', 'This treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance.\tThis treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance.', 'This treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance.\tRapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity.', 'This treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance.\tHepatic glucose production decreased after rapamycin pre-treatment (-\u20091.1\u2009±\u20091.1 mg/kg/min, p\u2009=\u20090.04) and after ITx (-\u20091.6\u2009±\u20090.6 mg/kg/min, p\u2009=\u20090.015),', 'This treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance.\tno changes in peripheral glucose disposal were observed.', 'This treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance.\tFasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: -\u20092.1\u2009±\u20091.4%, p\u2009=\u20090.002),', 'This treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance.\tfasting C-peptide (+0.5\u2009±\u20090.3 nmol/l, p\u2009=\u20090.002) and SUITO index increased (+57.4\u2009±\u200939.7, p\u2009=\u20090.016), without differences between the two groups.', 'This treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance.\tDIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (-\u200937\u2009±\u200915 vs. -\u200919\u2009±\u200913 U/day, p\u2009=\u20090.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta\u2009=\u200918.2\u2009±\u20095.9, p\u2009=\u20090.006).', 'This treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance.\tWe found a significant reduction in DIR after rapamycin pre-treatment (-\u20098\u2009±\u20096 U/day, mean\u2009±\u2009SD, p\u2009<\u20090.001) and 1 year after ITx.', 'Rapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity.\tThe immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.', 'Rapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity.\tThis treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance.', 'Rapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity.\tRapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity.', 'Rapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity.\tHepatic glucose production decreased after rapamycin pre-treatment (-\u20091.1\u2009±\u20091.1 mg/kg/min, p\u2009=\u20090.04) and after ITx (-\u20091.6\u2009±\u20090.6 mg/kg/min, p\u2009=\u20090.015),', 'Rapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity.\tno changes in peripheral glucose disposal were observed.', 'Rapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity.\tFasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: -\u20092.1\u2009±\u20091.4%, p\u2009=\u20090.002),', 'Rapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity.\tfasting C-peptide (+0.5\u2009±\u20090.3 nmol/l, p\u2009=\u20090.002) and SUITO index increased (+57.4\u2009±\u200939.7, p\u2009=\u20090.016), without differences between the two groups.', 'Rapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity.\tDIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (-\u200937\u2009±\u200915 vs. -\u200919\u2009±\u200913 U/day, p\u2009=\u20090.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta\u2009=\u200918.2\u2009±\u20095.9, p\u2009=\u20090.006).', 'Rapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity.\tWe found a significant reduction in DIR after rapamycin pre-treatment (-\u20098\u2009±\u20096 U/day, mean\u2009±\u2009SD, p\u2009<\u20090.001) and 1 year after ITx.', 'Hepatic glucose production decreased after rapamycin pre-treatment (-\u20091.1\u2009±\u20091.1 mg/kg/min, p\u2009=\u20090.04) and after ITx (-\u20091.6\u2009±\u20090.6 mg/kg/min, p\u2009=\u20090.015),\tThe immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.', 'Hepatic glucose production decreased after rapamycin pre-treatment (-\u20091.1\u2009±\u20091.1 mg/kg/min, p\u2009=\u20090.04) and after ITx (-\u20091.6\u2009±\u20090.6 mg/kg/min, p\u2009=\u20090.015),\tThis treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance.', 'Hepatic glucose production decreased after rapamycin pre-treatment (-\u20091.1\u2009±\u20091.1 mg/kg/min, p\u2009=\u20090.04) and after ITx (-\u20091.6\u2009±\u20090.6 mg/kg/min, p\u2009=\u20090.015),\tRapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity.', 'Hepatic glucose production decreased after rapamycin pre-treatment (-\u20091.1\u2009±\u20091.1 mg/kg/min, p\u2009=\u20090.04) and after ITx (-\u20091.6\u2009±\u20090.6 mg/kg/min, p\u2009=\u20090.015),\tHepatic glucose production decreased after rapamycin pre-treatment (-\u20091.1\u2009±\u20091.1 mg/kg/min, p\u2009=\u20090.04) and after ITx (-\u20091.6\u2009±\u20090.6 mg/kg/min, p\u2009=\u20090.015),', 'Hepatic glucose production decreased after rapamycin pre-treatment (-\u20091.1\u2009±\u20091.1 mg/kg/min, p\u2009=\u20090.04) and after ITx (-\u20091.6\u2009±\u20090.6 mg/kg/min, p\u2009=\u20090.015),\tno changes in peripheral glucose disposal were observed.', 'Hepatic glucose production decreased after rapamycin pre-treatment (-\u20091.1\u2009±\u20091.1 mg/kg/min, p\u2009=\u20090.04) and after ITx (-\u20091.6\u2009±\u20090.6 mg/kg/min, p\u2009=\u20090.015),\tFasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: -\u20092.1\u2009±\u20091.4%, p\u2009=\u20090.002),', 'Hepatic glucose production decreased after rapamycin pre-treatment (-\u20091.1\u2009±\u20091.1 mg/kg/min, p\u2009=\u20090.04) and after ITx (-\u20091.6\u2009±\u20090.6 mg/kg/min, p\u2009=\u20090.015),\tfasting C-peptide (+0.5\u2009±\u20090.3 nmol/l, p\u2009=\u20090.002) and SUITO index increased (+57.4\u2009±\u200939.7, p\u2009=\u20090.016), without differences between the two groups.', 'Hepatic glucose production decreased after rapamycin pre-treatment (-\u20091.1\u2009±\u20091.1 mg/kg/min, p\u2009=\u20090.04) and after ITx (-\u20091.6\u2009±\u20090.6 mg/kg/min, p\u2009=\u20090.015),\tDIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (-\u200937\u2009±\u200915 vs. -\u200919\u2009±\u200913 U/day, p\u2009=\u20090.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta\u2009=\u200918.2\u2009±\u20095.9, p\u2009=\u20090.006).', 'Hepatic glucose production decreased after rapamycin pre-treatment (-\u20091.1\u2009±\u20091.1 mg/kg/min, p\u2009=\u20090.04) and after ITx (-\u20091.6\u2009±\u20090.6 mg/kg/min, p\u2009=\u20090.015),\tWe found a significant reduction in DIR after rapamycin pre-treatment (-\u20098\u2009±\u20096 U/day, mean\u2009±\u2009SD, p\u2009<\u20090.001) and 1 year after ITx.', 'no changes in peripheral glucose disposal were observed.\tThe immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.', 'no changes in peripheral glucose disposal were observed.\tThis treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance.', 'no changes in peripheral glucose disposal were observed.\tRapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity.', 'no changes in peripheral glucose disposal were observed.\tHepatic glucose production decreased after rapamycin pre-treatment (-\u20091.1\u2009±\u20091.1 mg/kg/min, p\u2009=\u20090.04) and after ITx (-\u20091.6\u2009±\u20090.6 mg/kg/min, p\u2009=\u20090.015),', 'no changes in peripheral glucose disposal were observed.\tno changes in peripheral glucose disposal were observed.', 'no changes in peripheral glucose disposal were observed.\tFasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: -\u20092.1\u2009±\u20091.4%, p\u2009=\u20090.002),', 'no changes in peripheral glucose disposal were observed.\tfasting C-peptide (+0.5\u2009±\u20090.3 nmol/l, p\u2009=\u20090.002) and SUITO index increased (+57.4\u2009±\u200939.7, p\u2009=\u20090.016), without differences between the two groups.', 'no changes in peripheral glucose disposal were observed.\tDIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (-\u200937\u2009±\u200915 vs. -\u200919\u2009±\u200913 U/day, p\u2009=\u20090.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta\u2009=\u200918.2\u2009±\u20095.9, p\u2009=\u20090.006).', 'no changes in peripheral glucose disposal were observed.\tWe found a significant reduction in DIR after rapamycin pre-treatment (-\u20098\u2009±\u20096 U/day, mean\u2009±\u2009SD, p\u2009<\u20090.001) and 1 year after ITx.', 'Fasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: -\u20092.1\u2009±\u20091.4%, p\u2009=\u20090.002),\tThe immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.', 'Fasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: -\u20092.1\u2009±\u20091.4%, p\u2009=\u20090.002),\tThis treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance.', 'Fasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: -\u20092.1\u2009±\u20091.4%, p\u2009=\u20090.002),\tRapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity.', 'Fasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: -\u20092.1\u2009±\u20091.4%, p\u2009=\u20090.002),\tHepatic glucose production decreased after rapamycin pre-treatment (-\u20091.1\u2009±\u20091.1 mg/kg/min, p\u2009=\u20090.04) and after ITx (-\u20091.6\u2009±\u20090.6 mg/kg/min, p\u2009=\u20090.015),', 'Fasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: -\u20092.1\u2009±\u20091.4%, p\u2009=\u20090.002),\tno changes in peripheral glucose disposal were observed.', 'Fasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: -\u20092.1\u2009±\u20091.4%, p\u2009=\u20090.002),\tFasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: -\u20092.1\u2009±\u20091.4%, p\u2009=\u20090.002),', 'Fasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: -\u20092.1\u2009±\u20091.4%, p\u2009=\u20090.002),\tfasting C-peptide (+0.5\u2009±\u20090.3 nmol/l, p\u2009=\u20090.002) and SUITO index increased (+57.4\u2009±\u200939.7, p\u2009=\u20090.016), without differences between the two groups.', 'Fasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: -\u20092.1\u2009±\u20091.4%, p\u2009=\u20090.002),\tDIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (-\u200937\u2009±\u200915 vs. -\u200919\u2009±\u200913 U/day, p\u2009=\u20090.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta\u2009=\u200918.2\u2009±\u20095.9, p\u2009=\u20090.006).', 'Fasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: -\u20092.1\u2009±\u20091.4%, p\u2009=\u20090.002),\tWe found a significant reduction in DIR after rapamycin pre-treatment (-\u20098\u2009±\u20096 U/day, mean\u2009±\u2009SD, p\u2009<\u20090.001) and 1 year after ITx.', 'fasting C-peptide (+0.5\u2009±\u20090.3 nmol/l, p\u2009=\u20090.002) and SUITO index increased (+57.4\u2009±\u200939.7, p\u2009=\u20090.016), without differences between the two groups.\tThe immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.', 'fasting C-peptide (+0.5\u2009±\u20090.3 nmol/l, p\u2009=\u20090.002) and SUITO index increased (+57.4\u2009±\u200939.7, p\u2009=\u20090.016), without differences between the two groups.\tThis treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance.', 'fasting C-peptide (+0.5\u2009±\u20090.3 nmol/l, p\u2009=\u20090.002) and SUITO index increased (+57.4\u2009±\u200939.7, p\u2009=\u20090.016), without differences between the two groups.\tRapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity.', 'fasting C-peptide (+0.5\u2009±\u20090.3 nmol/l, p\u2009=\u20090.002) and SUITO index increased (+57.4\u2009±\u200939.7, p\u2009=\u20090.016), without differences between the two groups.\tHepatic glucose production decreased after rapamycin pre-treatment (-\u20091.1\u2009±\u20091.1 mg/kg/min, p\u2009=\u20090.04) and after ITx (-\u20091.6\u2009±\u20090.6 mg/kg/min, p\u2009=\u20090.015),', 'fasting C-peptide (+0.5\u2009±\u20090.3 nmol/l, p\u2009=\u20090.002) and SUITO index increased (+57.4\u2009±\u200939.7, p\u2009=\u20090.016), without differences between the two groups.\tno changes in peripheral glucose disposal were observed.', 'fasting C-peptide (+0.5\u2009±\u20090.3 nmol/l, p\u2009=\u20090.002) and SUITO index increased (+57.4\u2009±\u200939.7, p\u2009=\u20090.016), without differences between the two groups.\tFasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: -\u20092.1\u2009±\u20091.4%, p\u2009=\u20090.002),', 'fasting C-peptide (+0.5\u2009±\u20090.3 nmol/l, p\u2009=\u20090.002) and SUITO index increased (+57.4\u2009±\u200939.7, p\u2009=\u20090.016), without differences between the two groups.\tfasting C-peptide (+0.5\u2009±\u20090.3 nmol/l, p\u2009=\u20090.002) and SUITO index increased (+57.4\u2009±\u200939.7, p\u2009=\u20090.016), without differences between the two groups.', 'fasting C-peptide (+0.5\u2009±\u20090.3 nmol/l, p\u2009=\u20090.002) and SUITO index increased (+57.4\u2009±\u200939.7, p\u2009=\u20090.016), without differences between the two groups.\tDIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (-\u200937\u2009±\u200915 vs. -\u200919\u2009±\u200913 U/day, p\u2009=\u20090.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta\u2009=\u200918.2\u2009±\u20095.9, p\u2009=\u20090.006).', 'fasting C-peptide (+0.5\u2009±\u20090.3 nmol/l, p\u2009=\u20090.002) and SUITO index increased (+57.4\u2009±\u200939.7, p\u2009=\u20090.016), without differences between the two groups.\tWe found a significant reduction in DIR after rapamycin pre-treatment (-\u20098\u2009±\u20096 U/day, mean\u2009±\u2009SD, p\u2009<\u20090.001) and 1 year after ITx.', 'DIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (-\u200937\u2009±\u200915 vs. -\u200919\u2009±\u200913 U/day, p\u2009=\u20090.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta\u2009=\u200918.2\u2009±\u20095.9, p\u2009=\u20090.006).\tThe immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.', 'DIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (-\u200937\u2009±\u200915 vs. -\u200919\u2009±\u200913 U/day, p\u2009=\u20090.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta\u2009=\u200918.2\u2009±\u20095.9, p\u2009=\u20090.006).\tThis treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance.', 'DIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (-\u200937\u2009±\u200915 vs. -\u200919\u2009±\u200913 U/day, p\u2009=\u20090.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta\u2009=\u200918.2\u2009±\u20095.9, p\u2009=\u20090.006).\tRapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity.', 'DIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (-\u200937\u2009±\u200915 vs. -\u200919\u2009±\u200913 U/day, p\u2009=\u20090.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta\u2009=\u200918.2\u2009±\u20095.9, p\u2009=\u20090.006).\tHepatic glucose production decreased after rapamycin pre-treatment (-\u20091.1\u2009±\u20091.1 mg/kg/min, p\u2009=\u20090.04) and after ITx (-\u20091.6\u2009±\u20090.6 mg/kg/min, p\u2009=\u20090.015),', 'DIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (-\u200937\u2009±\u200915 vs. -\u200919\u2009±\u200913 U/day, p\u2009=\u20090.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta\u2009=\u200918.2\u2009±\u20095.9, p\u2009=\u20090.006).\tno changes in peripheral glucose disposal were observed.', 'DIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (-\u200937\u2009±\u200915 vs. -\u200919\u2009±\u200913 U/day, p\u2009=\u20090.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta\u2009=\u200918.2\u2009±\u20095.9, p\u2009=\u20090.006).\tFasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: -\u20092.1\u2009±\u20091.4%, p\u2009=\u20090.002),', 'DIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (-\u200937\u2009±\u200915 vs. -\u200919\u2009±\u200913 U/day, p\u2009=\u20090.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta\u2009=\u200918.2\u2009±\u20095.9, p\u2009=\u20090.006).\tfasting C-peptide (+0.5\u2009±\u20090.3 nmol/l, p\u2009=\u20090.002) and SUITO index increased (+57.4\u2009±\u200939.7, p\u2009=\u20090.016), without differences between the two groups.', 'DIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (-\u200937\u2009±\u200915 vs. -\u200919\u2009±\u200913 U/day, p\u2009=\u20090.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta\u2009=\u200918.2\u2009±\u20095.9, p\u2009=\u20090.006).\tDIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (-\u200937\u2009±\u200915 vs. -\u200919\u2009±\u200913 U/day, p\u2009=\u20090.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta\u2009=\u200918.2\u2009±\u20095.9, p\u2009=\u20090.006).', 'DIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (-\u200937\u2009±\u200915 vs. -\u200919\u2009±\u200913 U/day, p\u2009=\u20090.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta\u2009=\u200918.2\u2009±\u20095.9, p\u2009=\u20090.006).\tWe found a significant reduction in DIR after rapamycin pre-treatment (-\u20098\u2009±\u20096 U/day, mean\u2009±\u2009SD, p\u2009<\u20090.001) and 1 year after ITx.', 'We found a significant reduction in DIR after rapamycin pre-treatment (-\u20098\u2009±\u20096 U/day, mean\u2009±\u2009SD, p\u2009<\u20090.001) and 1 year after ITx.\tThe immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.', 'We found a significant reduction in DIR after rapamycin pre-treatment (-\u20098\u2009±\u20096 U/day, mean\u2009±\u2009SD, p\u2009<\u20090.001) and 1 year after ITx.\tThis treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance.', 'We found a significant reduction in DIR after rapamycin pre-treatment (-\u20098\u2009±\u20096 U/day, mean\u2009±\u2009SD, p\u2009<\u20090.001) and 1 year after ITx.\tRapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity.', 'We found a significant reduction in DIR after rapamycin pre-treatment (-\u20098\u2009±\u20096 U/day, mean\u2009±\u2009SD, p\u2009<\u20090.001) and 1 year after ITx.\tHepatic glucose production decreased after rapamycin pre-treatment (-\u20091.1\u2009±\u20091.1 mg/kg/min, p\u2009=\u20090.04) and after ITx (-\u20091.6\u2009±\u20090.6 mg/kg/min, p\u2009=\u20090.015),', 'We found a significant reduction in DIR after rapamycin pre-treatment (-\u20098\u2009±\u20096 U/day, mean\u2009±\u2009SD, p\u2009<\u20090.001) and 1 year after ITx.\tno changes in peripheral glucose disposal were observed.', 'We found a significant reduction in DIR after rapamycin pre-treatment (-\u20098\u2009±\u20096 U/day, mean\u2009±\u2009SD, p\u2009<\u20090.001) and 1 year after ITx.\tFasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: -\u20092.1\u2009±\u20091.4%, p\u2009=\u20090.002),', 'We found a significant reduction in DIR after rapamycin pre-treatment (-\u20098\u2009±\u20096 U/day, mean\u2009±\u2009SD, p\u2009<\u20090.001) and 1 year after ITx.\tfasting C-peptide (+0.5\u2009±\u20090.3 nmol/l, p\u2009=\u20090.002) and SUITO index increased (+57.4\u2009±\u200939.7, p\u2009=\u20090.016), without differences between the two groups.', 'We found a significant reduction in DIR after rapamycin pre-treatment (-\u20098\u2009±\u20096 U/day, mean\u2009±\u2009SD, p\u2009<\u20090.001) and 1 year after ITx.\tDIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (-\u200937\u2009±\u200915 vs. -\u200919\u2009±\u200913 U/day, p\u2009=\u20090.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta\u2009=\u200918.2\u2009±\u20095.9, p\u2009=\u20090.006).', 'We found a significant reduction in DIR after rapamycin pre-treatment (-\u20098\u2009±\u20096 U/day, mean\u2009±\u2009SD, p\u2009<\u20090.001) and 1 year after ITx.\tWe found a significant reduction in DIR after rapamycin pre-treatment (-\u20098\u2009±\u20096 U/day, mean\u2009±\u2009SD, p\u2009<\u20090.001) and 1 year after ITx.']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]"
"['Fracture risk is increased in individuals with type 2 diabetes (T2D).\tFracture risk is increased in individuals with type 2 diabetes (T2D).', 'Fracture risk is increased in individuals with type 2 diabetes (T2D).\tThe choice of insulin treatment is not influencing BTMs,', 'Fracture risk is increased in individuals with type 2 diabetes (T2D).\tmetformin treatment may decrease BTMs,', 'Fracture risk is increased in individuals with type 2 diabetes (T2D).\timprovement of glycaemic control may influence bone resorption activity.', 'Fracture risk is increased in individuals with type 2 diabetes (T2D).\tHbA1c was inversely associated with CTX but not P1NP.', 'Fracture risk is increased in individuals with type 2 diabetes (T2D).\tNeither metformin nor rosiglitazone plasma concentrations was associated with BTMs.', 'Fracture risk is increased in individuals with type 2 diabetes (T2D).\tMetformin and metformin\u202f+\u202frosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).', 'Fracture risk is increased in individuals with type 2 diabetes (T2D).\tAllocation of insulin regimens was not associated with different levels of BTMs.', 'Fracture risk is increased in individuals with type 2 diabetes (T2D).\tBTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p\u202f<\u202f0.001), respectively.', 'The choice of insulin treatment is not influencing BTMs,\tFracture risk is increased in individuals with type 2 diabetes (T2D).', 'The choice of insulin treatment is not influencing BTMs,\tThe choice of insulin treatment is not influencing BTMs,', 'The choice of insulin treatment is not influencing BTMs,\tmetformin treatment may decrease BTMs,', 'The choice of insulin treatment is not influencing BTMs,\timprovement of glycaemic control may influence bone resorption activity.', 'The choice of insulin treatment is not influencing BTMs,\tHbA1c was inversely associated with CTX but not P1NP.', 'The choice of insulin treatment is not influencing BTMs,\tNeither metformin nor rosiglitazone plasma concentrations was associated with BTMs.', 'The choice of insulin treatment is not influencing BTMs,\tMetformin and metformin\u202f+\u202frosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).', 'The choice of insulin treatment is not influencing BTMs,\tAllocation of insulin regimens was not associated with different levels of BTMs.', 'The choice of insulin treatment is not influencing BTMs,\tBTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p\u202f<\u202f0.001), respectively.', 'metformin treatment may decrease BTMs,\tFracture risk is increased in individuals with type 2 diabetes (T2D).', 'metformin treatment may decrease BTMs,\tThe choice of insulin treatment is not influencing BTMs,', 'metformin treatment may decrease BTMs,\tmetformin treatment may decrease BTMs,', 'metformin treatment may decrease BTMs,\timprovement of glycaemic control may influence bone resorption activity.', 'metformin treatment may decrease BTMs,\tHbA1c was inversely associated with CTX but not P1NP.', 'metformin treatment may decrease BTMs,\tNeither metformin nor rosiglitazone plasma concentrations was associated with BTMs.', 'metformin treatment may decrease BTMs,\tMetformin and metformin\u202f+\u202frosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).', 'metformin treatment may decrease BTMs,\tAllocation of insulin regimens was not associated with different levels of BTMs.', 'metformin treatment may decrease BTMs,\tBTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p\u202f<\u202f0.001), respectively.', 'improvement of glycaemic control may influence bone resorption activity.\tFracture risk is increased in individuals with type 2 diabetes (T2D).', 'improvement of glycaemic control may influence bone resorption activity.\tThe choice of insulin treatment is not influencing BTMs,', 'improvement of glycaemic control may influence bone resorption activity.\tmetformin treatment may decrease BTMs,', 'improvement of glycaemic control may influence bone resorption activity.\timprovement of glycaemic control may influence bone resorption activity.', 'improvement of glycaemic control may influence bone resorption activity.\tHbA1c was inversely associated with CTX but not P1NP.', 'improvement of glycaemic control may influence bone resorption activity.\tNeither metformin nor rosiglitazone plasma concentrations was associated with BTMs.', 'improvement of glycaemic control may influence bone resorption activity.\tMetformin and metformin\u202f+\u202frosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).', 'improvement of glycaemic control may influence bone resorption activity.\tAllocation of insulin regimens was not associated with different levels of BTMs.', 'improvement of glycaemic control may influence bone resorption activity.\tBTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p\u202f<\u202f0.001), respectively.', 'HbA1c was inversely associated with CTX but not P1NP.\tFracture risk is increased in individuals with type 2 diabetes (T2D).', 'HbA1c was inversely associated with CTX but not P1NP.\tThe choice of insulin treatment is not influencing BTMs,', 'HbA1c was inversely associated with CTX but not P1NP.\tmetformin treatment may decrease BTMs,', 'HbA1c was inversely associated with CTX but not P1NP.\timprovement of glycaemic control may influence bone resorption activity.', 'HbA1c was inversely associated with CTX but not P1NP.\tHbA1c was inversely associated with CTX but not P1NP.', 'HbA1c was inversely associated with CTX but not P1NP.\tNeither metformin nor rosiglitazone plasma concentrations was associated with BTMs.', 'HbA1c was inversely associated with CTX but not P1NP.\tMetformin and metformin\u202f+\u202frosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).', 'HbA1c was inversely associated with CTX but not P1NP.\tAllocation of insulin regimens was not associated with different levels of BTMs.', 'HbA1c was inversely associated with CTX but not P1NP.\tBTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p\u202f<\u202f0.001), respectively.', 'Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.\tFracture risk is increased in individuals with type 2 diabetes (T2D).', 'Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.\tThe choice of insulin treatment is not influencing BTMs,', 'Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.\tmetformin treatment may decrease BTMs,', 'Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.\timprovement of glycaemic control may influence bone resorption activity.', 'Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.\tHbA1c was inversely associated with CTX but not P1NP.', 'Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.\tNeither metformin nor rosiglitazone plasma concentrations was associated with BTMs.', 'Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.\tMetformin and metformin\u202f+\u202frosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).', 'Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.\tAllocation of insulin regimens was not associated with different levels of BTMs.', 'Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.\tBTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p\u202f<\u202f0.001), respectively.', 'Metformin and metformin\u202f+\u202frosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).\tFracture risk is increased in individuals with type 2 diabetes (T2D).', 'Metformin and metformin\u202f+\u202frosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).\tThe choice of insulin treatment is not influencing BTMs,', 'Metformin and metformin\u202f+\u202frosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).\tmetformin treatment may decrease BTMs,', 'Metformin and metformin\u202f+\u202frosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).\timprovement of glycaemic control may influence bone resorption activity.', 'Metformin and metformin\u202f+\u202frosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).\tHbA1c was inversely associated with CTX but not P1NP.', 'Metformin and metformin\u202f+\u202frosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).\tNeither metformin nor rosiglitazone plasma concentrations was associated with BTMs.', 'Metformin and metformin\u202f+\u202frosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).\tMetformin and metformin\u202f+\u202frosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).', 'Metformin and metformin\u202f+\u202frosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).\tAllocation of insulin regimens was not associated with different levels of BTMs.', 'Metformin and metformin\u202f+\u202frosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).\tBTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p\u202f<\u202f0.001), respectively.', 'Allocation of insulin regimens was not associated with different levels of BTMs.\tFracture risk is increased in individuals with type 2 diabetes (T2D).', 'Allocation of insulin regimens was not associated with different levels of BTMs.\tThe choice of insulin treatment is not influencing BTMs,', 'Allocation of insulin regimens was not associated with different levels of BTMs.\tmetformin treatment may decrease BTMs,', 'Allocation of insulin regimens was not associated with different levels of BTMs.\timprovement of glycaemic control may influence bone resorption activity.', 'Allocation of insulin regimens was not associated with different levels of BTMs.\tHbA1c was inversely associated with CTX but not P1NP.', 'Allocation of insulin regimens was not associated with different levels of BTMs.\tNeither metformin nor rosiglitazone plasma concentrations was associated with BTMs.', 'Allocation of insulin regimens was not associated with different levels of BTMs.\tMetformin and metformin\u202f+\u202frosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).', 'Allocation of insulin regimens was not associated with different levels of BTMs.\tAllocation of insulin regimens was not associated with different levels of BTMs.', 'Allocation of insulin regimens was not associated with different levels of BTMs.\tBTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p\u202f<\u202f0.001), respectively.', 'BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p\u202f<\u202f0.001), respectively.\tFracture risk is increased in individuals with type 2 diabetes (T2D).', 'BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p\u202f<\u202f0.001), respectively.\tThe choice of insulin treatment is not influencing BTMs,', 'BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p\u202f<\u202f0.001), respectively.\tmetformin treatment may decrease BTMs,', 'BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p\u202f<\u202f0.001), respectively.\timprovement of glycaemic control may influence bone resorption activity.', 'BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p\u202f<\u202f0.001), respectively.\tHbA1c was inversely associated with CTX but not P1NP.', 'BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p\u202f<\u202f0.001), respectively.\tNeither metformin nor rosiglitazone plasma concentrations was associated with BTMs.', 'BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p\u202f<\u202f0.001), respectively.\tMetformin and metformin\u202f+\u202frosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).', 'BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p\u202f<\u202f0.001), respectively.\tAllocation of insulin regimens was not associated with different levels of BTMs.', 'BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p\u202f<\u202f0.001), respectively.\tBTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p\u202f<\u202f0.001), respectively.']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
"['Chronic HFHT compared with LFLT intake significantly increased plasma theobromine (p < 0.0001).\tChronic HFHT compared with LFLT intake significantly increased plasma theobromine (p < 0.0001).', 'Chronic HFHT compared with LFLT intake significantly increased plasma theobromine (p < 0.0001).\tCompared with LFLT, acute HFHT intake significantly increased plasma epicatechin and theobromine (p < 0.0001), decreased AIx (p < 0.0001) and increased diastolic BP (3.49 ± 3.40 mmHg increase in HFHT group vs 1.55 ± 2.59 mmHg increase in LFLT group, p = 0.0008).', 'Chronic HFHT compared with LFLT intake significantly increased plasma theobromine (p < 0.0001).\tAcute consumption of HFHT, compared to LFLT, increased plasma epicatechin and theobromine concentrations and decreased arterial stiffness, with no effect on endothelial function and a marginal increase in diastolic BP.', 'Chronic HFHT compared with LFLT intake significantly increased plasma theobromine (p < 0.0001).\tChronic HFHT intake increased plasma theobromine, though it did not have positive impacts on endothelial function, arterial stiffness or BP when compared to LFLT in pregnant women at risk of PE.', 'Compared with LFLT, acute HFHT intake significantly increased plasma epicatechin and theobromine (p < 0.0001), decreased AIx (p < 0.0001) and increased diastolic BP (3.49 ± 3.40 mmHg increase in HFHT group vs 1.55 ± 2.59 mmHg increase in LFLT group, p = 0.0008).\tChronic HFHT compared with LFLT intake significantly increased plasma theobromine (p < 0.0001).', 'Compared with LFLT, acute HFHT intake significantly increased plasma epicatechin and theobromine (p < 0.0001), decreased AIx (p < 0.0001) and increased diastolic BP (3.49 ± 3.40 mmHg increase in HFHT group vs 1.55 ± 2.59 mmHg increase in LFLT group, p = 0.0008).\tCompared with LFLT, acute HFHT intake significantly increased plasma epicatechin and theobromine (p < 0.0001), decreased AIx (p < 0.0001) and increased diastolic BP (3.49 ± 3.40 mmHg increase in HFHT group vs 1.55 ± 2.59 mmHg increase in LFLT group, p = 0.0008).', 'Compared with LFLT, acute HFHT intake significantly increased plasma epicatechin and theobromine (p < 0.0001), decreased AIx (p < 0.0001) and increased diastolic BP (3.49 ± 3.40 mmHg increase in HFHT group vs 1.55 ± 2.59 mmHg increase in LFLT group, p = 0.0008).\tAcute consumption of HFHT, compared to LFLT, increased plasma epicatechin and theobromine concentrations and decreased arterial stiffness, with no effect on endothelial function and a marginal increase in diastolic BP.', 'Compared with LFLT, acute HFHT intake significantly increased plasma epicatechin and theobromine (p < 0.0001), decreased AIx (p < 0.0001) and increased diastolic BP (3.49 ± 3.40 mmHg increase in HFHT group vs 1.55 ± 2.59 mmHg increase in LFLT group, p = 0.0008).\tChronic HFHT intake increased plasma theobromine, though it did not have positive impacts on endothelial function, arterial stiffness or BP when compared to LFLT in pregnant women at risk of PE.', 'Acute consumption of HFHT, compared to LFLT, increased plasma epicatechin and theobromine concentrations and decreased arterial stiffness, with no effect on endothelial function and a marginal increase in diastolic BP.\tChronic HFHT compared with LFLT intake significantly increased plasma theobromine (p < 0.0001).', 'Acute consumption of HFHT, compared to LFLT, increased plasma epicatechin and theobromine concentrations and decreased arterial stiffness, with no effect on endothelial function and a marginal increase in diastolic BP.\tCompared with LFLT, acute HFHT intake significantly increased plasma epicatechin and theobromine (p < 0.0001), decreased AIx (p < 0.0001) and increased diastolic BP (3.49 ± 3.40 mmHg increase in HFHT group vs 1.55 ± 2.59 mmHg increase in LFLT group, p = 0.0008).', 'Acute consumption of HFHT, compared to LFLT, increased plasma epicatechin and theobromine concentrations and decreased arterial stiffness, with no effect on endothelial function and a marginal increase in diastolic BP.\tAcute consumption of HFHT, compared to LFLT, increased plasma epicatechin and theobromine concentrations and decreased arterial stiffness, with no effect on endothelial function and a marginal increase in diastolic BP.', 'Acute consumption of HFHT, compared to LFLT, increased plasma epicatechin and theobromine concentrations and decreased arterial stiffness, with no effect on endothelial function and a marginal increase in diastolic BP.\tChronic HFHT intake increased plasma theobromine, though it did not have positive impacts on endothelial function, arterial stiffness or BP when compared to LFLT in pregnant women at risk of PE.', 'Chronic HFHT intake increased plasma theobromine, though it did not have positive impacts on endothelial function, arterial stiffness or BP when compared to LFLT in pregnant women at risk of PE.\tChronic HFHT compared with LFLT intake significantly increased plasma theobromine (p < 0.0001).', 'Chronic HFHT intake increased plasma theobromine, though it did not have positive impacts on endothelial function, arterial stiffness or BP when compared to LFLT in pregnant women at risk of PE.\tCompared with LFLT, acute HFHT intake significantly increased plasma epicatechin and theobromine (p < 0.0001), decreased AIx (p < 0.0001) and increased diastolic BP (3.49 ± 3.40 mmHg increase in HFHT group vs 1.55 ± 2.59 mmHg increase in LFLT group, p = 0.0008).', 'Chronic HFHT intake increased plasma theobromine, though it did not have positive impacts on endothelial function, arterial stiffness or BP when compared to LFLT in pregnant women at risk of PE.\tAcute consumption of HFHT, compared to LFLT, increased plasma epicatechin and theobromine concentrations and decreased arterial stiffness, with no effect on endothelial function and a marginal increase in diastolic BP.', 'Chronic HFHT intake increased plasma theobromine, though it did not have positive impacts on endothelial function, arterial stiffness or BP when compared to LFLT in pregnant women at risk of PE.\tChronic HFHT intake increased plasma theobromine, though it did not have positive impacts on endothelial function, arterial stiffness or BP when compared to LFLT in pregnant women at risk of PE.']","[0, 0, 1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]"
